Design, Synthesis and Biological Activity of Novel Reversible Peptidyl FVIIa Inhibitors Rh-Catalyzed Enantioselective Synthesis of Diaryl Amines by Storgaard, Morten
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 17, 2017
Design, Synthesis and Biological Activity of Novel Reversible Peptidyl FVIIa Inhibitors
Rh-Catalyzed Enantioselective Synthesis of Diaryl Amines
Storgaard, Morten; Tanner, David Ackland
Publication date:
2010
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Storgaard, M., & Tanner, D. A. (2010). Design, Synthesis and Biological Activity of Novel Reversible Peptidyl
FVIIa Inhibitors Rh-Catalyzed Enantioselective Synthesis of Diaryl Amines. Kgs. Lyngby, Denmark: Technical
University of Denmark (DTU).
Morten Storgaard
PhD-Thesis
January 2010
Design, Synthesis and Biological 
Activity of Novel Reversible
Peptidyl FVIIa Inhibitors
Rh-Catalyzed Enantioselective
Synthesis of Diaryl Amines
Design, Synthesis and Biological
Activity of Novel Reversible
Peptidyl FVIIa Inhibitors
Rh-Catalyzed Enantioselective
Synthesis of Diaryl Amines
Morten Storgaard
PhD-Thesis
Novo Nordisk A/S
Biopharm Chemistry
2760 Ma˚løv
Technical University of Denmark
Department of Chemistry
2800 Kgs. Lyngby
January 2010
Abstract in English
This thesis describes two different projects. The first project deals with the design,
synthesis and biological activity of novel reversible peptidyl FVIIa inhibitors (Chapter
1–3). FVIIa was launced as NovoSeven R© over a decade ago by Novo Nordisk A/S for
the treatment of hemophilia A and B complicated by antibodies. FVIIa is a serine pro-
tease and hence liquid formulations are not stable due to autoproteolysis. A reversible
inhibitor would stabilize FVIIa making a liquid formulation possible, representing an im-
portant follow-up product for Novo Nordisk A/S. Peptidyl benzyl ketones was chosen
as a new class of potential inhibitors, whose sequence was rationally selected from a
previously reported FVIIa-TF specificity profile.
Since arginine was found to be the most active P1-amino acid, a mild and efficient
synthesis of the corresponding arginyl benzyl ketone building block was sought. Two
stategies were proposed, the one involving a tetramic acid key intermediate being the
most straightforward. For introduction of the benzyl functionality, a palladium-catalyzed
α-arylation was developed. This transformation occurs under mild conditions showing
high functional group tolerance. Unfortunately, these α-aryl tetramic acids were too
unreactive and ring opening toward the synthesis of the building block did not succeed.
However, α-aryl tetramic acids are interesting compounds due to their potential biological
activity.
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The building block 3.15 (P1) was instead synthesized via a Weinreb amide and a small
library of peptides were prepaired by solution-phase Boc/Bn-synthesis. Different P3-P2
sequences (tyrosine, threonine, phenylalanine, leucine) and N-terminals (P4; H-, Ac-,
BnSO2- and Cbz-) were examined. Unfortunately, O-debenzylation was found to be
very difficult which restricted the number of peptides containing tyrosine and threonine.
Cbz-D-Phe-Phe-Arg-bk (3.50) was identified as the most potent FVIIa inhibitor with a
Ki = 8 µM (IC50 = 16 µM) and with a 35- and 28-fold selectivity against thrombin and
FXa, respectively. A SAR revealed that a bulky aromatic Cbz-terminal was crucial for
potency.
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The second project deals with the rhodium-catalyzed enantioselective synthesis of diaryl
amines, which is an important class of compounds (Chapter 4). For example it is found
in the third generation anti-histaminic agent levocetirizine. Development of efficient
synthetic routes is therefore of considerably interest. The rhodium-catalyzed enantios-
elective synthesis employing α-carbamoyl sulfones and arylboronic acids was therefore
investigated using the chiral ligand (R,R)-deguPHOS. Rh(acac)(coe)2 was originally uti-
lized requiring the use of a glovebox, but through catalyst screening [RhCl(cod)]2 was
found to be equally efficient. Contrary to Rh(acac)(coe)2, this new catalyst is air-stable,
commercially available and inexpensive. [RhCl(cod)]2 and (R,R)-deguPHOS was prein-
cubated prior to use to secure excellent enantioselectivity. A cannulation technique was
implemented for application outside the glovebox. A low content of boroxine in the
arylboronic acid batch was found to be crucial for a satisfactory outcome. The highly
functionalized α-diaryl methylamine 4.13 was synthesized in good yield and excellent
enantioselectivity in gram-scale. The absolute configuration was determined by X-ray
crystallography to be the (S)-enantiomer.
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Resume´ p˚a dansk
Denne afhandling omhandler to forskellige projekter. Det første projekt omhandler de-
sign, syntese og biologisk aktivitet af nye, reversible peptid-baserede FVIIa-inhibitorer
(Kapitel 1–3). FVIIa blev lanceret som NovoSeven R© for over 10 a˚r siden af Novo Nordisk
A/S for behandling af hæmofili A og B kompliceret af antistoffer. FVIIa er en serine-
protease og flydende formuleringer er derfor ikke stabile p˚a grund af autoproteolyse. En
reversibel inhibitor der stabiliserer FVIIa ville kunne gøre en flydende formulering mulig,
og dermed udgøre en vigtig produktudvidelse for Novo Nordisk A/S. Peptid-baserede
benzylketoner blev valgt som en ny klasse af potentielle inhibitorer hvis sekvens rationelt
blev udvalgt p˚a baggrund af en tidligere publiceret FVIIa-TF specificitetsprofil.
Da arginin blev fundet til at være den mest aktive P1-aminosyre, var det ønsket at
udvikle en mild og effektiv syntese af den tilsvarende arginyl benzylketon-byggeblok.
To strategier blev foresl˚aet, men de´n strategi der involverer en tetramsyre som nøgle-
intermediat var den mest enkle. En palladium-katalyseret α-arylering blev udviklet for
introduktion af benzyl-funktionaliteten. Denne reaktion forløber under milde betingelser
og udviser høj tolerance overfor funktionelle grupper. Desværre er α-aryl tetramsyrer
ureaktive og ring˚abning for syntese af byggeblokken var derfor ikke succesfuld. Imidlertid
udgør disse stoffer en interessant gruppe p˚a grund af deres potentielle biologiske aktivitet.
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Byggeblokken 3.15 (P1) blev i stedet syntetiseret via et Weinreb-amid og et lille bib-
liotek af peptider blev fremstillet ved solution-phase Boc/Bn-syntese. Forskellige P3-P2
sekvenser (tyrosin, threonin, phenylalanin, leucin) og N-terminaler (P4; H-, Ac-, BnSO2-
and Cbz-) blev undersøgt. Desværre viste det sig, at O-debenzyleringen var svær at ud-
føre hvilket gav en begrænsning p˚a antallet af peptider indeholdende tyrosin og threonin.
Cbz-D-Phe-Phe-Arg-bk (3.50) blev fundet til at være den mest potente FVIIa inhibitor
med Ki = 8 µM og med en selektivitet p˚a 35- og 28-gange overfor hhv. thrombin
og FXa. En struktur-aktivitetsanalyse viste, at Cbz-terminalen og D-aminosyren var
afgørende for at opn˚a lav-mikromolær aktivitet. Trods moderat aktivitet og selektivitet
samt lav opløselighed i vandige medier, udgør denne inhibitor en rimelig kandidat for den
videre udvikling af flydende formuleringer af FVIIa.
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Det andet projekt omhandler den rhodium-katalyserede enantioselektive syntese af di-
arylaminer, som er en vigtig stofklasse (Kapitel 4). Foreksempel findes den i tredje-
generations antihistaminet levocetirizin. Udvikling af effektive synteseveje er derfor af
stor interesse. Den rhodium-katalyserede enantioselektive syntese med den chirale lig-
and (R,R)-deguPHOS og α-carbamoylsulfoner og arylborsyrer som udgangsstoffer blev
undersøgt. Rh(acac)(coe)2 var den oprindelige katalysator, som tillige krævede anven-
delsen af en handskebox. Gennem screening blev [RhCl(cod)]2 fundet til at en lige s˚a
effektiv katalysator. Den er tilmed luftstabil, kommerciel tilgængelig og billig i modsæt-
ning til Rh(acac)(coe)2. [RhCl(cod)]2 og (R,R)-deguPHOS blev præinkuberet før brug
for at opn˚a en høj enantioselektivitet. En kanyleringsteknik blev implementeret for at
kunne udføre reaktionen udenfor handskeboxen. Et lavt indhold af boroxin i arylborsyren
blev fundet at være afgørende for et tilfredsstillende resultat. Den højtfunktionaliseret
α-diarylmethylamin 4.13 blev syntetiseret i gram-skala i godt udbytte og høj enantiose-
lektivitet. Den absolutte konfiguration blev bestemt ved røntgen-krystallografi til at være
(S)-enantiomeren.
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Preface
This PhD thesis consists of six chapters covering two independent projects. The first
project is ’Design, Synthesis and Biological Activity of Novel Reversible Peptidyl FVIIa
Inhibitors’ (Chapter 1–3) and the second project is ’Rhodium-Catalyzed Enantioselective
Synthesis of Diaryl Methyl Amines’ (Chapter 4). An overall list of references (Chapter
5) and list of related publications (Chapter 6) are also included. References are num-
bered consecutively throughout the entire thesis, whereas compounds are numbered
consecutively according to which chapter they appear in: e.g. 3.2 is compound no.
2 in Chapter 3. Peptide nomenclature is used whenever appropriate. Chymotrypsin
numbering of amino acid residues in FVIIa is used throughout the thesis. Supporting in-
formation, such as NMR spectra and HPLC chromatograms are available electronically
upon request, if not included with this hardcopy. The first project (January 2007 to
May 2008 and December 2008 to January 2010) was carried out at Novo Nordisk A/S,
Ma˚løv in the Department of Biopharm Chemistry under the supervision of Dr. Bernd
Peschke (Novo Nordisk A/S) and Professor David Tanner from The Technical University
of Denmark (DTU), Department of Chemistry. The second project (June to November
2008) was carried out at University of California at Berkeley, College of Chemistry under
the supervision of Professor Jonathan (’Jon’) A. Ellman.
First of all, I would like to address a thanks to my two supervisors, Bernd and David.
They have both provided me with great inspiration throughout the years. Bernd was al-
ways ready to help me during my stay at Novo Nordisk and providing me with feedback,
whenever I needed it. With his huge knowledge of industrial drug discovery, he was a
valuable mentor. On the other hand, David was the best supervisor in organic chemistry
you could ask for. He gave me many good advices and he taught me a lot of organic
chemistry. Bernd and David are also thanked for proofreading this thesis.
Not to forget, I would like to thank my two former supervisors at Novo Nordisk; Dr.
Janne E. Tønder and Dr. Florencio (’Flo’) Zaragoza Do¨rwald. Janne was the one who
made it possible for me to do my PhD studies at Novo Nordisk, but unfortunately she
had to leave the company after just one month due to the sudden discontinuation of
the small molecule research. However, I am grateful to her for the effort that she put
in the PhD application and for her everlasting enthusiasm and friendly spirit. Flo was
my supervisor for approximately seven months thereafter, when he decided to leave
Denmark to take up a job at Lonza in Schwitzerland. He was the one who formulated
the final project regarding design and synthesis of FVIIa inhibitors. Despite our short
time of collaboration, he taught me many valuable experimental skills and I appreciate
his profound knowledge of chemistry.
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time in the C9.2.08-lab, which I will definitely miss. Moreover, I would like to thank Hen-
rik Stephensen for tuning the HRMS, Claus Bruun for shimming the NMR instrument,
Paw Block for making sure that all the HPLC/UPLC’s are running perfectly, Sonja Bak
for providing me with solvents and letting me borrow a lot of her lab-equipment, Johnny
for helping me with the preparative HPLC and Helle with the lyophilization. Rie Kristine
Schjeltved, Carsten Behrens and Henning Stennicke are all thanked for teaching me how
to perform the competitive binding assays. Berit Lassen is thanked for providing me
with hFXa.
Novo Nordisk and Corporate Research Affairs (CORA) are thanked for financial support.
Berit Albrechtsen, Marianne Søndergaard and Lis Vejle Pedersen are thanked for helping
me out with all the administrative work. Moreover, I would like to thank Oticon Fonden,
Augustinus Fonden and Ingeniør Alexandre Haynman and Hustru Nina Haynmans Fond
for additional financial support during my stay in the USA.
At the Department of Chemistry (DTU) I would like to thank all employees in building
201. Many of you have been there since my early beginning in 2001 as a first-year
chemistry student, and it was always great to be back, although my visits were usually
quite short. Dr. Masood Hosseini is thanked for many fun hours and great scientific
discussions.
Last but not least, I would like to address a thanks to Jon for letting me do research
in his group. He was a very enthusiastic supervisor and he was always ready to provide
me with new and interesting inputs to the project. In addition, I would like to thank
the entire Ellman group for beeing very friendly and helpful. Especially, I would like to
thank Melissa Leyva, Denise Colby, MaryAnn Robak and Tyler Baguley for making the
908 Latimer Hall-lab a good place to work. Denise is moreover thanked for helping me
with the glovebox and MaryAnn for preparing crystals for X-ray crystallography. Besides
of the fun time I had with the people from the Ellman group, my 60 house-mates in the
Hillegass-Parker coop definately also made my stay in the USA funny and memorable,
and in particular they made it more vegetarian...
Morten Storgaard, M.Sc.Eng.
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[α]20D Optical rotation (sodium D line at 20
oC)
A Alanine
Ac Acetyl
ACC 7-Amino-4-carbamoylmethylcoumarin
Ac2O Acetic acid anhydride
AcOH Acetic acid
acac Acetylacetonate
Ala Alanine
Arg Arginine
Asn Asparagine
Asn* Glycosylated asparagine
Asp Aspartic acid
AT Antithrombin
ATR Attenuated total reflection
BAL Backbone amide linker
9-BBN 9-Borabicyclo[3.3.1]nonane
BINAP 2,2’-Bis(diphenylphosphino)-1,1’-binaphthyl
Boc tert-Butoxycarbonyl
Boc2O Di-tert-butyl dicarbonate
bod* Bicyclo[2.2.2]octadiene
BOP Benzotriazolyl-N-oxytrisdimethylaminophosphonium PF−6
bk Benzyl ketone
Bn Benzyl
BnBr Benzylbromide
BnOH Benzyl alcohol or phenylmethanol
BnSO2Cl Phenylmethanesulfonyl chloride
Bt Benzotriazole
Bzl Benzyl
calcd. Calculated
CaR Calcium-sensing receptor
Cbz Benzyloxycarbonyl
CDI Carbonylimidazole
Cha Cyclohexylalanine
cHex-JohnPhos 2-(Dicyclohexylphosphino)biphenyl
CLND Chemiluminescent nitrogen detection
cmk Chloromethyl ketone
coe Cyclooctaene
cod Cyclooctadiene
conc. Concentrated
IX
18-Crown-6 1,4,7,10,13,16-Hexaoxacyclooctadecane
D Aspartic acid
DavePhos 2-Dicyclohexylphosphino-2’-(N,N-dimethylamino)biphenyl
dba Dibenzylideneacetone
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCC N,N ’-Dicyclohexylcarbodiimide
DCM Dichloromethane
de Diastereomeric excess
deguPHOS (1-Benzyl-3,4-bis(diphenylphosphino)pyrrolidine
decomp. Decomposed
DHUA 10,11-Dihydroxy-undecanoic acid
DIBAL-H Diisobutylaluminium hydride
DIC N,N’-Diisopropylcarbodiimide
DIPEA Diisopropylethylamine
DMAP N,N-Dimethyl-4-aminopyridine
DMF Dimethyl formamide
DMSO Dimethylsulphoxide
DNA Deoxyribonucleic acid
dppbenz 1,2-Bis(diphenylphosphino)benzene
DPPF 1,1’-Bis(diphenylphosphino)ferrocene
dr Diastereomeric ratio
DTU The Technical University of Denmark
E Glutamic acid
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EDG Electron-donating group
ee Enantiomeric excess
EGF Epidermal growth factor-like domain
elem. anal. Elemental analysis
equiv Equivalent
ESI Electronspray ionization
Et Ethyl
Et3N Triethyl amine
Et2O Diethyl ether
EtOAc Ethyl acetate
EtOH Ethanol
EtOTs Ethyl tosylate or ethyl 4-toluene sulphonate
EWG Electron-withdrawing group
F Phenylalanine
FDA Food and Drug Administration (USA)
Fmoc 9-Fluorenylmethoxycarbonyl
FT-IR Fourier transform infrared spectroscopy
X
FVa Activated factor V
FVII Factor VII
FVIIa Activated factor VII
FIX Factor IX
FIXa Activated factor IX
FX Factor X
FXa Activated factor X
FX act. Degree of FX activation
FXIa Activated factor XI
G Glycine
Gla Glutamic acid-rich domain
Gln Glutamine
Glu Glutamic acid
Gly Glycine
GlyGly Glysylglycine (diglycine)
H Histidine
h Hour
H1 Histamine 1 (receptor)
HATU O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium PF−6
HBTU O-(Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium PF−6
HEPES (4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
hFXa Human activated factor X
His Histidine
HIV Human immunodeficiency virus
HMPA Hexamethylphosphoramide
HOAt 7-Aza-1-hydroxybenzotriazole
HOBt 1-Hydroxy-1H-benzotriazole
HONb N-Hydroxy-5-norbornene-2,3-dicarboxylimide
HPLC High performance liquid chromatography
HRMS High resolution mass spectroscopy
HSTU O-(N-Succimidyl)-N,N,N’,N’-bis(tetramethylene)uronium PF−6
HTS High throughput screening
I Isoleucine
IBCF Isobutyl chloroformate
IC50 Half maximal inhibitory concentration
Ile Isoleucine
IPCF Isopropenyl chloroformate
iPr Isopropyl
iPrOH Isopropyl alcohol or 2-propanol
IR Infrared spectrometry
J J-coupling or indirect dipole dipole coupling
XI
JohnPhos 2-(Di-tert-butylphosphino)biphenyl
K Lysine
KHMDS Potassium bis(trimethylsilyl)amide
L Ligand or leucine
LC-MS Liquid chromatography mass spectroscopy
LDA Lithium diisopropylamide
Leu Leucine
LMWH Low molecular weight heparins
L-Selectride Lithium tri-sec-butylborohydride
Lys Lysine
Ki Binding affinity
m-CPBA meta-Chloroperoxybenzoic acid
Me Methyl
MeCN Acetonitrile
MeOH Methanol
MePhos 2-Dicyclohexylphosphino-2’-methylbiphenyl
Me2S Dimethyl sulfide
MS Molecular sieves or mass spectrometry
MSD Mass storage device
Mtr (4-Methoxy-2,3,6-trimethylphenyl)sulfonyl
Mw Molecular weight
m/z Mass-to-charge ratio
N Asparagine
Na(acac) Sodium acetylacetonate
NaHMDS Sodium bis(trimethylsilyl)amide
NaOEt Sodium ethoxide
NaOtBu Sodium tert-butoxide
Nbb 2-Nitrobenzyl bromide
NMM N-Methylmorpholine
NMR Nuclear Magnetic Resonance
Ns Nosyl (4-nitrobenzenesulfonyl)
OD Optical density or absorbance
OEG Oligo(ethoxy)ethylene glycol (oligo(8-amino 3,6-dioxaoctanoic acid))
Orn Ornithine
OSu O-Succinimidyl ester
P Proline
P* Chiral phosphine ligand
PAF Platelet activating factor
PAL Peptide amide linker
Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl
PEG Polyethylene glycol
XII
Pfp Pentafluorophenyl
Pg Protection group
Ph Phenyl
PhDavePhos 2-Diphenylphosphino-2’-(N,N-dimethylamino)biphenyl
Phe Phenylalanine
PhSH Thiophenol
Phth Phthaloyl
Pip Pipecolic acid or piperidine-2-carboxylic acid
PMA Phosphomolybdic acid
Pmc 2,2,5,7,8-Pentamethylchroman-6-sulfonyl
Pn Amino acid residue
pNA para-Nitro anilide or para-Nitro aniline
PPh3 Triphenylphosphine
PPTS Pyridinium p-toluenesulfonate
Pro Proline
PS Polystyrene
psi Pound per square inch
PS-SCL Positional scanning, synthetic combinatorital libraries
PyBOP Benzotriazol-1-yl-oxytri(pyrrolidino)phosphonium PF−6
Q Glutamine
R Arginine
rac Racemic
Rf Retention factor
rFVIIa Recombinant activated factor VII
rFVIII Recombinant factor VIII
rFIX Recombinant factor IX
rFXIII Recombinant factor XIII
rt Room temperature
S Serine
Sn Binding site/pocket
SAR Structure activity relationship
Sat. Saturated
Ser Serine
(S)-ShiP Phenyl-[(S)-1,1-spirobiindane-7,7-diyl]-phosphite
SNAr Nucleophilic aromatic substitution
SPhos 2-Dicyclohexylphosphino-2’,6’-dimethoxybiphenyl
sTF1−219 Soluble tissue factor (residues 1-219)
T Threonine
TAFI Thrombin-activatable fibrinolytic inhibitor
TATU O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium BF−4
TBAF Tetrabutylammonium fluoride
XIII
TBDMS tert-Butyldimethylsilyl
TBTU O-Benzotriazol-1-yl-1,1,3,3-tetramethyluronium tetrafluoroborate
tBu tert-Butyl
tBu-DavePhos 2-Di-tert-butylphosphino-2’-(N,N-dimethylamino)biphenyl
tBu-MePhos 2-Di-tert-butylphosphino-2’-methylbiphenyl
tBuOH tert-Butyl alcohol or 2-methyl-2-propanol
tBu-XPhos 2-Di-tert-butylphosphino-2’,4’,6’-triisopropylbiphenyl
TF Tissue factor
Tf Triflate or trifluoromethanesulfonate
TFA Trifluoroacetic acid
Tf2O Triflate anhydride
TFMSA Trifluoromethanesulfonic acid
THF Tetrahydrofuran
Thr Threonine
thr Thrombin
TLC Thin layer chromatography
TMS Trimethylsilyl
TMSCl Trimethylsilyl chloride
TMSOTf Trimethylsilyl trifluoromethanesulfonate
TOF Time of flight
Tos Tosyl or (para-toluenesulfonyl
Trp Tryptophan
trp Trypsin
Trt Trityl or triphenylmethyl
Ts Tosyl or (para-toluenesulfonyl
TsOH p-Toluenesulfonic acid
TSTU O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
Tween80 Polyoxyethylene (20) sorbitan monooleate
Tyr Tyrosine
U Enzyme unit (mass enzyme/µmole substrate converted/minute)
UC University of California
UCB Union Chimique Belge
UNCA Urethane N-carboxyanhydride
UPLC Ultra Performance Liquid Chromatography
UV Ultraviolet
V Valine
v Enzyme velocity
Val Valine
W Tryptophan
wt. Weight
Xantphos 4,5-Bis(diphenylphosphino)-9.9-dimethylxanthene
XIV
XPhos 2-Dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl
Y Tyrosine
XV
XVI
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Chapter 1
Design and application of serine
protease inhibitors
1.1 Project introduction
In 1996 Novo Nordisk introduced NovoSeven R© in Denmark and in 1999 it was launched
in the USA. NovoSeven R© is recombinant activated Factor VII (rFVIIa), a serine pro-
tease primarily used for treatment of hemophilia A and B complicated with inhibitors
(antibodies).1,2 Within the last decade, Novo Nordisk has worked within the field of
hemostasis and research and development of blood coagulation factors. Currently, sev-
eral other products are in the R&D pipeline, such as rFVIII, long-acting rFIX and rFXIII
for patients undergoing cardiac surgery, a fast-acting rFVIIa and a long-acting rFVIIa.1
NovoSeven R© is administrated intravenously by reconstituting lyophilized rFVIIa in a
solvent prior to injection. In 2009 a room temperature stable lyophilized rFVIIa was
launched, but an aqueous liquid formulation is still absent primarily due to autoproteoly-
sis of the enzyme.2 The reconstituted solution is only stable for use for 24 hours at room
temperature.3 FVIIa undergoes degradation by several pathways, including aggregation,
oxidation, precipitation and as mentioned also autoproteolysis. Degradation leads to
a decreased FVIIa activity thus giving non-homogeneity of dosage, but also a serious
risk of increased toxicity and immunogenicity due to formation of protein by-products.3
Precipication can lead to thrombosis and clogging of syringes.3 It would be a great im-
provement for the patient compliance if a liquid formulation was developed. This would
also eliminate reconstitution errors and thereby increase dosage accuracy and simplify
the use of the product.3 A ready-to-use rFVIIa would represent an important improve-
ment of the hemostasis product portfolio of Novo Nordisk.
Protein stability can be affected by many factors, such as ionic strength, pH, temperature
and addition of stabilizers. Decrease of activity may be due to chemical factors (pro-
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teolysis, deamidation, oxidation, racemization or β-elimination) as well as physical fac-
tors (aggregation, precipitation, denaturation or surface adsorption).4 Novo Nordisk has
claimed several peptides3,5 and small molecules6–8 in the patent literature as stabilization
agents for liquid formulations of rFVIIa. The peptide propyloxycarbonyl-Phe(4-amidino)-
Glu-Asn-Cha-(OEG)5-NH2 (1.1) was tested in aqueous formulations of 40K-PEGylated
rFVIIa (20 mg/mL) at room temperature for 3 months (see Figure 1.1.1).3 It was found
that the best effect of 1.1 was obtained above 1 mM concentrations, e.g. 10 mM of 1.1
retained a rFVIIa activity of 85%. In the absence of the inhibitor, no FVIIa activity was
retained at all after 3 months. Furthermore, stabilization might be enhanced by addition
of other excipients such as surfactants (e.g. polysorbate or Tween), antioxidants (e.g.
ascorbic acid, methionine or cysteine), calcium, magnesium or zinc salts.9–11 It is also
well-known, that proteins can be formulated as liposomes for increased stability.12–14
However, none of these last-mentioned methods have been reported in attempts to im-
prove the liquid formulations of rFVIIa.
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Figure 1.1.1: The peptide propyloxycarbonyl-Phe(4-amidino)-Glu-Asn-Cha-
(OEG)5-NH2 (1.1) was tested as a stabilization agent for rFVIIa formulation.
With an inhibitor concentration of 10 mM, a rFVIIa activity of 85% was retained
after incubation in 3 months at room temperature.3
Addition of an appropriate inhibitor is a useful formulation-aid for stabilization of rFVIIa.3
The inhibitor should be reversible and sufficient potent to require only minor concentra-
tions present in the final product. However, a highly potent inhibitor is not desirable,
because that would completely inhibit rFVIIa and prevent it to initiate blood coagula-
tion clinically. Moreover, the inhibitor should be non-toxic, exhibit favorable solubility in
aqueous media and be selective against FVIIa without inhibiting other coagulation factors
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substantially, e.g. thrombin, FXa, FIXa and FXIa.3 Formulation of rFVIIa containing a
stabilizing peptide, should exhibit improved stability and allow prolonged storage, prefer-
ably up to 36 months at room temperature.3
Concurrently with the development and application of peptide 1.1 toward a liquid formu-
lation of NovoSeven R©, other peptidyl inhibitors were explored at Novo Nordisk. One of
these classes was the peptidyl benzyl ketones which is the topic of this thesis. Benzyl ke-
tones as serine proteases have only been described once in connection with development
of thrombin inhibitors, and therefore represent an unexplored class of inhibitors. Selec-
tive FVIIa peptidyl inhibitors are in addition rather unknown, as well as probing the S1’
binding pocket for achieving potency against FVIIa. Design, synthesis and evaluation of
the biological activity of peptidyl benzyl ketones therefore represent an unexplored part
of the discovery of potent and selective serine protease inhibitors.
1.1.1 Hemostatic control of blood coagulation
Hemostasis is a highly regulated process that maintains the right viscosity of the blood. It
regulates blood coagulation, anticoagulation and fibrinolysis and consists of a combined
activity of vascular, platelet and plasma factors.15–18 Hemostatic abnormalities can lead
to uncontrolled bleedings (hemophilia) or adnormal blood clot formation (thrombophilia)
in the circulating blood.19,20 Hemophilia is a group of hereditary genetic disorders,
whereas thromophilia can be a result of an inherited or acquired disease with a higher
risk of blood clot formation (thrombosis).20 Hypercoagulability may also be provoked by
drugs to treat hemophilia, surgery, inflammation and in particular artherosclerosis, which
is the presence of fatty plaques, such as cholesterol, in the blood. Artherosclerosis is a
growing problem due to metabolic syndroms and it is now recognized as a serious public
health problem that affects up to 45% of the population (in particular people over 50
years old from USA).21 Smoking is also known to induce artherosclerosis.22 The presence
of fat in the blood may cause an unpredictable, sudden disruption of fatty plaques which
can lead to platelet activation23 and thrombosis. Abnormal blood coagulation can there-
fore result in severe intravascular coagulation, venous thrombosis, pulmonary embolism,
unstable angina, myocardial infarction or thrombotic stroke. These indications are all
being the major causes of morbidity and mortality worldwide.24
The blood coagulation is predominantly initiated by a response to trauma, e.g. by injury
of a blood vessel.25 However, the first response, the primary hemostasis, is not the actual
blood coagulation, but involves vascular and platelet factors. Local vasoconstriction and
compression of injured vessels by extravasation of blood into surrounding tissues are the
immediate reactions to injury. Then, vessel walls trigger the attachment and activation
of platelets forming aggregates.25 Simultanously, the plasma factors are activated mainly
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by the so-called extrinsic pathway ultimately generating fibrin strands, which bind ag-
gregated platelets to help form the platelet-fibrin hemostatic plug.15–18
Figure 1.1.2: The blood coagulation initiates by exposure of FVIIa from the
blood stream to tissue factor (TF) located on cell membranes within and around
the blood vessel injury. This leads to activation of FIX and FX.26–28
The extrinsic coagulation pathway is initiated by exposure of FVIIa from the circulating
blood to tissue factor (TF) located on cell membranes within and around the injury
(see Figure 1.1.2).27,28 The FVIIa-TF complex initiates the secondary hemostasis and a
highly regulated cascade of reactions takes place. These events are capable of amplifying
a small signal associated with a vessel injury into a major biological event, the formation
of a blood clot. FVIIa-TF then activates FIX and FX, and FXa binds to the site of injury
with FVa. The amplification phase is then started by conversion of small amounts of
prothrombin into thrombin triggered by the FXa-FVa complex.15–18 Thrombin activates
the generation of several activated coagulation factors; FVIIIa, FVa and FXIa and to the
further activation of platelets (see Figure 1.1.3).
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Figure 1.1.3: Amplification of the secondary hemostasis starts by formation of
small amounts of thrombin, which leads to generation of several activated coag-
ulation factors and activation of platelets.15–18,26
The activated platelets then activate FX, and the resulting complex ultimately activates
huge amounts of prothrombin generating a thrombin burst - a propagation of the bio-
logical event. Thrombin is the last enzyme in the coagulation cascade, and leads to con-
version of large amounts of fibrinogen into fibrin. Together with the activated platelets,
fibrin forms a hemostatic plug preventing the bleeding to proceed (see Figure 1.1.4).15–18
This plug is firm and well-structured and resistant to premature proteolysis and capable
of maintaining hemostasis until the wound healing process is established. A full thrombin
burst is necessary for the formation of a tight fibrin structure and for the activation of the
thrombin-activatable fibrinolytic inhibitor (TAFI), which protects the blood clot against
premature proteolysis.29,30
These processes are highly regulated by the hemostasis,25,31 involving several mecha-
nisms and plasma inhibitors, e.g. the heparin-antithrombin (AT) interaction,32,33 the
tissue factor pathway inhibitor (TFPI),34–36 thrombin-activatable fibrinolytic inhibitor
(TAFI),29 activated protein C,37 protein S35,36 and the fibrinolytic systems involving
plasmin.38 Antithrombin (AT) which is a serine protease inhibitor, is the best known due
to its important function in the indirect inhibition of thrombin.33 It degrades thrombin,
FIXa, FXa, FXIa and FXIIa and is constantly active. However, its adhesion to these
coagulation factors is greatly increased by the presence of heparin, which is a highly
sulfated glycosaminoglycan. Heparin is stored within the secretory granules of mast cells
and released only into the areas around the tissue injury. Ca2+ is another important
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regulator of the secondary hemostasis, because it is involved in the formation of the
FVIIa-TF complex and at many other points in the coagulation cascade.25 The coagula-
tion factors cannot bind to phospholipid surfaces without Ca2+ being present. Vitamin
K is also essential for the hemostasis, because it is responsible for the post-translatorial
γ-carboxylation of glutamic acid residues on thrombin, FVII, FIX, FX as well as on pro-
tein C and protein S.25 Vitamin K-deficiency can therefore lead to aquired hemophilia.
Figure 1.1.4: Propagation of the coagulation cascade takes place by forming a
complex consisting of activated platelets and several activated factors generating
huge amounts of thrombin. This enzyme catalyzes the conversion of fibrinogen to
fibrin, which forms the hemostatic plug.15–18,26
1.1.1.1 Hemophilia and treatment with NovoSeven R©
Although thrombophilia is a much more predominant disorder of the hemostasis, hemophilia
is still a severe abnormality which is identified as an impair of the ability of the body to
control blood coagulation. Around 400,000 males worldwide suffer from hemophilia.39
Symptoms can be prolonged bleedings, joint bleedings, bleeding in muscles and in sub-
cutanous tissues and, deep internal bleedings and intracranial bleedings and varing with
severity.39 Hemophilia is a group of recessive sex-linked, X-chromosome disorders, thus
only males typically exhibit symptoms. Females have two X-chromosomes and because
hemophilia is rare, the chance of a female having two defective copies of the gene is very
low. Females are almost exclusively asymptomatic carriers of the disorder.39
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Figure 1.1.5: Exogenous rFVIIa in pharmacological doses binds to the thrombin-
activated platelet surface with low affinity, requiring higher concentrations of the
blood coagulation factor than those normally found in circulating blood.26,29
Approximately 90% of the patients suffering from hemophilia have hemophilia A, which
is characterized by a deficiency of FVIII, whereas hemophilia B is a deficiency of FIX.29,30
Hemophilia causes the formation of loose, fragile fibrin plugs. These blood clots may
stop a bleeding initially, but are easily dissolved by proteolytic enzymes, which causes
rebleeding repeatedly. Since FVIII or FIX is lacking in the blood circulation, the full
thrombin burst does not occur upon FVIIa-TF activation of the coagulation cascade,
and the hemostatic plug becomes loose and unstructued. Moreover, TAFI is not fully
activated, which leads to premature proteolysis of the blood clot.29,30
The typical treatment of hemophilia A and B is a replacement therapy, providing the
patient with FVIII or FIX, respectively. However, approximately 20% of the patients have
developed inhibitors (antibodies) against these unfamiliar coagulation factors.29 An ef-
ficient treatment of those patients was therefore lacking until researchers found, that
hemophilia patients infused with FVIIa achieved hemostasis (see Figure 1.1.5).40 In the
late 1980s, Novo Nordisk developed a recombinant FVIIa (rFVIIa) for substitution ther-
apy of hemophilia complicated by inhibitors against FVIII and FIX, with only minimal risk
of transmission of infectious agents.41 The idea was to develop an easily available and
convenient treatment of those patients, decreasing the number of bleedings. Moreover,
major surgeries on was made possible.29 Clearance rate and the capacity to generate
thrombin on the platelet surface vary widely among individuals. Therefore, the optimal
dose is showing great variation in a wider population.40
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Pharmacological doses of rFVIIa have shown to provide hemostasis in patients with
severe hemophilia A and B. This was a breakthrough in the understanding of the im-
portance of FVIIa-TF for hemostasis.29 rFVIIa binds to the thrombin-activated platelet
surface with low affinity, requiring higher concentration of the coagulation factor than
those found normally in circulating blood (see Figure 1.1.5).29 The hemostatic effect of
exogenous rFVIIa thus seems to be mediated by an enhanced rate of thrombin genera-
tion, resulting in further activation of platelets at the site of injury and fibrin formation.29
Treatment with NovoSeven R© is very safe and no side-effects were observed in healthy
volunteers. The incidence of thrombotic events was extremely low, around 1.5% out of
11,000 patients.29 Almost all of the incidences occured in non-hemophilia patients with
underlying conditions predisposing them to thrombosis. Not all thromboses could be
attributed to rFVIIa, and all-cause mortality was 0.3%.41 No indication of the formation
of antibodies against rFVIIa has been observed in patients with hemophilia treated with
rFVIIa. However, FVII-deficient patients are at risk for development of antibodies against
FVII.42
1.1.1.2 Regulation of hemostasis indirectly
Many biologically active compounds have been synthesized to regulate the coagula-
tion cascade. The research has predominantly been focusing on inhibitors of thrombin.
Thrombin represents an excellent target for antithrombotic therapy, because this en-
zyme has an important position in the propagation of the coagulation cascade.32 It is
the final enzyme in the cascade and it is the most potent activator of platelets and their
aggregation, via the platelet thrombin receptor.43 The most widely used strategies to
prevent thrombosis is by inhibiting generation of thrombin indirectly, either via heparin-
like induced activation of AT or by antagonizing the vitamin K-regeneration affecting
the post-translatorial γ-carboxylation of glutamic acid residues on many coagulation fac-
tors.32
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Figure 1.1.6: Fondaparinux, a sulfated glycosaminoglycan, binds to AT with high
affinity resulting in an induced activity of AT. This primarily leads to a decreased
activation of FX.44
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The heparin-like induced activation of AT is typically maintained by low molecular weight
heparins (LMWH), e.g. tinzaparin, enoxaparin and fondaparinux which consists of the
specific sulfated glycosaminoglycan pentasaccharide known from heparin (see Figure
1.1.6). This sequence binds to AT with high affinity,45 and increases the inactivation
rate of the serine proteases.46 LMWHs are poorly absorbed when taken orally, thus
they have to be administrated parentally. Vitamin K-antagonists are on the other hand
orally available, such as warfarin or other coumarin derivatives (see Figure 1.1.7), which
are well-known anticoagulants, but they exhibit a slow on-set of action. The risk of
prolonged bleedings is the primary risk by using these anticoagulants which is thought to
be principally due to their lack of specificity toward numerous serine proteases involved
in the blood coagulation.47
O
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O
Warfarin                                Phenprocoumon
O
O
HO
Figure 1.1.7: Warfarin and the coumarin derivative phenprocoumon inhibit the
vitamin K-dependent synthesis of the biologically active forms of several coagula-
tion factors and regulatory factor proteins.48
Development of new serine proteases providing better selectivity, potency, pharmacoki-
netics and oral bioavailability has therefore been a major research topic for several
decades.47 Three-dimensional X-ray crystal structures of the key enzymes in the blood
coagulation cascade have aided the design of direct synthetic inhibitors.49–52 The major-
ity of the inhibitors have been designed for thrombin, whereas the work on the synthesis
of potent and selective inhibitors of FVIIa has been limited.47
1.1.2 Serine proteases and catalytical mechanism
Most of the blood coagulation factors are serine proteases,18,53 except for a few such
as FV and FVIII, which are non-enzymatic glycoproteins. Serine proteases are a group
of enzymes that cleave peptide bonds in proteins and they have a characteristic serine
in the active site. Closely related enzymes are cysteine and threonine proteases. In
mammals, serine proteases evolved by gene duplication to serve functions for example in
blood coagulation, digestion, immune system and inflammation. The amide bond clea-
vage happens indirectly by involvement of a catalytic triad consisting of Ser195, His57
and Asp102 (chymotrypsin numbering).54,55
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The catalytic mechanism is initiated by a nucleophilic attack from the residue of Ser195,
which is facilitated by hydrogen bonding to His57 (see Figure 1.1.9). The resulting
tetrahedral intermediate56 is stabilized by an oxyanion hole formed by the backbone of
Ser195 and Gly193.54,55 Elimination of the amine product occurs by flip of His57,57 pro-
ton donation and formation of an acyl-enzyme complex.58 Water occupies the vacant
S1’ binding pocket, adds to the acyl enzyme complex and generates a carboxylic acid by
elimination through another tetrahedral intermediate56 and His57 ring flip57 (not shown
on Figure 1.1.9).
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Figure 1.1.8: Nomenclature of the active site of a serine protease.59 Pn des-
ignate amino acid residues of the peptide substrate, whereas Sn designate the
corresponding binding sites. The scissile bond is P1–P1’.
The specificity of serine proteases arises from the binding pockets (sites) (Sn) positioned
on both sides of the scissile bond. Each of these substrate binding pockets are able to
accommodate complementary specific amino acid residues (Pn) (see Figure 1.1.8).59
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Figure 1.1.9: The catalytic mechanism of a serine protease initiates by formation
of an enzyme-substrate complex. Through a tetrahedral intermediate the amine
product is eliminated first, then, after addition of water to an acyl-enzyme complex,
the carboxylic acid product is also eliminated.54,55
1.1.3 Inhibitors of serine proteases
Enzyme inhibitors can be classified as competitive or non-competitive as well as reversible
or irreversible.60 Competitive inhibitors bind to the active site of the enzyme, whereas
non-competitive inhibitors bind to other sites thus resulting in an allosteric regulation of
the enzyme leading to conformational changes.60
Competitive inhibitors of serine proteases strongly resemble the natural substrate and
therefore the compounds compete with each other for binding to the active site. Re-
versible inhibitors can bind to the active site covalently or non-covalently, however ir-
reversible inhibitors of serine proteases always bind covalently. Reversible, covalently
bound inhibitors react with Ser195 in the active site, thus forming a covalent bond.54
Irreversible inhibitors also alkylate His57 by elimination of a good leaving group from
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Figure 1.1.10: Binding of a competitive reversible inhibitor to a serine protease.
The R-group is the rest of the inhibitor molecule which is embedded non-covalently
to the binding pockets of the enzyme.54 The trifluoro ketone inhibitor illustrated
here is a reversible inhibitor because -CF3 and -F are poor leaving groups.
the inhibitor molecule. In the absence of such a leaving group, the inhibitor becomes
reversible in nature (see Figure 1.1.10).
In general, molecules containing a neutral electrophilic group (serine trap) in the P1–P1’
position such as a boronic acid, a trifluoromethyl ketone, an aldehyde, an α-keto car-
boxylate or an α-keto heterocycle, are potential inhibitors of serine proteases (see Figure
1.1.11). Several reviews on synthetic and natural inhibitors containing one of these
functionalities exist in the literature.61,62
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B OH
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R CF3
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O
N
XR H
O
AldehydesTrifluoromethyl-
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α-Keto
carboxylates
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heterocycles
Figure 1.1.11: Molecules containing an electrophilic functionality (serine trap)
in the P1–P1’ position such as boronic acids, trifluoromethyl ketones, activated
ketones and aldehydes are potential competitive, reversible inhibitors of serine
proteases.54
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As shown in Figure 1.1.10, Ser195 forms a covalent bond with the inhibitor generating
a hemiacetal. The resulting negative charge is stabilized by the oxyanion hole, whereas
the positive charge on His57 is stabilized by Asp102 making the process favorable.54
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Figure 1.1.12: Chloromethyl ketones (cmk) are well-known irreversible inhibitors
of serine proteases. After formation of a hemiacetal with Ser195, His57 is forming
a covalent bond with the inhibitor molecule, either directly63 or through formation
of an epoxide.64 The alkylation of His57 is an irreversible reaction.
The inhibitory process is quite similar for the irreversible protease inhibitors (see Figure
1.1.12). It is the nucleophilic and the basic residues of the catalytic triad which are
targeted by these compounds.54,65 One of the most classical active site-directed irre-
versible inhibitors of serine proteases is the peptidyl chloromethyl ketones (cmk).65–67
These compounds alkylate His57 in the active site thus providing the irreversible nature.
Due to the inherent unreactivity of carbon-fluorine bonds, peptide fluoromethyl ketones
are reversible inhibitors of serine proteases (c.f. Figure 1.1.10).65 Chloromethyl ketones
are believed to inhibit the serine proteases by first forming a hemiacetal with Ser195,
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and then either a direct substitution takes place forming a covalent bond with His5763
or an indirect substitution through the formation of an epoxide.64
Chloromethyl ketones (cmk) are potent alkylating agents and absolute specificity with
a particular protease would be difficult to achieve.65 Because of their potential toxicity
that results from non-selective alkylation of cellular nucleophiles, peptidyl chloromethyl
ketones have very little biological utility. However, they have been used as tools in vivo to
identify whether a particular serine protease inhibitor might have a therapeutic effect on
a disease state or in animal models.65 Other potential irreversible inhibitors of serine pro-
teases are compounds containing e.g. carbamate esters,68–72 O-acylhydroxylamines,73–79
β-lactams,80 isocoumarins,81–83 benzoxazin-4-ones,84,85 saccharins,86,87 sulfonyl fluo-
rides88 and many other functionalities that are more specific toward cysteine proteases.65
1.1.3.1 Thrombin inhibitors
Because of the important role in the blood coagulation cascade, many inhibitors of
thrombin have been developed. In general, these inhibitors have been designed as struc-
tural variations of the P4–P1’ positions as peptides or peptidomimetics. Using pep-
tidomimetics has the goal to diminish as much as possible of their peptidic character
in order to avoid in vivo hydrolysis and improve bioavailability, e.g. by substituting the
basic arginine with a less basic surrogate,55 or by converting the amidine group into a
prodrug, e.g. an alkoxy-amidine, a carbamate89,90 or a N,N’-dihydroxyamidine,91 which
will reduce basicity and polarity and hence improve the pharmacokinetics.
O
H
H
N
NH
H2N NH
O
N
O
HN
Me
1.2
Ki = 16 nM (thr), 32 nM (trp)
O
H
H
N
NH
H2N NH
O
N
O
HN
Me
Me
1.3
IC50 = 1.0 µM (thr), 240 µM (trp)
Figure 1.1.13: Tripeptide aldehydes, such as 1.292 and 1.393 with the gen-
eral D-Phe-Pro-Arg structure were among the first synthetic reversible thrombin
inhibitors.
Decades ago it was discovered that leupeptins are reversible inhibitors of serine proteases.
Leupeptins are C -terminal aldehydes with an acetylated or propionylated N-terminal, e.g.
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Ac-Leu-Leu-DL-Arg-H and analogs in which Leu is replaced with Val or Ile.94 These com-
pounds are produced by various species of actinoycete bacterias.95 Later on, it was found
that H-D-Phe-Pro-Arg-cmk was a selective affinity label for thrombin96 and inspired by
these results, Bajusz et al. reported that N-Me-D-Phe-Pro-Arg-H (1.2) is a highly ac-
tive, reversible inhibitor of thrombin,97 however not selective against trypsin (trp)92 (see
Figure 1.1.13). Introducing an α-methyl group at the P1 position resulted in 1.3, which
showed a decreased potency against thrombin, but on the other hand exhibited an im-
proved selectivity against trypsin and other related serine protases such as plasmin and
FXa.93 This clearly illustrates the challenge in designing protease inhibitors; potency and
selectivity are indeed not always optimized at the same time.
The potency of the peptidyl sequence in 1.2 was improved by substituting the alde-
hyde C -terminal functionality with a trifluoromethyl group, which gave Ki < 1 nM
against thrombin.98 Apparently, the aldehyde carbonyl is less electrophilic than the tri-
fluoromethyl ketone carbonyl. One of the most potent synthetic peptidyl thrombin
inhibitor is the H-D-Phe-Pro-boroArg-OH with Ki = 41 pM.
99 Specificity for the S1
binding pocket was examined with different P1 residues, such as ornithine, lysine and
homolysine but none of them were superior to the arginine derivative.100 However, po-
tencies in the nanomolar range were still observed.
OH
N
NH
H2N NH
O
N
O
HN
Me
1.4
Ki = 0.19 nM (thr), 3.1 nM (trp)
S
N
OH
N
O
N
O
HN
NH2
O
O
HO O
1.5
Ki = 1.1 nM (thr)
Figure 1.1.14: Examples of other reversible thrombin inhibitors; 1.4101 which is
a 2-benzothiazole and 1.5102 which is an α-keto isopropyl carboxylate derivative
both demonstrating high potencies.
Synthesis of peptidyl α-ketobenzoxazoles by Strimpler and co-workers in 1992 was the
first example of a carbonyl activated by a heterocycle; Ac-Val-Pro-Val-(2-benzoxazole)
as an inhibitor of elastase. Furthermore, it was the first example of an inhibitor designed
to interact with both Ser195 and non-covalently with His57 in the active site.103 From
the X-ray structure it was found that nitrogen from the benzoxazole group interacted
with the protonated His57. These prior results were used for development of potent
thrombin inhibitors proping the binding pocket near S1’ as a novel interaction site with
thrombin.97 The best inhibitor was found to be N-Me-D-Phe-Pro-Arg-(2-benzothiazole)
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(1.4) with Ki = 0.19 nM (see Figure 1.1.14).
101
A variety of different heterocycles were tested, among others 2-thiazole, 2-benzoxazole,
2-pyridine and N-Me-2-imidazole, but none of them were as potent as 1.4. Once again,
selectivity for trypsin was poor. It seems to be a general property of inhibitors with the
D-Phe-Pro-Arg motif.101 However, the heterocycle was shown to exhibit key interactions
near and in the S1’ region of the active site of thrombin. The benzothiazole ring forms
a hydrogen bond with His57 and an aromatic stacking interaction with a tryptophan
residue originating from the unique insertion loop of thrombin.101 An in-depth study of
this class of thrombin inhibitors utilizing the S1’ binding pocket has been reported.104
The study revealed that the preferred α-ketoheterocycle was a pi-rich 2-substituted azole
with at least two heteroatoms proximal to the carbon bearing the keto group. The
2-benzothiazole was unfortunately found to cause hypertension and electrocardiogram
abnormalities in animals.104 Therefore, a 2-benzothiazole-6-carboxylic acid derivative of
1.4 was developed showing a much better therapeutic profile. The carboxylic acid was
found to form a salt bridge with Lys192.104
In the search for orally available thrombin inhibitors, it was found that the α-keto acid
H-D-Phe-Pro-Lys-COCOOH was potent with Ki = 1.4 nM.
102 Through lead optimiza-
tion Adang et al. discovered 1.5 (see Figure 1.1.14) as another potent inhibitor of
thrombin (Ki = 1.1 nM) with imporved pharmacokinetics, such as increased half-life
and bioavailability.102
To elucidate whether a high potency is a result of electron withdrawing effects giving
a electrophilic carbonyl or enhanced hydrophobic interactions in the S1’ region with
the aromatic moiety, Steinmetzer and Konishi performed a small comparative study.105
Three different thrombin inhibitors with the general structure H-D-Cha-Pro-Arg were
tested; a peptidyl pyridinium methyl ketone 1.6 containing a strongly electron deficient
carbonyl and a hydrophobic moeity in the P1’ region, a peptidyl benzyl ketone 1.7 con-
taining only the hydrophobic moiety and a peptidyl methyl ketone 1.8 containing neither
of the properties (see Figure 1.1.15).
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Figure 1.1.15: Comparative study of H-D-Cha-Pro-Arg thrombin inhibitors re-
vealed that both electronic withdrawing effects and hydrophobicity was important
for high potency against thrombin.105
The results clearly indicated that the high potency is based on both electron withdraw-
ing and hydrophobic effects.105 Compared to the peptidyl pyridinium methyl ketone 1.6,
the benzyl ketone inhibitor 1.7 lacking the permanent positive charge, had a ten-fold
reduced inhibitory activity. However, 1.7 is still a potent thrombin inhibitor. A much
more pronounced decrease in activity was observed with the peptidyl methyl ketone 1.8,
which had a Ki = 60 nM.
105 It seems that hydrophobic interactions with the P1’ moiety
are of greater importance than the electrophilicity of the carbonyl group.105
The tripeptide scaffold has accounted for many other thrombin inhibitors, containing
electrophilic serine traps such as α-hydroxy and α-ketoesters,106 amide and α-keto
carbonyls,107 phosphonic acid esters108 and β-lactams.109,110 Moreover, ketomethylene
pseudopeptides111 and macrocyclic peptides, e.g. cyclotheonamide A (1.9)112,113 (see
Figure 1.1.16), have been found to be potent inhibitors of thrombin.
To improve the selectivity and other pharmacokinetic properties, many small molecules
have been synthesized lacking the electrophilic serine trap.55 These molecules inhibit
thrombin in a non-covalent manner thus decreasing in activity. With careful structure-
activity relationship studies and lead optimization potent inhibitors have been designed,
e.g. the morpholinone-based benzamidine analog 1.10,114 the heterocyclic arginine
mimetic 1.11,115,116 the Cbz-protected non-basic sulfonyl-O-methylisourea 1.12117 (see
Figure 1.1.16) and many others.53,55,118–120
Despite the immense numbers of thrombin inhibitors reported in the literature, the de-
velopment of new compounds is still ongoing today.121,122 Unfortunately, very few of
the inhibitors possess all of the required properties regarding potency, selectivity and
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Figure 1.1.16: A variety of different thrombin inhibitors; Cyclotheonamide A
(1.9)112,113 and three non-covalent binding peptidomimetics 1.10–1.12.114–117
The latter shows enhanced bioavailability due to the less basic arginine-mimetic
functionality.
pharmacokinetic properties to be used as an antithrombotic agent.
As of 2009, several direct inhibitors of thrombin (thr) and FXa are in clinical trials,123
including compounds from pharmaceutical companies such as AstraZeneca, Lilly, Bristol-
Myers Squibb and Sanofi-Aventis. Only a few serine protease inhibitors have entered
the market, one of them is argatroban (see Figure 1.1.17), which is an inhibitor of
thrombin,124,125 administrated parenterally and used as an anticoagulant.120
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Figure 1.1.17: Argotroban is one of the few serine protease inhibitors on the
market.120 It is a potent reversible thrombin inhibitor with Ki = 39 nM,
124,125
but with low bioavailability and thus has to be administrated parenterally.
1.1.3.2 Structural distinctiveness of FVIIa
In the circulating blood FVII exists as a zymogen consisting of an amino-terminal γ-
carboxy glutamic acid-rich (Gla) domain, followed by two epidermal growth factor (EGF)-
like domains, a shorter linker peptide and a carboxy-terminal serine protease domain.51
The active enzyme, FVIIa, is generated by specific cleavage of the peptide bond between
Arg15 and Ile16 at the end of the linker peptide, giving a N-terminal light chain of 152
residues and a heavy chain of 254 residues linked by a disulphide bridge. FVIIa does only
reach its full enzymatic potential when complexed to TF in the presence of Ca2+ ions.51
The catalytic domain and the EGF2-domain are shown in Figure 1.1.18.
Although the serine proteases have a highly homologous three-dimensional structure127
and the catalytic domain of FVIIa has a core structure common within the throm-
bin/trypsin family,51 they display significant differences in specificity and catalytic ac-
tivity. A number of surface loops defines the nature and extent of the hydrophobic
substrate/inhibitor binding pockets because of the varying lenghts and compositions of
the loops.127 These differences result primarily in different S3 and S2 binding pock-
ets. Contrarily, the S1 pocket is very similar among the serine proteases such as FVIIa,
thrombin and FXa. However Ser190 positioned in S1 is unique for FVIIa.128 In addition,
FVIIa contains a unique primary structure; the 170-loop which has five extra amino acid
residues compared to related proteases. This loop is close to the TF-contacting surfaces
and is important for the FVIIa interaction with TF.127
Comparing the S3 and S2 binding pockets of FVIIa with thrombin and FXa reveals
several differences. First of all, FVIIa has a relatively large, hydrophilic and negatively
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Figure 1.1.18: The catalytic domain (blue) and the EGF2-domain (grey) of
FVIIa complexed with benzamidine. Sulphate groups and glycerol moieties are
also shown (ball and sticks) as well as Ca2+ ions (green).126
charged S2 pocket due to the unique presence of Asp60.129 Secondly, the S3 pocket is
small consisting of several amino acids including Gln217130 and thirdly, the unique 170-
loop is just long enough to interfere with substrate binding in S3.51 Contrarily, thrombin
has a hydrophobic S2 with bulky substituents,131–133 and a large and hydrophobic S3
pocket.132 Utilizing the unique structural features of FVIIa would be advantageous in
gaining selectivity against other serine proteases.130 Selectivity could be introduced by
inhibitors interacting with Asp60, Ser190, Lys192, Gln217, the 170-loop,130 but also by
varying the sizes of P3 and P2 residues, e.g. introducing a small group at the P3 position.
Structure-based inhibitor design to achieve potent and selective inhibitors of FVIIa-TF
was initiated by X-ray crystal structures of FVIIa-TF complexed with different inhibitors.
Structure determination of FVIIa-TF was pioneered by Banner et al. in 1996 reporting
the X-ray structure of FVIIa-TF in complex with H-D-Phe-Phe-Arg-cmk.51 Besides of
structure-based design, new FVIIa inhibitors have been designed from high throughput
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screening (HTS) results,134 or as analogs from thrombin/FXa inhibitor libraries.135,136
1.1.3.3 FVIIa inhibitors
Development of specific FVIIa inhibitors became an interesting field of research, when
problems with inhibition of the late-stage coagulation enzymes were discovered, e.g. in-
hibition of thrombin or FXa. One of the major problems with direct thrombin inhibitors
as anticoagulants is prolonged bleedings. Inhibition of the coagulation cascade at its
initial stage by inhibition of FVIIa-TF was found to be an alternative and promising
approach for the development of new anticoagulants. This observation was confirmed
by several animal models.137–141 However, inhibiting FVIIa to gain anticoagulation is on
the other hand challenging, because only minor amounts of this enzyme is required for
initiation of the blood coagulation cascade.
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Figure 1.1.19: A variety of small molecule reversible FVIIa inhibitors; 1.13 is
a pyridine analog of a 2-aryl substituted hetero annullated 1,3-oxazin-4-one,135
1.14 is a 2-substituted 5-amidinobenzoindole142 and 1.15 is a phenylglycine ana-
log.143,144 FX act.: Inhibitory effect against FVIIa measured indirectly as degree
of FX activation.
The number of reported FVIIa-TF inhibitors is rather limited, compared to the number
of thrombin inhibitors. The vast majority of the reported inhibitors are small molecules
that do not covalently bind to the active site. These compounds show superior pharma-
cokinetics, such as improved half-life and bioavailablity. Some of the first FVIIa inhibitors
were reported 10 years ago by Novo Nordisk135,145 (e.g. 1.13, see Figure 1.1.19), No-
vartis Pharmaceuticals134 and Ono Pharmaceuticals.146
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Among the FVIIa small molecule inhibitors, compound classes such as amidinonaph-
thols,134 2-aryl substituted hetero anullated 1,3-oxazin-4-ones (e.g. the pyridine analog
1.13),135 indolizidinones,147 dysinosin A (aeruginosins),148,149 pyrazinones,150–153 ami-
dophenylureas,154 2-pyridones,155,156 2-substituted 5-amidinobenzoindoles (e.g. 1.14),142,157
fluorobenzenes,158 benzoquinones,158 2-substituted-4-amidinophenylpyrivic acids,136 flu-
oropyridines,159 phenylglycines (e.g. 1.15),143,144 non-amidine leucine amides,160 5-
aminopyrrolo[3,2-b]pyridines,161 1,5-benzothiazepine-4-ones,162 benzoimidazole succinic
acids163 and biphenyls129,157 have been reported. Genereally, FVIIa inhibitors incorporate
a basic P1 guanidino, amidino or amino group which interacts with Asp189 in the S1
binding pocket.
Recently, Ayral et al.162 reported the design and synthesis of 1,5-benzothiazepine-4-ones
with a benzyl sulfonyl P3 residue as FVIIa-TF inhibitors. They found that 1.16 was the
best inhibitor with a IC50 = 2.16 µM against FVIIa-TF, but with poor selectivity against
thrombin (see Figure 1.1.20). Four different P3 residues were explored; succinyl (81.0
µM), acetyl (90.0 µM), HOOC-CH2- (15.9 µM) and Ph2CHCO- (33.0 µM), but all
of them gave lower potencies (IC50-values stated in brackets).
162 X-ray crystallography
revealed that the benzylsulfonyl group in 1.16 pointed outside S3 and was close to S4,
making a hydrophobic interaction with the side-chain of Gln217.162
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Figure 1.1.20: The 1,5-benzothiazepine-4-one 1.16 was found to be the best
inhibitor in the group of 1,5-benzothiazepine-4-ones designed and synthesized by
Ayral et al.,162 whereas Parlow and co-workers found that the N-isopropyl deriva-
tive 1.17 was the best inhibitor among a variety of pyrazinones.151
The Parlow group has also explored alternative N-terminal-like modifications. For the
synthesis of pyrazinones as FVIIa inhibitors,151 it was found that the N-isopropyl deriva-
tive 1.17 was the best, whereas PhCH2CH2- (0.62 µM), which resembles the benzylsul-
fonyl hydrophobic part, had a decreased potency against FVIIa.151
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Shiraishi et al.130 reported in 2009 a range of peptidomimetics with a glutamine moeity
at P2, a D-tryptophan moeity at P3 and a N-terminal sulfonyl functionality at P4. This
resulted in a series of potent FVIIa inhibitors 1.18–1.20 (see Figure 1.1.21). Three
different P4 substituents were tested; the benzyl sulfonyl 1.18, the meta-carboxyl ben-
zyl sulfonyl 1.19 and the carboxyl methyl sulfonyl 1.20, and all of them were potent
FVIIa inhibitors with 1.19 beeing the best. Compared to the benzyl sulfonyl 1.18, 1.19
showed an increased selectivity against thrombin, but decreased selectivity against FXa.
The most selective inhibitor was the carboxyl methyl sulfonyl 1.20, which on the other
hand showed less potency against FVIIa.130
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Figure 1.1.21: Potent peptidomimetic inhibitors of FVIIa exploring different N-
sulfonylation terminals and the binding mode of the best inhibitor.130
A crystal structure of FVIIa-TF bound to 1.20 shows the typical binding modes in S1
forming a salt bridge with Asp189 (see Figure 1.1.21). Moreover, the P2 glutamine
probed the S2 binding pocket with unique hydrogen bonds to Thr98, Tyr94 and Asp60.
P3 D-tryptophan occupies the S3 site and has large contact areas with Gln217 and the
unique 170-loop residues. The sulfonyl group forms a long-distance (4.2 A˚) ionic interac-
tion with Lys192 in the sub site of the S1 binding pocket. Lys192 is not conserved among
the proteases, and only FVIIa and FXIa have Lys192 at this position.130 The carboxyl
methyl substituent in 1.20 extends to the direction of the S4 site, but it does not reach
it (not shown in Figure 1.1.21). In the case of the presence of a benzyl sulfonyl group,
van der Waals contracts with a number of amino acids in the subsite of the S1 binding
pocket exists, and by introduction of the meta-carboxylic acid ionic interactions were
observed with Lys192.164 Lys192 has also been reported making favorable interactions
in the S1’ pocket with a 2-hydroxyphenyl P1’ substituent.157 The sudden occupancy of
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Lys192 near the oxyanion hole relays on a 180o-rotation, which is unique for FVIIa and
is due to hydrogen bonding to Gln143.157 Probing S1’ is thus another way to develop
selective and potent inhibitors.
One of the surprises reported by Shiraishi et al. was the discovery of an increased se-
lectivity against thrombin and FXa when increasing the size of P3, e.g. going from
phenylalanine to biphenyl increased selectivity significantly.130 From X-ray crystal struc-
tures it was found that only FVIIa is capable of accepting large P3 moieties, as a result
of ligand-induced conformational changes of the 170-loop. This has not been observed
previously. Even though FVIIa has an apparently smaller S3 than thrombin and FXa,
this binding pocket surprisingly accepts larger groups than other serine proteases due to
conformational changes.130
Only a few reports exist on the design and synthesis of peptidyl FVIIa inhibitors. Parlow
and co-workers have pioneered the work on developing inhibitors for FVIIa and in addi-
tion they have been working on α-ketothiazole peptidyl libraries using a D-Phe-AA-Arg
scaffold.165,166 This resulted in a range of low-micromolar FVIIa inhibitors proping S2
with different P2 substituents (see Figure 1.1.22).
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Figure 1.1.22: α-Ketothiazole peptidyl FVIIa inhibitors proping the S2 binding
site with a variety of different P2 substituents.165,166
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Many compounds were synthesized probing S2 and the best one was 1.23 showing
good potency for FVIIa and a selectivity factor of 500 against thrombin (see Figure
1.1.22). However, no selectivity at all was observed against FXa. Several carbonyl-
reduced compounds were tested for biological activity, and as expected none of them
inhibited FVIIa-TF.165,166 An X-ray crystal structure of 1.23 revealed the binding mode
of this inhibitor in the active site of FVIIa (see Figures 1.1.23 and 1.1.24).
Figure 1.1.23: Crystal structure of 1.23 bound in the active site of FVIIa-TF
complex. Some of the key side chains of FVIIa are displayed (C: green, N: dark
blue, O: red, S: yellow, H: orange). The carbon atoms of the inhibitor are shown
in gold color. The hydrogen bonds formed by the inhibitor and a bound water
molecule in the S2 binding pocket are shown in dotted white lines. The close
interaction between the bound solvent and the pyridyl nitrogen is shown in the
dotted green line.166
25
Project introduction
N
H
H
N
NH
NH2H2N
O
O
N
OO
Asp189
HO
Ser190
O
NH
Gly219
O
NH
NHGly193
Ser195
NH
NH His57
O
O Asp102
NH
Gly216
HO
H
O
O Asp60
OH
Tyr94
NHGly97
HN
S O
O
S3
O
HN
Thr98
S4
S1
O
NS
S2
Figure 1.1.24: Binding mode of 1.23 determined by X-ray crystallography of
FVIIa complexed with the inhibitor.165,166
The P1 arginine residue forms the usual salt bridge with Asp189. The Ser195 side-chain
forms a covalent bond to the activated carbon of the inhibitor.165,166 The resulting oxyan-
ion is stabilized in the oxyanion hole by the backbones of Ser195 and Gly193. Moreover,
P1 forms two additional hydrogen bonds with the backbone of Gly219 and the Ser190.
Ser190 is a unique feature of the S1 binding pocket of FVIIa, versus Ala190 in thrombin
and FXa.128 The thiazole ring interacts with the side-chain of His57. Binding in the
S2 pocket with the unique Asp60 is achieved through multiple hydrogen bonds with
water, whereas no specific bindings in the S3 pocket were observed.165,166 The sulfonyl
N-terminal forms a hydrogen bond with Gly219, which is located deep in the subsite
of S1. From these results it seems that the benzyl sulfonyl group is occupying the S3
pocket rather than the S4 pocket. However, no specific binding with this group was
observed from the X-ray crystal structure of FVIIa-TF complexed with 1.23.165,166
1.1.4 Activity-based inhibitor design
A design and rational development of selective peptidyl protease inhibitors can be estab-
lished using activity-based methods based on positional scanning, synthetic combinatorial
libraries (PS-SCL).167 The primary function of proteases is to discriminate among the
many possible substrates available to it and to cleave specific proteins or peptides. The
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understanding of the specificity and identification of the substates of the enzyme is there-
fore of great importance, which might also be used for design of protease inhibtitors.167
Since each binding pocket imparts its own specificity for an amino acid, the PS-SCL
activity-based approach is to screen a protease against a synthetic combinatorial library
composed of small molecules, in a format that systematically probes each binding pocket
and collectively generates a positional profile based on ACC-linked peptides.167
Figure 1.1.25: The specificity profile of FVIIa-TF. In each library, the apparent
second-order rate constant of the substrate hydrolysis were normalized to the
sublibrary with the highest activity. Single-letter amino acid notation is used.168
The typical PS-SCL is targeted against the non-prime side of the protease and is designed
as a series of diverse sublibraries where one amino acid in a tetrapeptide is fixed and the
remaining positions are a randomized mixture of amino acids.167 One aspect that such
libraries do not always fully address is the potential interdependence between the different
binding pockets. Only one substrate-binding pocket is profiled at a time and therefore
no steric considerations or interdependency between the pockets are investigated.168
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PS-SCL has been used for design of a novel hexapeptide diphenylphosphonate inhibitor
of Kaposi’s sarcoma-associated herpes virus protease,169,170 but never for designing of
a specific serine protease inhibitor. However, a PS-SCL specificity profiling has been
reported for FVIIa by researchers at Novo Nordisk (see Figure 1.1.25).168 As expected,
FVIIa only accepts arginine and lysine residues in the S1 pocket, with arginine being
favored three-fold over lysine.168 In the S2 pocket, β-branched or hydrophobic amino
acids were allowed, with threonine > leucine > phenylalanine > valine being the pre-
ferred residues, whereas in the P3 position, large aromatic residues such as Phe, tyrosine
and tryptophan were preferred.
The S4 pocket appeared to be highly promiscuous, although a slight preference for tryp-
tophan was detected (see Figure 1.1.25). An identical specificity profile of FVIIa was
obtained in the absence of TF, indicating that the cofactor did not alter the substrate
specificity of FVIIa.168 The most specific sequence was determined to be Trp-Tyr-Thr-
Arg, which was subsequently crystallized with rFVIIa-TF as H-Trp-Tyr-Thr-Arg-cmk
(see Figure 1.1.26). Of particular interest is the binding mode in S2 where the threonine
residue was positioned adjunct to the catalytic triad with a distance of 3.4 A˚ to His57.
This was the closest contact to any residue in the S2 pocket. Furthermore, the residue
was within hydrogen-bonding distance with two water molecules and could be part of a
hydrogen-bonding network of the S2 pocket involving the para-positioned hydroxy group
of Tyr94, the carboxylate group of Asp60, the carbonyl of Thr98 and amides of both
Gly97 and Thr98.168 The P3 tyrosine residue interacted with the 170-loop including both
a hydrogen bond and with hydrophobic interactions. The carbonyl group of the tyrosine
residue hydrogen bonds with the amide group of Gly216 as well as with a water molecule.
Thus, the preference for tyrosine, even compared with phenylalanine and tryptophan, is
reflected by the extra hydrogen-bond donor of the side-chain, which leads to the more
stabilized pocket as observed for the 170-loop.168
From modeling studies, the P4 tryptophan was expected to make favorable pi-pi interac-
tions with Trp215 in the bottom of the putative S4 pocket. However, the residue had
no electron density corresponding to the P4 tryptophan, indicating that there is not a
well-defined S4 binding pocket in FVIIa, despite the clear preference observed within the
PS-SCL’s.168 This is to some extent supported by the structure as well as the fact that
the natural substrate for FVIIa is the Asn*-Leu-Thr-Arg↓Ile-Val-Gly-Gly site of FX (*
indicates that the amino acid is glycosylated amino acid).168 The specificity profile of
FVIIa clearly shows that this enzyme is not a very discriminative protease with a low
degree of active-site specificity.
To elucidate any interdependency between the S4–S1 binding pockets, FVIIa was assayed
with a total of 23 different ACC-linked tetrapeptides having arginine in P1, threonine or
leucine in P2, tryptophan, tyrosine, leucine or alanine in P3 and tryptophan, phenylala-
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Figure 1.1.26: Crystal structure of FVIIa-sTF and Trp-Tyr-Thr-Arg-cmk ob-
tained at a 2.05 A˚ resolution. Specific interactions between the selected active-
site residues and the covalently bound inhibitor are highlighted. The S1, S2 and
S3 compositions are shown with brackets, and residue identification are with chy-
motrypsin numbering.168
nine or asparagine in P4.168 These substrates were selected partly to address different
levels of activity based on the specificity profile and partly to explore the space around
the natural FX cleavage site Asn*-Leu-Thr-Arg↓Ile-Val-Gly-Gly.168 It was found, that S3
selectivity is probably driven or influenced by P4 occupancy, because P4 substitution of
asparagine to tryptophan or phenylalanine is very different for substrates with different
P3 residues, whereas minor differences were observed between similar substrates with
leucine or threonine in P2. The optimal binding pocket occupancy does therefore not
translate into one optimal substrate.
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1.2 Aim of the thesis
The aim of this PhD thesis (Chapter 1–4) is to synthesize a range of reversible FVIIa
inhibitors. The ultimate inhibitor is water soluble with high selectivity against FVIIa and
with medium to high potency (low micromolar to nanomolar). It should be non-toxic
in vivo, possess a high plasma clearance and finally be able to stabilize rFVIIa in a liq-
uid formulation of NovoSeven R© for storage at room temperature for at least 36 months.
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P2O
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H2N NH
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S3
S4
S1
S1'
Serine trap
N
H
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H
NHN
O
Pg1
Pg2
R'
Arginyl benzyl ketone
building block
Target FVIIa inhibitor
Figure 1.2.1: The target peptidyl FVIIa inhibitors consists of a tripeptide se-
quence with a benzyl ketone serine trap, which potentially also probes the S1’
pocket. Such inhibitors are projected to be synthesized from the arginyl benzyl
ketone building block shown to the right.
A peptidyl inhibitor scaffold was chosen (see Figure 1.2.1), partly because sequence al-
ternation is much easier done to explore the SAR, partly because a peptide much better
resembles the natural substrate of FVIIa and finally because peptides usually show lower
toxicity than small molecules as they degrades into natural building blocks. Bioavailabil-
ity is not a concern for those target molecules. Ideally, they should only inhibit FVIIa
in the formulation and not in the body. Synthesis of novel peptidyl FVIIa inhibitors is
furthermore of great interest due to the almost absence of this class of selective serine
protease inhibitors in the literature.
Design of reversible and selective FVIIa inhibitors is based on two strategies; first of
all, introduction of an electrophilic functionality (serine trap) in the P1–P1’ position (C -
terminal). Many serine traps have been reported for thrombin and other serine proteases,
but the benzyl ketone C -terminal functionality is almost completely unexplored for any
of these proteases. As well as the interesting exploration of this unknown serine trap, it
could be a way for the introduction of functional groups probing the S1’ binding pocket
of FVIIa. Favorable interactions of the P1’ residue might induce increased selectivity and
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potency. Secondly, selection of the peptide sequence will be based on a specificity profile
for FVIIa.168 Such a strategy has not previously been utilized for design of selective blood
coagulation serine inhibitors. Based on the FVIIa specificity profile a tripeptide sequence
will be considered, because the S4 binding pocket seems to be rather undefined.168 An
arginine residue has to be chosen at the P1 position exclusively, because the S1 binding
pocket has a 3-fold selectivity for arginine over lysine, but does not accept any other
amino acid residue there.168 Finally, different N-terminals will be explored inspired by the
literature, which has demonstrated some interactions with subsites of S1 or interactions
reaching the putative S4 binding pocket.
For appropriate functionalization of the arginyl benzyl ketone C -terminal building block,
two new synthetic methodologies will be investigated utilizing mild reaction conditions
(see Chapter 2). The target building block synthesis is projected to employ cheap and
commercially available starting materials. Furthermore, all transformations should be
easy and robust, preferable with catalytic rather than stoichiometric reagents not lead-
ing to any significant racemization.
When an appropriate building block synthesis is established a library consisting of the
novel peptidyl benzyl ketone inhibitors will be synthesized (see Chapter 3). To elucidate
the potency and selectivity of the peptides, several in vitro competitive binding assays will
be run for a variety of blood coagulation serine proteases. Based on potency, selectivity
and solubility in aqueous media, the peptides will be evaluated for potential usage as a
stabilization agent for liquid formulations of FVIIa. However, development of new FVIIa
formulations as well as long-term studies of the enzyme stability are beyond the scope
of this project.
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Chapter 2
Building block synthesis via
palladium-catalyzed α-arylation
The aim of this chapter of the thesis is to describe novel methods toward the synthesis
of the arginyl benzyl ketone building block. These methods should utilize mild reaction
conditions providing a high functional group tolerance, they should be easy to perform
and use commercially available starting materials only. These improvements would first
of all allow the introduction of a variety of functional groups at the benzyl group for
probing the S1’ pocket of FVIIa. Such an approach is almost absent in the literature
and would provide valuable information about the FVIIa pharmacophore and potentially
improve selectivity and potency of the synthesized inhibitors. Furthermore, development
of mild reactions would be an advantage for industrial scale-up and production, which
is of great relevance for Novo Nordisk.
2.1 Synthetic strategies
Two stategies are proposed here involving two different key intermediates; a γ-amino-β-
keto ester and a tetramic acid, respectively (see Scheme 2.1.1). These two intermediates
can both be synthesized by C -acylation of Meldrum’s acid (2.1),171–174 which represents
a remarkable, mild method for C -C bond formation.
Both strategies involve, in the second step, an α-arylation, which requires the selection
of suitable conditions among different coupling partners, catalysts, ligands and solvents.
This transformation will afford a γ-amino-α-aryl-β-keto ester or an α-aryl tetramic acid,
respectively. In fact palladium-catalyzed α-arylation reactions are often performed in
mild conditions with a high functional group tolerence. Moreover, the reactions are run
with catalytic conditions, which is both convenient for the subsequent purification and
environmental economically. The last step of both strategies is an ester/lactam hydrolysis
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Scheme 2.1.1: Synthetic strategies toward the benzyl ketone building block
through either a γ-amino-β-keto ester or a tetramic acid.
followed by a decarboxylation which would lead to the benzyl ketone building block in
both cases (see Figure 2.1.1). Phenylalanine will be used for reaction development,
but ultimately the chemistry should be applied to arginine (P1) with an appropriate
Nω-protection for the subsequent peptide synthesis.
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2.1.1 γ-Amino-β-keto esters
2.1.1.1 Traditional syntheses
γ-Amino-β-keto esters are a group of important compounds for the synthesis of e.g. the
corresponding β-hydroxy acids175 which are found in many natural products. Tradition-
ally γ-amino-β-keto esters are synthesized by cross-Claisen condensation with lithium
enolates typically with a CDI-activation. This method has been employed for the syn-
thesis of (3S,4R)-statines,176,177 total synthesis of the cyclodepsipeptides didemnins A, B
and C,178 ketomethylene and hydroxymethylene peptide isosters179–181 in modest to good
yield (see Scheme 2.1.2 for an example). Magnesium enolates have also been applied
affording good yields.182–185 C -Acylation is favored over O-acylation when magnesium
enolates are used. These reagents are almost neutral which provide a better functional
group tolerance than lithium enolates,186 but the use of organometallic reagents in ex-
cess is always a concern especially regarding to functional group tolerance.
N
H O
OHCbz
1. CDI, THF
   rt, 1h
2. −78 oC, 40 min
O OLi
OBn
N
H O
Cbz
OBn
O
O
79% yield
Scheme 2.1.2: Synthesis of Cbz-protected γ-amino-β-keto tert-butyl ester by
reaction with a lithium enolate.180
The CDI group has shown to be the most efficient activation group for the preparation
of β-keto esters,176–180,187–190 whereas other activations such as mixed anhydride, acid
chlorides and Weinreb amides gave only moderate yields.191–193 Unfortunately, CDI is
rather expensive for industrial use. Optimizations of the cross-Claisen condensation have
been reported, e.g. by using N,N-dibenzyl phenylalanine benzyl esters.194
Besides of the cross-Claisen condensation described above, γ-amino-β-keto esters can
also be synthesized by treating urethane N-carboxyanhydrides (UNCAs) with lithium
enolates23,195 (see Scheme 2.1.3) or by ozonolysis and reductive work-up of cyclohexadi-
ene derivatives.196 Unfortunately, these methods require starting materials that are not
readily available.
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then AcOH
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H O O
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70% yieldUrethane 
N-carboxyanhydride (UNCA)
Scheme 2.1.3: Synthesis of a γ-amino-β-keto ester by treatment of a urethane
N-carboxyanhydride (UNCA) with lithium enolate of EtOAc.195
2.1.1.2 Facile synthesis using Meldrum’s acid
In 1999 Franck and co-workers174 reported a facile synthesis of γ-amino-β-keto esters by
C -acylation of Meldrum’s acid (2.1). Unfortunately, yields were very low (up to 30%)
because of the competitive formation of the corresponding tetramic acid. For exam-
ple, the γ-amino-β-keto ester 2.3 was synthesized in 30% yield, giving in addition the
tetramic acid 2.4 as the major (by)-product (see Scheme 2.1.4).
N
H O
OHBoc +
O O
OO
1. DCC, DMAP
    DCM, 0 oC, 20 min
    then rt, 90 min
2. EtOH (2 equiv)
    benzene, ∆, 4h
N
H O
Boc
O
OEt
+ N O
O
Boc
2.2                          2.1                                                                  2.3 (30%)                        2.4 (60%)
Scheme 2.1.4: Synthesis of the γ-amino-β-keto ester 2.3 by C-acylation of
Meldrum’s acid (2.1) with Boc-Phe-OH (2.2). Unfortunately, the yield is very
low (30%) due to formation of the tetramic acid (2.4).174
It was however noted, that N-phthaloylglycine gave exclusively the γ-amino-β-keto es-
ter because the amino group was fully protected.174,197 Another successful application
of this method was the preparation of δ-amino-β-keto esters. Protected aspartic acid
2.5 was converted to the ethyl ester 2.6 with Meldrum’s acid (2.1) in 92% yield (see
Scheme 2.1.5). This synthesis afforded no cyclization, presumably because 6-membered
rings form less easily compared to 5-membered rings.174
Usually, tetramic acids are synthesized analogously, but with refluxing EtOAc instead
of EtOH/benzene. The explanation of formation of either the γ-amino-β-keto ester or
the tetramic acid may be found in the mechanism. The mechanism consists of four
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O O 1. IPCF, DMAP
    DCM, 0 oC
2. EtOH (2 equiv)
    benzene, ∆, 4h
NH OBoc
O
BnO OEt
O
2.5                             2.1                                                                    2.6
92% yield
Scheme 2.1.5: C-Acylation of Meldrum’s acid (2.1) with protected aspartic acid
2.5 afforded the ethyl ester 2.6 in high yield. No cyclization was observed.174
steps;171 i) activation of the amino acid, ii) C -acylation of Meldrum’s acid (2.1),198 iii)
intramolecular attack from an alcohol or intermolecular attack from the amino group
resulting in a cyclization, iv) elimination of CO2 and acetone.
Figure 2.1.1 shows steps ii -iv of the mechanism, which can lead to both of the key
intermediates depending on the work-up conditions of the common intermediate 2.8.
This intermediate is formed by activation of a N-Boc protected amino acid initially
forming an O-acylisourea intermediate 2.7 (if a carbodiimide is used for activation),
which is subsequently attacked by the enolate of Meldrum’s acid (2.1-enolate) resulting
in 2.8. The two possible products, the γ-amino-β-keto ester and the tetramic acid, are
formed upon treatment with EtOH/benzene (path a) or EtOAc (path b), respectively.
Formation of the tetramic acid is highly favored by hydrogen bonding facilitating an
intermolecular attack.171 These observations explain why the γ-amino-β-keto ester is
only formed in low yield with the tetramic acid as the major (by)-product, and why N-
phthaloylglycine gave the corresponding β-keto ester exclusively. However, the literature
does not contain any specific details why intermolecular attack is less favored in benzene
and more favored in EtOAc.
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Figure 2.1.1: Mechanism for the formation of a γ-amino-β-keto ester or a
tetramic acid, respectively, by C-acylation of Meldrum’s acid (2.1). a: EtOH
(2 equiv), benzene, ∆. b: EtOAc, ∆.
2.1.2 Tetramic acids
Tetramic acids are β-keto-γ-lactams which are slightly acidic (pK a ≈ 6.4).
199,200 De-
pending on solvent, concentration and temperature, tetramic acids can exist as both an
enol and a keto tautomer, with the latter of the two known as 2,4-pyrrolidindiones.199,201–203
The structural unit of tetramic acids has been known for more than 100 years,204,205
and it is found in many biologically active natural products,201,202 typically either as
3-acyl or 4-O-alkyl derivatives, examples being althiomycin,206,207 dolastatin 15,208,209
and epicoccamide210 (see Figure 2.1.2).
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Figure 2.1.2: Althiomycin206,207 and epicoccamide210 are two natural products
containing the tetramic acid moiety.
Althiomycin, which is a N-acyl-4-methoxy-3-pyrrolin-2-one, was isolated from Strepto-
myces althioticus in 1957206 and is a broad-spectrum antibiotic functioning by inhibition
of the DNA translation.207 So far, it is unknown which enantiomer is the active one,
because purification of althiomycin results in racemization.201 More recently in 2003,
epicoccamide was isolated from the fungus Epicoccum purpurascens .210 This natural
product consists of three different substructures; a glycoside, a fatty acid and a tetramic
acid (see Figure 2.1.2). However, the biological function of epicoccamide has not yet
been found.
N O
O
H + OtBu
O
H2N
1. 3Å MS, iPrOH/AcOH (9:1)
    55 oC, 24h
2. 25 mol% PtO2, 60 bar H2
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>95% de
N
H
N
O
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OOH
N
Boc
83% yield
>95% de
Scheme 2.1.6: Incorporation of tetramic acids into peptides which increased the
in vitro stability compared to the parent tripeptide.211,212
Tetramic acids are furthermore imporant intermediates in the synthesis of statins,171,213
γ-amino-β-hydroxy acids214 and lactam renin inhibitors215 Moreover, tetramic acid deriva-
tives have been reported as key intermediates for the synthesis of analogs of penicillins
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and cephalosporins216 and 4-substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives217
which are inhibitors of glycolic acid oxidase. 2-Ethyl-4,6-dimethylphenyl-substituted
tetramic acid derivatives have been described in the patent literature as novel pesticides
and herbicides.218 Recently, methods for incorporation of amino acid-derived tetramic
acids into peptides have been developed,211,212,219 giving rise to more stable tripeptides
in vitro (see Scheme 2.1.6).
Previously, tetramic acids were synthesized by base-catalyzed Dieckmann-cyclizations,199,201
which led to 10–30% racemization220 and formation of an anhydrodimer.199 The method
therefore is not very convenient and requires several synthetic steps. In 1987, P. Jouin
et al.171 developed a synthesis of amino acid-derived tetramic acids giving no racemiza-
tion. Later on, several groups reported the use of carbodiimides (e.g. DCC172,173 and
EDC211,212,219) as coupling agents instead of the originally reported IPCF (see Scheme
2.1.7).
N
H
P1
O
OHBoc
1. Meldrum's acid (2.1)
    EDC  HCl, DMAP
    DCM, 0 oC to rt, 16h
2. EtOAc, ∆, 30 min
N O
O
P1
Boc
Tetramic acid
(enol)
N OH
O
P1
Boc
Tetramic acid
(keto)91 − 93%
Scheme 2.1.7: Synthesis of amino acid-derived tetramic acids from a N-Boc-
protected amino acid and Meldrum’s acid (2.1).219
Carbodiimides are excellent activation agents and are traditionally used for peptide syn-
thesis.221 They are robust and do not require anhydrous reaction conditions like acid
chlorides, anhydrides or IPCF.171,221 The urea derivative by-product from DCC may be
difficult to remove hen using solution phase synthesis,222 therefore the acid soluble EDC
is a better choice for solution-phase peptide couplings.211,212,219,223
2.1.3 Palladium-catalyzed α-arylations
No general procedures exist in the literature for preparation of γ-amino-α-aryl-β-keto es-
ters or α-aryl tetramic acids. However, both classes of compounds have been described.
For example, Palomo and Coss`ıo23 has reported the synthesis of a γ-amino-α-aryl-β-keto
ester synthesized from an UNCA by reaction with methyl 2-phenylacetate (see Scheme
2.1.8).
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OMe
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γ-Amino-α-aryl-β-keto ester
84%
Scheme 2.1.8: One of the only reports describing the synthesis of an γ-amino-
α-aryl-β-keto ester is the reaction of an UNCA with methyl 2-phenylacetate upon
treatment with LDA.23
α-Aryl tetramic acids are also only briefly described in the literature,224,225 the most
important being 3-phenyl 5-olefinic tetramic acids as novel glycine site N-methyl-D-
aspartate receptor antagonists for the treatment of neurological diseases (see Figure
2.1.3).226
NH OH
O
OPh
IC50 = 0.7 µM                               3.0 µM                                       9.5 µM
NH OH
O
O
NH OH
O
Figure 2.1.3: 3-Phenyl 5-olefinic tetramic acid show inhibition of the binding of
[3H]-L-689,560 to the strychnine insensitive glycine site on the rat brain mem-
branes down to IC50 = 0.7 µM.
226
The development of a solid-phase synthesis of substituted α-aryl tetramic acids has also
been described227 (see Scheme 2.1.9). However, none of these methods utilize the easy
synthesis of N-Boc protected tetramic acids described above, and the methods are not
general, requiring the use of strong base (e.g. LDA or NaOEt), consist of several syn-
thetic steps and use non-general N-protection groups. These methods do not represent
an efficient synthesis for a broad range of α-aryl substituted amino acid-derived tetramic
acids.
Traditionally, α-arylated ketones or carboxylic acid derivatives have been synthesized by
nucleophilic aromatic substitution reactions (SNAr) of aryls substituted with electron-
withdrawing groups by reaction with stabilized enolates228 or via copper-catalyzed eno-
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Scheme 2.1.9: Solid-supported synthesis of α-aryl tetramic acids by reaction
with a 2-phenylpropanoic acid derivative.227
late reactions with 2-bromobenzoic acid.229 These methods all have drawbacks and are
not very general. Usually, they require harsh reaction conditions, which are not suitable
for protected, enantiomerically pure amino acid derivatives. Using a palladium-catalyzed
α-arylation would be much more efficient since these reactions are typically more gen-
eral, mild and broad in substrate scope.
Br
tBu
+
O
O 1 mol% Pd(OAc)2
K3PO4 (2.3 equiv)
THF, 80 oC, 23h O
O
tBu
P(tBu)2 96% yield2.2 mol%
Scheme 2.1.10: α-Arylation of cyclopentane-1,3-dione with an aryl bromide in
the presence of 1 mol% Pd(OAc)2 and 2.2 mol%
tBu-MePhos ligand.230
The literature reports a number of palladium catalyzed α-arylation conditions for different
substrates containing electron-withdrawing groups such as ketones,230 aldehydes,231 mal-
onates,232 cyanoesters,232 sulfones,233 esters,234 amides,235 protected amino acids,236
piperidinones237 and nitriles.238 Only few examples of α-arylation of 1,3-dicarbonyls
have been described, and most of them are non-chiral and synthetically simple com-
pounds. Most of the substrates are reported by Buchwald230 and Hartwig,232 using
substrates such as diethyl malonate, 1,3-cyclohexanedione, 1,3-cyclopentanedione and
amino acids (see Scheme 2.1.10 for an example). α-Arylation of γ-amino-β-keto esters
has not been reported in the literature, but Buchwald and co-workers230 have arylated
diethyl malonate with 1-bromo-4-tert-butylbenzene under almost the same conditions as
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showed on Scheme 2.1.10 (70 ◦C, 10h, 92% yield). Very recently more functionalized
substrates have been subjected to palladium-catalyzed arylations, e.g. the sp2 arylation
of azine N-oxides,239 α-arylation of highly functionalized cyclohexanones,240 and asym-
metric intramolecular α-arylation of aldehydes.241
Even though no general reaction conditions exist in the literature, it is possible to discern
a general trend for the reaction of substrates similar to β-keto esters and tetramic acids.
It was found that an α-arylation is usually conducted with either Pd(OAc)2 or Pd2(dba)3
using an aryl bromide or iodide.230–238 Aryl chlorides are often too unreactive for this
type of chemistry. Many different solvents can be used, but THF, toluene, dioxane,
MeCN or DMF are the most common. The bases used can be divided into two groups;
weak inorganic bases such as Cs2CO3, K2CO3, K3PO4, Na3PO4 or Na2CO3 and strong
organic bases such as NaOtBu, KHMDS, NaHMDS, LDA or LiN(SiMe2Ph)2. The choice
of base is strongly dependent on the pK a value of the substrate but, in general, strong
bases can be used for most simple substrates. However, if base sensitive functionalities
are present in the molecule or deprotonation can cause racemization, strong bases may
give problems. Sometimes strong bases even require a two-step procedure with addition
of base at reduced temperature and then the actual arylation at elevated temperature.237
Buchwald and co-workers230 reported the first use of a weak inorganic base (K3PO4)
in palladium catalyzed α-arylations of ketones. Finally, a very important parameter is
the choice of ligand. An appropriate ligand can be difficult to find, since many different
ligands have been reported to work in α-arylation of carbonyl substrates, with a broad
variety of stereo- and electronic properties. Thus, in general the ligands are either mono-
or bis-phosphines, such as P(tBu)3, BINAP, Xantphos and biaryl phosphines.
230
2.1.3.1 Utilization of aryldiazonium salts
In the literature, several reports on palladium-catalyzed cross-couplings utilizing aryl-
diazonium salts have been published. Diazonium salts are synthesized from the corre-
sponding anilines by treatment with NaNO2 in the presence of an acid, e.g. HCl,
242
HBr,243 H2SO4,
244 HPF6
245 or HBF4
246–248 determining the diazonium salt counterion
(see Scheme 2.1.11 for an example). Most of the diazonium salts are considerably un-
stable resulting in elimination of nitrogen (which is an excellent leaving group)249,250 and
thus they are potentially explosive. However, salts featuring low nucleophilic counteri-
ons, e.g. tetrafluoroborates or hexafluorophosphates, can be isolated and manipulated
and many of them are commercially available.251 One-pot procedures forming the dia-
zonium salt in situ is a convenient alternative to procedures where it has to be isolated.252
The advantages of using diazonium salts as coupling partners are economically because
anilines are cheaper than the corresponding aryl halides and it furthermore broadens the
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NH2
Cl
NaNO2
42% HBF4, H2O
0 oC, 1h
N
Cl
N BF4
89% yield
Scheme 2.1.11: Aryldiazonium tetrafluoroborates are synthesized from the cor-
responding anilines by treatment with NaNO2 in aqueous HBF4.
246–248
substrate scope. Utilization of aryldiazonium salts might also open the possibility of
using remarkably mild reaction conditions (MeCN, H2O, no ligand or base, rt), cheaper
catalysts (PdCl2 or Pd/C) and allow for synthesis of ortho-substituted α-aryl tetramic
acids, since such conditions are often used in connection with aryldiazonium salts.253–255
R
N
N
Pd(0)
R
Pd
Cu(I)
CH2=CH-EWG
R
EWG
X
Meerwein arylation
R
F
Balz-Schiemann
reaction
Reducing
agent or acid
R
H
N NH2
Arylhydrazine
synthesis
R
N N
R'
Arylazo
synthesis
Anilines or
phenols
R
X
Sandmeyer 
reaction
CuX
         X = CN, 
     Br, Cl,  
  SO3H
R' = OH, NH2
R
R'
Heck coupling
R
R'
Suzuki or Stille
couplingR
Nu
O
Carbonylative
coupling
R'B(OH)2 or
Sn(R')4
R
O O
OR'
KOH
R
H
N N O
OR'
Japp-Klingemann
hydrazone synthesis
CO
NuH
Diazonium
salt
    HF or
HBF4
Figure 2.1.4: Aryldiazonium salts are involved in many other reactions besides of
palladium-catalyzed cross-couplings making them useful intermediates in synthetic
chemistry.253
Many examples exist in the literature illustrating the broad utilization of aryldiazodium
salts in palladium-catalyzed reactions, such as Heck,255–257 Suzuki,258,259 Stille260 and
carbonylative261–263 cross-couplings (see Figure 2.1.4). Moreover, aryldiazonium salts
can participate in a variety of non-palladium-catalyzed reactions, such as the Meer-
wein,264 Sandmeyer,265 Balz-Schiemann266 and Japp-Klingemann267 reaction as well as
reactions forming arylhydrazines268,269 and arylazo compounds.270
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In the literature, many interesting examples exist of palladium-catalyzed cross-couplings
performed under remarkable mild conditions. For example, Beller and co-workers255 de-
scribed a Heck cross-coupling catalyzed by Pd/C (see Scheme 2.1.12).
N2BF4
MeO
+
O
OEt
Pd/C (0.01 equiv)
EtOH, 0 oC, 
then 60 oC, 12h MeO
OEt
O
98% yield
Scheme 2.1.12: Heck cross-coupling using an aryldiazonium salt catalyzed by
Pd/C in excellent yield (many examples).255
A palladium-catalyzed carboxylation of an aryldiazonium inner salt catalyzed by 1 mol%
PdCl2 was reported by Siegrist and co-workers (see Scheme 2.1.13).
254 This afforded
2-sulfo-4-methoxybenzoic acid in high yield, which is a key intermediate for the synthe-
sis of a herbicide. The synthesis can be carried out as a two-step procedure as shown
or as a one-pot reaction with no isolation of the aryldiazonium salt, which would give
considerably cost savings on industrial scale.254
NH2
SO3H
OMe
NaNO2, HCl
H2O, 10 oC, 3h
N
SO3
OMe
N
1 mol% PdCl2
MeCN:H2O (4:1),
8 bar CO, 60 oC, 3h
SO3H
OMe
COOH
98% yield 97% yield
Scheme 2.1.13: Synthesis of 2-sulfo-4-methoxybenzoic acid in high yield from
the aryldiazonium salt through a palladium-catalyzed carboxylation.254
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One of the major problems with in situ-generated aryldiazonium salts is the oxidizing
character of NaNO2, which could interfere with the Pd(0) species assumed to insert into
the C-N+2 bond via an oxidative addition.
254 For this reason, the excess of nitrite could
be destroyed after the diazotization, e.g. with sulfamic acid (H3NSO3).
254 However, this
is not always the case; Zaragoza has reported a one-pot diazotization and Heck coupling
for the synthesis of 3-arylpropanals (see Scheme 2.1.14).271
NH2
O
OMe
+ OH H
O
OMe
O
0.6 mol% PdCl2
NaNO2 (1.2 equiv), 
H2SO4 (2.0 equiv), 
MeCN:H2O (3:2), rt, 4h
60% yield
Scheme 2.1.14: One-pot diazotization and Heck coupling of methyl anthranilate
affording a 3-arylpropanal in good yield.271
This reaction is unusual in many ways; it takes place in MeCN and H2O and thus an-
hydrous solvents are not required, neither is an inert atmosphere and the reaction does
not have to be heated or cooled. Only a catalyst loading of 0.5–1.0 mol% PdCl2 was
required.271 Last but not least, the reaction proceeds smoothly with ortho-substituted
anilines with electron-withdrawing groups such as alkoxycarbonyl, cyano, acetyl and halo-
gens.271
2.1.4 Hydrolysis and decarboxylation
The last step in the synthetic strategy is a ring opening (hydrolysis) and decarboxylation
of the α-aryl tetramic acid or hydrolysis and decarboxylation of the γ-amino-α-aryl-
β-keto ester, respectively. It is assumed that ester hydrolysis and decarboxylation of
γ-amino-α-aryl-β-keto esters would be rather straightforward, whereas ring opening of
α-aryl tetramic acids might be more difficult. Ring opening of tetramic acids is usually
performed by a two-step procedure with reduction of the ketone functionality as the first
step.171,272 This indicates that the conjugated system present in tetramic acids makes
them more stable than simple lactams. Therefore this section is dedicated to methods
for ring opening of tetramic acids rather than methods for hydrolysis/decarboxyaltion of
β-keto ester systems.
Following the ketone reduction of tetramic acids, which can be accomplished chemically
with NaBH4 or catalytically with H2/Pt2O (Adam’s catalyst),
171,272 they are easily ring
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opened with 1M NaOH or 2M HCl. For example, the tetramic acid 2.9 was stereos-
electively and chemoselectively reduced with NaBH4 to the 4-hydroxy derivative 2.10,
which was hydrolyzed to the corresponding N-Boc statine 2.11 in good yield (see Scheme
2.1.15 for an example).171 This approach has been used by several research groups as
facile synthesis of statines and analogs hereof.273–275
N OH
O
Boc NaBH4
DCM:AcOH (10:1),
0 oC, 4h
N OH
O
Boc 1M NaOH
Acetone, 
rt, 5 min
70% yield 90% yield
OH
COOH
2.9                                                                   2.10                                                             2.11
N
H
Boc
Scheme 2.1.15: Ring opening of tetramic acids is done in a two-step procedure,
first by reduction of the ketone followed by ring cleavage with 1M NaOH affording
the enantiomerically pure N-Boc statine 2.11.171
Cleavage of 4-O silyl derivatives has been reported using mild conditions such as Cs2CO3
in MeOH276 and catalytic KCN in EtOH/THF277 affording the corresponding esters.
N
Me
OMe
O
O
Me
O
H2N
O
Cl ClMe
Cl Cl
LiOH, H2O2
N
H
MeO
Me
O
H2N
O
Cl ClMe
Cl Cl
OMe
HOOC
TFA:H2O (3:1),
5−10 oC, 20h
Mirabimide E 2.12
Scheme 2.1.16: The 4-O methyl tetramic acid moiety in mirabimide E was ring
opened using lithium hydroperoxide affording the corresponding carboxylic acid
2.12.278
Utilization of LiOOH (LiOH and H2O2) was initially reported by Evans and co-workers
for the highly regioselective hydrolysis of carboximides,279 but it has also been reported
to afford ring opening of N-Boc lactams in general.280–283 For example, these conditions
afforded ring opening of the 4-O methyl tetramic acid moiety in mirabimide E to the
carboxylic acid 2.12278 (see Scheme 2.1.16).
Samarium(II) iodide (SmI2) represents the third and last example of potential methods
for ring opening of tetramic acids. SmI2 can be used in a variety of different reac-
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N
O
O 1. SmI2 (2 equiv)
    THF, 20 oC, 5 min
2. EtOH (2 equiv)
3. H3O+
H
N
O
O
H
2.13 2.14
+
H
N
O
O
OEt
2.15
75% yield 10−15% yield
Scheme 2.1.17: Treatment of the N-acyl lactam 2.13 with SmI2 in the presence
of a proton donor (EtOH) gave the amidoaldehyde 2.14 in good yield accompanied
by minor amounts of the amido ethyl ester 2.15.284
tions; radical cyclizations,285 Barbier286–288 and Reformatsky-type reactions,286,289 con-
jugated additions,290 sequential radical processes,291 radical-anionic sequences289 and
many other radical cyclizations.292 However, it has never been used for cleavage of
tetramic acids. Nevertheless, a SmI2-mediated ring opening of N-acyl lactams has been
reported284 and these substrates resemble the N-Boc protected tetramic acids a lot (see
Scheme 2.1.17).
N
O
2.13
O
I2Sm
N
SmI2
O
O
SmI2 N
SmI2
O
O
SmI2
EtOH
2.14
2.16
Scheme 2.1.18: Proposed mechanism for the SmI2-mediated ring cleavage of
the N-acyl lactam 2.13 through a transient acyl samarium species 2.16, which is
trapped by EtOH forming primarily the aldehyde 2.14.284
The N-acyl lactam 2.13 was cleaved to the amidoaldehyde 2.14 by treatment with SmI2
in the presence of a proton donor (EtOH) in good yield.284 The amido ethyl ester 2.15
was afforded in minor amounts, probably as a result of nucleophilic attack of the samar-
ium ethoxide on the lactam carbonyl group. These results are similar to those reported
for Sm(II)-mediated reactions of acid chlorides.293 They support the hypothesis of the
formation of an acyl radical, that is reduced into a transient acyl samarium species 2.16,
which is trapped by an electrophile (EtOH)284 (see Figure 2.1.18). N-Methylsuccinimide
and N-methylglurarimide were both unreactive under the same experimental conditions,
presumably because the ring cleavage of N-acyl lactams occurs in a SmI2-acyl lactam
complex with samarium chelated by the two carbonyl groups.284
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2.2 Results and discussion
2.2.1 Synthesis of γ-amino-β-keto esters
2.2.1.1 Optimization of the C-acylation of Meldrum’s acid
To optimize the synthesis of the γ-amino-β-keto ethyl ester 2.3 reported by Franck and
co-workers,174 different conditions for work-up of the intermediate 2.8 were tested using
pure EtOH or toluene/EtOH (see Table 2.2.1). Boc-Phe-OH (2.2) was used as a simple
model compound for optimization purposes.
Table 2.2.1: Screening of reaction conditions for intermediate 2.8 work-up.
N
OH
O
O
O
H
O
Boc
2.8
N
H O
OHBoc
EDC  HCl, DMAP
Meldrum's acid (2.1)
DCM
0 oC to rt, 4h
2.2
EtOH
solvent
∆, 30 min
N
H
Boc
O O
OEt
N OH
O
Boc
2.3
+
2.4
entry solvent EtOH (equiv) temp. (◦C) 2.3 : 2.4 (%)a
1 – ∞ 80 5 : 95
2 toluene 2.0 110 13 : 87
3 toluene 2.0 80 30 : 70
4 toluene 4.0 80 30 : 70
a: Ratio between γ-amino-β-keto ethyl ester 2.3 and Boc-pyPhe-OH (2.4) determined
by 1H NMR of the crude product.
Initially, work-up of 2.8 was performed in pure EtOH at reflux (entry 1). Unfortunately,
these reaction conditions led to an almost exclusive formation of the Boc-pyPhe-OH
(2.4)a tetramic acid and only traces of the desired γ-amino-β-keto ethyl ester 2.3 was
observed on LC-MS and 1H NMR.
aThe prefix ’py ’ is used to indicate that the amino acid is converted to a tetramic acid.211,212,219
49
Results and discussion
Inspired by Franck and co-workers,174 who obtained 30% yield of 2.3 by using EtOH (2
equiv) in refluxing benzene, a series of experiments were conducted in toluene (see Table
2.2.1, entries 2–4). Using 2 equiv of EtOH in refluxing toluenea gave 13% of 2.3 (see
entry 2), but lowering the temperature to 80 ◦C, which corresponds to the boiling point
of benzene, increased the yield to 30% (entry 3). Increasing the equiv of EtOH to 4.0
did not change the yield of 2.3 (see entry 4). Apparently, an intermolecular attack from
the amino group is less favored in apolar solvents like benzene and toluene, whereas a
polar solvent completely favors an intermolecular attack.
Running reactions at neutral pH might be problematic if more than one product can
be formed. To test this, 5% TsOH or 20% pyridine, respectively, was added to toluene
experiments. Pyridine did not have any influence on the outcome, whereas TsOH com-
pletely decomposed the intermediate 2.8 and neither the γ-amino-β-keto ethyl ester
2.3 nor the tetramic acid 2.4 was formed. Addition of NaOEt (1.10 equiv) was not
beneficial either.
N
O O
OEtBoc
EtOH
∆ N
O
O
Boc
2.3                                                                            2.4
H
Scheme 2.2.1: The γ-amino-β-keto ethyl ester 2.3 could not be converted into
the corresponding tetramic acid 2.4 by treatment with refluxing EtOH.
So far, only yields comparable with those obtained by Franck and co-workers174 were
achieved. One plausible explanation for the low yield of the γ-amino-β-keto ethyl ester
2.3 could be the conversion of 2.3 into the tetramic acid 2.4. Intermolecular attack
from the amino group to the carbonyl group would serve as a direct way for forma-
tion of 2.4 upon elimination of EtOH. That would represent another path for tetramic
acid formation. However, experiments treating the γ-amino-β-keto ethyl ester 2.3 with
refluxing EtOH did not convert the compound into the corresponding tetramic acid
2.4. This suggests that whenever 2.3 is formed, it is not converted into the undesired
tetramic acid, and that formation of 2.4 happens exclusively through different reaction
paths from the common intermediate.
aBenzene was substituted with toluene for safety reasons.
50
Results and discussion
2.2.1.2 Syntheses of Boc2-Phe-OH
To avoid formation of a tetramic acid by cyclization of the intermediate 2.8, a N,N-
diprotection approach was investigated. Franck and co-workers174 demonstrated that N-
phthaloylglycine exclusively formed the corresponding γ-amino-β-keto ester. Although
some N-phthaloyl protected amino acids are commercially available, functionalized amino
acids and in particular the arginine derivative is not available. Furthermore, deprotection
is usually performed using hydrazine,294,295 which is highly toxic and dangerously unsta-
ble. Some simple amino acids with an additional N-methyl protection are commercially
available,251 but once again functionalized amino acids are absent N-demethylation also
requires harsh and non-general removal conditions,296 such as LiClO/O2/9,10-dicyano-
anthracene/hν,297 m-CPBA/FeCl2
298 or PhSeH/160 ◦C299 and most of the methods
are developed for deprotection of tertiary amines. In addition, N-methylamino acids are
also enhancely prone to racemization under basic conditions, probably because of the
absence of the Nα-H, whose ionization would suppress ionization of the neightboring
Cα-H bond.300 Imine derivatives is another amine N,N-diprotection, which is fairly easy
to introduce, but due to their instability they have not been extensively used in syn-
thesis.301 The most widely used imines are, however, the benzylidene302 and diphenyl-
methylene303,304 imine derivatives, typically introduced by transimination.
N
H
Boc
O
OH
1. Cs2CO3 to pH=7
2. BnBr
    DMF, rt, 10 min
N
H
Boc
O
OBn
86−97% yield
1. Boc2O (excess)
    DMAP, MeCN
    rt, 1 day
2. H2, 5% Pd-C
    MeOH
    rt, overnight
NBoc
O
OH
64−83% yield
Boc
2.2                                                             2.17                                                                2.18
>95% ee
Boc2O (excess), DMAP, MeCN, rt
Scheme 2.2.2: Synthesis of N,N-diprotected Boc2-Phe-OH (2.18) via the ben-
zyl ester 2.17 in high overall yield and >95% ee determined by 1H NMR upon
derivatization with (R)-1-phenyl ethylamine.305,306 A one-pot approach directly
from 2.2 did not work.
Boc-protection is, on the other hand, known as a very convenient protecting group for
amines, and therefore a Boc2-protection was considered. Gunnarsson and Ragnarsson
306
reported in 1990 a N,N-diprotection of amino acids through a temporary benzyl ester
protection. Introduction of a second Boc-group has previously been reported to avoid
cyclization.307 Using this approach, Boc-Phe-OH (2.2) was protected as the benzyl 2.17
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in yields up to 97% yield (see Figure 2.2.2). Then, the amine was further protected with
an additional Boc-group by reaction with excess Boc2O followed by catalytic hydrogenol-
ysis affording Boc2-Phe-OH (2.18) in high overall yield. A one-pot approach directly
from 2.2 using excess of Boc2O did not form the desired diprotected product 2.18.
To reduce the number of steps toward to synthesis of Boc2-Phe-OH (2.18), which was
selected as the model compound for the proceeding reaction development, another stat-
egy was tested. N-Boc α-amino benzyl esters (such as 2.17) are not commercially
available, but the methyl esters are. By using a preprotected compound, the sequence
could be reduced by one step. Boc-Phe-OMe (2.19) was initially Boc-protected with an
excess amount of Boc2O affording the Boc2-Phe-OMe (2.20) in excellent yield. Then, a
series of hydrolysis experiments were set up to find optimized conditions for preparation
of Boc2-Phe-OH (2.18) (see Table 2.2.2).
Table 2.2.2: Testing of hydrolysis conditions for O-deprotection of 2.20.
N
H O
OMeBoc
Boc2O (excess)
DMAP (1 equiv), 
MeCN, rt, overnight
N
O
OMeBoc
Boc
93−99% yield
Hydrolysis
N
O
OHBoc
Boc
 2.19                                                                2.20                                                  racemic-2.18
base:solvent (1:3)
entry basea solvent temp. (◦C) time (h) yield (%)b ee (%)c
1 LiOH THF rt to ∆ 16 70d –e
2 LiOH MeOH ∆ 0.5 77d –e
3 LiOH MeOH rt 16 88 0
4 NaOH MeOH rt 0.5 85 0
5 NaOH MeOH 5 7.5 91 0
a: Saturated aqueous solution. b: Isolated yield. c: Enantiomeric excess determined by coupling of
product with (R)-1-phenyl ethylamine and subsequently analyzed by 1H NMR. d: Impure product. e: ee
not determined due to impure products.
LiOH in THF was tested (entry 1), but the hydrolysis was very sluggish and had to be
heated to reflux to secure conversion of the starting material. Unfortunately, the product
2.18 was quite impure. The same result was obtained with LiOH in MeOH at reflux,
which gave full conversion after only 30 minutes (entry 2). Lowering the temperature
to room temperature gave 88% yield of pure Boc2-Phe-OH (2.18) after 16 hours, but
unfortunately, complete racemization had occurred (entry 3). NaOH was tested as an al-
ternative to avoid racemization. This base hydrolyzed the methyl ester 2.20 much faster
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than LiOH, and the reaction was complete after just 30 minutes at room temperature.
Unfortunately, complete racemization was observed (entry 4). Further temperature re-
duction to 5 ◦C, did still not give any noteworthy enantiomeric excess (entry 5).
Deprotection of Boc-Phe-OMe (2.19) was tested using NaOH in MeOH at room tem-
perature, which did not lead to any racemization. This result indicates clearly that the
N,N-diprotected amino acids are much more prone to racemization, apparently because
of an increased acidity of the α-proton. Furthermore, it was discovered, that the two
Boc-groups did not have the same lability. The second Boc-group was much more labile
than the first one, which might be due to electronic and steric effects.
2.2.1.3 Utilization of Boc2-Phe-OH in β-keto ester synthesis
Using the optimized reaction conditions developed for the tetramic acid synthesis,211,212,219
Boc2-Phe-OH (2.18) was applied for the synthesis of a range of γ-amino-β-keto esters
2.21–2.25 (see Table 2.2.3).
Table 2.2.3: Synthesis of γ-amino-β-keto esters.
N
O
OHBoc + O O
O O
1. EDC  HCl (1.5 equiv),
    DMAP (1.5 equiv),
    DCM, 0 oC to rt, 4h
2. Dry ROH, ∆ , 45 minBoc
N
O
Boc
Boc
OR
O
2.18                              2.1                                                                        2.21 − 2.25
entry R product yield (%)a
1 Me 2.21 94
2 Et 2.22 95
3 iPr 2.23 98
4 tBu 2.24 97
5 Bn 2.25 (>95)b
a: Isolated yield. Purity determined by HPLC to be
greater than 95%. b: Conversion determined by TLC,
but otherwise not characterized.
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Initially it was observed that 2.18 reacted slightly slower compared to the mono-protected
amino acid, Boc-Phe-OH (2.2). The reaction rate was improved by increasing the equivs
of EDC and 2.1 from 1.13 to 1.50. Furthermore, it was found that the intermediate
formed from 2.18 was less stable compared to 2.8, therefore immediate work-up with
cold solvents is recommended. Last but not least, small amounts of the methyl ketone
derivative of 2.18 was observed in the product (5–12%), which was probably due to
hydrolysis of the β-keto ester followed by decarboxylation. Formation of this methyl
ketone was suppressed by using dried alcohols in the work-up step. Increased reaction
times up to 45 minutes secured full conversion.
With these optimized conditions five different N,N-diprotected γ-amino-β-keto esters
2.21–2.24 were synthesized in good yield (94–98%, entries 1–4). The additional Boc-
group was stable under the chosen reaction conditions. No difference in product yields
was observed among the different alcohols tested, despite that fact that MeOH (entry
1) is a better nucleophile than tBuOH (entry 4). The N,N-diprotected γ-amino-β-keto
benzyl ester 2.25 (entry 5) was also easily formed, but isolation of the product was
complicated by the high boiling point of BnOH. Based on the previous results, it seems
evident that the β-keto benzyl ester also could be formed by treating the intermediate
2.8 with toluene and BnOH (2 equiv) at reflux. However, this method was not tested.
2.2.1.4 Application of strategy to functionalized amino acids
So far, the method has only been applied to the simple Boc2-Phe-OH (2.18). There-
fore, the strategy was tested with more functionalized amino acids. Initially a range of
carboxylic protected amino acids were synthesized (see Table 2.2.4).
The benzyl ester was once again utilized (entires 1–3), but for the compounds with Cbz-
protection on the side-chain, an allyl ester was chosen (entries 4–6). This protection
was introduced by using allylbromide.306 The allyl carboxylic protection can be removed
orthogonally to the Cbz-protection by treatment with Rh(PPh3)3.
308
Introduction of the benzyl or allyl esters proceeded nicely for a wide range of function-
alized amino acids in good yields (see Table 2.2.4). Basically, the two protection groups
were introduced equally easy, however, the allylbromide reacted somewhat slower than
benzylbromide.
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Table 2.2.4: Carboxylic protection of functionalized amino acids.
N
H
P1
Boc
O
OH
1. Cs2CO3 to pH 7−9
2A. BnBr
      DMF, rt, 40 min
             -or-
2B. Allylbromide
      DMF, rt, 2h
N
H
P1
Boc
O
OPg
                                                                           2.26 − 2.28
entry side-chain (P1)a routeb protection (Pg) product yield (%)c
1 Arg(Pbf) A Bn 2.26 80–88
2 Orn(Cbz) B Allyl 2.27 92
3 Lys(Cbz) B Allyl 2.28 95
a: Notation corresponds to the respective amino acid side-chain (P1). b: Route A corresponds to benzyl
protection with BnBr, whereas route B corresponds to allyl protection with allylbromide. c: Isolated yield.
With the carboxylic protected amino acids in hand, the introduction of the additional
Nα-protection was tested for a variety of different substrates (see Table 2.2.5). As with
the Boc-Phe-OBn (2.17), the Boc-group was projected to be introduced with an excess
of Boc2O.
Table 2.2.5: Synthesis of fully protected functionalized amino acids.
N
H
P1
Boc
O
OPg
    Boc2O (excess)
NBoc
O
OAllyl
Boc
DMAP, MeCN
rt, 1 day
2.26 − 2.28
CH2
N Cbz
Boc
n
2.30 (n = 1)
2.31 (n = 2)
NBoc
O
OBn
Boc
NH
HN
H
N Pbf
2.29
- or -
entry substrate (P1, Pg) product yield (%)a
1 Boc-Arg(Pbf)-OBn (2.26) 2.29 –b
2 Boc-Orn(Cbz)-OAllyl (2.27) 2.30 72
3 Boc-Lys(Cbz)-OAllyl (2.28) 2.31 73
a: Isolated yields. b: Product was not isolated due to formation of many unde-
fined products and severe contamination of Boc2O.
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Unfortunately, introduction of an additional Nα-protection was not straightforward when
several nucleophilic nitrogen atoms were present in the molecule. Apparently no differ-
ence in reactivity was observed among the Nα and the side-chain nitrogen atom, e.g.
in the guadinine group (Nω) or the lysine group (Nǫ), although these functionalities
were appropriately protected with Cbz or Pbf (see Table 2.2.5). This resulted in mix-
tures of products with different degrees of Boc-protection, ranging from introduction of
only one additional Boc-group, with unknown regioselectivity, to many additional Boc-
groups. Because of these problems with regioselectivity, the many compounds formed
upon treatment of Boc-Arg(Pbf)-OBn (2.26) with Boc2O were not further isolated (en-
try 1). Such a procedure would never be desirable and does indeed not represent a
conveninent and rapid procedure for N,N-diprotected amino acids. Introduction of the
additional Boc-group was however easier with Boc-Orn(Cbz)-OAllyl (2.27) and Boc-
Lys(Cbz)-OAllyl (2.28), which simply resulted in the fully protected amino acids 2.30
and 2.31, respectively (entries 2 and 3). For both of these compounds it was possible
to force the reaction to completion and one defined product could be obtained.
Further optimization of the chemistry regarding the γ-amino-β-keto esters was discon-
tinued at this point. This key intermediate seemed to be more difficult to synthesize
via Meldrum’s acid (2.1) than expected, and synthesis of N,N-diprotected amino acids
was uphill when functionalized side-chains were present. The traditional syntheses of
γ-amino-β-keto esters requiring the use of organometallic reagents in excess, would nei-
ther be an alternative because of the resulting low functional group tolerance.
2.2.1.5 Summary
A mild synthesis of amino acid-derived γ-amino-β-keto esters has been developed. In
this way, a range of phenylalanine-derived β-keto esters 2.21–2.24 were synthesized in
excellent yield (94–98%). The method does not require strong bases which is usually
employed for synthesis of such compounds. Instead, the synthesis employs the N,N-
diprotected amino acid Boc2-Phe-OH (2.18) and commercially available Meldrum’s acid
(2.1). Boc2-Phe-OH (2.18) was synthesized in three steps in good overall yield (up to
80%) with no racemization. Unfortunately, this method seemed only really applicable for
non-functionalized amino acids due to poor regioselectivity of the additional Boc-group
introduction. Synthesis of Boc2-Arg(Pbf)-OH (2.29), which is crucial for applicability
of the chemistry for preparation of the desired arginyl benzyl ketone building block, was
found to be unsuitable. In spite of several attempts, optimization of the synthesis of
γ-amino-β-keto esters from mono-protected amino acids failed, and only up to 30% of
the desired product was isolated. Apparently formation of the tetramic acid is highly
favored and very difficult, if not impossible, to avoid.
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2.2.2 Synthesis of tetramic acids
Based on how easily amino acid-derived tetramic acids are synthesized from N-Boc-
protected amino acids and Meldrum’s acid (2.1), the strategy using this key intermedi-
ate seemed to be more likely to succeed.
A variety of different tetramic acids were therefore synthesized in excellent yield accord-
ing to literature procedures.171–173,211,212,219 EDC was selected as coupling reagent due
to the easy work-up procedure using diluted acid for removal of the corresponding urea
by-product.
Table 2.2.6: Synthesis of amino acid-derived tetramic acids.
N
H
P1
O
OHBoc + O O
O O
1. EDC  HCl (1.5 equiv),
    DMAP (1.5 equiv),
    DCM, 0 oC to rt, 4h
2. EtOAc, ∆ , 30 min
N
P1
OH
O
Boc
2.1 2.4, 2.32 − 2.38
entry side-chain (P1)a product yield (%)b
1 Phe 2.4 76–98
2 Arg(Pbf) 2.32 77–99
3 Tyr(tBu) 2.33 quant.c
4 Lys(Cbz) 2.34 78–99
5 Thr(tBu) 2.35 quant.c
6 Asp(tBu) 2.36 94
7 Gly 2.37 99
8 Orn(Cbz) 2.38 94%
a: Notation corresponds to the respective amino acid side-chain (P1). b:
Isolated yield. c: Yield was determined to be >100% because of solvent
contaminations which could not removed in high vaccum.
A variety of different tetramic acids was synthesized in excellent yield and purity with
no need of flash chromatography. Compared to the previously described facile synthesis
of γ-amino-β-keto esters, tetramic acids are formed very easily with no significant com-
peting by-product formation. Furthermore, the chemistry was compatible with a variety
of different functionalities and protecting groups. Boc-pyArg(Pbf)-OH (2.32) which is
the most interesting tetramic acid for the arginyl benzyl ketone building block synthesis,
did also form smoothly (see Table 2.2.6, entry 2).
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2.2.3 Palladium-catalyzed α-arylation of tetramic acids
With the access to a variety of different amino acid-derived tetramic acids, the sub-
sequent α-arylation was then investigated. Palladium-catalyzed cross-couplings usually
require extensive screening and optimization and therefore it was decided to base the
experiments on the general trends in α-arylation of carbonyl compounds, as described
in section 2.1.3. This transformation is not only one of the key steps in the application
of tetramic acids for the synthesis of the benzyl ketone building block, but also a new
possible way for preparation of α-aryl tetramic acids. These compounds are themselves
interesting due to their potential biological activity.
2.2.3.1 Initial screening of bases and ligands
Initially, arylation of Boc-pyPhe-OH (2.4) with 4-bromoanisole (2.39) in the presence
of 2 mol% Pd(OAc)2 was tested for the synthesis of the α-aryl tetramic acid 2.40 (see
Table 2.2.7).
Four different weak, inorganic bases were tested; Cs2CO3, K3PO4, Na2CO3 and K2CO3,
respectively, in 2.3 equivs inspired by results published by Buchwald and co-workers.230
Screening of a variety of weak bases was prioritized because they are much more com-
patible with functional groups, and because tetramic acids are only slightly acidic (pK a
≈ 6.4).199,200
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Table 2.2.7: Results from initial screening of bases and ligands.
N OH
O
Boc +
Br
MeO
2 mol% Pd(OAc)2
base (2.3 equiv), THF
80 oC, overnight
N OH
O
Boc
OMe
2.4                              2.39                                                                         2.40
4 mol% ligand
entry ligand base conv. (%)a
1 P(tBu)3 all four
b <5
2 P(o-tolyl)3 all four
b <5
3 rac-BINAP all fourb <5
4 Xantphos all fourb <5
5 DPPF all fourb <5
6 tBu-MePhos (2.41) Cs2CO3 15
7 tBu-MePhos (2.41) K3PO4 36
8 tBu-MePhos (2.41) Na2CO3 –
c
9 tBu-MePhos (2.41) K2CO3 36
a: Determined by 1H NMR. b: Ligand tested with Cs2CO3, K3PO4,
Na2CO3 and K2CO3, respectively. c: No significant product formed
based on 1H NMR and LC-MS.
The phosphine ligands P(tBu)3, P(o-tolyl)3, rac-BINAP, Xantphos and DPPF (see Fi-
gure 2.2.1) were screened with the four bases in 20 initial experiments (see Table 2.2.7,
entries 1–5). Unfortunately, none of these conditions gave rise to any significant product
formation (conv.: <5%) and only starting materials were isolated upon acidic work-up.
However, screening experiments with 4 mol% tBu-MePhos 2.41, a biaryl phosphine lig-
and, gave promising results (entries 6–9). Not surprisingly, a major difference among
the bases was observed, K3PO4 and K2CO3 gave comparable results, 36% conversion
(entries 7 and 9), whereas Na2CO3 did not give any product formation at all (entry 8).
Cs2CO3 gave a modest result with a conversion of 15% (entry 6).
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P
P(o-tolyl)3
P
P(tBu)3
O
P P
Xantphos
PPh2
PPh2
P(tBu)2
tBu-MePhos (2.41)
rac-BINAP
Fe
PPh2
PPh2
DPPF
Figure 2.2.1: Ligands used in the initial screening experiments.
2.2.3.2 Variation of temperature and equivalents
To further increase the conversion with 4 mol% tBu-MePhos 2.41 and 2.3 equiv K3PO4,
a series of experiments at elevated temperature (100 ◦C) and a series with prolonged
reaction time (3 days) were conducted (see Table 2.2.8). No significant change in
conversions was observed after 3 days (entries 1–4) at 80 ◦C. On the other hand, the
conversion was increased at 100 ◦C overnight, especially with K3PO4 which almost gave
a two-fold increase in conversion to 71% (entry 6). In both experimental series, the use
of Na2CO3 still did not give any significant product formation (entries 3 and 7). Fur-
thermore, experiments at room temperature were conducted but no product formation
was observed.
Inefficient activation of the catalyst may cause the low to moderate conversions ob-
tained so far. Therefore the screening reaction was tested at 80 ◦C with all four bases,
respectively, with 2 mol% Pd2(dba)3 as a direct source of Pd(0). However, there was
no improvement in conversion, and it is therefore assumed that the problem with low
conversion is not due to the nature of the palladium catalyst.
Having a set of reaction conditions giving a moderate conversion and a catalyst that
presumably is sufficiently activated, a set of different equiv with regard to 4-bromoanisole
(2.39), Pd(OAc)2, ligand 2.41 and K3PO4 was screened (see Table 2.2.9). Increasing
the equiv of 2.39 from 1.0 to 2.0 only increased the conversion slightly (entry 1), whereas
increasing the equiv of K3PO4 to 5.0 gave a significant reduction in conversion (entry
2). Furthermore, the effect of catalyst and ligand loading was examined. Increasing the
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Table 2.2.8: Increased temperature and prolonged reaction time.
N OH
O
Boc +
Br
MeO base (2.3 equiv), THF
N OH
O
Boc
OMeP(
tBu)2
2 mol% Pd(OAc)2
2.4                              2.39                                                                          2.40
2.41
(4 mol%)
entry base temp (◦C) time (h) conv. (%)a
1 Cs2CO3 80 72 21
2 K3PO4 80 72 33
3 Na2CO3 80 72 <5
4 K2CO3 80 72 32
5 Cs2CO3 100 16 25
6 K3PO4 100 16 71
7 Na2CO3 100 16 <5
8 K2CO3 100 16 52
aDetermined by 1H NMR.
loading of catalyst and ligand to 4 and 8 mol%, respectively, gave full conversion (entry
3). The same was true with increased ligand loading only (entry 4). It was found that
an excess of ligand was essential since 4 mol% Pd(OAc)2 and 4 mol%
tBu-MePhos 2.41
only gave a conversion of 79% (entry 5).
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Table 2.2.9: Variation of equivalents.
N OH
O
Boc +
Br
MeO K3PO4, THF
80 oC, overnight
N OH
O
Boc
OMeP(tBu)2
Pd(OAc)2
2.4                              2.39                                                                          2.40
2.41
entry Ar-Br 2.39 Pd(OAc)2 ligand 2.41 K3PO4 conv.
(equiv) (mol%) (mol%) (equiv) (%)a
1 2.0 2 4 2.3 43
2 1.0 2 4 5.0 15
3 1.0 4 8 2.3 >95
4 1.0 2 8 2.3 >95
5 1.0 4 4 2.3 79
aDetermined by 1H NMR.
2.2.3.3 Screening of biaryl phosphine ligands
Based on these results, it seemed likely that screening other biaryl phosphine ligands
might give full conversion without increasing the ligand loading. Three classes of com-
mercially available biaryl phosphine ligands were therefore screened; a series of di-tert-
butyl biaryl phosphines 2.42–2.44, a series of dicyclohexyl biaryl phosphines 2.45–2.51
and one diphenyl biaryl phosphine, the Ph-DavePhos (2.52) (see Figure 2.2.2). Buch-
wald and co-workers309 reported in 2000 an improved and efficient one-pot synthesis of
functionalized dicyclohexyl- and di-tert-butylphosphinobiphenyl ligands,309 however the
presented ligands here are all commercially available.310
Only tBu-XPhos (2.44) gave full conversion with 4 mol% ligand loading (see Table
2.2.10, entry 3). The two other di-tert-butyl biaryl phosphines, JohnPhos (2.42) and
tBu-DavePhos (2.43) gave only poor conversion (entries 1 and 2). All dicyclohexyl
biaryl phosphine ligands 2.45–2.51 (with interesting names such as MePhos, DavePhos,
XPhos and SPhos) and the Ph-DavePhos ligand 2.52 gave only traces of product. Appar-
ently, this reaction requires a sterically hindered ligand, and the di-tert-butyl substituents
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P(tBu)2 P(tBu)2
NMe2
P(tBu)2
iPr
iPr
iPr
PCy2 PCy2
PCy2
NMe2
PCy2
iPr
iPr
iPr
PCy2
OMeMeO
PCy2
OiPriPrO
PCy2
OMeMeO
SO3Na
PPh2
NMe2
JohnPhos
(2.42)
tBu-DavePhos
(2.43)
tBu-XPhos
(2.44)
cHex-JohnPhos
(2.45)
MePhos
(2.46)
DavePhos
(2.47)
XPhos
(2.48)
SPhos
(2.49) 2.50 2.51
Ph-DavePhos
(2.52)
Figure 2.2.2: Biaryl phosphine ligands; di-tert-butyl (2.42–2.44) and dicyclo-
hexyl (2.45–2.51) ligands and a diphenyl ligand (2.52).
are essential for reactivity. This was demonstrated by the absence of reactivity with the
analogous dicyclohexyl biaryl phosphine ligand, XPhos (2.48).
Table 2.2.10: Screening of different biaryl phosphine ligands.
N OH
O
Boc +
Br
MeO
2 mol% Pd(OAc)2
K3PO4 (2.3 equiv), THF
80 oC, overnight
N OH
O
Boc
OMe(4 mol%)
R
R'
2.4                              2.39                                                                          2.40
2.42 − 2.52
entry ligand conv. (%)a
1 2.42 5
2 2.43 21
3 2.44 >95
4 2.45–2.52b <5
aDetermined by 1H NMR. b: Tested individually
in 8 different experiments.
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2.2.3.4 Substrate scope and limitations
Having arrived at these optimized reaction conditions it would be desirable to exam-
ine the scope and limitations of the reaction. This was initially done by testing other
different aryl coupling partners, namely aryl chlorides, iodides, tosylates and triflates.
For comparison reasons it was chosen to screen 4-methoxy derivatives only (see Table
2.2.11). It was delightful to discover that 4-chloroanisole (2.53) reacted identically com-
pared to 4-bromoanisole (2.39) (entry 1), as did the aryl triflate 2.56 (entry 4). Use
of aryl triflates expands the scope of the reaction further because it allows conversion
of phenols into functional coupling partners very easily. Aryl iodide 2.54 and tosylate
2.55 gave only minor amounts or traces of product 2.40, respectively (entries 2 and
3). This observation is important because aryl chlorides are generally much cheaper
than the corresponding iodides and a wider range of commercially available compounds
exists. Moreover, this chemistry shows a reverse reactivity as aryl chlorides are usually
too unreactive for palladium-catalyzed coupling reactions.
Table 2.2.11: Testing of different coupling partners.
N OH
O
Boc +
X
MeO
2 mol% Pd(OAc)2
K3PO4 (2.3 equiv), THF
80 oC, overnight
N OH
O
Boc
OMe(4 mol%)
P(tBu)2iPr
iPr
iPr
2.4                        2.53 − 2.56                                                                     2.40
2.44
97% ee
entry X conv. (%)a
1 Cl (2.53) >95
2 I (2.54) <5
3 OTs (2.55) 8
4 OTf (2.56) >95
aDetermined by 1H NMR.
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Using the optimized reaction conditions a broad range of aryl chlorides were tested with
different substituents, electron-donating (EDG) as well as electron-withdrawing groups
(EWG), and with different disubstitution patterns (see Table 2.2.12).
Table 2.2.12: Substrate scope with different aryl chlorides.
N OH
O
Boc +
X
K2CO3 (2.3 equiv), THF
80 oC, 1 hour
N OH
O
Boc
P(tBu)2iPr
iPr
iPr
 2 mol% Pd(OAc)2
R'
R'
(4 mol%)2.4                                                                                                     2.40, 2.57 − 2.70
2.44
entry R’ (X=Cl) time (h) product yield (%)a
1 H 1 2.57 75
2 4-OMe 1 2.40 79
3 3-OMe 1 2.58 78
4 2-OMe 16 2.59 –b
5 2-OMe (X=Br) 1 2.59 –b
6 4-OH 16 2.60 72
7 4-NH2 16 2.61 (>95%)
c
8 4-NHBoc 1 2.62 75
9 4-C2H4NH2 1 2.63 –
b
10 4-CN 1 2.64 74
11 2-CN 16 2.65 –b
12 4-NO2 16 2.66 60
13 4-COCH3 1 2.67 74
14 4-COOH 16 2.68 (>95%)c
15 4-COOMe 1 2.69 75
16 4-Br 1 2.70d 77
aPurified by flash chromatography. bNo significant product formation determined
by 1H NMR or LC-MS. cNot purified by flash chromatography, but conversion
determined by crude 1H NMR. dOnly the 4-chlorobenzene product was observed
determined by LC-MS.
Both meta- and para-disubstituted aryl chlorides reacted efficiently giving full conversion
after just 1 hour for most of the substrates. Electron-donating groups such as ethers,
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alcohols and amines (entries 3, 6 and 7) worked well and the same was true for a variety
of electron-withdrawing groups like nitriles, nitro groups, ketones and esters (entries 10,
12, 13 and 15). Chlorobenzene itself also reacted smoothly giving full conversion af-
ter 1 hour (entry 1). Coupling of 4-chlorophenol, 4-chloroaniline, 4-chloronitrobenzene
and 4-chlorobenzoic acid did not proceed to completion after 1 hour (entries 6, 7, 12
and 14), but full conversion was achieved overnight (16 hours). Apparently, the unpro-
tected functional groups slowed down the reaction. Protection of the aniline nitrogen
as in (N-Boc)-4-chloro-aniline gave full conversion after 1 hour (entry 8). In the case
of a free aliphatic amine (entry 9), the unprotected nitrogen completely quenched the
reaction. To synthesize a halogen-substituted product, the chemistry with 1-bromo-4-
chlorobenzene (entry 16) was tested and the 4-chloro product 2.80 was formed exclu-
sively. This is reasonable because bromides react faster than chlorides. Finally, a couple
of ortho-substituted aryl chlorides were examined, but none of them gave any significant
product formation after 16 hours (entries 4 and 11). For ortho-methoxy substitution,
2-bromoanisole was tested with the more reactive bromide (entry 5), but no reaction
was observed. It is not surprising that ortho-substituted aryl halides did not react at all,
since there is much more steric hindrance around the halogen on these coupling partners.
The enantiomeric purity of 2.40 was analyzed by means of chiral HPLC. Fortunately,
only minor racemization had occurred (97% ee), which was expected due to the use of
mild base.
Besides of the aryl chlorides, the scope of the reaction was also examined with a series
of heterocycles. Three different chloro-pyridines, 2-chloropyrimidine, 5-chloro-1-methyl-
1H-imidazole, two chloro-thiophenes and 3-bromothiophene were tested. Unfortunately,
none of them gave any significant formation of product after 16 hours. It is plausible
that the heterocycles simply coordinate to palladium resulting in an unreactive complex.
Finally, the scope of the reaction was expanded by testing other tetramic acids than
Boc-pyPhe-OH (2.4). A series of functionalized tetramic acids were chosen; Boc-
pyArg(Pbf)-OH (2.32), Boc-pyTyr(tBu)-OH (2.33), Boc-pyLys(Cbz)-OH (2.34), Boc-
pyThr(tBu)-OH (2.35), Boc-pyAsp(tBu)-OH (2.36) and Boc-pyGly-OH (2.37). These
were all subjected to the optimized reaction conditions with 4-chloroanisole (2.53) as the
coupling partner (see Table 2.2.13). The chosen tetramic acids represent a broad variety
of functional side-chains and different protecting groups. Most of them gave similar
yields compared to the simpler phenylalanine model compound. Boc-pyAsp(tBu)-OH
(2.36) and especially Boc-pyGly-OH (2.37) gave however much lower yield of the cor-
responding α-aryl tetramic acids 2.75 and 2.76, respectively (entries 5 and 6).
The reaction between Boc-pyPhe-OH (2.4) and 4-chloroanisole (2.53) was tested with
microwave heating and it was found that full conversion (>95%) was achieved within
only 5 minutes at 110 ◦C.
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Table 2.2.13: Substrate scope with different tetramic acids.
N
P1
OH
O
Boc +
Cl
MeO
2 mol% Pd(OAc)2
K2CO3 (2.3 equiv), THF
80 oC, 1 hour
N
P1
OH
O
Boc
OMe(4 mol%)
P(tBu)2iPr
iPr
iPr2.32 − 2.37                        2.53                                                                   2.71 − 2.76
2.44
entry side-chain (P1)a time (h) product yield (%)b
1 Arg(Pbf) (2.32) 16 2.71 67
2 Tyr(tBu) (2.33) 1 2.72 69
3 Lys(Cbz) (2.34) 1 2.73 69
4 Thr(tBu) (2.35) 1 2.74 62
5 Asp(tBu) (2.36) 16 2.75 45
6 Gly (2.37) 16 2.76 28c
a: Notation corresponds to the respective amino acid side-chain (P1). b: Purified
by flash chromatography. c: Flash chromatography did not successfully purify the
product.
2.2.3.5 Solvent screening
So far, all reactions were conducted in THF. The initial reaction was revisited and other
solvents were tested (see Table 2.2.14). Dioxane, MeCN and DMF gave only traces of
product (<5%) no matter which base was used (Cs2CO3, K3PO4, Na2CO3 and K3CO3,
respectively) (entries 1–3).
However, running the reaction in toluene gave a significantly different result (entries
4–7). First of all, conversions were all much higher than the equivalent experiments
in THF (c.f. Table 2.2.7, entries 6–9), even with Na2CO3 a conversion of 29% was
achieved (see Table 2.2.14, entry 6). Full conversion was achieved with K3PO4, which
gave only 36% conversion in THF with the same ligand, tBu-MePhos (2.41). Steric
properties of the ligand are therefore not the only factor dependent on the efficiency of
the catalytic system.
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Table 2.2.14: Solvent screening using the initial reaction.
N OH
O
Boc +
Br
MeO K3PO4 (2.3 equiv), solvent80 oC, overnight
N OH
O
Boc
OMeP(
tBu)2
2 mol% Pd(OAc)2
2.4                             2.39                                                                          2.40
2.41
(4 mol%)
entry solvent base conv. (%)a
1 dioxane all fourb <5
2 MeCN all fourb <5
3 DMF all fourb <5
4 toluene Cs2CO3 86
5 toluene K3PO4 >95
6 toluene Na2CO3 29
7 toluene K2CO3 88
a: Determined by 1H NMR. b: Tested with the four bases
Cs2CO3, K3PO4, Na2CO3, and K2CO3, respectively in
four different experiments.
2.2.3.6 Keto/enol equilibrium of α-aryl tetramic acids
In all cases, the crude product was isolated as the enol tautomer upon acidic work-up.
However, during flash chromatography some degree of shifting in equilibrium towards the
keto tautomer was discovered. That gave more complex NMR spectra and decreased
solubility in organic solvents. To shift back the equilibrium, the compound was sus-
pended in EtOAc and treated with 10% aqueous KHSO4, which subsequently dissolved
the compound as the equilibrium was shifted toward the enol tautomer.
An example of this equilibrium shifting is shown in Figure 2.2.3 with the α-aryl tetramic
acid 2.40. For both the enol and the keto tautomers, LC-MS showed only one peak with
the same retention time. The acidic conditions on the LC-MS column apparently shift
the equilibrium to one of the tautomers independent of the initial equilibrium position.
However, the 1H NMR spectrum of 2.40-keto is more complex than the spectrum of
2.40-enol because of broad peaks which might be a result of the coexistence of both
a cis- and trans-tautomer. The chemical shift of H5 is 4.71 ppm (dd) for the enol
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tautomer, but 4.28 ppm (m) for the keto tautomers (H5
′
). The coupling pattern of the
H6 diastereotopic protons also changes; for the enol-tautomer the two protons are two
well-resolved double doublets (H6a + H6b), whereas the keto tautomers show a multiplet
in the region slightly upfield (H6
′a + H6
′b). Based on 1H NMR it was not possible to
determine the ratio between the cis/trans tautomers.
N OH
O
Boc
OMe
N O
O
Boc
OMe
+ N O
O
Boc
OMe
5
6
5' 5'
6' 6'
H5
OMe
H6a + H6b H5'
OMe
H6'a + H6'b
2.40                                                           2.40-keto (cis)                              2.40-keto (trans)
Figure 2.2.3: The observed tautomeric equilibrium and appurtenant 1H NMR
spectra (upfield region); the spectrum to the left belongs to the enol tautomer of
2.40 and the spectrum to the right to the keto tautomers (cis/trans).
Surprisingly, the crude product isolated from the toluene/K3PO4 reaction was exclu-
sively the keto tautomer (2.40-keto cis/trans, see Figure 2.2.3), whereas THF gave
the enol tautomer 2.40, when the same acidic work-up procedure was used. To in-
vestigate this point further, the equilibrium of the enol tautomer 2.40 was tried to be
shifted by dissolution in toluene, but nothing happened based on TLC analysis. When
adding 10% aqueous KHSO4 the enol-tautomer was slowly shifted towards the keto tau-
tomers (2.40-keto cis/trans). Isolation as the keto tautomers was unfortunately not
always straightforward. It was found that it is easily shifted back to the enol tautomer.
Formation of the less stable keto tautomers is not easy and it is rather unpredictable,
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probably because the equilibrium position is dependent on concentration, temperature,
pH and solvent. This corresponds with the literature regarding the keto-enol equilibrium
of tetramic acids.199,201–203
2.2.3.7 Reaction mechanism
Based on the literature230 the following mechanism for the coupling reaction is proposed
(see Figure 2.2.4).
N O
O
Boc
PdLn
N OH
O
Boc
LnPd(0)
Cl
N OK
O
Boc
N O
O
Boc
2.57
N OH
O
Boc
2.4
K2CO3
Acidic
work-up
H
Reductive 
elimination (C)
Oxidative
addition (A)
Trans-
metallation (B)
LnPd(II)
Reduction
Pd Cl
L
L
Figure 2.2.4: Proposed mechanism for the α-arylation of tetramic acids.
The catalytic cycle is assumed to be initiated by reduction of Pd(II) to the active Pd(0),
which might happen by a homo-coupling of the tetramic acids. Oxidation of the phos-
phine ligand is another well-known pathway for generation of Pd(0). However, Barder
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and Buchwald reported recently that dialkylbiaryl phoshines are highly resistant towards
oxidation by molecular oxygen.311
Following reduction of Pd(II) to Pd(0), oxidative addition of the aryl halide takes place
(A), then transmetallation by the potassium enolate of the tetramic acid 2.4 (B). Upon
reductive elimination the product is released (C) and Pd(0) re-enters the catalytic cycle.
The desired product 2.57 can be isolated by acidic work-up. It seems evident, that the
position of the keto/enol equilibrium is not determined by the reaction mechanism, but
rather by the work-up procedure and the solvent used.
2.2.3.8 Utilization of aryldiazonium salts
Based on the known reports on palladium-catalyzed cross-couplings utilizing an aryldia-
zonium salt,253,254,271 it seems evident that these conditions also could be applicable for
the α-arylation of tetramic acids. Utilization of aryldiazonium salts as coupling partners
would be a further broadning af utility and substrate scope. Hence, anilines could be
used by in situ generation of the corresponding diazonium salt. It was therefore desided
to briefly investigate the possibility to perform an α-arylation on a 1,3-dicarbonyl system
with an aryldiazonium salt, but also to implement the unusually mild reaction conditions
typically reported for this type of chemistry.253,254,271
O
O
+
N2BF4
Br
5 mol% PdCl2
MeCN:H2O (4:1)
rt to 50 oC, overnight
O
O
Br
2.77                         2.78                                                                   2.79(and other conditions)
Scheme 2.2.3: Attempted cross-coupling of cyclopentane-1,3-dione (2.77) with
the aryldiazonium salt 2.78, but no product 2.79 was formed. Many screening
conditions were tested, but they were all found to be unsuccessful.
Cyclopentane-1,3-dione 2.77 was selected as the model compound resembling the 1,3-
dicarbonyl system of a tetramic acid. Inspired by Zaragoza271 (c.f. Scheme 2.1.13),
initial coupling conditions consisting of 5 mol% PdCl2 in a solvent mixture of MeCN and
H2O were chosen with the commercially available aryldiazonium tetrafluoroborate 2.78
(see Scheme 2.2.3).
Unfortunately, the product 2.79 was not formed with 2.78 as coupling partner. Only
the corresponding hydrazone/diazene 2.80 was observed in minor to moderate quanti-
ties formed by addition of the nucleophilic α-carbon to the electrophilic nitrogen of the
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diazonium salt (see Scheme 2.2.4). The formation of 2.90 was observed on LC-MS and
1H NMR of the crude product. This reaction is known as the Japp-Klingemann reaction,
which is usually promoted by strong base.267
O
O
+
N2BF4
Br
O
O
2.77                         2.78
Japp-
Klingemann
N
N
Br
O
O N
HN
Br
2.80-diazene                 2.80-hydrazone
Scheme 2.2.4: Formation of hydrozone/diazene 2.80 through directly nucle-
ophilic attack of cyclopentane-1,3-dione (2.77) to the electrophilic diazonium
salt 2.78. This reaction is known as the Japp-Klingemann reaction.267
Furthermore, different temperatures were tested for the model reaction (see Scheme
2.2.3), but that did not afford 2.79. Neither did addition of H2SO4 (2 equiv) and/or
NaNO2 (0.10 equiv), respectively, which would resemble reaction conditions for an in
situ-generated aryldiazonium salt. Addition of acid would also prevent partial deprotona-
tion of 2.77 and thereby potentially prevent the Japp-Klingemann reaction to proceed.
Again, that was not observed, indicating that no palladium-catalyzed reaction took place.
This was confirmed by running reactions in the absence of PdCl2 affording similar prod-
ucts as with the presence of the catalyst. Altering the order of addition was also tested,
e.g. by addition of the aryldiazonium salt at last, but that did not change the reaction
outcome.
Utilization of PdCl2 restricts the use of solvents, because a pure alcohol cannot be used.
Predissolving PdCl2 in e.g. MeOH or EtOH did only result in ’palladium black’ and not
a clear, orange solution as was obtained by prestirring PdCl2 with MeCN overnight. A
solvent mixture consisting of MeOH:MeCN:H2O (5:3:2) was successful for predissolution
of PdCl2, but did not afford any formation of the desired product 2.79. 5 mol% Pd/C
in MeOH was tested analogously to the results reported by Beller,255 but only a messy
crude product was obtained.
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Sengupta and co-workers reported in 1993 a Heck cross-coupling utilizing 4-methoxy-
benzenediazonium tetrafluoroborate 2.81 and 2 mol% Pd(OAc)2 in MeOH (see Scheme
2.2.5).312 Inspired by these results, the same catalytical conditions were applied to the
screening reaction (c.f. Scheme 2.2.3), but the altered catalyst, solvent and coupling
partner did not give successful results. Addition of H2SO4 (1.0 equiv) or K3PO4 (1.0
equiv), respectively, was not successful.
MeO
NH2 NaNO2 (1.02 equiv)42% HBF4
1h, 0 oC MeO
N N BF4
2.81
2 mol% Pd(OAc)2
MeOH, 60 oC, 1h
O
OEt
MeO
OEt
O
2.82
71% yield
Scheme 2.2.5: Palladium-catalyzed Heck cross-coupling utilizing in situ-
generated aryldiazonium tetrafluoroborate 2.81 affording the the ethyl ester 2.82
in good yield.
So far, no coupling was observed with aryldiazonium tetrafluoroborates (2.78 or 2.81)
and the cyclopentane-1,3-dione (2.77) as a model substrate. To investigate if the un-
reactivity was a result of decomposed catalysts or a pronounced unreactivity of the
tetrafluoroborates (since these salts are significantly more stable than other diazonium
salts), a range of reference reactions were performed. Basically, the results published by
Beller,255 Zaragoza271 and Sengupta312 were easily reproduced and the cross-couplings
proceeded as described in the literature. These results indicated that all three cata-
lysts (Pd/C, PdCl2 and Pd(OAc)2) were not decomposed on the shelf and still active
under the tested conditions. Furthermore, the results of Sengupta and co-workers312
were tested with both in situ-generated and commercially available aryldiazonium salt
2.81. Both reactions proceeded nicely, in fact, a better yield was obtained with commer-
cially available 2.81 (83%). Thus, NaNO2 and HBF4 were not required for a successful
palladium-catalyzed coupling.
One plausible explanation for the unreactivity seen so far of the cyclopentane-1,3-dione
(2.77) might be that this chemistry works much better with electron-poor alkenes anal-
ogously to the Heck reaction. Furthermore, the reactivity and solubility of the aryldiazo-
nium salt might also influence the overall outcome. For example the reaction conditions
reported by Zaragoza271 were tested with 4-bromobenzenediazonium tetrafluoroborate
2.78 and allyl alcohol, but no reaction took place. Apparently, this reaction requires a
much more reactive coupling partner. Finally, solubility of aryldiazonium salts is low in
THF, toluene and MeCN, which are usually successful solvents for cross-couplings. Con-
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trarily, aryldiazonium salts are soluble in mixtures of MeCN/H2O as well as in MeOH,
EtOH, DMF and DMSO. These solubilities were tested for 4-bromobenzenediazonium
tetrafluoroborate 2.78.
Selection of catalyst may also be crucial, especially if a source of Pd(II) is used, be-
cause reduction to Pd(0) is required for reactivity. This activation of the catalyst may
take place e.g. by homo-coupling or oxidation of an added ligand. Phosphines (e.g.
(PPh3)3), if added, may add to the electrophilic nitrogen of aryldiazonium salt followed
by a decomposition and release of N2, thus forming a cationic arylpalladium complex,
313
which might undergo a cross-coupling. On the other hand, phosphines are also known to
transfer an electron to the aryldiazonium salt affording an aryl radical, which ultimately
gives the reduction product Ar-H and phosphine oxide.253 This explains why phosphines
are not ligands of choice in palladium-catalyzed reactions with aryldiazonium salts.
Based on these disappointing results, implementation of aryldiazonium salts in the α-
arylation of tetramic acids was discontinued. Apparently, 1,3-dicarbonyl substrates are
not suitable for a ligand-free cross-coupling catalyzed by PdCl2, Pd/C or Pd(OAc) in
MeCN:H2O. Yet, these reaction conditions are rather thankless compared to traditional
cross-coupling conditions. Implementation of the aryldiazonium salt in the previously
developed α-arylation of tetramic acids was not tested, primarily because of its little
impact if the remarkable mild reaction conditions could not also be used.
2.2.3.9 Summary
A new, mild, and racemization-free palladium-catalyzed α-arylation of tetramic acids
has been developed giving rise to α-aryl phenylalanine-derived tetramic acids (2.40 and
2.57–2.70) in good yield (60–79%). Through optimization it was found that 2 mol%
Pd(OAc)2 and 4 mol%
tBu-XPhos (2.44) gave full conversion in THF at 80 ◦C after 1
hour for most substrates. The two weak inorganic potassium bases, K2CO3 and K3PO4,
worked equally well. tBu-MePhos (2.41), which is a less sterically hindered ligand, gave
full conversion with K3PO4 in toluene. A variety of different substrates was tested and a
wide range of functionalities was tolerated, e.g. ethers, esters, ketones, alcohols, nitriles
and nitro groups. With respect to the substitution pattern of the aryl chloride, electron-
withdrawing as well as electron-donating groups showed similar reactivity and meta-
and para-substituted aryl chlorides reacted identically. Due to steric hindrance ortho-
substituted aryl chlorides did not react. Aryl chlorides, bromides and triflates all coupled
nicely, whereas aryl iodides and tosylates did not work. The α-arylation can be facilitated
by microwave heating with reaction time down to 5 minutes at 110 ◦C. Functionalized
amino acid-derived tetramic acids were also applicable for this chemistry, giving rise to
e.g. tyrosine- (2.72), lysine- (2.73) and more importantly the arginine-derived (2.71)
74
Results and discussion
α-aryl tetramic acid in good yield (67–69%). Heterocycles and unprotected amines
were not compatible with the chemistry. Utilization of aryldiazonium tetrafluoroborates
as coupling partners for the α-arylation of a 1,3-dicarbonyl model compound was not
found to be useful with either Pd(OAc)2, PdCl2 or Pd/C in MeCN/H2O or MeOH.
2.2.4 Cleavage of α-aryl tetramic acids
The most appropriate approach for cleavage of the α-aryl tetramic acids would be a
one-step procedure, which does not require a reduction of the ketone functionality prior
to ring opening. Initially the opening of Boc-pyPhe-OH (2.4) was attempted with con-
centrated aqueous NaOH or concentrated HCl, respectively. NaOH did not give any ring
opening, probably because of salt formation. Concentrated HCl on the other hand, led
to ring cleavage upon heating to reflux for 4 hours (see Scheme 2.2.6).
N OH
O
Boc conc. HCl
∆, 4h O
H3N
Cl
conv. >95%
2.4                                                      2.83
Scheme 2.2.6: Boc-pyPhe-OH (2.4) was cleaved to the corresponding methyl
ketone 2.83 by treatment with concentrated HCl at reflux for 4 hours.
The corresponding methyl ketone 2.83 was achieved in full conversion (>95%). No
ring cleavage was afforded by treatment with concentrated HCl at room temperature,
not even with reaction times as long as several days. Analogously, Boc-pyArg(Pbf)-
OH (2.32), Boc-pyLys(Cbz)-OH (2.34) and Boc-pyOrn(Cbz)-OH (2.38), respectively,
were subjected to concentrated HCl at reflux revealing similar reactivity of 2.32 and
2.34 (Boc- and Pbf-protections were lost). Ring opening was, on the other hand not
obtained by treating Boc-pyOrn(Cbz)-OH (2.38) with concentrated HCl which led to
messy crude products.
To test if these promising conditions also could cleave α-aryl tetramic acids, the previ-
ously synthesized compounds 2.40, 2.57 and 2.66 were subjected to concentrated HCl
at reflux for 4 hours (see Scheme 2.2.7).
Unfortunately, no ring cleavage was observed indicating that α-aryl tetramic acids are
much more stable than the parent tetramic acids. Prolonged reaction times did still
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N OH
O
Boc
conc. HCl
∆, 4h O
H3N
Cl
2.40: R' = 4-OMe
2.57: R' = H
2.66: R' = 4-NO2
R'
R'
2.84: R' = 4-OMe
2.85: R' = H
2.86: R' = 4-NO2
Scheme 2.2.7: Attempted ring cleavage of the α-aryl tetramic acids 2.40, 2.57
and 2.66 with concentrated HCl was not successful.
not give any traces of product. Ring opening would probably be possible under basic
conditions, if the acidic proton of the α-aryl tetramic acid was removed. This would
avoid salt formation and the ring system might be cleaved leading to the corresponding
γ-amino-α-aryl-β-keto carboxylate.
N OH
O
Boc
2.57
N
O
Boc
2.87
OEt
1. KHDMS (1.03 equiv)
    THF, 0 oC, 10 min
2. EtOTs, 18-crown-6,
    THF, 0 oC to rt
Scheme 2.2.8: Conversion of the α-aryl tetramic acid 2.57 into the correspond-
ing ethyl enol ether 2.87 did not work.
It was therefore attempted to convert the α-aryl tetramic acid 2.57 into the correspond-
ing ethyl enol ether 2.87 (see Scheme 2.2.8), inspired by a similar reaction developed
for tetramic acids.212 Formation of an alkyl enol ether would remove the acidity of the
tetramic acid and prevent salt formation upon treatment with base. Unfortunately 2.57
was unreactive under these reaction conditions.
One reason for this increased stability and unreactivity might be the enhanced conjugated
system present in the α-aryl tetramic acids. To reduce this conjugation and to decrease
the acidity, reduction of the ketone functionality of 2.57, forming the β-hydroxy deriva-
tive 2.88 was attempeted with a variety of reducing agents; NaBH4, LiBH4, DIBAL-H,
L-selectride, LiAl(OtBu)3H and 9-BBN (see Scheme 2.2.9). Unfortunately, for all of
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them only the starting material 2.57 was isolated upon work-up. Different tempera-
tures were tested, ranging from –78 ◦C to reflux as well as different equivalents of the
reducing agent, but no change in the outcome was observed. Addition of AcOH did
not lead to product formation. Some of the reducing agents were also tested with the
α-aryl tetramic acids 2.40 and 2.66, but no change in reactivity was observed despite
the altered electrondensity of the aryl group.
N OH
O
Boc
2.57
Reducing agent
Solvent, −78 oC to ∆
N OH
O
Boc
2.88
Scheme 2.2.9: The α-aryl tetramic acid 2.57 was attempted to be reduced
to 2.88 with a variety of different reducing agents (NaBH4, LiBH4, DIBAL-H,
L-selectride, LiAl(OtBu)3H and 9-BBN), but none of them worked.
So far, none of the approaches for ring cleavage, reduction of the ketone functionality
or ethyl enol ether formation afforded the desired product. It was therefore decided to
change strategy radically. LiOOH (path A)278 and SmI2 (path B),
284 respectively, were
tested (see Scheme 2.2.10).
Both of these methods represent mechanistically different approaces for ring cleavage
compared to the methods previously tested. Neither of the methods gave any product
formation, 2.89 or 2.90, respectively.
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N OH
O
Boc
2.57
A. H2O2 (35%), LiOH   
     (2.5 equiv), THF, 0 oC to rt
N
H
Boc
O O
R
                  -or-
B. SmI2 (2 equiv), THF, 20 oC, 
     5 min, then EtOH (2 equiv), 1h
2.89: R = OH (path A)
2.90: R = H (path B)
Scheme 2.2.10: Neither LiOOH (path A) nor SmI2 (path B) afforded any clea-
vage of the α-aryl tetramic acid 2.57 to the corresponding carboxylic acid 2.89
and the aldehyde 2.90, respectively.
2.2.4.1 Summary
Ring opening of the synthesized α-aryl tetramic acids did not work. Apparently, these
compounds are much more stable than the parent tetramic acids, and hence unreactive
upon treatment with concentrated HCl or with reducing agents such as NaBH4, LiBH4,
DIBAL-H, L-Selectride, LiAl(OtBu)3H or 9-BBN. Treatment with LiOOH or SmI2, re-
spectively, did not work either. Ethyl enol ether derivatization for subsequent basic ring
opening was not successful, once again due to the unreactivity of the α-aryl tetramic
acids.
78
Conclusion
2.3 Conclusion
Optimization of the facile synthesis of γ-amino-β-keto esters failed due to formation of
the corresponding tetramic acid. To avoid this cyclization, Boc2-Phe-OH (2.18) was
synthesized in three steps from the parent Boc-Phe-OH (2.2) in excellent yield with
no racemization. This diprotected amino acid was subjected to the reaction conditions
and a variety of different γ-amino-β-keto esters 2.21–2.24 were synthesized in high
yield. Unfortunately, this strategy was inconvenient for functionalized amino acids due
to lack of selectivity among the Nα- and the side-chain nitrogens resulting in many
undefined products. The tetramic acids were therefore selected as the key intermediate
of choice for further synthetic development. Tetramic acids were easily synthesized in
high yield from the corresponding amino acids and Meldrum’s acid (2.1) with no by-
product formation. A palladium-catalyzed α-arylation of the tetramic acids was then
developed by careful screening of multiple reaction parameters such as different ligands,
bases, coupling partners and solvents. The most appropriate conditions were 2 mol%
Pd(OAc)2 and 4 mol%
tBu-XPhos (2.44) in THF (80 ◦C, 1–16h) which afforded a broad
range of α-aryl tetramic acids 2.40, 2.57–2.70 showing a very good functional group
tolerance. Moreover, arylchlorides and aryltriflates showed similar reactivity compared
to arylbromides. The chemistry was also applicable with microwave heating at 110 ◦C
for 5 minutes. Aryldiazonium tetrafluoroborates were not found to be suitable for α-
arylation of 1,3-dicarbonyl compounds. The α-aryl tetramic acids were subjected to
many different approaces for ring opening toward to the synthesis of the desired benzyl
ketone building block, but that did not succeed. Apparently, these arylated compounds
are much more stable than the parent tetramic acids. Hydrolysis with concentrated HCl,
reduction with a variety of different reducing agents and treatment with LiOOH or SmI2,
respectively, did only afford recovery of the starting material. Based on the surprising
unreactivity of α-aryl tetramic acids, development of a new, mild and convenient building
block synthesis was not successful.
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2.4 Outlook
Despite the many attempts to ring open the α-aryl tetramic acids, this strategy seems
to be useless due to the pronounced unreactivity. Going back to the other key intermedi-
ate, the γ-amino-β-keto esters, these compounds might be useful if another diprotection
strategy is considered. Some phthaloyl-protected amino acids are commercially avail-
able,251,314 but arginine-derived compounds are not. This protecting group therefore has
to be introduced prior to synthesis of the β-keto ester (see Scheme 2.4.1).
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Scheme 2.4.1: Proposed synthesis of the arginyl benzyl ketone building block
2.96 by phthaloyl N,N-protection to avoid tetramic acid formation during β-keto
ester synthesis.
N,N-Protection of H-Arg(NO2)-OH (2.91) has been reported in the literature using
phthalic anhydride giving Phth-Arg(NO2)-OH (2.92) in modest yield.
315 However, this
reaction was reported to be selective and only the amino group was protected. This
selectivity is important in contrast ti the non-selective introduction of an additional
Boc-group, which was found inconvenient for functionalized amino acids such as argi-
nine. The diprotected amino acid 2.92 is then though to be converted into the corre-
sponding β-keto methyl ester 2.93 by C -acylation of Meldrum’s acid (2.1) and work-up
with MeOH. Due to the fully protected amino-group, no tetramic acid will be formed
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by cyclization.174 Using appropriate reaction conditions, the aryl-group could be intro-
duced by a palladium-catalyzed reaction. Unfortunately, this may require another careful
screening of possible ligands, solvents and bases if the previously reported conditions for
α-arylation of tetramic acids cannot be used. Followed by basic hydrolysis of the methyl
ester with LiOH in MeOH/H2O
316 giving the protected arginyl ketone building block
2.95, the desired building block 2.96 is believed to be prepared by N,N-deprotection
by treatment with hydrazine.294,295,317 The -NO2 guadinine protection can be removed
after peptide synthesis by reduction with H2 over Pd/C.
318 Utilization of the highly toxic
hydrazine is a major drawback of this strategy as well as the lack of commercially avail-
able starting materials and the use of non-standardized amino acid protection groups.
However, it might represent a possible synthetic route for functionalized benzyl ketone
building blocks.
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Scheme 2.4.2: Proposed synthesis of the arginyl benzyl ketone building block
2.106 via ornithine, which after β-keto ester formation and α-arylation is amidi-
nated and Pmc-protected.
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To avoid the nucleophilic behavoir of the guadinine group, an arginine precursor could
be used instead. The non-DNA encoded amino acid ornithine (Orn) is an obvious pre-
cursor of arginine. Cbz-Orn-OH is thought to be converted to Cbz-Orn-OAllyl, and then
to (Boc,Cbz)-Orn(Boc)2-OAllyl (2.97), analogously with preparation of Boc2-Orn(Cbz)-
OAllyl (2.30) described in Section 2.2.1.4. The reverse order of the Cbz group (Nα versus
Nδ) is chosen to secure regioselective deprotection for amidination of the δ-amino group
only. Removal of the allyl group could be done by treating 2.97 with (Ph3P)3RhCl afford-
ing the carboxylic acid 2.98,319 which is then converted to the γ-amino-β-keto methyl
ester 2.99 as previously described (see Scheme 2.4.2). The aryl-group is introduced by
a palladium-catalyzed cross-coupling giving 2.100, which is then hydrolyzed to the β-
keto acid following a decarboxylation upon treatment with TFA which is thought to give
the amine 2.101. Treatment with TFA promotes the decarboxylation but also removes
all the Boc-groups. The free δ-amino group is then amidinated using 4-benzyl-3,5-
dimethyl-1H-pyrazole-1-carboxamidine hydrochloride (2.102) affording the unprotected
arginine 2.103.320 The amidinating agent 2.102 can be synthesized easily in two steps
from benzaldehyde, acetylacetone and aminoguanidine hydrochloride.320 Introduction of
the Nω-Pmc protection is thought to be accomplished by reaction with the commer-
cially available Pmc-Cl 2.104 under basic conditions,321 and the final preparation of the
arginyl benzyl ketone building block 2.106 is achieved by removal of the Cbz-group upon
catalytic hydrogenolysis.322
Both of these alternative strategies are somewhat tedious because of the many protecting
group manipulations. However, they might also represent possible routes to functional-
ized benzyl ketones for probing of the S1’ binding pocket of FVIIa, which could otherwise
not be introduced. Probing of the S1’ site represents an important strategy for designing
of potent and selective serine protease inhibitors - a strategy that is almost unexplored.
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2.5 Experimental
General procedures
Chemicals and reagents were all commercially available and used without further purifi-
cation. Solvents were of HPLC quality and used without further purification. THF and
DMSO-d6 were dried over 3A˚ molecular sieves (1.6 mm pellets) prior to use, whereas
alcohols for γ-amino-β-keto ester synthesis were dried over 4A˚ molecular sieves. Evapo-
ration in vacuo was performed on Bu¨chi Vacuum Rotavapor R-205 at approx. 40 ◦C and
down to approx. 20 mbar. Microwave heating was achieved in a Biotage R© InitiatorTM
Microwave Synthesizer (single-mode) set with high absorption. The reaction was per-
formed in a Biotage R© 10 mL microwave vial sealed with a septum cap, and prestirred
in the synthesizer for 1 minute and then heated to 110 ◦C, after which the reaction
was stirred for 5 minutes. Finally, the vial was cooled to below 50 ◦C with air over a
few minutes. During the reaction both temperature (IR-sensor) and pressure (bowing
of the septum) were monitored automatically by the instrument. TLC was performed
using Merck Silica gel 60 F254 aluminum sheets. The plates were visualized in UV light
(254 nm), stained with either 0.5% ninhydrin in EtOH, 5% MoO3/H3PO4 in EtOH or
1.5% KMnO4 in conc. H2SO4, respectively, and subsequently heated with a heating gun.
Flash chromatography was performed on a Biotage R© FlashMaster purification system.
The eluent ratios given are vol%. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra
were recorded on a Bruker Avance DRX 400 instrument using deuterated solvents as
internal references. Chemical shifts (δ) are given in ppm and coupling constants (J)
in Hertz. HRMS was performed on a Agilent Technologies 1200 Series LC/MSD-TOF
instrument using a C18 column (5%→95% MeCH in H2O, 15 minutes). The found
mass (m/z) was stated along with the appurtenant fragment, which varies less than 5
ppm compared to the calculated exact mass. MS was determined on a Perkin Elmer
200 Series PE Sciex API 3000 LC/MS/MS Turbo Ionspray system (5%→90% MeCH in
H2O, 10 minutes). Elemental analysis was performed by Micro Kemi AB, Sweden and
varied less than 0.4% compared to the calculated values. In some instances elemental
analysis varied more than 0.4% compared to the calculated composition, even though
analytical HPLC showed a pure compound. Melting points were measured on a Bu¨chi
535 Melting Point Apparatus and given in degrees Celsius (◦C), uncorrected. Analytical
UPLC (TFA) was performed on a Waters Acquity Ultra Performance LC using a gradient
of 5%→95% (or variations hereof) MeCH in H2O (16 minutes) containing 0.05% TFA
on a C18 column (1.7 µm, 2.1×50 mm). IR analysis was carried out on a Bruker Alpha
FT-IR spectrometer using attenuated total reflection (ATR) sampling technique. Only
the strongest or structurally most significant peaks are included in the experimental sec-
tion, stated in cm−1. Chiral HPLC was run on an Agilent 1100 series instrument with an
AS-H column (amylose tris[(S)-α-methylbenzyl-carbamate] coated on 5 µm silica gel),
L = 250 mm, I.D. = 4.6 mm. 15 vol% EtOH in hexanes was used as eluent (isocratic);
flow rate was 1.00 mL/min, max. 70 bars and a run time of 15 minutes. 5 µL sample
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was injected from a solution of the compound in 15 vol% EtOH in hexanes (sample
concentration: 1 mg/mL). Enantiomeric excess was calculated using the average of the
peak integrals at the following wavelengths: 210, 222, 230, 254 and 280 nm, respectively.
General synthesis of tetramic acids (A)
To a solution of a N-Boc amino acid (12.5 mmol, 1.0 equiv) in DCM (165 mL), Mel-
drum’s acid (2.1) (2.70 g, 18.8 mmol, 1.5 equiv) and DMAP (2.29 g, 18.8 mmol, 1.5
equiv) were added. The mixture was cooled to 0 ◦C and EDC·HCl (3.60 g, 18.8 mmol,
1.5 equiv) was added while stirring. Stirring was continued at 0 ◦C for 15 minutes and
then at room temperature for 4 hours. The yellow mixture was transferred to a sepa-
ratory funnel with EtOAc (490 mL) and washed with brine (2 × 250 mL), 5% aqueous
citric acid (2 × 250 mL) and finally with brine again (250 mL). The organic layer was
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. EtOAc (100 mL) was
added and the mixture was heated to reflux for 30 minutes. The solution was cooled
to ambient temperature and the solvent was removed by evaporation in vacuo and the
residue was coevaporated with toluene (3 × 50 mL) and dried in high vacuum overnight.
This afforded the desired tetramic acid, which was used without purification.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-1,5-dihydro-pyrrol-2-one
(Boc-pyPhe-OH) (2.4)171
Following the general synthesis of tetramic acids (A) using Boc-Phe-OH (2.2) as amino
acid starting material, afforded the product as a pale, yellow solid (3.48 g, 96%). 1H
NMR (DMSO-d6) δ 12.41 (broad s, 1H), 7.27–7.19 (m, 3H), 7.01–6.98 (m, 2H), 4.65
(s, 1H), 4.62 (dd, J = 5.3, 2.6 Hz, 1H), 3.35 (dd, J = 13.9, 5.3 Hz, 1H), 3.06 (dd, J =
13.9, 2.3 Hz, 1H), 1.50 (s, 9H). HRMS (m/z) calcd. for C32H38N2O8Na [2M + Na]
+:
601.2520, found: 601.2516. HPLC purity (TFA): >92.2%. Mp ≈ 154 ◦C (decomp.)
(lit.:171 120–124 ◦C).
General synthesis of benzyl/allyl amino acid-derived esters (B)
A N-Boc protected amino acid (1.42 mmol, 1.00 equiv) was dissolved in MeOH (10 mL)
and H2O (1.5 mL) was added. The solution was neutralized to pH 7 with 20% aqueous
Cs2CO3 (30 drops). The mixture was evaporated to dryness in vacuo and the residue
was coevaporated with DMF (2 × 25 mL). The cesium salt was stirred with BnBr (300
µL, 292 mg, 1.71 mmol, 1.20 equiv) or allylbromide (150 µL, 189 mg, 1.56 mmol, 1.10
equiv) in DMF (10 mL) at room temperature for 40 min (BnBr) or 2 hours (allylbromide).
The reaction mixture was transferred to a separatory funnel with EtOAc (60 mL) and
extracted with brine (2 × 60 mL). The organic layer was dried over anhydrous Na2SO4
and evaporated to dryness in vacuo. The product was used without further purification.
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(2S)-Benzyl 2-(tert-butoxycarbonyl)amino-3-phenylpropanoate (Boc-Phe-OBn)
(2.17).306
Following the general synthesis of benzyl carboxylic-protected amino acids (B) with Boc-
Phe-OH (2.2) and BnBr (5.9 mL, 49.76 mmol, 1.1 equiv) as starting materials, afforded
the product as a slightly yellow solid (15.64 g, 97%). 1H NMR (300 MHz, CDCl3), δ
7.27–7.12 (m, 8H), 6.95–6.93 (m, 2H), 5.07 (d, J = 12.3, 1H), 5.00 (d, J = 12.2, 1H),
4.90 (d, J = 8.2, 1H), 4.53 (dd, J = 14.2, 6.0, 1H), 3.05–2.92 (m, 2H), 1.31 (s, 9H).
HRMS (m/z) calcd. for C21H25NO4Na [M + Na]
+: 378.1676, found: 378.1671. Mp
62–63 ◦C (lit.:306 64–65 ◦C).
General synthesis of N,N-Boc2-protected amino acids (C)
To a solution of a benzyl/allyl N-Boc amino acid-derived ester (45.23 mmol, 1.0 equiv)
in MeCN (60 mL) was added DMAP (0.55 g, 4.52 mmol, 0.1 equiv) and Boc2O (10.86 g,
49.76 mmol, 1.1 equiv). The reaction was stirred at room temperature overnight. Addi-
tional Boc2O (≈ 5 g, 24.88 mmol, 0.51 equiv) was added repeatedly until TLC and/or
LC-MS showed full conversion of the starting material. The mixture was evaporated
to dryness in vacuo and then transferred to a separatory funnel with EtOAc (150 mL).
Washed with 5% aqueous citric acid solution (150 mL) and brine (150 mL). The yellow
organic layer was dried over anhydrous Na2SO4, evaporated to dryness in vacuo and the
residue was coevaporated with toluene (3 × 150 mL) and dried in high vacuum. The
product was used without further purification.
Carboxylic deprotection was achieved by dissolving the N,N-Boc2 protected benzyl
ester in MeOH (2.5 mL/g) adding 5 wt.% Pd/C. Hydrogenated with H2 gas applied by
a balloon (1 atm) at room temperature and stirred vigorously overnight. The catalyst
was removed by filtration through Celite R© and rinsed with MeOH (3 × 10 mL). The
filtrates were evaporated to dryness in vacuo and dried in high vacuum. Deprotection
of the allyl esters was never tried.
Enantiomeric excess was determined by derivatization with (R)-1-phenyl ethylamine:
a carboxylic acid sample (0.20 mmol, 1.00 equiv) was dissolved in DCM (4 mL), which
was added HOBt (40 mg, 0.30 mmol, 1.50 equiv) and EDC·HCl (29 mg, 0.24 mmol,
1.20 equiv). After stirring at ambient temperature for 5 minutes, DIPEA (170 µL) was
added and the reaction mixture was stirred overnight securing full conversion (>95%).
Then EtOAc (15 mL) was added and the mixture was washed with H2O (25 mL), brine
(25 mL), 0.5M HCl (25 mL) and finally with brine again (25 mL). The organic layer was
dried over anhydrous Na2SO4 and evaporated to dryness in vacuo, which gave the de-
sired derivative. The enantiomeric excess was determined by 1H NMR analysis in CDCl3
using the chemical shifts for the methyl group. A reference with racemic carboxylic acid
sample was run to determine the shifts of the methyl groups in both diastereomers.
(2S)-2,2-di(tert-Butoxycarbonyl)amino-3-phenylpropanoic acid (Boc2-Phe-OH)
(2.18)306,323
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Following the general synthesis of N,N-Boc2-protected amino acids (C) with Boc-Phe-
OBn (2.17) as starting material, afforded Boc2-Phe-OBn as a viscous orange oil (19.02
g, 92%). 1H NMR (CDCl3), 7.36–7.16 (m, 10H), 5.24–5.15 (m, 3H), 3.45 (dd, J =
15.0, 6.0, 1H), 3.24 (dd, J = 15.0, 12.0, 1H), 1.35 (s, 18H). Upon hydrogenolysis of the
benzyl ester, the crude product crystallized spontaneously to a pale, yellow solid (11.57
g, 70%). Smaller scale gave up to 90% yield. Purification was achieved by recrystal-
lization from toluene (2 mL/g crude product), which afforded 2.18 as white crystals
(81% recovery from recrystallization). 1H NMR (CDCl3) δ d 7.31–7.17 (m, 5H), 5.24
(dd, J = 9.0, 6.0, 1H), 3.43 (dd, J = 12.0, 3.0, 1H), 3.24 (dd, J = 15.0, 9.0, 1H),
1.40 (s, 18H). 13C NMR (CDCl3) δ 176.3, 151.6, 137.3, 129.5, 128.4, 126.6, 83.3, 59.2,
35.8, 27.8. HRMS (m/z) calcd. for C38H54N2O12Na [2M + Na]
+: 753.3568, found:
753.3583. Elem. anal. calcd. for C19H27NO6: C 62.45, H 7.45, N 3.83, found: C
62.77, H 7.53, N 3.74. Mp 142–144 ◦C (litt.: 137–138 ◦C). IR (KBr): ν 2987, 1723
(strong), 1371, 1318, 1249, 1121, 1053, 847, 783, 703 cm−1. The enantiomeric excess
was determined to be >95% (diagnostic chemical shift: δ 1.49 (d, J = 7.16 Hz, 3H),
diastereomeric reference: δ 1.47 (d, J = 6.78 Hz, 3H) was not observed).
(2S)-Methyl 2,2-di(tert-butoxycarbonyl)amino-3-phenylpropanoate (Boc2-Phe-
OMe) (2.20)324
Following the general synthesis of N,N-Boc2-protected amino acids (C) (except the sec-
ond step, the hydrogenolysis) with Boc-Phe-OMe (2.19) as starting material, afforded
the product as an oil (1.32 g, 97%). 1H NMR (CDCl3) δ 7.30–7.16 (m, 5H), 5.15 (dd, J
= 10.2, 4.9 Hz, 1H), 3.75 (s, 3H), 3.43 (dd, J = 14.1, 5.1 Hz, 1H), 3.21 (dd, J = 13.9,
10.6 Hz, 1H), 1.38 (s, 18H). 13C NMR (CDCl3) δ 170.9, 151.6, 137.6, 129.5, 128.3,
126.5, 82.9, 59.4, 52.2, 36.2, 27.8. MS (m/z) calcd. for C20H29NO6Na [M + Na]
+:
402.2, found: 402.1.
Attempted basic hydrolysis of Boc2-Phe-OMe (2.20) for preparation of enan-
tiomerically pure Boc2-Phe-OH (2.18)
Boc2-Phe-OMe (2.20) (200 mg, 0.53 mmol, 1.00 equiv) was dissolved in MeOH (or
THF) (7.5 mL) and cooled to 5 ◦C (other experiments were performed at room tem-
perature or at reflux). Sat. aqueous NaOH (or LiOH) (2.5 mL) was added and the
reaction was stirred at the chosen temperature between 30 minutes and 16 hours. The
base was quenched with 10% aqueous HCl to pH 2 and the mixture was transferred to a
separatory funnel with EtOAc (20 mL) and washed with H2O (20 mL). The organic layer
was dried over anhydrous Na2SO4, evaporated to dryness in vacuo and dried overnight in
high vacuum. This afforded Boc2-Phe-OH (2.18) as a pale, yellow solid (175 mg, 91%)
(when NaOH was used at 5 ◦C for 7.5 hours). Characterization was in accordance with
the previously synthesized compound. Enantiomeric excess was determined as described
above (general method C) and it was found that in all cases basic hydrolysis led to
complete racemization.
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General synthesis of phenylalanine-derived γ-amino-β-keto esters (D)
To a solution of Boc2-Phe-OH (2.18) (500 mg, 1.37 mmol, 1.0 equiv) in DCM (15 mL),
Meldrum’s acid (2.1) (296 mg, 2.05 mmol, 1.5 equiv) and DMAP (251 mg, 2.05 mmol,
1.5 equiv) were added. The mixture was cooled to 0 ◦C and EDC·HCl (393 mg, 2.05
mmol, 1.5 equiv) was added. Stirring was continued for 15 minutes and then at room
temperature for 4 hours. The yellow reaction mixture was transferred to a separatory
funnel with cold EtOAc (65 mL) and the organic phase was washed with cold brine (2 ×
30 mL), cold 5% aqueous citric acid (2 × 30 mL) and finally with cold brine again (30
mL). The purification had to be done quickly and with cold solutions to avoid forma-
tion of the corresponding methyl ketone. The organic layers were dried over anhydrous
Na2SO4 and evaporated to dryness in vacuo. This afforded the crude product as an oil,
which was subsequently dissolved in a dry alcohol (15 mL) and the mixture was heated
to reflux for 45 minutes. The desired γ-amino-β-keto ester was isolated by evaporation
to dryness in vacuo and thorough drying in vacuum.
(4S)-Methyl 4,4-di(tert-butoxycarbonyl)amino-3-oxo-5-phenylpentanoate (Boc2-
Phe-CH2COOMe) (2.21)
Following the general synthesis of phenylalanine-derived γ-amino-β-keto esters (D) af-
forded the product as a slightly yellow low-melting solid (541 mg, 94%) using dry MeOH
for work-up of the intermediate. 1H NMR (CDCl3) δ 7.29–7.13 (m, 5H), 5.05 (dd, J =
9.8, 4.5, 1H), 3.73 (s, 3H), 3.57 (d, J = 18.0, 1H), 3.48 (d, J = 15.0, 1H), 3.46 (dd, J =
9.0, 6.0, 1H), 2.97 (dd, J = 15.0, 12.0, 1H), 1.39 (s, 18H). 13C NMR (CDCl3) δ 198.8,
167.5, 151.3, 137.5, 129.5, 128.4, 126.6, 83.9, 66.0, 52.3, 45.2, 34.6, 27.7. HRMS
(m/z) calcd. for C22H31NO7Na [M + Na]
+: 444.1993, found: 444.1989. IR (neat) υ
2979, 2943, 1752 (strong), 1703 (strong), 1368, 1306, 1252, 1230, 1136, 1108, 873,
755, 697 cm−1.
(4S)-Ethyl 4,4-di(tert-butoxycarbonyl)amino-3-oxo-5-phenylpentanoate
(Boc2-Phe-CH2COOEt) (2.22)
Following the general synthesis of phenylalanine-derived γ-amino-β-keto esters (D) af-
forded the the product as an oil, which crystallized spontaneously upon storage at room
temperature to a slightly yellow, low-melting solid (565 mg, 95%) using dry EtOH for
work-up of the intermediate. 1H NMR (CDCl3) δ 7.29–7.13 (m, 5H), 5.06 (dd, J =
9.0, 3.0, 1H), 4.19 (q, J = 6.9, 2H), 3.56 (d, J = 15, 1H), 3.46 (d, J = 18, 1H), 3.46
(dd, J = 15.0, 3.0), 2.97 (dd, J = 14.3, 9.8, 1H), 1.39 (s, 19H), 1.27 (t, J = 7.2,
3H). 13C (CDCl3) δ 198.9, 167.0, 151.2, 137.5, 129.5, 128.4, 126.5, 83.87, 65.9, 61.3,
45.3, 34.6, 27.7, 14.1. HRMS (m/z) calcd. for C23H33NO7Na [M + Na]
+: 458.2149,
found: 458.2160. Elem. anal. calcd. for C23H33NO7: C, 63.43; H, 7.64; N, 3.22, found:
C, 63.06; H, 7.70; N, 3.38. IR (neat) υ 2979, 2943, 1752, 1704 (strong), 1688, 1367,
1306, 1250, 1136, 1108, 873, 697 cm−1.
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(4S)-Isopropyl 4,4-di(tert-butoxycarbonyl)amino-3-oxo-5-phenylpentanoate (Boc2-
Phe-CH2COO
iPr) (2.23)
Following the general synthesis of phenylalanine-derived γ-amino-β-keto esters (D) af-
forded the product as a yellow viscous oil (604 mg, 98%) using dry iPrOH for work-up
of the intermediate. 1H NMR (CDCl3) δ 7.29–7.13 (m, 5H), 5.09–5.03 (m, 2H), 3.52
(d, J = 15.0, 1H), 3.47 (dd, J = 14.3, 4.5, 1H), 3.44 (d, J = 15.0, 1H), 2.97 (dd,
J = 14.1, 9.9, 1H), 1.39 (s, 18H), 1.27 (d, J = 3.0, 3H), 1.25 (d, J = 3.4, 3H). 13C
NMR (CDCl3) δ 190.0, 166.6, 151.2, 137.5, 129.5, 128.4, 126.5, 83.9, 69.0, 66.0, 45.5,
34.6, 27.7, 21.7. HRMS (m/z) calcd. for C24H35NO7Na [M + Na]
+: 472.2306, found:
472.2306. Elem. anal. calcd. for C24H35NO7: C, 64.12; H, 7.85; N, 3.12, found: C,
63.96; H, 7.96; N, 3.42. IR (neat) υ 2981, 2936, 1793, 1721 (strong), 1697, 1455, 1366,
1307, 1240, 1133 (strong), 1104, 699 cm−1.
(4S)-tert-Butyl 4,4-di(tert-butoxycarbonyl)amino-3-oxo-5-phenylpenta-
noate (Boc2-Phe-CH2COO
tBu) (2.24)
Following the general synthesis of phenylalanine-derived γ-amino-β-keto esters (D) af-
forded the the product as a yellow viscous oil (616 mg, 97%) using dry tBuOH for
work-up of the intermediate. 1H NMR (CDCl3) δ 7.29–7.13 (m, 5H), 5.06 (dd, J =
9.8, 4.5, 1H), 3.50 (d, J = 15.0, 1H), 3.45 (dd, J = 15.0, 6.0, 1H), 3.36 (d, J = 15.0,
1H), 2.97 (dd, J = 15.0, 12.0, 1H), 1.46 (s, 9H), 1.39 (s, 19H). 13C NMR (CDCl3)
δ 199.4, 166.3, 151.2, 137.6, 129.5, 128.4, 126.5, 83.8, 82.0, 66.0, 46.3, 34.7, 27.97,
27.7. HRMS (m/z) calcd. for C25H37NO7Na [M + Na]
+: 486.2462, found: 486.2465.
Elem. anal. calcd. for C25H37NO7: C, 64.77; H, 8.05; N, 3.02, found: C, 64.70; H,
8.17; N, 3.10. IR (neat) υ 2979, 2935, 1794, 1720 (strong), 1698, 1367, 1307, 1245,
1133 (strong), 963, 872 cm−1.
Attempted synthesis of (4S)-benzyl 4,4-di(tert-butoxycarbonyl)amino-3-oxo-5-
phenylpentanoate (Boc2-Phe-CH2COOBn) (2.25)
Following the general synthesis of phenylalanine-derived γ-amino-β-keto esters (D) af-
forded complete conversion (>95%) based on TLC analysis, Rf = 0.85 (EtOAc), using
dry BnOH for work-up of the intermediate. The excess BnOH could not be removed by
evaporation in vacuo and the experiment was terminated.
(2S)-Benzyl 2-(tert-butoxycarbonyl)amino-5-(3-(2,2,4,6,7-pentamethyl-
dihydrobenzofuran-5-sulfonyl)guanidino)pentanoate (Boc-Arg(Pbf)-OBn) (2.26)
Following the general synthesis of benzyl amino acids-derived esters (B) with Boc-
Arg(Pbf)-OH and BnBr as starting materials, afforded the product as a white solid
(386 mg, 88%). 1H NMR (CDCl3) δ 7.40–7.26 (m, 5H), 6.28 (m, 2H), 5.34 (d, J =
7.2 Hz, 1H), 5.09 (s, 2H), 4.22 (m, 1H), 3.22–3.10 (m, 2H), 2.91 (s, 2H), 2.54 (s, 3H),
2.48 (s, 3H), 2.06 (s, 3H), 1.85–1.74 (m, 1H), 1.67–1.60 (m, 1H), 1.54–1.50 (m, 2H),
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1.43 (s, 6H), 1.38 (s, 9H). HRMS (m/z) calcd. for C31H44N4O5S [M + H]
+: 617.3004,
found: 617.2981. Mp 79–86 ◦C.
(2S)-Allyl 5-(benzyloxycarbonyl)amino-2-(tert-butoxycarbonyl)amino-
pentanoate (Boc-Orn(Cbz)-OAllyl) (2.27)
Following the general synthesis of allyl amino acid-derived esters (B) with Boc-Orn(Cbz)-
OH and allylbromide as starting materials, afforded the product as a pale, yellow oil (512
mg, 92%). 1H NMR (CDCl3) δ 7.36–7.31 (m, 5H), 5.96–5.84 (m, 1H), 5.29 (m, 2H),
5.09 (s, 2H), 4.91 (broad s, 1H), 4.63 (d, J = 5.7 Hz, 2H), 4.33–4.29 (m, 1H), 3.22 (q,
J = 6.2 Hz, 2H), 1.96–1.83 (m, 1H), 1.72–1.51 (m, 3H), 1.44 (s, 9H). HRMS (m/z)
calcd. for C21H30N2O6Na [M + Na]
+: 429.1996, found: 429.1988.
(2S)-Allyl 6-(benzyloxycarbonyl)amino-2-(tert-butoxycarbonyl)amino-
hexanoate (Boc-Lys(Cbz)-OAllyl) (2.28)
Following the general synthesis of allyl amino acid-derived esters (B) with Boc-Lys(Cbz)-
OH and allylbromide as starting materials, afforded the product as a pale, yellow oil (524
mg, 95%). 1H NMR (CDCl3) δ 7.36–7.29 (m, 5H), 5.97–5.84 (m, 1H), 5.36–5.23 (m,
2H), 5.09 (s, 3H), 4.91 (broad s, 1H), 4.63–4.61 (m, 2H), 4.30 (m, 1H), 3.19 (q, J =
6.4 Hz, 2H), 1.88–1.71 (m, 1H), 1.69–1.62 (m, 1H), 1.56–1.48 (m, 2H), 1.43 (s, 9H),
1.42–1.32 (m, 2H). HRMS (m/z) calcd. for C22H32N2O6Na [M + Na]
+: 443.2152,
found: 443.2155.
Attempted regioselective Nα-protection of Boc-Arg(Pbf)-OBn (2.26) by treat-
ment with Boc2O toward the synthesis of 2.29
Following the general synthesis of N,N-Boc2-protected amino acids (C) (except the sec-
ond step, the hydrogenolysis) with Boc-Arg(Pbf)-OBn (2.26) as the starting material.
The reaction was very sluggish and full conversion could only be achieved by addi-
tion of several portions of 0.50 equiv Boc2O over the course of 4 days. Unfortunately,
this resulted in many undefined multiple Boc-protected products and extensively Boc2O
contamination. These findings were based on LC-MS analysis. MS (m/z) calcd. for
C36H53N4O9S [M + H]
+: 717.35, found: 717.36.
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(2S)-Allyl 5,5-(benzyloxycarbonyl,tert-butoxycarbonyl)amino-2,2-di(tert-butoxycarbonyl)aminopentanoate
(Boc2-Orn(Boc,Cbz)-OAllyl) (2.30)
Following the general synthesis of N,N-Boc2-protected amino acids (C) (except the sec-
ond step, the hydrogenolysis) with Boc-Orn(Cbz)-OAllyl (2.27) as starting material with
2.20 equiv of Boc2O and 0.20 equiv of DMAP. The reaction was rather sluggish and
many additional portions of 0.50 equiv Boc2O had to be added to secure full conversion
based by LC-MS. The fully protected product was isolated as a brown, viscous oil (494
mg, 72%). 1H NMR (CDCl3) δ 7.40–7.30 (m, 5H), 5.94–5.83 (m, 1H), 5.33–5.21 (m,
4H), 4.90 (m, 1H), 4.60 (d, J = 5.3 Hz, 2H), 3.69 (t, J = 7.0 Hz, 2H), 2.17–2.08
(m, 1H), 1.91–1.86 (m, 1H), 1.68–1.63 (m, 2H), 1.48 (s, 9H), 1.47 (s, 18H). 13C NMR
(CDCl3) δ 170.2, 153.8, 152.1, 151.9, 135.5, 131.8, 128.5, 128.1, 118.0, 83.0, 82.7,
68.3, 65.6, 57.8, 45.9, 27.9, 26.8, 25.8. HRMS (m/z) calcd. for C31H46N2O10Na [M +
Na]+: 629.3044, found: 629.3029.
(2S)-Allyl 6,6-(benzyloxycarbonyl, tert-butoxycarbonyl)amino-2,2-di(tert-butoxycarbonyl)aminohexanoate
(Boc-Lys(Cbz)-OAllyl) (2.31)
Following the general synthesis of N,N-Boc2-protected amino acids (C) (except the
second step, the hydrogenolysis) with Boc-Lys(Cbz)-OAllyl (2.28) as starting material
with 2.20 equiv Boc2O and 0.20 equiv of DMAP. The reaction was rather sluggish and
many additional portions of 0.50 equiv Boc2O had to be added to secure full conversion
based by LC-MS. The fully protected product was isolated as a brown, viscous oil (506
mg, 73%). 1H NMR (CDCl3) δ 7.41–7.30 (m, 5H), 5.93–5.86 (m, 1H), 5.35–5.28 (m,
1H), 5.24–5.19 (m, 3H), 4.87–4.82 (m, 1H), 4.62–4.58 (m, 2H), 3.66–3.60 (m, 2H),
2.18–2.09 (m, 1H), 1.93–1.85 (m, 1H), 1.66–1.59 (m, 2H), 1.49 (s, 9H), 1.49–1.47 (m,
18H), 1.41–1.30 (m, 2H). 13C NMR (CDCl3) δ 170.5, 153.9, 152.2, 152.0, 135.6, 131.9,
128.5, 128.2, 118.0, 83.0, 82.7, 68.2, 65.6, 58.1, 46.4, 29.4, 28.7, 28.0, 23.6. HRMS
(m/z) calcd. for C32H48N2O10Na [M + Na]
+: 643.3201, found: 643.3199.
(5S)-1-(tert-Butyloxycarbonyl)-4-hydroxy-5-(3-(2,2,4,6,7-pentamethyl-
2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)-propyl)-1,5-dihydro-pyrrol- 2-one
(Boc-pyArg(Pbf)-OH) (2.32)
Following the general synthesis of tetramic acids (A) using Boc-Arg(Pbf)-OH as amino
acid starting material, afforded the product as a pale, yellow solid (6.80 g, 99%). 1H
NMR (DMSO-d6) δ 12.30 (broad s, 1H), 6.73 (broad s, 1H), 6.40 (broad s, 2H), 4.87
(s, 1H), 4.39 (m, 1H), 3.03 (q, J = 6.6 Hz, 2H), 2.96 (s, 2H), 2.47 (s, 3H), 2.42 (s,
3H), 2.01 (s, 3H), 1.95–1.89 (m, 1H), 1.81–1.73 (m, 1H), 1.42 (s, 9H), 1.41 (s, 6H),
1.25–1.15 (m, 2H). 13C NMR (DMSO-d6) δ 176.6, 169.2, 157.5, 156.0, 148.7, 137.3,
134.1, 131.4, 124.3, 116.3, 94.1, 86.3, 80.9, 58.9, 42.5, 28.3, 27.7, 26.3, 18.9, 17.6,
12.3. HRMS (m/z) calcd. for C26H39N4O7S [M + H]
+: 551.2534, found: 551.2537.
HPLC purity (TFA): >78.8%. Mp 142–148 ◦C. IR (neat): ν 3441, 3332, 2973, 2930,
1755, 1617, 1548 (strong), 1367, 1299, 1240, 1152, 1083 cm−1.
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(5S)-5-(4-tert-Butoxybenzyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-1,5-
dihydro-pyrrol-2-one (Boc-pyTyr(tBu)-OH) (2.33)
Following the general synthesis of tetramic acids (A) using Boc-Tyr(tBu)-OH as amino
acid starting material, afforded the product in quantitative yield as a pale, yellow foam
(4.81 g, 106%). 1H NMR (DMSO-d6) δ 12.34 (broad s, 1H), 6.92 (d, J = 8.0 Hz, 2H),
6.82 (d, J = 8.0 Hz, 2H), 4.69 (s, 1H), 4.57 (dd, J = 5.2, 2.4 Hz, 1H), 3.32 (dd, J
= 13.9, 5.3 Hz, 1H), 3.03 (dd, J = 13.9, 2.3 Hz, 1H), 1.50 (s, 9H), 1.24 (s, 9H). 13C
NMR (DMSO-d6) δ 175.5, 168.7, 153.8, 149.0, 130.1, 129.1, 123.1, 94.9, 80.9, 77.6,
59.8, 33.7, 28.5, 27.9. HRMS (m/z) calcd. for C20H27NO5Na [M + Na]
+: 384.1781,
found: 384.1793. HPLC purity (TFA): 82%. Mp 73–76 ◦C. IR (neat): ν 2976, 2932,
1754 (strong), 1710, 1607, 1505, 1363, 1234, 1148 (strong), 1074 cm−1.
(5S)-5-(4-(Benzyloxycarbonyl)butyl)-1-(tert-butyloxycarbonyl)-4-hydroxy- 1,5-
dihydro-pyrrol-2-one (Boc-pyLys(Cbz)-OH) (2.34)
Following the general synthesis of tetramic acids (A) using Boc-Lys(Cbz)-OH as amino
acid starting material, afforded the product as a pale, yellow foam (800 mg, 94%). 1H
NMR (DMSO-d6) δ 12.24 (broad s, 1H), 7.38–7.28 (m, 5H), 5.00 (s, 2H), 4.89 (s, 1H),
4.39 (dd, J = 5.1, 2.5 Hz, 1H), 2.96 (q, J = 6.5 Hz, 2H), 2.03–1.95 (m, 1H), 1.81–1.75
(m, 1H), 1.44 (s, 9H), 1.41–1.35 (m, 2H), 1.17–1.03 (m, 2H). 13C NMR (DMSO-d6)
176.7, 169.3, 156.1, 148.8, 137.3, 128.31, 127.7, 94.2, 80.8, 65.1, 59.2, 40.3, 29.4, 28.5,
27.8, 19.1. HRMS (m/z) calcd. for C42H56N4O12Na [2M + Na]
+: 831.3786, found:
831.3790. HPLC purity (TFA): 83%. Mp 43–46 ◦C. IR (neat): ν 3324, 2974, 2933,
1756, 1702 (strong), 1613, 1530, 1365, 1299, 1246, 1152 (strong), 1076 cm−1.
(5S)-5-((1S)-1-tert-Butoxyethyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-1,5-dihydro-
pyrrol-2-one (Boc-pyThr(tBu)-OH) (2.35)
Following the general synthesis of tetramic acids (A) using Boc-Thr(tBu)-OH as amino
acid starting material, afforded the product in quantitative yield as a viscous, yellow
oil (3.73 g, 100%), which solidified upon storage to a low-melting solid. 1H NMR
(DMSO-d6) δ 11.71 (s, 1H), 4.89 (s, 1H), 4.31 (d, J = 3.5 Hz, 1H), 4.19 4.13 (m, 1H),
1.45 (s, 9H), 1.15 (s, 9H), 0.95 (d, J = 6.3 Hz, 3H). 13C NMR (DMSO-d6) δ 176.3,
169.0, 149.3, 94.8, 81.1, 73.7, 65.6, 63.3, 27.9, 27.8, 17.5. HRMS (m/z) calcd. for
C15H25NO5Na [M + Na]
+: 322.1625, found: 322.1628. HPLC purity (TFA): >85.8%.
IR (neat): ν 2977, 2933, 1704 (strong), 1677, 1586, 1306 (strong), 1285, 1150, 1093
cm−1.
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(5S)-5-(2-tert-Butoxy-2-oxoethyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (Boc-pyAsp(tBu)-OH) (2.36)
Following the general synthesis of tetramic acids (A) using Boc-Asp(tBu)-OH as amino
acid starting material, afforded the product as a pale, yellow solid (3.68 g, 94%). 1H
NMR (DMSO-d6) δ 12.39 (s, 1H), 4.85 (s, 1H), 4.56 (dd, J = 6.3, 2.8 Hz, 1H), 2.81
(dd, J = 16.0, 8.0 Hz, 1H), 2.73 (dd, J = 16.0, 4 Hz, 1H), 1.45 (s, 9H), 1.33 (s,
9H). 13C NMR (DMSO-d6) δ 175.8, 168.8, 167.9, 148.6, 93.9, 80.9, 80.1, 56.7, 35.9,
27.7, 27.5. HRMS (m/z) calcd. for C30H46N2O12Na [2M + Na]
+: 649.2942, found:
649.2932. HPLC purity (TFA): >75.2%. Mp 73–76 ◦C. IR (neat): ν 2978, 2943, 1738,
1716 (strong), 1368, 1317, 1245, 1149, 848 cm−1.
(5S)-1-(tert-Butyloxycarbonyl)-4-hydroxy-1,5-dihydro-pyrrol-2-one (Boc-pyGly-
OH) (2.37)325
Following the general synthesis of tetramic acids (A) using Boc-Gly-OH as amino acid
starting material, afforded the product as a pale, yellow solid (2.47 g, 99%). 1H NMR
(DMSO-d6) δ 12.17 (broad s, 1H), 4.87 (s, 1H), 4.13 (s, 2H), 1.43 (s, 9H). HRMS
(m/z) calcd. for C9H13NO4Na [M + Na]
+: 222.0737, found: 222.0745. HPLC purity
(TFA): >97.3%. Mp 123–127 ◦C (lit.:325 N/A).
(5S)-5-(4-(Benzyloxycarbonyl)propyl)-1-(tert-butyloxycarbonyl)-4-hy-
droxy-1,5-dihydro-pyrrol-2-one (Boc-pyOrn(Cbz)-OH) (2.38)
Following the general synthesis of tetramic acids (A) using Boc-Orn(Cbz)-OH as start-
ing material, afforded the product as a white solid (804 mg, 94%). 1H NMR (CDCl3) δ
7.37–7.30 (m, 5H), 5.17–5.03 (m, 3H), 4.87 (broad s, 1H), 4.49–4.39 (m, 1H), 3.24–3.07
(m, 3H), 2.17–1.88 (m, 2H), 1.72–1.60 (m, 1H), 1.54, 1.51 (2 × s, 9H), 1.46–1.41 (m,
1H). 13C NMR (CDCl3) δ 204.0, 172.6, 167.4, 156.9, 156.4, 149.3, 149.0, 136.4, 136.1,
128.6, 128.2, 128.1, 84.5, 83.0, 67.0, 66.7, 59.9, 42.9, 40.3, 28.1, 28.0, 26.3, 24.8, 22.9.
HRMS (m/z) calcd. for C20H26N2O6Na [M + Na]
+: 413.1683, found: 413.1689. Mp
48–54 ◦C.
General synthesis of α-aryl tetramic acids (E)
A pressure resistant glass vial was charged with a magnetic stir bar, dry THF (3.0 mL),
tetramic acid (1.00 mmol, 1.00 equiv), tBu-XPhos (2.44) (17 mg, 0.04 mmol, 0.04
equiv), K2CO3 (318 mg, 2.30 mmol, 2.30 equiv) and an aryl chloride coupling partner
(1.00 mmol, 1.00 equiv). N2 was bubbled through the reaction mixture and Pd(OAc)2
(4 mg, 0.02 mmol, 0.02 equiv) was added, the vial was filled with N2, sealed with a
screw cap and placed in an aluminum heating block. The mixture was stirred vigorously
at 80 ◦C for 1 hour (or 16 hours, c.f. Tables 2.2.12 and 2.2.13). After cooling to am-
bient temperature, the crude mixture was transferred to a separatory funnel with 10%
aqueous KHSO4 (10 mL) and extracted with EtOAc (30 mL + 20 mL). The combined
organic phases were dried over anhydrous Na2SO4 and evaporated to dryness in vacuo.
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The yellow crude product was purified by flash chromatography (5→10 vol% MeOH in
EtOAc, in some cases up to 20 vol% MeOH) affording the pure product typically as a
keto/enol tautomer mixture. The product was subsequently suspended in EtOAc (50
mL). 10% aqueous KHSO4 (50 mL) was added and the biphasic system was stirred vig-
orously at room temperature until complete dissolution of the compound. The mixture
was transferred to a separatory funnel and the organic layer was separated. The aqueous
layer was extracted with EtOAc (20 mL) and the combined organic layers were dried
over anhydrous Na2SO4, evaporated to dryness in vacuo and dried overnight in high
vacuum which afforded the pure product mostly as the enol-tautomer.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-methoxyphenyl)-1,5-dihydro-
pyrrol-2-one (2.40)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-chloroanisole (2.53) as coupling partners, afforded the product as a pale, brown
solid (313 mg, 79%). 1H NMR (DMSO-d6) δ 12.35 (broad s, 1H), 7.22–7.12 (m, 6H),
6.99 (d, J = 6.8 Hz, 2H), 6.76 (dd, J = 8.0, 1.6 Hz, 1H), 4.73 (dd, J = 4.6, 2.5 Hz,
1H), 3.70 (s, 3H), 3.45 (dd, J = 14.0, 4.9 Hz, 1H), 3.27 (dd, J = 13.9, 2.3 Hz, 1H),
1.54 (s, 9H). 13C NMR (DMSO-d6) δ 170.4, 167.4, 158.7, 149.0, 134.1, 131.8, 129.5,
128.7, 127.9, 126.8, 120.0, 113.2, 111.7, 105.1, 81.3, 57.9, 54.8, 34.6, 27.9. HRMS
(m/z) calcd for C46H50N2O10Na [2M + Na]
+: 813.3358, found: 813.3367. Elem. anal.
calcd. for C23H25NO5: C, 69.86; H, 6.37; N, 3.54, found: C, 69.84; H, 6.52; N, 3.49.
HPLC purity (TFA): >98.1%. Mp 142–145 ◦C. IR (neat): ν 2975, 2930, 1750 (strong),
1363, 1284, 1251, 1147, 1095, 833, 699 cm−1. Chiral HPLC: 4.57 minutes (minor) and
5.78 minutes (major) gave an enantiomeric excess of 97%.
Microwave assisted synthesis of (5S)-5-benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-
3-(4-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.40)
A microwave vial was charged with Boc-pyPhe-OH (2.4) (289 mg, 1.00 mmol, 1.00
equiv), tBu-XPhos (2.44) (17 mg, 0.04 mmol, 0.04 equiv), Pd(OAc)2 (4 mg, 0.02
mmol, 0.02 equiv) and K2CO3 (318 mg, 2.30 mmol, 2.30 equiv). Dry THF (3.0 mL)
was added and used to carefully rinse the inside of the vial (for safety reasons no solid
may be stuck on the glass!). 4-Chloroanisole (2.53) (143 mg, 0.08 mL, 1.00 equiv) was
added and N2 was bubbled into the vial to secure an inert reaction atmosphere. The vial
was capped, sealed and heated to 110 ◦C in a microwave synthesizer for 5 minutes. After
cooling to ambient temperature, the crude product was neutralized with 10% aqueous
KHSO4 (10 mL) and EtOAc (30 + 20 mL) was added. The combined organic layers were
dried over anhydrous Na2SO4 and evaporated to dryness in vacuo. The crude product
was analyzed by 1H NMR in DMSO-d6 which showed full conversion (>95%) and the
spectrum was identical with that of the product obtained by conventional heating (80
◦C, 1 hour).
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4-Methoxyphenyl tosylate (2.55)326
To a solution of 4-methoxyphenol (1.24 g, 10.00 mmol, 1.00 equiv) in pyridine (10 mL),
TsCl (2.10 g, 11.00 mmol, 1.10 equiv) was added portionwise at room temperature and
the mixture was stirred at 45 ◦C overnight. After cooling to ambient temperature, H2O
(25 mL) was added and stirred at room temperature for 3 hours. This mixture was
diluted with toluene (200 mL) and washed with H2O (150 mL), 10% HCl (3 × 150
mL), sat. aqueous NaHCO3 (2 × 150 mL) and finally with brine (2 × 150 mL). The
organic layer was dried over anhydrous Na2SO4, filtered and evaporated in vacuo to an
oil, which crystallized upon drying in high vacuum. The tosylate 2.55 was obtained as
a white solid (2.62 g, 94%). 1H NMR (DMSO-d6) δ 7.70 (d, J = 7.3 Hz, 2H), 7.45 (d,
J = 7.6 Hz), 6.92–6.87 (m, 4H), 3.70 (s, 3H), 2.40 (s, 3H). HRMS (m/z) calcd. for
C14H14O4SNa [M + Na]
+: 301.0510, found: 301.0410. Mp 66–71 ◦C (lit.:326 69–70 ◦C).
4-Methoxyphenyl triflate (2.56)327
To a cooled (0 ◦C) mixture of toluene (20 mL) and 30% aqueous K3PO4 (20 mL) was
added 4-methoxyphenol (1.24 g, 10.00 mmol, 1.00 equiv). Tf2O (1.34 mL, 2.29 g, 12.00
mmol, 1.10 equiv) was added dropwise under vigorously stirring at a rate to maintain
the reaction temperature below 10 ◦C. The reaction was allowed to warm ambient tem-
perature and stirred for 30 minutes. The organic phase was separated and then washed
with H2O (20 mL), dried over anhydrous Na2SO4 and evaporated to dryness in vacuo.
The product 2.56, which was a yellow liquid, was dried in high vacuum overnight (1.80
g, 70%). 1H NMR (DMSO-d6) δ 7.41 (d, J = 9.09 Hz, 2H), 7.08 (d, J = 9.09 Hz,
2H), 3.79 (s, 3H). Contained 10% of the 4-methoxyphenol starting material: 1H NMR
(DMSO-d6) δ 6.74 (m, 2H), 6.68 (m, 2H), 3.65 (s, 3H).
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-phenyl-1,5-dihydro-pyrrol-
2-one (2.57)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and chlorobenzene as coupling partners, afforded the product as a pale, brown solid (273
mg, 75%). 1H NMR (DMSO-d6) δ 12.30 (broad s, 1H), 7.52 (dd, J = 8.3, 1.3 Hz, 2H),
7.28 (t, J = 7.6 Hz, 2H), 7.22–7.15 (m, 4H), 7.01–6.98 (m, 2H), 4.73 (dd, J = 4.8, 2.5
Hz, 1H), 3.45 (dd, J = 13.9, 4.8 Hz, 1H), 3.27 (dd, J = 14.0, 2.4 Hz, 1H), 1.54 (s, 9H).
13C NMR (DMSO-d6) δ 170.2, 167.4, 149.0, 134.2, 130.5, 129.5, 127.9, 127.7, 127.5,
126.8, 126.3, 105.4, 81.2, 57.9, 34.6, 27.9. HRMS (m/z) calcd. for C44H46N2O8Na
[2M + Na]+: 753.3146, found: 753.3153. Elem. anal. calcd. for C22H23NO4: C, 72.31;
H, 6.34; N, 3.83, found: C, 71.97; H, 6.60; N, 3.96. Mp 86–88 ◦C. IR (neat): ν 3082,
3061, 2977, 2928, 1753, 1702, 1661, 1645 (strong), 1397, 1359, 1298, 1149, 694 cm−1.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(3-methoxyphenyl)-1,5-dihydro-
pyrrol-2-one (2.58)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
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and 3-chloroanisole as coupling partners, afforded the product as a pale, brown solid (310
mg, 78%). 1H NMR (DMSO-d6) δ 12.35 (broad s, 1H), 7.22–7.12 (m, 6H), 6.99 (d, J
= 6.8 Hz, 2H), 6.76 (dd, J = 8.0, 1.4 Hz, 1H), 4.72 (dd, J = 4.4, 2.4 Hz, 1H), 3.70 (s,
3H), 3.45 (dd, J = 13.9, 4.8 Hz, 1H), 3.27 (dd, J = 13.9, 2.0 Hz, 1H), 1.54 (s, 9H).
13C NMR (DMSO-d6) δ 170.4, 167.4, 158.7, 149.0, 134.1, 131.8, 129.5, 128.7, 127.9,
126.8, 120.0, 113.2, 111.7, 105.1, 81.3, 57.9, 54.8, 34.6, 27.9. HRMS (m/z) calcd.
for C46H50N2O10Na [2M + Na]
+: 813.3358, found: 813.3377. Elem. anal. calcd. for
C23H25NO5: C, 69.86; H, 6.37; N, 3.54, found: C, 69.65; H, 6.60; N, 3.46. Mp 136–138
◦C. IR (neat): ν 3196, 2974, 2929, 1736 (strong), 1680, 1653, 1407, 1340, 1308, 1147,
1108, 755, 700 cm−1.
Attempted synthesis of (5S)-5-benzyl-1-(tert-butyloxycarbonyl)-4-hy-
droxy-3-(2-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.59)with 2-chloro- anisole
as coupling partner
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 2-chloroanisole as coupling partners (16 hours), did not afford any significant pro-
duct based on LC-MS and 1H NMR.
Attempted synthesis of (5S)-5-benzyl-1-(tert-butyloxycarbonyl)-4-hy-
droxy-3-(2-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.59)with 2-bromo- anisole
as coupling partner
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 2-bromoanisole as coupling partners (16 hours), did not afford any significant pro-
duct formation based on LC-MS and 1H NMR.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-hydroxyphenyl)-1,5-dihydro-
pyrrol-2-one (2.60)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-chlorophenol as coupling partners and 16 hours reaction time, afforded the pro-
duct as a pale, brown solid (273 mg, 72%). 1H NMR (DMSO-d6) δ 11.95 (broad s,
1H), 9.34 (broad s, 1H), 7.36 (d, 2H, J = 8.6 Hz), 7.22–7.15 (m, 3H), 6.99 (d, J =
6.8 Hz, 2H), 6.69 (d, J = 8.6 Hz, 2H), 4.68 (dd, J = 4.7, 2.0 Hz, 1H), 3.43 (dd, J =
13.8, 4.7 Hz, 1H), 3.26 (dd, J = 13.5, 2.0 Hz, 1H), 1.53 (s, 9H). 13C NMR (DMSO-d6)
δ 168.3, 167.8, 155.9, 149.1, 134.3, 129.6, 128.8, 127.9, 126.8, 126.8, 121.2, 114.6,
105.6, 81.2, 57.8, 34.6, 27.9. HRMS (m/z) calcd. for C44H46N2O10Na [2M + Na]
+:
785.3044, found: 785.3046. Elem. anal. calcd. for C22H23NO5: C, 69.28; H, 6.08; N,
3.67, found: C, 69.49; H, 6.31; N, 3.52. Mp 136–139 ◦C. IR (neat): ν 3370 (broad),
2978, 2932, 1726 (strong), 1516, 1396, 1358, 1147, 812, 700 cm−1.
(5S)-3-(4-Aminophenyl)-5-benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (2.61)
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Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-chloroaniline as coupling partners and 16 hours reaction time, afforded the desired
product (conv. >95%) based on 1H NMR, which was not further purified. 1H NMR
(DMSO-d6) δ 7.37 (d, J = 8.6 Hz, 2H), 7.21–7.14 (m, 3H), 6.97 (d, J = 7.8 Hz, 2H),
6.68 (d, J = 8.3 Hz, 2H), 6.67 (s, 1H), 4.66 (dd, J = 4.8, 2.5 Hz, 1H), 3.41 (dd, J =
13.9, 5.1 Hz, 1H), 3.24 (dd, J = 14.0, 1.9 Hz, 1H), 1.52 (s, 9H). HRMS (m/z) calcd.
for C44H48N4O8Na [2M + Na]
+: 783.3364, found: 783.3367.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-3-(4-tert butyl phenylcarbamat)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (2.62)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and N-tert-butyl 4-chlorophenylcarbamate as coupling partners, afforded the product as
a brown solid (360 mg, 75%). 1H NMR (DMSO-d6) δ 12.09 (broad s, 1H), 9.29 (s,
1H), 7.45 (d, J = 8.5, 2H), 7.36 (d, J = 8.6, 2H), 7.23–7.13 (m, 3H), 6.99 (d, J =
6.82, 1H), 4.70 (dd, J = 4.7, 2.4 Hz, 1H), 3.44 (dd, J = 13.9, 4.8 Hz, 1H), 3.26 (dd, J
= 13.9, 2.0 Hz, 1H), 1.53 (s, 9H), 1.47 (s, 9H). 13C NMR (DMSO-d6) δ 169.1, 167.5,
152.7, 149.1, 137.8, 134.2, 129.5, 127.7, 127.7, 126.7, 124.4, 117.5, 105.2, 81.2, 78.9,
57.9, 34.6, 28.1, 27.9. HRMS (m/z) calcd. for C54H64N4O12Na [2M + Na]
+: 983.4412,
found: 983.4403. HPLC purity (TFA): >94.6%. Mp 140–143 ◦C. IR (neat): ν 3359,
2976, 2931, 1750, 1732, 1590, 1522, 1392, 1367, 1309, 1228, 1228, 1149 (strong) cm−1.
Attempted synthesis of (5S)-5-benzyl-1-(tert-butyloxycarbonyl)-3-(4-cy-
anophenyl)-4-hydroxy-1,5-dihydro-pyrrol-2-one (2.63)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 2-(4-chlorophenyl)ethaneamine as coupling partners, did not afford any significant
product formation based on LC-MS and 1H NMR.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-3-(4-cyanophenyl)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (2.64)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-chlorobenzonitrile as coupling partners, afforded the product as a pale, brown solid
(288 mg, 74%). 1H NMR (DMSO-d6) δ 7.88 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.6 Hz,
2H), 7.20–7.13 (m, 3H), 6.96 (d, J = 6.8 Hz, 2H), 4.75 (dd, J = 4.8, 2.5 Hz, 1H), 3.44
(dd, J = 14.0, 4.9 Hz, 1H), 3.28 (dd, J = 14.0, 2.4 Hz, 1H), 1.53 (s, 9H). 13C NMR
(DMSO-d6) δ 173.6, 167.0, 148.9, 136.0, 134.1, 131.7, 129.4, 127.9, 127.1, 126.8,
119.1, 108.0, 103.0, 81.4, 58.3, 34.7, 27.9. HRMS (m/z) calcd. for C46H44N4O8Na
[2M + Na]+: 803.3052, found: 803.3025. HPLC purity (TFA): >94.4%. Mp 225–230
◦C (decomp.). IR (neat): ν 2974, 2928, 2225, 1748 (strong), 1644, 1603, 1352 (strong),
1302 (strong), 1149, 699, 550 cm−1.
Attempted synthesis of (5S)-5-benzyl-1-(tert-butyloxycarbonyl)-3-(2-cyano-phenyl)-
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4-hydroxy-1,5-dihydro-pyrrol-2-one (2.65)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 2-chlorobenzonitrile as coupling partners (16 hours), did not afford any significant
product formation based on LC-MS and 1H NMR.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-nitrophenyl)-1,5-dihydro-
pyrrol-2-one (2.66)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-nitrobenzene as coupling partners and 16 hours reaction time, afforded the pro-
duct as a pale, brown solid (244 mg, 60%). 1H NMR (DMSO-d6) δ 8.15 (d, J = 9.1
Hz, 2H), 8.01 (d, J = 9.1 Hz, 2H), 7.20–7.11 (m, 3H), 6.97 (d, J = 6.6 Hz, 2H),
4.78 (dd, J = 4.8, 2.5 Hz, 1H), 3.46 (dd, J = 14.0, 4.9 Hz, 1H), 3.29 (dd, J = 14.0,
2.4 Hz, 1H), 1.54 (s, 9H). 13C NMR (DMSO-d6) δ 174.6, 167.0, 148.9, 144.6, 138.3,
134.0, 129.4, 127.9, 127.0, 126.8, 123.1, 102.6, 81.4, 58.4, 34.7, 27.8. HRMS (m/z)
calcd. for C44H44N4O12Na [2M + Na]
+: 843.2848, found: 843.2863. Elem. anal. calcd.
for C22H22N2O6: C, 64.38; H, 5.40; N, 6.83, found: C, 64.61; H, 5.65; N , 6.52. Mp
approx. 250 ◦C (decomp.). IR (neat): ν 2973, 2931, 2225, 1761, 1714, 1600, 1425,
1340 (strong), 1146, 850, 702 cm−1.
(5S)-3-(4-Acetylphenyl)-5-benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (2.67)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 1-(4-chlorophenyl)ethanone as coupling partners, afforded the product as a pale,
brown solid (302 mg, 74%). 1H NMR (DMSO-d6) δ 7.87 (d, J = 8.0 Hz, 2H), 7.79
(d, J = 8.0 Hz, 2H), 7.21–7.14 (m, 3H), 6.97 (d, J = 6.6 Hz, 2H), 4.77 (dd, J =
4.8, 2.5 Hz, 1H), 3.45 (dd, J = 13.9, 5.1 Hz, 1H), 3.28 (dd, J = 14.0, 2.4 Hz, 1H),
2.53 (s, 3H), 1.54 (s, 9H). 13C NMR (DMSO-d6) δ 197.3, 172.5, 167.1, 149.0, 135.7,
134.3, 134.1, 129.5, 127.9, 127.8, 126.8, 104.0, 81.4, 58.2, 34.7, 27.9, 26.6. HRMS
(m/z) calcd. for C48H50N2O10Na [2M + Na]
+: 837.3358, found: 837.3345. Elem. anal.
calcd. for C24H25NO5: C, 70.74; H, 6.18; N, 3.44, found: C, 70.89; H, 6.43; N , 3.46.
Mp 227–230 ◦C (decomp.). IR (neat): ν 2973, 2926, 1763, 1713, 1680 (strong), 1603
(strong), 1357, 1264 (strong), 1143 cm−1.
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(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-3-(4-carboxyphenyl)-4-hydroxy-1,5-dihydro-
pyrrol-2-one (2.68)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 4-chlorobenzoic acid as coupling partner and 16 hours reaction time, afforded the
desired product (conv. >95%) based on 1H NMR, which was not further purified. 1H
NMR (DMSO-d6) δ 12.79 (broad s, 1H), 7.86 (d, J = 8.0 Hz, 2H), 7.75 (d, J =
8.0 Hz, 2H), 7.21–7.14 (m, 3H), 6.98 (d, J = 6.8 Hz, 2H), 4.77 (dd, J = 4.6, 2.5
Hz, 1H), 3.46 (dd, J = 14.0, 4.9 Hz, 1H), 3.29 (dd, J = 13.9, 2.0 Hz, 1H), 1.54 (s,
9H). HRMS (m/z) calcd. for C46H46N2O12Na [2M + Na]
+: 841.2942, found: 841.2942.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-(methoxycarbo- nyl)phenyl)-
1,5-dihydro-pyrrol-2-one (2.69)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and methyl 4-chlorobenzoate as coupling partner, afforded the product as a pale, brown
solid (317 mg, 75%). 1H NMR (DMSO-d6) δ 7.88 (d, J = 8.0 Hz, 2H), 7.80 (d, J =
8.0 Hz, 2H), 7.23–7.14 (m, 3H), 6.99 (d, J = 7.8 Hz, 2H), 4.78 (dd, J = 4.8, 2.5 Hz,
1H), 3.82 (s, 3H), 3.47 (dd, J = 13.9, 5.1 Hz, 1H), 3.30 (dd, J = 14.0, 2.4 Hz, 1H),
1.54 (s, 9H). 13C NMR (DMSO-d6) δ 172.6, 167.1, 166.1, 149.0, 135.9, 134.1, 131.0,
129.5, 128.7, 127.9, 126.9, 103.8, 81.4, 58.2, 52.0, 34.6, 27.9. HRMS (m/z) calcd.
for C48H50N2O12Na [2M + Na]
+: 869.3256, found: 869.3235. Elem. anal. calcd. for
C24H25NO6: C, 68.07; H, 5.95; N, 3.31, found: C, 68.01; H, 5.93; N, 3.51. Mp 210–212
◦C (decomp.). IR (neat): ν 2951, 2930, 1751, 1715 (strong), 1605, 1355, 1274 (strong),
1149, 1079, 699 cm−1.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-3-(4-chlorophenyl)-4-hydroxy-
1,5-dihydro-pyrrol-2-one (2.70)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyPhe-OH (2.4)
and 1-bromo-4-chlorobenzene as coupling partner, afforded the product as a pale, brown
solid (307 mg, 77%). 1H NMR (DMSO-d6) δ 7.64 (d, J = 8.8 Hz, 2H), 7.35 (d, J =
8.6 Hz, 2H), 7.22–7.13 (m, 3H), 6.98 (d, J = 6.6 Hz, 2H), 4.75 (dd, J = 4.9, 2.7 Hz,
1H), 3.46 (dd, J = 14.0, 4.9 Hz, 1H), 3.28 (dd, J = 14.2, 2.5 Hz, 1H), 1,53 (s, 9H). 13C
NMR (DMSO-d6) δ 170.8, 167.2, 149.0, 134.1, 130,7, 129.5 (two peaks), 128.9, 127.9,
127.8, 126.8, 104.0, 81.4, 58.0, 34.6, 27.9. HRMS (m/z) calcd. for C44H44Cl2N2O8Na
[2M + Na]+: 821.2366, found: 821.2360. MS (m/z) for [2M + Na]+: 821.20 (26%),
822 (9%), 823.21 (20%), 824 (4%). HPLC purity (TFA): >97.0%. Mp 240–244 ◦C
(decomp.). IR (neat): ν 3027, 2926, 2680, 1750 (strong), 1611, 1587, 1390, 1361,
1273, 1150, 1090, 825, 677 cm−1.
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(5S)-1-(tert-Butyloxycarbonyl)-4-hydroxy-3-(4-methoxyphenyl)-5-(3-(2,2,- 4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)-propyl)-1,5-dihydro-
pyrrol-2-one (2.71)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyArg(Pbf)-OH
(2.32) and 4-chloroanisole (2.53) as coupling partners and 16 hours reaction time, af-
forded the product as a pale, brown solid (437 mg, 67%). Purification required approx.
15 vol% MeOH in EtOAc to eluate the product completely. 1H NMR (DMSO-d6) δ
11.96 (broad s, 1H), 7.75 (d, J = 9.1 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.71 (s,
broad), 6.36 (s, broad), 4.53 (t, J = 3.5 Hz, 1H), 3.75 (s, 3H), 3.07–2.98 (m, 2H), 2.92
(s, 3H), 2.46 (s, 3H), 2.40 (s, 3H), 2.13–2.04 (m, 1H), 1.99 (s, 4H), 1.95–1.88 (m, 1H),
1.46 (s, 9H), 1.40 (s, 9H). 13C NMR (DMSO-d6) δ 170.0, 168.2, 157.7, 157.5, 155.9,
148.7, 137.3, 134.0, 131.5, 128.6, 124.3, 123.0, 116.3, 113.3, 104.1, 86.3, 81.1, 59.7,
57.0, 55.0, 42.4, 28.2, 27.7, 26.2, 20.7, 18.9, 17.5, 14.0, 12.2. HRMS (m/z) calcd. for
C33H45N4O8S [M + H]
+: 657.2953, found: 657.2961. HPLC purity (TFA): >88.6%.
Mp 172–174 ◦C. IR (neat): ν 3445, 3332, 2969, 2928, 1749, 1610, 1550 (strong), 1514,
1350, 1292, 1246, 1153, 1089 (strong), 834, 781, 660, 566 cm−1.
(5S)-5-(4-tert-Butoxybenzyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-3-
(4-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.72)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyTyr(tBu)-OH
(2.33) and 4-chloroanisole (2.53) as coupling partners, afforded the product as a pale,
brown solid (324 mg, 69%). 1H NMR (DMSO-d6) δ 12.02 (s, 1H), 7.42 (d, J = 9.1
Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 9.1 Hz, 2H), 6.77 (d, J = 8.6 Hz),
4.66 (dd, J = 4.6, 2.8 Hz, 1H), 3.71 (s, 3H), 3.39 (dd, J = 13.9, 4.6 Hz, 1H), 3.19
(dd, J = 13.9, 2.5 Hz, 1H), 1.53 (s, 9H), 1.16 (s, 9H). 13C NMR (DMSO-d6) δ 168.8,
167.6, 157.7, 153.7, 149.0, 130.0, 128.9, 128.7, 123.2, 122.8, 113.1, 105.4, 81.1, 77.7,
57.9, 55.0, 34.1, 28.4, 27.9. HRMS (m/z) calcd. for C54H66N2O12Na [2M + Na]
+:
957.4508, found: 957.4516. HPLC purity (TFA): >91.7%. Mp 147–153 ◦C. IR (neat):
ν 2975, 2932, 1748, 1643, 1607, 1514, 1392, 1363, 1290, 1247, 1150 (strong), 1095,
894, 830 cm−1.
(5S)-5-(4-(Benzyloxycarbonyl)butyl)-1-(tert-butyloxycarbonyl)-4-hydroxy3-(4-methoxyphenyl)-
1,5-dihydro-pyrrol-2-one (2.73)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyLys(Cbz)-OH
(2.34) and 4-chloroanisole (2.53) as coupling partners, afforded the product as a brown
solid (353 mg, 69%). 1H NMR (DMSO-d6) δ 11.90 (broad s, 1H), 7.76 (d, J = 9.1
Hz, 2H), 7.37–7.29 (m, 5H), 6.92 (d, J = 8.8 Hz, 2H), 4.97 (s, 2H), 4.52 (dd, J =
4.2, 3.2 Hz, 1H), 3.75 (s, 3H), 2.94 (q, J = 6.6 Hz, 2H), 2.16–2.07 (m, 1H), 1.98–1.90
(m, 1H), 1.47 (s, 9H), 1.40–1.36 (m, 2H), 1.09–0.99 (m, 2H). 13C NMR (DMSO-d6)
δ 170.1, 168.3, 157.7, 156.0, 148.8, 137.2, 129.2, 128.7, 128.3, 127.6, 123.1, 115.7,
113.3, 104.1, 81.0, 65.1, 57.4, 55.0, 29.3, 28.3, 27.8, 18.5. HRMS (m/z) calcd. for
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C28H34N2O7Na [M + Na]
+: 533.2258, found: 533.2255. HPLC purity (TFA): >93.4%.
Mp 53–55 ◦C. IR (neat): ν 2931, 1692 (strong), 1633, 1546 (strong), 1517, 1367, 1240,
1152, 1104, 834 cm−1.
(5S)-5-((S)-1-tert-Butoxyethyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-
3-(4-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.74)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyThr(tBu)-OH
(2.35) and 4-chloroanisole (2.53) as coupling partners, afforded the product as a pale,
brown solid (253 mg, 62%). 1H NMR (DMSO-d6) δ 10.7 (s, 1H), 7.75 (d, J = 8.8
Hz, 2H), 6.93 (d, J = 9.1 Hz, 2H), 4.47 (d, J = 3.5 Hz, 1H), 4.36 4.31 (m, 1H), 3.75
(s, 3H), 1.49 (s, 9H), 1.17 (s, 9H), 1.00 (d, J = 6.6 Hz, 3H). 13C NMR (DMSO-d6)
δ 169.1, 168.3, 157.7, 149.2, 128.6, 122.9, 113.4, 105.1, 81.5, 74.7, 66.4, 60.8, 55.0,
27.9, 27.7, 17.8. HRMS (m/z) calcd. for C44H62N2O12Na [2M + Na]
+: 833.4194,
found: 833.4223. HPLC purity (TFA): >94.6%. Mp 152–156 ◦C. IR (neat): ν 2977,
2932, 1742, 1702, 1680, 1609, 1515, 1369, 1328 (strong), 1251, 1160 (strong), 1136,
1069, 1031, 983, 810 cm−1.
(5S)-5-(2-tert-Butoxy-2-oxoethyl)-1-(tert-butyloxycarbonyl)-4-hydroxy-
3-(4-methoxyphenyl)-1,5-dihydro-pyrrol-2-one (2.75)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyAsp(tBu)-OH
(2.36) and 4-chloroanisole (2.53) as coupling partners and 16 hours reaction time, af-
forded the product as a brown solid (187, 45%). 1H NMR (DMSO-d6) δ 12.0 (broad s,
1H), 7.73 (d, J = 9.1 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.63 (dd, J = 5.4, 2.7 Hz, 1H),
3.75 (s, 3H), 3.04 (dd, J = 14.2, 5.6 Hz, 1H), 2.87 (dd, J = 13.9, 2.8 Hz, 1H), 1.49
(s, 9H), 1.24 (s, 9H). 13C NMR (DMSO-d6) δ 168.8, 167.8, 167.6, 157.6, 148.6, 128.6,
123.0, 113.2, 104.0, 81.1, 80.0, 54.9 (two peaks), 35.8, 27.7, 27.3. HRMS (m/z) calcd.
for C44H58N2O14Na [2M + Na]
+: 861.3780, found: 861.3815. HPLC purity (TFA):
>95.4%. Mp 127–131 ◦C. IR (neat): ν 2975, 2929, 1750 (strong), 1727, 1640, 1608,
1515, 1390, 1351 (strong), 1283, 1242, 1155, 1097, 837, 584 cm−1.
(5S)-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-methoxyphenyl)-1,5-dihy- dro-pyrrol-
2-one (2.76)
Following the general synthesis of α-aryl tetramic acids (E) with Boc-pyGly-OH (2.37)
and 4-chloroanisole (2.53) as coupling partners and 16 hours reaction time, afforded the
product as a pale, brown solid (85 mg, 28%). Purification required up to 20% MeOH
in EtOAc to eluate the product completely. 1H NMR (DMSO-d6) δ 12.16 (s, 1H), 7.80
(d, J = 9.1 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 4.24 (s, 2H), 3.75 (s, 3H), 1.48 (s,
9H). 13C NMR (DMSO-d6) δ 168.1, 167.9, 157.5, 149.0, 128.3, 123.5, 113.3, 103.4,
81.0, 55.0, 47.8, 27.8. HRMS (m/z) calcd. for C16H19NO5Na [M + Na]
+: 328.1155,
found: 328.1164. HPLC purity (TFA): >72.0%. Mp ≈ 250 ◦C (decomp.). IR (neat):
ν 2980, 2924, 2853, 1745 (strong), 1635, 1610, 1513, 1430, 1393, 1350, 1289, 1247,
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1160, 1093, 984, 858, 797, 750, 578 cm−1.
Attempted utilization of aryldiazonium salts for the α-arylation of cyclopentane-
1,3-dione (2.77) for the synthesis of 2.79
A solution of PdCl2 (2 mg/mL) was prepared prior to use by suspending the catalyst in
MeCN at room temperature and stirred overnight. This resulted in a clear, orange so-
lution of the active catalyst (Pd(MeCN)2Cl2). Cyclopentane-1,3-dione (2.77) (49 mg,
0.50 mmol, 1.00 equiv) and 4-bromobenzenediazonium tetrafluoroborate (2.78) (135
mg, 0.50 mmol, 1.00 equiv) were dissolved in MeCN (750 µL) and H2O (650 µL). In
some experiments 8% aqueous H2SO4 (650 µL) was added instead of H2O and in other
experiments NaNO2 (3 mg, 0.05 mmol, 0.10 equiv) was added at this point. While
stirring, the Pd(MeCN)2Cl2 solution was added (2 mL). For the experiment employing
Pd/C, the catalyst (10 mg) was added under a nitrogen atmosphere in MeOH (2.75
mL) instead of the above-mentioned solvent system. Pd(OAc)2 was also used directly in
the solvent (MeOH or EtOH). The reaction was stirred at room temperature (or heated
to 50 ◦C) overnight and periodically monitored by TLC (EtOAc:MeOH (1:1), KMnO4
development), LC-MS and 1H NMR. The crude product was transferred to a separatory
funnel with EtOAc (10 mL) and washed with brine (2 × 10 mL), dried over anhydrous
Na2SO4 and evaporated to dryness in vacuo affording a colorful/black solid. Analysis
by LC-MS and 1H NMR revealed that no product was formed. Only minor to moderate
amounts of the corresponding hydrazone/diazene 2.80, as well as starting materials,
were found.
3-Amino-4-phenylbutan-2-one hydrochloride (2.83)
Boc-pyPhe-OH (2.4) (200 mg, 0.69 mmol, 1.00 equiv) was dissolved in 37% conc. HCl
(10 mL) and heated to 100 ◦C for 4 hours, at which LC-MS showed full conversion
(>95%). The crude product was evaporated to dryness in vacuo, the residue was co-
evaporated with iPrOH (3 × 20 mL) and dried overnight in vacuum to a brown solid
(135 mg, 98%), which was subsequently washed several times with cold MeCN to re-
move (colored) impurities. The hydrochloride 2.83 was obtained as a off-white solid
(56 mg, 40%). 1H NMR (DMSO-d6) δ 8.32 (broad s, 3H), 7.39–7.27 (m, 5H), 4.41
(t, J = 6.8 Hz, 1H), 3.21–3.14 (m, 1H), 3.13–3.06 (m, 1H), 2.16 (s, 3H). 13C NMR
(DMSO-d6) δ 204.1, 134.9, 129.5, 128.7, 127.3, 59.2, 35.0, 27.7. MS (m/z) calcd. for
C10H14NO [M + H]
+: 164.1, found: 164.2.
Attempted ring opening of α-aryl tetramic acids with conc. HCl for the sys-
thesis of 2.84, 2.85 and 2.86
The α-aryl tetramic acid 2.40 (200 mg, 0.51 mmol, 1.00 equiv) was dissolved in 37%
conc. HCl (10 mL) and heated to 100 ◦C for 4 hours, at which LC-MS showed no traces
of the desired product 2.84. Only the expected Boc-deprotection had happen. The
reaction was therefore stirred at reflux overnight. LC-MS showed almost no conversion
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of the deprotected α-aryl tetramic acid, but traces of the corresponding product which
has lost the methyl-group, 3-amino-1-(4-hydroxyphenyl)-4-phenylbutan-2-one, was seen.
MS (m/z) calcd. for C16H18NO2 [M + H]
+: 256.1, found: 256.1. Similar reactivity was
found for 2.57 and 2.66 for the synthesis of 2.85 or 2.86, respectively.
Attempted synthesis of ethyl enol ether 2.87 from the α-aryl tetramic acid
2.57
A round-bottomed flask was charged with the α-aryl tetramic acid 2.57 (23 mg, 0.06
mmol, 1.00 equiv) and an inert atmosphere was introduced by evacuation and back-
filling with nitrogen three times. Through a septum, dry THF (1.0 mL) was added and
the solution was cooled to 0 ◦C while stirring. KHMDS (0.5M solution in toluene) (120
µL, 13 mg, 0.07 mmol, 1.03 equiv) was added dropwise, and the reaction mixture was
stirred at 0 ◦C for 10 minutes. Then, EtOTs (15 mg, 0.08 mmol, 1.20 equiv) and 18-
crown-6 (18 mg, 0.07 mmol, 1.07 equiv) were added as a solution in THF (0.2 mL) and
the reaction was aged by slowly heating to ambient temperature during the course of 1
hour. The crude product mixture was analyzed by LC-MS, but no traces of 2.87 were
observed. Only the starting material 2.57 was present (with reagents) in the mixture.
Attempted reduction of α-aryl tetramic acids for the synthesis of the β-hydroxy
derivative 2.88 with a variety of reducing agents
α-Aryl tetramic acid (2.57) (50 mg, 0.14 mmol, 1.00 equiv) was dissolved in a solvent
(700 µL; DCM, THF or MeOH) and eventually glacial AcOH (70 µL) was added. The
mixture was cooled to 0 ◦C and the reducing agent (0.28 mmol, 2.00 equiv; NaBH4,
DIBAL-H, L-selectride, LiAl(OtBu)3H, LiBH4 or 9-BBN) was added portionwise. Bubbles
were observed when NaBH4 and AcOH were used in combination. In some experiments
the reducing agent was added at –78 ◦C and then heated to ambient temperature. The
mixture was heated to reflux in other experiments after addition of the reducing agent.
After a couple of hours of stirring, water was added to quench the reaction and the
organic layer was separated and evaporated to dryness in vacuo. Analysis by LC-MS
revealed that no reaction had happen and only the starting material 2.57 was recovered.
The two other α-aryl tetramic acids 2.40 and 2.66 were also subjected to a variety of
reducing agents, but the same unreactivity was observed.
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Attempeted ring opening of 2.57 with LiOOH for the synthesis of the β-keto
acid 2.89
In a mixture of THF (4.0 mL) and H2O (1.3 mL) was added the α-aryl tetramic acid
2.57 (185 mg, 0.51 mmol, 1.00 equiv) and the solution was cooled to 0 ◦C. LiOH
(30 mg, 1.26 mmol, 2.50 equiv) and 35% H2O2 (0.25 mL) were added. The reaction
mixture was stirred at 0 ◦C for 30 minutes and then slowly heated to ambient temper-
ature. Quenced by addition of sat. aqueous Na2SO3 (10 mL) and diluted with brine
(10 mL). Extracted with EtOAc (3 × 15 mL), acidified with 2M HCl to pH 2 and
then extracted with EtOAc again (3 × 15 mL). The combined organic layers were dried
over anhydrous Na2SO4 and evaporated to dryness in vacuo. The crude product was
analyzed by LC-MS, which showed no product formation at all and only recovery of 2.57.
Attempted ring opening of 2.57 with SmI2 for the synthesis of the β-keto
aldehyde 2.90
A nitrogen-filled flask was charged with the α-aryl tetramic acid 2.57 (21 mg, 0.06 mmol,
1.00 equiv) and dry THF (2 mL) was added. While stirring at room temperature was
added SmI2 (0.1M in THF) (1.15 mL, 46 mg, 0.12 mmol, 2.00 equiv) quickly in one
portion. The reaction mixture became immediately blackish in color. After 5 minutes of
stirring, 99.9% EtOH (10 µL, 5 mg, 0.12 mmol, 2.00 equiv) was added and the reaction
was stirred for 1 hour. LC-MS analysis of the mixture revealed no product formation
and only the starting material 2.57 was seen.
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Chapter 3
Synthesis and biological activity of
FVIIa inhibitors
3.1 Synthesis of C-terminal modified peptides
Synthesis of peptides is usually performed using a standardized Fmoc solid-phase ap-
proach.328 However, synthesis of C -terminal modified peptides is less straightforward.
This introduction will therefore cover different possible synthetic strategies; solution-
phase, polymer-assisted and solid-phase peptide synthesis.
3.1.1 Solution-phase peptide synthesis
It is reasonable to consider a solution-phase synthesis of small peptides, because the num-
ber of coupling/deprotection steps is limited. If the selected C -terminal modification can
resist these conditions, a solution-phase strategy is probably the most straightforward
for a rapid preparation of a variety of small modified peptides. Formation of peptide
bonds is a well known process and hence the optimization should hopefully be relatively
easy.
Boc/Bn-amino acids are usually the building blocks of choice for solution-phase peptide
synthesis. However, other protection groups exist and may be considered for optimal
orthogonal Nα-deprotection during the peptide synthesis. Although Fmoc-groups are
easily removed by treatment with 20% piperidine in DMF,328 the fulvene-piperidine
adduct is difficult to remove in solution-phase and may lead to unwanted by-products.
Several methods have been reported as improved removal conditions in solution-phase,
e.g. the use of tris(2-aminoethyl)amine,329 AlCl3/toluene
330 or DBU/1-octanethiol.331
However, Boc-groups are still easier to deprotect because the by-product is simply re-
moved by evaporation. TFA in DCM are typically the removal conditions of choice, but
105
Synthesis of C -terminal modified peptides
conditions such as BF3-OEt2,
332 AlCl3,
333 85% aqueous H3PO4,
334 Sn(OTf)2
335 and
H2O/150
◦C336 have been reported as milder and more selective reagents. Besides of a
Nα-protection, functionalized amino acids have to be side-chain protected.
Another parameter to consider is the choice of coupling agent. An appropriate agent
should be selected to provide high yield and easy purification. Solid-phase peptide syn-
thesis uses coupling agents in excess and purification simply by filtration.328 This is not
possible in the solution-phase and the amount of coupling agent should therefore be kept
to a minimum for optimal purification.
3.1.1.1 Side-chain protection groups
Arginine is Nω-protected to prevent deguanidination337 and δ-lactam formation as a re-
sult of the nucleophilicity of the guanidino group.338 On the other hand, deprotection of
guanidino groups is rather difficult and due to their basicity (pK a = 12.5), they are pro-
tonated almost entirely throughout the peptide synthesis.339,340 In principle, protection
of all nitrogen atoms would be required to fully mask its nucleophilicity, but practically
only one or two of them is protected.
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Figure 3.1.1: A variety of arginine Nω-protection groups used to avoid deguani-
dination337 and δ-lactam formation during peptide synthesis338
The most widely used Nω-protecting for the Boc/Bn-strategy is Tos,341 whereas for the
Fmoc/tBu strategy Pbf or Pmc338 is usually used (see Figure 3.1.1). Tos is removed by
harch conditions such as HF, TFMSA-TFA-thioanisole or Na/NH3.
342 Pmc and Pbf are
much easier to remove, simply by treatment with TFA.321,343 Pbf is more acid-labile than
Pmc and quite cheaper.344 During deprotection of the Pmc/Pbf-group there is a risk
of migration and hence a sulfonation of tryptohpan, serine and threonine residues.345
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However, this migration can be minimized by addition of suitable scavengers.346 Other
common Nω-protection groups are Mts (removed by TFMSA-TFA-thioanisole),347,348
Mtr (TFA-thioanisole),349 –NO2 (HF or H2-Pd/C)
350 and Cbz2 (H2-Pd/C)
351 with re-
moval conditions stated in brackets (see Figure 3.1.1).
Bn tBu
Trt
Si
TBDMS
Figure 3.1.2: Common threonine and tyrosine O-protecting groups used to avoid
O-acylation and other side reactions.338
Threonine is O-protected to avoid dehydratation and O-acylation possibly followed by
O-N migration.338 Protection of the hydroxy group is in fact more important in solid-
phase peptide synthesis, because an excess of coupling agent is used. Coupling with
unprotected threonine has been reported for several syntheses, including solid-supported
approaches.218,352 The O-protection is typically introduced as ethers because they are
more stable than carbamates or esters. The most widely used protection group for the
Boc/Bn stategy is a Bn-protection (see Figure 3.1.2), which is removed with HF353 or by
hydrogenolysis catalyzed by Pd/C.354 A catalyst combination of Pd/C and Pd(OH)2/C
(Pearlman’s catalyst) in equal amounts has been reported as a more efficient catalytical
system for O-debenzylation,355 because Pd(OH)2/C turned out to be more active than
Pd/C.356 Selection of appropriate deprotection conditions may require screening of sev-
eral different catalysts, solvents and concentrations.356 A variety of Lewis acids can also
be used for O-debenzylation, e.g. TiCl4 and SnCl4.
357
Use of unprotected tyrosine can also lead to O-acylation because of the nucleophilicity
of the phenolate ion under basic conditions as well as ortho-alkylation because of the
eletron-rich aromatic ring.338 The most commonly used O-protections of tyrosine are
the Bn- and tBu-groups, which are removed by catalytic hydrogenolysis354 or TFA,358
respectively. Protecting groups such as Cbz (removed with HF),359 Boc (TFA)360 and
TBDMS (TBAF)361 have also been used as O-protection of tyrosine, with deprotection
conditions stated in brackets (see Figure 3.1.2).
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3.1.1.2 Coupling agents
Formation of peptide bonds is performed using a coupling agent, which can be selected
among hundreds of different compounds.362 The most commonly used agents are car-
bodiimides (e.g. DIC363 or EDC364), 1H-benzotriazole-based uronium/aminium salts
(e.g. HATU,365,366 HBTU,365–367 TATU368 and TBTU369), phosphonium salts (e.g.
BOP370 and PyBOP371) or 2-hydroxysuccinimide-based coupling agents (e.g. TSTU369
or HSTU372) (see Figure 3.1.3).
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Figure 3.1.3: The most commonly used coupling agents for peptide synthesis,
and two epimerization-suppressing agents: HOBt and HOAt.362
Carbodiimides and 2-hydroxysuccinimide-based coupling agents are used in combination
with an epimerization-suppressing agent, such as HOBt373,374 or HOAt.368 Additives
can be avoided by using a coupling reagent based on the HOAt/HOBt system, such as
HATU and TBTU. These coupling agents are available as hexafluorophosphonium (PF6)
or tetrafluoroborate (BF4) salts, respectively. However the counterion has been found
not to have any practical influence on the reactivity.367,369 On the other hand, it has
been demonstrated, that coupling reagents based on HOAt, e.g. HATU and TATU, gave
superior results compared to HBTU and TBTU, in terms of reaction speed, efficiency
and epimerization.368,375
Another family of coupling reagents based on the HOAt/HOBt system uses a phos-
phnium group and includes BOP, PyBOP and many others agents. The advantage of
using these compounds is that they do not yield any guanidinium by-products via re-
action of the coupling reagent with amines.362 The use of BOP370 is, however, limited
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due to the carcinogenicity and respiratority toxicity associated with hexamethylphos-
phoramide,362 and therefore PyBOP was developed371 and highly recommended as a
substitute. TSTU and HSTU are one of the few coupling reagents incorporating an-
other system than HOAt/HOBt. These agents are based on the hydroxysuccinimide
system,369,372 and hence also have to be used in combination with an epimerization-
suppressing additive.369
Selecting appropriate coupling reagents may be difficult. However, the differences be-
tween the many reagents are small. In general DIC/HOBt or HOAt remains an excellent
choice for many substrates, and selecting suitable coupling reagents should be kept sim-
ple and ’exotic’ reagents should be avoided.362 HOAt as an additive is superior to HOBt
for stepwise/linear peptide synthesis with respect to reaction rate and degree of racem-
ization.376
Several coupling agent systems have been reported as especially appropriate for solution-
phase synthesis of peptides, e.g. DCC/HOBt or HONb,377 EDC/HOBt378,379 and Py-
BOP.380 EDC is slightly cheaper than PyBOP, but compared to DIC and DCC both of
these coupling agents are quite expensive.251
3.1.2 Polymer-assisted solution-phase peptide synthesis
The advantage of solid-phase peptide synthesis is the possibility to use coupling agents in
excess, which secures successful coupling with less reactive amino acids/peptides. More-
over, the purification is very simple, because the reagents can by removed by a simple
filtration.381 However, when the C -terminal is modified, standard methods for anchoring
to the solid support cannot be used. As an alternative, polymer-assisted reagents can
be used, e.g. immobilized coupling agents and bases.
A library of α-ketothiazole FVIIa inhibitors were synthesized using polymer-assisted
solution-phase peptide synthesis from the reduced building block 3.1 (see Scheme
3.1.1).165,166 These inhibitors (1.21–1.24) were presented in Chapter 1 (c.f. Figure
1.1.22). The first peptide coupling afforded the dipeptide 3.2 using immobilized cy-
clohexyl carbodiimide and diisopropyl amine. Purification was accomplished by using
immobilized trimethylammonium carbonate and di(2-aminoethyl)amine. Then a Nα-
deprotection afforded the free amine 3.3 and subsequently another peptide coupling was
carried out with N-(benzylsulfonyl)-D-phenylalanine 3.4, giving the N-terminal modified
tripeptide 3.5, which was converted into the desired Nω-protected α-ketothiazole 3.7
upon oxidation with the periodinane Dess-Martin reagent 3.6. Once again immobilized
bases were used for purification. A deprotection with TFA/thioanisole afforded the tar-
get peptides. Overall yields ranged from 9 to 45% based on mass recovery and purity
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was 82% on average.165,166
N
H
H
N
OH
N
S
NH
NHMtrHN
O
R
N
H
R
O
OHBoc
HOBt, Et3N
N
C
N
DCM, DMF N
H
R
O
OBtBoc
OH
N
SH3N
NH
NHMtrHN
Cl
DCM, DMF
N
BocNH O
OHS
O O
Repeat step 1 and 2
Then:
N
2
CO32-
N
NH2
NH2
HCl
H3N
H
N
OH
N
S
NH
NHMtrHN
O
R
Cl
N
H
H
N
OH
N
S
NH
NHMtrHN
O
ROH
NS
O O
O
I
O
AcO OAc
OAc
DCM
Then:
N
2
S2O32-
N
N
H
H
N
O
N
S
NH
NHMtrHN
O
ROH
NS
O O
1. TFA
    Thioanisole
2. Trituration
1.21−1.24
and many other compounds
3.1
3.23.3
3.4
3.5
3.6
3.7
Scheme 3.1.1: Polymer-assisted solution-phase synthesis of α-ketothiazoles as
FVIIa peptidyl inhibitors.165,166
The α-heterocyclic building block can be synthesized in different ways,382 but the Wein-
reb amide strategy is one of the most general ones. Usage of Weinreb amides was
introduced in 1981 to avoid overaddition of an organometallic reagent giving the unde-
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sired tertiary alcohol.383 Overaddition is not observed because a stable metal-chelate is
formed upon addition of the first equiv (see Scheme 3.1.2 for a general example).383
Upon hydrolysis the chelate is decomposed affording the desired ketone product.
R N
O
O N
O
OR
Mg
H3O
R
O
MgCl
Weinreb amide Ketone product
Metal chelate
Scheme 3.1.2: Weinreb amides are easily converted into ketones upon addition
of e.g. a Grignard reagent. Only one equivalent is added due to formation of a
stable chelate.383 Here is shown a general example.
Traditionally, α-amino ketones have been synthesized from the corresponding Weinreb
amide by addition of a Grignard193,384–387 or a lithium reagent.388 Unfortunately, the
method requires an excess of the organometallic reagent, because the amino acid con-
tains at least one exchangeable proton (Nα-H). If the organometallic reagent is expensive
and not commercially available, pre-deprotonation can be achieved by addition of 1 equiv
of a simple alkyl Grignard base, such as iPrMgCl or MeMgCl.389
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Scheme 3.1.3: Synthesis of the α-ketobenzothiazole 3.9 via the Weinreb amide
3.8 followed by reduction and N-deprotection.104
By this procedure, the α-ketone benzothiazole building block 3.9 was synthesized by
addition of a metalated heterocycle to the Weinreb amide 3.8 in good yield (see Sceme
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3.1.3).104 The ketone formed, even though it is desired in the final product, was re-
duced to the secondary alcohol by NaBH4 to avoid epimerization of the α-stereocenter
during peptide synthesis and to avoid unwanted reactions.382 A similar approach was
used for the preparation of the reduced α-ketothiazole building block 3.1 (c.f. Scheme
3.1.1).165,166 Due to the electron deficiency of the carbonyl group in these inhibitors,
epimerization of the adjacent stereogenic center in the final inhibitor is rapidly occuring
in whole blood390 or under mild alkaline aqueous conditions.104 This demonstrates why
the reduced form of the building block is used during synthesis of these very electron
deficient ketones. However, no reports in the literature states if this pronounced epimer-
ization causes any decrease in biological activity in vitro or in vivo.
3.1.3 Solid-phase peptide synthesis
Solid-phase syntheses of C -terminal modified peptides have been described in the liter-
ature,391 by choosing a resin/linker depending on the desired C -terminal functionality.
Solid-phase procedures for the synthesis of such peptides are complicated due to the
fact that the C -terminal residue is generally attached to the resin through its α-carboxyl
group in the most commonly used C→N synthetic approach.391 Two alternative strate-
gies have therefore been used for solid-phase synthesis of C -terminal modified peptides;
i) direct synthesis involving the use of specialized linkers or resins that are appropriately
designed to allow anchoring of the C -terminal and to generate a specific end group
upon cleavage, or ii) methods of general applicability regardless of the C -terminal func-
tional group present, e.g. side-chain or backbone amide lining (BAL) as well as inverse
solid-phase peptide synthesis.391 The latter is a non-traditional N→C directional ap-
proach,392–395 which has only been reported briefly in the literature primarily because of
low yields and high degree of racemization.391
3.1.3.1 C-Terminal carbonyl anchoring via specialized linkers
Only a few linkers/resins have been reported for the direct synthesis of C -terminal modi-
fied peptide ketones, as most of the examples afford aldehydes (for example via a thiazo-
lidine linker,396 oxazolidine397,398 or a Wittig resin399–401). However, synthesis of ketone
C -terminal modified peptides has been reported using a semicarbazone linker402–404 for
the preparation of trifluoromethyl ketones or a semicarbazidyl resin405 for the prepara-
tion of chloromethyl ketones (see Figure 3.1.4). The products are released from the
solid-support by treatment with TFA.405 A variety of cysteine protease inhibitors was
synthesized in this way.405
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Figure 3.1.4: The semicarbazone linker and the semicarbazidyl resin enable the
anchoring of the C-terminal carbonyl group to a solid support.402–405
Carbonyl groups can also be anchored to a solid support through acetal formation.
For example, the peptide aldehyde 3.12 was synthesized in this way. At first, the O-
protected DHUA linker (10,11-dihydroxy-undecanoic acid) was synthesized in three steps
from undec-10-enoic acid (see Scheme 3.1.4). The P1-amino acid-derived aldehyde was
anchored to the linker mediated by TMSOTf giving the acetal linker 3.10, which was
subsequently attached to a solid support under traditional coupling conditions giving
3.11. Classical Fmoc/tBu solid-phase peptide synthesis (BOP, HOBt, DIPEA) afforded
the anchored tripeptide acetal, which was released as the peptidyl aldehyde 3.12 upon
treatment with 95% TFA in water with no racemization observed406 (see Scheme 3.1.4).
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Scheme 3.1.4: Synthesis of the DHUA-linker 3.10 and synthesis of the peptide
aldehyde 3.12 through classical Fmoc/tBu solid-phase peptide synthesis.406
This approach is very cost-effective and does not involve reduction or oxidation proce-
dures.406 The utilization of diol linkers for anchoring of carbonyl groups as acetals has
also been reported in connection with chemical modifications of terephthaldehydes and
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isophthaldehydes,407,408 solid-supported Suzuki-Miyaura cross-couplings409 and synthe-
sis of a steroidal ketone derivative,410 demonstrating different linker-coupling methods,
such as azeotropic reflux and acetal exchange catalyzed by Sc(OTf)3.
410
3.1.3.2 Side-chain linking
Side-chain attachment does not involve the C -terminal carboxyl group, which allows
considerably flexibility in terms of modification of the terminal and an easy and direct
preparation of peptides containing a variety of C -terminal modifications can be accom-
plished (see Figure 3.1.5).
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OAllylBoc
O
OO
NO2
N
H
O
Serine attached to a resin
N
H O
OAllylFmoc
NH
HN
H
N S
O
O
O NH
Arginine attached to a resin
O
Figure 3.1.5: Serine and arginine are two amino acids that can be anchored to a
solid support through the side-chain functionality.411–415
However, the general applicability of this approach is clearly limited to relatively few tri-
functional amino acid residues that are suitable positioned in the peptidyl sequence.391
Anchoring the side-chains of aspartic and glutamic acid,416 lysine and ornithine,417 ser-
ine,411,412 threonine,412 tyrosine418,419 and arginine413–415 have been reported (see Figure
3.1.5). For example, serine can be anchored to a carboxyloxymethyl Nbb resin, which
can be cleaved from the solid support upon hν (350 nm) radiation,411 whereas arginine
can be anchored through a Pmc-like linker and released with TFA.415
3.1.3.3 Backbone amide linking (BAL)
Anchoring the backbone amide is better known as the BAL-strategy. It is usually
based on the 2,4,6-trisalkoxybenzyl amide linker (PAL) system420,421 (see Figure 3.1.6),
but other systems have also been used for construction of BAL-resins, such as 2-
nitrobenzylamide,422 4-alkoxybenzylamide,423 and the 3-indole system.424
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Figure 3.1.6: Peptide anchored to a solid support through the backbone amide
based on the 2,4,6-trisalkoxybenzyl amide linker (PAL) system.420,421
The approach using a BAL-resin has been used for preparation of C -terminal peptide
aldehydes by anchoring amino acetals to PALdehyde-PS by NaBH3CN-promoted reduc-
tive amination. After appropriate peptide synthesis, the peptide was cleaved from the
linker upon treatment with 95% TFA (see Scheme 3.1.5). These conditions also hy-
drolyze the acetal hence forming the desired C -terminal aldehyde.425
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Scheme 3.1.5: Synthesis of peptidyl aldehydes using the backbone amide linking
(BAL) approach for solid-phase peptide synthesis.425
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In general, two steps need to be carefully considered when using the BAL-strategy.
Primarily, an optimized procedure for on-resin reductive aminination involving mixing a
resin-bound aldehyde, an amino acid derivative, and NaBH3CN simultaneously. Under
these neutral to slightly acidic conditions, the reaction should proceed to completion
without any detectable racemization. Secondly, acylation of the resulting secondary α-
amine attached to the BAL-resin is a more challenging step compared to acylations of
unsubstituted primary amines.391
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3.2 Results and discussion
3.2.1 Design of peptidyl benzyl ketone FVIIa inhibitors
Based on the FVIIa specificity profile168 presented in Section 1.1.4, four different tripep-
tide sequences were selected (see Figure 3.2.1). These sequences were chosen among
the most active amino acids in each of the three positions, P3-P1. Arginine was signif-
icantly more active in the P1-position than any other amino acid,168 and therefore all
peptides will contain an arginine at that position.
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Figure 3.2.1: Selected tripeptide sequences chosen from the FVIIa specificity
profile168 among the most active amino acids in each of the three positions, P3-
P1.
Moreover, a small variety of different N-terminals will be tested; a free N-terminal (P4
= H), an acetyl group (P4 = Ac) or a benzylsulfonyl group (P4 = BnSO2). The free
N-terminal would be the most convenient, because no further modification is needed
and the peptide can be obtained by a simple deprotection. However, since FVIIa is
an endopeptidase, inhibitors with a free N-terminal is most likely not the most active
ones. Acetylation of the N-terminal is a simple way for capping the amino group, and
therefore this group will be briefly investigated. In the literature, there is precedence for
that a N-BnSO2-terminal would be an appropriate choice,
130,165,166 and therefore this
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group is included as one of the possible N-terminals. The benzyloxy carbamate group
(P4 = Cbz) will be tested as an alternative to the BnSO2-group, because Cbz can be
conveniently introduced directly with the P3-amino acid.
Many of the reported inhibitors have a D-amino acid in the P3 position, but unnatural
configurations were not investigated in the FVIIa specificity profile.168 In the literature
it is not stated if the usage of D-amino acids is to increase the in vivo stability (D-amino
acids are not recognized by proteases/peptidases) or to increase the activity of the in-
hibitor. Therefore, some of the peptides in this project will be prepared and tested with
a D-amino acid in the P3-position.
An unsubstituted benzyl ketone (P1’) will be used and no further functionalization will
be investigated at this point. Mainly this is because a mild and rapid synthetic route
of the building block is still lacking, and thus it has to be synthesized via a Weinreb
amide (c.f. Section 3.2.2) using excesses of a Grignard reagent. Moreover, the simple
building block has been selected to limit the number of peptides to be synthesized.
Eventually, functionalization of the benzyl ketone would be of great interest; as a probe
for the S1’ binding pocket, but also for a potential alteration of the electrophilicity of
the carbonyl group. Consequently, this might alter the potency of the inhibitors. When
one or more potent FVIIa inhibitors have been identified by altering the P4-P1 scaffold,
a SAR study of the P1’ benzyl ketone would be possible using commercially available
benzylmagnesium Grignard reagents with substituents such as halides (Cl, Br, F), alkyl
(Me, iPr, tBu), alkoxy (OMe, OEt, OBn, OCF3) and thioethers (SEt).
426 Many different
substitution-patterns are available, including ortho-substituted reagents, but functiona-
lities such as ketones, aldehydes, esters and nitrils are of course not available, which is
a significant limitation in a medicinal chemistry project.
3.2.2 Synthesis of arginyl benzyl ketone building block
In view of the fact that a novel and mild synthesis of the arginyl benzyl ketone building
block could not be achieved (c.f. Chapter 2), a traditional method was used. As de-
scribed above, ketone building blocks have successfully been synthesized via a Weinreb
amide.104,165,166 Thus, the building block 3.15 was prepared in two steps from Boc-
Arg(Pmc)-OH (3.13) via the Weinreb amide 3.14 (see Scheme 3.2.1).
Boc-Arg(Pmc)-OH (3.13) was chosen as the starting material for several reasons. First
of all, a Boc-protected amino acid is stable under basic conditions. In fact, attempts
with a Fmoc-protection group resulted in its removal and no product was formed during
reaction with the benzyl Grignard reagent. Secondly, a Nω-protection with Pmc was
selected, because it is much easier to remove than Tos or NO2, and yet less acid-labile
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Scheme 3.2.1: The arginyl benzyl ketone building block 3.15 was synthesized
in two steps from Boc-Arg(Pmc)-OH 3.13 via the Weinreb amide 3.14 in good
overall yield and with no racemization.
than Pbf and Mtr, which are also common protection groups of arginine. Boc-Arg(Pmc)-
OH (3.13) therefore seems to be the most appropriate, commercially available starting
material for the building block synthesis.
Formation of the Weinreb amide 3.14 was afforded using PyBOP as coupling agent,
inspired by previous results using BOP.214 This step proceeded smoothly giving rise to
the Weinreb amide 3.14 in good yield. Formation of the benzyl ketone 3.15 was accom-
plished by treating the Weinreb amide 3.14 with excess amounts of benzylmagnesium
chloride, initially at 0 ◦C and then heating to room temperature. It was found, that
approx. 6 equiv of the Grignard reagent was necessary for complete conversion of 3.14.
The reaction was rather slow at low temperatures (–78 ◦C to 0 ◦C), but when heated
to room temperature it proceeded smoothly affording good yield and no racemization
as determined by chiral HPLC.
Usage of 6 equiv of this basic nucleophilic reagent indeed demonstrates the drawback
of this method for preparation of the arginyl benzyl ketone building block 3.15. There
are no reasons for why such a huge excess is needed, other than that at least 1 equiv is
deprotonating the Nα-proton. A commercially available Grignard reagent was used, but
neither a new nor a old bottle changed the requirement of such a large excess. However,
on laboratory-scale and with a non-functionalized Grignard reagent, this method in fact
seems to be the best way for a rapid and easy preparation of the building block 3.15 in
gram-scale.
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3.2.3 Solution-phase C-terminal modified peptide synthesis
Choosing a synthetic strategy is always a balance between advantages and disadvan-
tages. Based on the literature reported on synthesis of C -terminal modified peptides, all
three major stategies seems usuable for this project. However, a solution-phase synthetic
approach is probably the most straight forward, if the building block 3.15 is compatible
with the repeating coupling/deprotection conditions. This method uses commercially
and readily available reagents, but the purification after each coupling step will be time-
consuming because each step needs to be purified individually. On the other hand,
peptide couplings are usually easy to form and optimization of the procedure should be
very limited giving a rapid access to a variety of interesting FVIIa inhibitors.
Polymer-assisted synthesis would definately be an improvement of the solution-phase
approach, but these reagents are not as readily available as the traditional ones. Using
immobilized reagents would most likely improve the purification of each step, but the re-
activity might be lower due to insufficient diffusion into the solid-phase and thus require
further optimization. It is, however, a rather simple approach to test if a solution-phase
method is already established.
Last but not least, a solid-supported method could be used, e.g. by anchoring the ketone
as an acetal, the arginine side-chain to a functionalized linker or by using a backbone
amide linking (BAL). Once again this method utilizes less readily available reagents and
the attachment is not general and may require lenghty optimization procedues. Further-
more, solid-phase chemistry is usually entirely based on the Fmoc Nα-protection, which
is not compatible with the Weinreb-stategy for the building block synthesis. Deviations
of these standardized conditions would be rather impractical for a convenient and easy
solid-supported synthesis. Using the building block 3.15 would be problematic, because
cleavage from the linker/resin is performed by treatment with TFA and acid in particular
is the reagent of choice for deprotection of Boc-groups and Pmc/Pbf. Screening of
milder and more selective conditions for deprotection of the Boc-group would therefore
be necessary. Attaching the carbonyl group to the solid-phase e.g. via a semicarbazidyl
resin or via an acetal, wpuld on the other hand serve as a protection of the functionality
and avoid by-product formation as a result of reactions with the electrophilic carbonyl.
Protection (or reduction) of electron deficient carbonyl functionalities is especially im-
portant due to their enhanced electrophilicity.
Based on the potential problems with a solid-supported synthesis it was decided to
synthesize the FVIIa inhibitors by solution-phase peptide synthesis. Hereby, a rapid
preparation of a range of peptides should be possible. The only previously reported pep-
tidyl benzyl ketone is the thrombin inhibitor H-D-Cha-Pro-Arg-bk (1.7) (bk = benzyl
ketone),105 which was described in Section 1.1.3.1. This inhibitor was synthesized by a
convergent approach coupling an arginyl benzyl ketone building block with the dipeptide
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Scheme 3.2.2: The benzyl ketone serine protease inhibitor 1.7 was synthesized
by coupling the dipeptide Boc-D-Cha-Pro-OH with the building block. However,
the authors do not comment on the high possibility of racemization.105
Boc-D-Cha-Pro-OH using IBCF as coupling agent (see Scheme 3.2.2). Convergent syn-
thesis of peptides usually requires specialized resins427 or other special conditions, such
as enzymatic condensation,428 to avoid racemization. In the case of 1.7, convergent
synthesis is successful because proline is the C -terminal residue. Minimization of the
risk of racemization can be achieved by having proline, glycine, alanine or arginine as C -
terminal residues.429 Unfortunately these amino acids are not included in the FVIIa-TF
specificity profile at the P2 position. A traditional linear synthetic approach therefore
seems to be the most rational choice for preparation of peptidyl benzyl ketone FVIIa
inhibitors.
3.2.3.1 Synthesis of the P3-P2 scaffold
With the P1-amino acid in hand, the next step was to synthesize a variety of different
tripeptides by two consequetive peptide couplings.
Initially, a chemoselective deprotection procedure was investigated to selectively remove
the Boc-group in the presence of the Pmc-group. Luckily, this was done easily by treat-
ment with 20% TFA in DCM at room temperature for 30 minutes (see Table 3.2.1).
LC-MS showed full conversion and no loss of the Pmc-group was observed.
Next, the peptide coupling was afforded using a Boc-protected amino acid and EDC/HOAt
as coupling agents. EDC was chosen over DIC and DCC because the corresponding urea
by-product is soluble in acid and therefore enhances the ease of purification. One draw-
back of using EDC is the price since this carbodiimide is almost 40 times more expensive
than e.g. DCC.251 Using EDC/HOAt, three dipeptides were synthesized (3.16–3.18) in
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Table 3.2.1: Synthesis of protected dipeptides (P2-P1).
N
H
NH
O
Boc
H
NHN Pmc
1. 20% TFA
    DCM, rt, 30 min
2. Boc-P2-OH, EDC  HCl, HOAt
    DIPEA, DCM, rt, 1h N
H
NH
O
H
NHN Pmc
OH
N
P2
Boc
3.15                                                                                                3.16 − 3.18
entry P2a product yield (%)b purity (%)c
1 Thr(Bn) 3.16 40–69 >96.4
2 Leu 3.17 34–62 >94.8
3 Phe 3.18 46–60 >91.7
a: Notation corresponds to the respective amino acid side-chain. b:
Purified yield. c: The lowest determined purity based on UPLC analysis
(TFA).
moderate to good purified yield (34–69%). The dipeptides were easily purified by flash
chromatography and subsequently subjected to the next peptide coupling.
In the next step, the synthesis of the tripeptides was not straightforward and gave only
very low yields (<30%) during the initial studies. One of the main problems was found
during the Nα-deprotection. Compared to an almost clean deprotection with the build-
ing block 3.15 itself, many more by-products were formed when subjecting one of the
dipeptides to 20% TFA in DCM. To circumvent by-product formation, the deprotection
was carried out at 0 ◦C, which resulted in prolonged reaction times, typically up to 4
hours. By this modification the by-product formation was almost completely suppressed
and clean reactions were obtained.
Having solved the problems in the deprotection step, new problems arrived with the
second peptide coupling. Once again cooling to 0 ◦C solved some of the problems, but
it was also found to be important at which point DIPEA was added. Significantly lower
yields of the corresponding tripeptide was obtained if DIPEA was added to form the free
amine of the dipeptide, before addition of the activated amino acid. This is quite reson-
able because a free amine in the presence of an electrophilic group (the benzyl ketone)
is subject to severe by-product formation. In fact, the free amine of the dipeptide is
lined up for a cyclization giving a 6-membered ring, a piperazine-2-one derivative (see
Scheme 3.2.3).
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Table 3.2.2: Synthesis of protected tripeptides (P3-P1).
1. 20% TFA
    DCM, 0 oC, 4h
2. Boc-P3-OH, EDC HCl, HOAt
    DIPEA, DCM, 0 oC, 1hN
H
NH
O
H
NHN Pmc
OH
N
P2
Boc
   3.16 − 3.18                                                                                                   3.19 − 3.25
N
H
NH
O
H
NHN Pmc
OH
N
P2O
N
H
P3
P4
entry P4 P3a P2a product yield (%)b purity (%)c
1 Boc Tyr(Bn) Thr(Bn) 3.19 40–69 >69.3
2 Boc Tyr(Bn) Leu 3.20 39–41 >79.2
3 Boc Phe Leu 3.21 29–31 >85.2
4 Boc Phe Phe 3.22 54 >88.5
5 Boc D-Phe Phe 3.23 27 >79.6
6 Cbz Phe Phe 3.24 32 69.3
7 Cbz D-Phe Phe 3.25 27 80.6
a: Notation corresponds to the respective amino acid side-chain. b: Purified yield. c: The lowest
determined purity based on UPLC analysis (TFA).
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Scheme 3.2.3: The free amine of the dipeptide is lined up for a cyclization
forming initially a piperazine-2-one derivative, which could lead to further by-
product formation. However, the shown derivatives here have not been observed
by LC-MS, but many other uncharacterized by-products have.
This derivative is believed to eliminate water formining an enamine and then react fur-
ther forming many by-products. However, the shown derivatives were not observed by
123
Results and discussion
LC-MS, but many other by-products were formed most likely via these species. Nev-
ertheless, addition of DIPEA after mixing the deprotected dipeptide and the activated
N-protected amino acid usually solved the problem and reasonable purified yields of the
tripeptides 3.19–3.25 were obtained (see Table 3.2.2) Some variation in the obtained
yields was still observed, which indicates some lack of reproducability. The tripeptides
were generally also less pure than the dipeptides, even after flash chromatography (c.f.
Tables 3.2.1 and 3.2.2).
Coupling using activated amino acids directly, such as Boc-Tyr(Bn)-OSu for the syn-
thesis of Boc-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.19) was investigated, but no successful
results were achieved with the dipeptide 3.16. Only traces of 3.19 were formed based
on LC-MS analysis along with many uncharacterized by-products. Using a preactivated
amino acid was therefore not successful. Despite the problems with the synthesis of the
tripeptides, the method still seems to be the best when using solution-phase synthesis.
3.2.3.2 Functionalization of the N-terminal
The acetyl N-terminal was easily introduced by chemoselective deprotonation of the
N-terminal with 20% TFA in DCM followed by reaction with Ac2O in the presence of
DIPEA. Upon purification, the N-acetylated tripeptides 2.26 and 3.27 were obtained in
good yield (67–70%) (see Table 3.2.3). Only these two peptide sequences were selected
because they represent two rather different rankings according to the FVIIa specificity
profile previously described.
The N-sulfonylation (BnSO2) is known from the literature used for capping of amino
groups,430,431 as well as N-terminals for serine protease inhibitors.130,165,166 Introduction
of the N-BnSO2-terminal proceeded, after deprotection of the N
α-protection, by reac-
tion with BnSO2Cl in the presence of a DIPEA (see Table 3.2.4) according to a literature
procedure.431
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Table 3.2.3: N-Acetylation of tripeptides.
1. 20% TFA
    DCM, rt, 30 min
2. Ac2O, DIPEA
    DCM, rt, 30 min
3.19, 3.22                                                                                               3.26, 3.27
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P3
Boc
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P3
Ac
entry P4 P3a P2a product yield (%)b purity (%)c
1 Ac Tyr(Bn) Thr(Bn) 3.26 67–70 >92.1
2 Ac Phe Phe 3.27 70 >89.6
a: Notation corresponds to the respective amino acid side-chain. b: Purified yield. c: The lowest
determined purity based on UPLC analysis (TFA).
Table 3.2.4: N-Sulfonylation of tripeptides.
1. 20% TFA
    DCM, rt, 30 min
2. BnSO2Cl, DIPEA
    DCM, rt, 30 min
3.19 − 3.23                                                                                                    3.28 − 3.32
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P3
Boc
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P3
BnSO2
entry P4 P3a P2a product conv. (%)b purity (%)c
1 BnSO2 Tyr(Bn) Thr(Bn) 3.28 35 >77.6
2 BnSO2 Tyr(Bn) Leu 3.29 79 >59.9
3 BnSO2 Phe Leu 3.30 >95 >50.8
4 BnSO2 Phe Phe 3.31 80 >63.5
5 BnSO2 D-Phe Phe 3.32 67 >39.1
a: Notation corresponds to the respective amino acid side-chain. a: Determined by
LC-MS. c: The lowest determined purity based on UPLC analysis (TFA).
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Unfortunately, the introduction of the N-BnSO2-terminal was not as easy as expected.
Initially, the reaction was performed using 2.50 equiv, but that led to approximately 20%
of the corresponding di(BnSO2)-product. Different equivs ranging from 1.10–2.50 were
tested, and 1.10 equiv was found to be the best effording a maximized conversion and
a minimized by-product formation. However, the reaction was rather unpredictable and
sometimes full conversion was achieved within 30 minutes and in other cases full con-
version was never reached. Besides of different equiv BnSO2Cl, different temperatures
(0 ◦C to reflux), different reaction times and different bases (DIPEA, Et3N and DMAP)
were tested, but in all cases the reaction remained tricky. Inspired by the previous results,
DIPEA was not added to the deprotected tripeptide until BnSO2Cl was added.
As well as unconverted starting material and product, the crude products also contained
many minor uncharacterized products as well as the di(BnSO2)-product. The rather im-
pure crude products were subjected to flash chromatography, but a successful procedure
was not found. Therefore, several of the N-sulfonylated peptides were used without
further purification and the impurities were removed upon preparative HPLC of the final
compounds.
In efforts to optimize the N-sulfonylation, another strategy was tested. In the literature,
this N-BnSO2 moiety has also been introduced directly along with the last amino acid,
serving as a N-protection during the last peptide coupling.165,166 Because the introduc-
tion of the N-BnSO2-group seems to be rather sluggish with these substrates, it would
be more efficient to introduce it with the P3-amino acid. Hereby, the low-yielding re-
action step is performed on a cheap starting material in stead of on an expensive and
synthetically time-consuming dipeptide.
H2N
O
OH BnSO2Cl (1.50 equiv)
Dioxane, 1M NaOH, 
0 oC, 4h
N
H O
OHS
OO
35% yield
3.33                                                                             3.34
Scheme 3.2.4: N-Terminal modification of H-Phe-OH (3.33) into the corre-
sponding BnSO2-amino acid 3.34 in moderate yield according to a literature
procedure.432
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To test this strategy, H-Phe-OH (3.33) was converted into the corresponding N-sulfonylated
amino acid 3.34 in moderate yield according to a literature procedure432 (see Scheme
3.2.4).
N
H O
NH
H
NHN
Pmc
OH
NBoc
1. 20% TFA
    DCM, 0 oC, 4h
2. BnSO2-Phe-OH (3.34)
    EDC  HCl, HOAt
    DIPEA, DCM, 0 oC, 1h
N
H O
NH
H
NHN
Pmc
OH
N
O
N
H
BnSO2
3.17                                                                                                                3.30
Scheme 3.2.5: Coupling the dipeptide 3.17 with the N-sulfonylated amino acid
3.34 did surprisingly not give the desired product BnSO2-Phe-Leu-Arg(Pmc)-bk
(3.30).
With the new P4/P3-amino acid 3.34 in hand, its usability was tested for the synthesis
of BnSO2-Phe-Leu-Arg(Pmc)-bk (3.30) under the previously optimized conditions for
synthesis of tripeptides (see Scheme 3.2.5).
The coupling of the dipeptide 3.17 with 3.34 did surprisingly not give the desired pro-
duct 3.30 despite that this approach has been reported by Parlow and co-workers.165,166
Instead of forming any product, many uncharacterized compounds were formed. No
further optimization was pursued.
3.2.3.3 O-Debenzylation of tyrosine and threonine
O-Debenzylation of Boc-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk was initially investigated using
catalytic hydrogenolysis over Pd/C (see Scheme 3.2.6 and Table 3.2.5).
The desired product 3.38 was obtained in 14% based on LC-MS when the hydrogenol-
ysis was performed with 3 bar H2 at room temperature overnight in EtOH (see entry
1). The two main components in the reaction mixture were unreacted starting material
3.19 and the mono O-debenzylated product 3.35 (see Scheme 3.2.6). This experiment
clearly indicated that O-debenzylation of tyrosine was much faster than O-debenzylation
of threonine.
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Scheme 3.2.6: Catalytic hydrogenolysis over Pd/C of Boc-Tyr(Bn)-Thr(Bn)-
Arg(Pmc)-bk (3.19) was investigated. Deprotection of threonine was much slower
than that of tyrosine and two reduced by-products (3.36 and 3.37) were some-
times also observed.
By increasing the pressure of H2 80 bar indeed forced the reaction toward the products,
but unfortunately, the main product (84%) was just the mono-O-debenzylated one 3.35
and only 16% of the desired product 3.38 was obtained (entry 2). Chainging the solvent
to MeOH gave no product and only the mono-O-debenzylated compound was found in
the crude product (entry 3). To force the reaction towards the product 3.38, a series of
experiments in MeOH at elevated temperature was carried out (entries 4–6). Up to 39%
3.38 was observed, but large amounts of the two reduced compounds 3.36 and 3.37
were also obtained (up to 45%). These two compounds are believed to be the mono-
and the di-O-debenzylated peptides, respectively, each containing a reduced tyrosine
residue.
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Table 3.2.5: Investigation of the catalytic O-debenzylation over Pd/C.
N
H
NH
H
NHN
O
OH
N
OBnO
N
H
BnO
Boc
3.19
H2, Pd/C
Pmc
Solvent N
H
NH
H
NHN
O
OH
N
OHO
N
H
HO
Boc
3.38
Pmc
+  3.35 − 3.37
entry solvent P (bar) temp. (◦C) time (h) 3.38 (%)a
1 EtOH 3 rt 16 14
2 EtOH 80 rt 16 16
3 MeOH 3 rt 16 0
4 MeOH 40 40 16 39
5 MeOH 80 50 3 18
6 MeOH 80 50 16 10
7 MeOHb 40 rt 3 0
8 MeOHb 40 rt 5 0
9 MeOHb 40 rt 16 60
10 MeOHb 80 rt 16 74
11 MeOHb 80 rt 24 87
12 MeOHb 80 rt 72 78
13 MeOHb 80 30 16 80
14 MeOHb 80 35 16 74
a: Formation of product 3.38 determined by LC-MS, UV 214 nm. Detailed crude
product distribution is included in the Experimental Section. b: 10% AcOH
added.
To confirm this a series of experiments with Boc-Thr(Bn)-Arg(Pmc)-bk (3.16) was set
up. Using the same conditions (c.f. entries 4–6, Table 3.2.5) no reduction was observed,
indicating that the reduction did not occur at the threonine residue nor at the benzyl
ketone. Heating the reaction seemed to be inappropriate and therefore roomtemperature
was chosen for further optimization.
Addition of AcOH is a well known additive in many hydrogenolyses322 and therefore
a set of experiments containing 10% AcOH in MeOH as solvent with 40 bar H2 was
investigated (entries 7–9). The reduced pressure of H2 was selected to avoid by-product
formation. Increasing the reaction time gave substantially higher amounts of the mono
O-debenzylated 3.35, but the desired product 3.38 was not observed until prolonged
periods were tested (entry 9). Once again the pressure was increased to 80 bar and ex-
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periments at room temperature with reaction times of at least 24 hours were performed
(entries 10–12). Gratifyingly, 80 bar at room temperature with a reaction time of 24
hours gave 87% of the desired product Boc-Tyr-Thr-Arg(Pmc)-bk (3.38) and only minor
amounts of the reduced tyrosine compounds 3.37 (7%) and 3.35 (6%) were formed.
Prolonged reaction time did not increase the amount of product but instead led to an
increased amount of the di-O-debenzylated reduced tyrosine 3.37. Last but not least,
gently heating to 30 or 35 ◦C, respectively was tested, but that was not beneficial.
The optimization of the O-debenzylation was also tested on the Nα/Nω-deprotected
tripeptide H-Tyr(Bn)-Thr(Bn)-Arg-bk. Once again it was found, that deproction of ty-
rosine occured much faster than that of threonine. Steric hindrance from the Boc- or
Pmc-groups was therefore not seen to be the reason for the difficulties of unprotecting
the threonine residue. It is more reasonble that the difference in reaction kinetics is
a result of the corresponding stability of the anions (phenolate ions are stabilized by
resonance).
Usage of the Pearlman’s catalyst (Pd(OH)2/C) in combination with Pd/C has been
described in the literature as a more active catalytic system for O-debenzylation.355
Therefore, the hydrogenolysis of 3.19 was tested with different loadings (10–25 wt%)
of Pd/C:Pd(OH)2/C (1:1) at different pressures (3–80 bar). Unfortunately, it turned
out that this catalytic system was too active and many by-products were formed. Less
Pd(OH)2/C was also tested with Pd/C, but was not beneficial. Reduction of the benzyl
ketone was probably one of the new by-products observed with the Pearlman’s catalyst
(based on LC-MS). Apparently, the more active catalyst is capable of reducing the ke-
tone functionality. Addition of 10% AcOH and decrease of H2 pressure to 3 bar did not
give any successful results.
Lewis acid-promoted O-debenzylation was also tested with the SnCl4 and TiCl4, respec-
tively. Once again it was observed that threonine was much more difficult to deprotect
than tyrosine. Eventhough an excess of the Lewis acid was used at reflux, no clean
deprotection was observed and this strategy was terminated.
Based on the optimization results, the catalytical hydrogenolysis at 80 bar H2 at room
temperature for 24 hours gave the best result (see Table 3.2.5, entry 11). Therefore the
synthesized tripeptides were subjected to these condition for O-debenzylation of those
peptides containing tyrosine and threonine residues (see Table 3.2.6).
Boc-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.19) and Ac-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.26)
were both succesfully O-debenzylated (conv. >90%) giving only minor amounts of the
corresponding mono-reduced spiecies (5–10%) (entries 1–2). The deprotected peptides
were used without further purification. Subjecting the N-sulfonylated peptides 3.28 and
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3.29 to the very same reaction conditions unfortunately did not afford any traces of
the desired products 3.40 or 3.41, respectively. The reaction time was increased to
several days, but only a mixture of the starting material and the mono-O-debenzylated
compounds were observed based on LC-MS analysis. Apparently, the benzylsulfonyl
N-terminal decreases the reactivity or is causing catalyst poisening, maybe due to coor-
dination to sulfur. Further optimization was not pursued, and the synthesis of BnSO2-
Tyr-Thr-Arg-bk (3.40) and BnSO2-Tyr-Leu-Arg-bk (3.41) did not succeed.
Table 3.2.6: Hydrogenolysis for O-debenzylation of tyrosine and threonine.
                                                                                3.38 − 3.41
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P4
N
H
NH
O
H
NHN
Pmc
OH
N
P2O
N
H
P4
H2 (80 bar)
10 wt% Pd/C
MeOH
10% AcOH, rt, 24h
BnO HO
entry P4a P3a P2a product conv. (%)b purity (%)c
1 Boc Tyr Thr 3.38 90 (5) >80.1
2 Ac Tyr Thr 3.39 95d (10) –
3 BnSO2 Tyr Thr 3.40 –
e –
4 BnSO2 Tyr Leu 3.41 –
e –
a: Notation corresponds to the respective amino acid side-chain. b: Conversion based on LC-MS.
Amount of reduced by-product stated in the brackets (%). c: The lowest determined purity based
on UPLC analysis (TFA). d: A reaction time of 2.5 days was required for full conversion. e: No
product was formed after 2.5 days. Mainly the mono-O-debenzylation was observed on LC-MS.
3.2.3.4 Deprotection, purification and lyophilization
Those peptides successfully synthesized were carried on to the final Boc/Pmc-deprotection
which was easily performed by treatment with 95% TFA in DCM. The crude products
were purfied by preparative HPLC using an appropriate gradient of H2O→MeCN. Upon
lyophilization of the pure fractions and nitrogen quantification by HPLC-CLND, nine
peptidyl benzyl ketones 3.42–3.50 were obtained in good (see Table 3.2.7).
Although the yields are modest (some of them are actually based on three steps), the
purity was prioritized when selecting the fractions from the preparative HPLC purifica-
tion. In all cases the purified peptide was lyophilized yielding the corresponding TFA-salt
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Table 3.2.7: Final deprotection and purification by preparative HPLC.
                                                                                           3.42 − 3.50
N
H
NH
O
H
NHN Pmc
OH
N
P2O
N
H
P3
P4
95% TFA
DCM, rt, 30 min N
H
NH
O
NH2HN
OH
N
P2O
N
H
P3
P4
3.38, 3.39, 3.30, 3.22, 
3.27, 3.31, 3.32, 3.24, 3.25
TFA
entry peptide product yield (%)b purity (%)c
1 H-Tyr-Thr-Arg-bk 3.42 35d >93.0
2 Ac-Tyr-Thr-Arg-bk 3.43 14d >87.9
3 BnSO2-Phe-Leu-Arg-bk 3.44 30 >95.3
4 H-Phe-Phe-Arg-bk 3.45 49 >95.4
5 Ac-Phe-Phe-Arg-bk 3.46 57 >95.9
6 BnSO2-Phe-Phe-Arg-bk 3.47 24
d >94.5
7 BnSO2-D-Phe-Phe-Arg-bk 3.48 29
d >85.0e
8 Cbz-Phe-Phe-Arg-bk 3.49 21 >74.3e
9 Cbz-D-Phe-Phe-Arg-bk 3.50 22 83.4e
a: Notation corresponds to the respective amino acid side-chain. b: Yield (2 steps) determined by
HPLC-CLND nitrogen quantification of purified peptide. c: The lowest determined purity based
on UPLC analysis (TFA, NH4HCO3 and/or Na2SO4). d: Yield based on three steps, because
N-terminal modification and/or deprotection step was used directly without purification. e: UPLC
(TFA) gave a purity of higher than 95%.
as a white solid compound.
3.2.4 Biological activity and SAR of the FVIIa inhibitors
The synthesized peptides were all subjected to three competitive binding assays for
screening of inhibitory activity against FVIIa, thrombin (thr) and FXa, respectively (see
Table 3.2.8). Solubility of the peptides in the assay buffer (50 mM HEPES, 100 mM
NaCl, 6.6 mM CaCl2, 0.01% Tween80) varied a lot. The tyrosine- and threonine-
containing peptides 3.42 and 3.43 were highly soluble in the buffer, whereas the N-
sulfonylated peptides 3.44, 3.47 and 3.48 and in particular the Cbz-modified peptides
3.49 and 3.50 were much less soluble. The highest concentration tested in the assay
therefore varied accordingly, but in general concentrations of more than 1400 µM were
not considered.
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Table 3.2.8: Inhibition of blood coagulation serine proteases.
IC50 (µM)
a
entry peptide FVIIa thr FXa Ki (µM) FVIIa/thr
b FVIIa/FXab
1 3.42 >1340 >1340 >1340 – – –
2 3.43 >1380 >1380 1078 – – >0.78
3 3.44 >580 >580 >580 – – –
4 3.45 >1480 >1480 >1480 – – –
5 3.46 >400 >400 >400 – – –
6 3.47 26 >590 >590 43 >23 >23
7 3.48 640 >640 >640 – >1 >1
8 3.49 109 >650 508 89 >6 >5
9 3.50 16 560 440 8 35 28
a: Estimated IC50-value determined by a competitive binding assay against FVIIa, thrombin or FXa, respectively.
Concentration of inhibitor was determined by HPLC-CLND. b: Selectivity over thrombin and FXa, respectively,
calculated using the IC50 values.
The most potent FVIIa inhibitor was found to be Cbz-D-Phe-Phe-Arg-bk (3.50) and
has an IC50 = 16 µM and Ki = 8 µM (entry 9). The inhibitor has a 35- and 28-fold
selectivity over thrombin and FXa, respectively. Two less potent inhibitors were found to
be BnSO2-Phe-Phe-Arg-bk (3.47) with Ki = 43 µM and Cbz-Phe-Phe-Arg-bk (3.49)
with Ki = 89 µM (entries 6 and 8). Inhibitor 3.47 posseses at least a 23-fold selec-
tivity against both thrombin and FXa, whereas 3.49 is almost equal potent against all
three blood coagulation enzymes. Cbz-D-Phe-Phe-Arg-bk (3.50) therefore represents
the most potent and selective FVIIa inhibitor of them all.
Based on the biological results, a bulky and aromatic N-terminal is crucial for activ-
ity. This P4-moiety is believed to probe the S4 and/or the subsite of the S1 binding
pocket.130,165,166 N-Sulfonylation has been reported previously,115,116,130,165,166 but Cbz-
modified peptides have only briefly been described in the literature in connection with
thrombin inhibitors (c.f. 1.12, Figure 1.1.16). Although it was concluded from the
FVIIa-TF specificity profile, that the S4 binding site is undefined,168 these results show
that probing of S4 binding pocket is highly important with this class of inhibitors.
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The influence of a D-amino acid at P3 is still not fully understood. Cbz-D-Phe-Phe-Arg-
bk (3.50) was slightly more potent than the corresponding L-diastereomer 3.49. The
reverse results were observed with BnSO2-Phe-Phe-Arg-bk (3.47) and BnSO2-D-Phe-
Phe-Arg-bk (3.48); the former was a potent FVIIa inhibitor with IC50 = 26 µM (Ki =
43 µM), but the latter was approximately 25-fold less potent (IC50 = 640 µM). The
effect of introducing a D-amino acid at P3 is not uniform among the inhibitors. However,
these results clearly show that D-amino acids are not only used for increasing the in vivo
stability, but also for altering the potency of the inhibitor.
Not surprisingly, the amino acid at P2 has an important role. If phenylalanine is com-
pared to leucine, the latter should be a more active amino acid according to the FVIIa-TF
specificity profile.168 However, that was not observed experimentally in this study. Com-
paring BnSO2-Phe-Leu-Arg-bk (3.44) and BnSO2-Phe-Phe-Arg-bk (3.47) shows that
3.47 is more than 20 times more potent against FVIIa than 3.44.
Eventhough H-Tyr-Thr-Arg-bk (3.42) and Ac-Tyr-Thr-Arg-bk (3.43) have the suppos-
edly most potent S3-S1 scaffolds, these compounds were not significantly active against
any of the tested serine proteases. Threonine is most likely forming a hydrogen bond
with Asp60 through a water molecule, which is a unique feature of the S2 binding pocket
of FVIIa. Despite such a favored interaction with the enzyume, the contribution of the
P4 group is apparently of much more importance. Presumably, this group forms hydro-
gen bonds with Lys192 and/or Gly219 as well as hydrofobic interactions within the S4
binding pocket. These bindings are apparently essential for achieving good potency with
this class of FVIIa inhibitors.
These results moreover indicate that a specificity profile cannot directly be translated
into synthetic compounds with similar biological activity. The main reason for this is
undoubtly due to interdependence resulting in conformational changes of the enzyme
upon binding of a certain substrate. These changes alter the specificity, and therefore it
is rather unpredictable.
Comparing Cbz-D-Phe-Phe-Arg-bk (3.50) with some of the reported FVIIa peptidyl in-
hibitors, this inhibitor is less potent compared to the most potent inhibitors reported.
For example, the α-ketothiazole 1.23 presented in Section 1.1.3.3 has a Ki = 0.20 µM
against FVIIa, and thus is 40 times more potent than 3.50.165,166 It also got a superior
selectivity against thrombin (500-fold), but no selectivity against FXa. One possible
explanation for the increased potency of 1.23 is that the α-ketothiazole is very electron-
withdrawing giving a electron-deficient and reactive carbonyl group. The benzyl ketone
is less electrophile, but still having the aromatic moiety, which in fact has been found to
be the most important part of the P1’ part of the molecule. In this regard, functional-
ization of the benzyl ketone would be a valuable extention of the SAR of these inhibitors.
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Selection of the most appropriate inhibitor for a liquid formulation of FVIIa is based on
many parameters. A potency in the low micromolar is likely a sufficient inhibitor to gain
some stabilization of FVIIa in a liquid formulation. Naturally, it is decided to minimize
the amount of inhibitor in the formulation, but on the other hand, a highly potent in-
hibitor would not be desirable. FVIIa binds to the surface of the thrombin-activated
platelets with low affinity (c.f. Figure 1.1.5). If a highly potent inhibitor was used, the
pharmacological respons would probably be impaired, which is not desirable. Selectivity
against other blood coagulation serine proteases is another parameter to consider. For
the usage as a stabilization agent, this issue is not as important than if the inhibitor
should itself be used in pharmacological doses. When co-injecting the inhibitor with
FVIIa, the resulting dilution is probably high enough to prevent the inhibitor to inhibit
any of the other coagulation factors substantially. In this regard, a high in vivo clearance
would be desirable.
Evaluating Cbz-D-Phe-Phe-Arg-bk (3.50) as a potential stabilization agent, it has a
practicable potency and selectivity. However, the solubily in aqueous media is low and
that is probably the biggest concern. Introduction of polar functionalities, e.g. at the P1’
position or as a part of the S4-S1 scaffold would contribute to a better solubility. This was
observed for the Tyr-Thr-containing peptides, which had a much better solubility. The
development of FVIIa inhibitors for liquid formulations of NovoSeven R© is not complete
yet and further optimization would be required before the desired goal has been achieved.
Besides of a the medicinal chemistry part of the project, development of new formulations
of FVIIa should be investigated, and especially the long-term stability of the enzyme is
of interest. Solutions of FVIIa (e.g. in the assay buffer) are stable for at least a week at
room temperature, because the proteolytic activity is significantly reduced in the absence
of TF. Evaluation of the long-term stability should therefore be done over the course
of several months. In addition, the activity of FVIIa should be determined in a clotting
assay measuring the ability of the enzyme to initiate the blood coagulation cascade.
These future applicabilities were however beyond the scope of this thesis.
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3.3 Conclusion
The arginyl benzyl ketone building block 3.15 was synthesized from Boc-Arg(Pmc)-OH
(3.13) via the Weinreb amide 3.14 in good yield without racemization. The P3-P1
sequence of the target peptides was selected from a previously reported FVIIa-TF speci-
ficity profile, giving that P1 should always be arginine and P3-P2 should be combinations
of tyrosine, threonine, phenylalanine and leucine. Different N-terminals (P4; H-, Ac-,
BnSO2- and Cbz-) were also examined. Thus, a small library of peptidyl benzyl ketones
was prepared by a Boc/Bn solution-phase peptide synthetic approach. Removal of the
Nα-deprotection was accomplished selectively with 20% TFA in DCM followed by an
EDC/HOAt-mediated peptide coupling. The first coupling proceeded smoothly, but the
second was challenging because of severe by-product formation. Through optimization,
this problem was solved by running the deprotection and the peptide coupling at 0 ◦C.
Furthermore, the order of addition was found to be crucial, in particular it was impor-
tant that DIPEA was added after mixing the deprotected amine and the activated amino
acid. A N-sulfonylation was introduced with BnSO2Cl, but the reaction was found to
be very sluggish and not reproducible. Screening of different reaction conditions did not
lead to optimization of the reaction. Tyrosine and threonine were O-debenzylated using
catalytic hydrogenolysis at 80 bar H2 over 10wt% Pd/C in 10% AcOH/MeOH. This gave
full conversion of the desired Boc- or N-acetylated peptides 3.38 and 3.39, with a min-
imal reduction of the tyrosine residue. The deprotection was found to be rather difficult
and especially the O-debenzylation of threonine was slow. Unfortunately these optimized
conditions were ineffective for O-deprotection of N-sulfonylated peptides, such as 3.40
and 3.41. This limitation restrics the number of tyrosine- and threonine-containing com-
pounds when using the solution-phase synthetic approach. Thus, nine peptidyl benzyl
ketones were synthesized (3.42–3.50) and their biological activity was evaluated in com-
petitive binding assays for FVIIa, thrombin and FXa. The most potent FVIIa inhibitor
was identified as Cbz-D-Phe-Phe-Arg-bk (3.50) with a Ki = 8 µM (IC50 = 16 µM) and
with a 35- and 28-fold selectitivity against thrombin and FXa, respectively. A bulky
aromatic N-terminal was crucial for activity. Cbz was found to be superior compared to
BnSO2. Eventhough the specificity profile showed that Tyr-Thr-Arg should be the most
potent sequence, the results here show that D-Phe-Phe-Arg in fact was the most potent
sequence of the synthesized compounds. Usability of Cbz-D-Phe-Phe-Arg-bk (3.50) as
a stabilizing agent for liquid formulations of FVIIa still remains unexplored, but based on
the potency and selectivity this inhibitor seems to be a promising candidate. However,
3.50 is rather insoluble in aqueous media which is a potential problem for the usage in
a drug formulation. Further optimization of the synthetic strategy would be necessary
to prepare Tyr-Thr-Arg-containing peptides with the appropriate N-terminals as well as
a thorough SAR study of the P1’ position.
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3.4 Outlook
Optimization of the synthetic route would be a valuable improvement for further synthe-
sis of novel peptidyl benzyl ketones as FVIIa inhibitors. Synthesizing more compounds
would give a better SAR and a better understanding of the probing of S4 (via the N-
terminal) and S1’ (via the benzyl ketone C -terminal) binding sites in order to gain higher
potency and selectivity. Furthermore, optimization of the solubulity would represent an
important improvement for applicability as a formulation-aid, because precipitation of
the inhibitor would be problematic. However, a potent inhibitor does not require high
concentrations, which might solve the problem.
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Scheme 3.4.1: Proposed solid-supported synthesis of the peptidyl benzyl ketone
FVIIa inhibitors anchored by the DHUA-linker forming an acetal, thus preventing
side-reactions with the electrophilic carbonyl.
Based on the known synthetic strategies for preparation of C -terminal modified peptides,
a polymer-assisted approach would be rather easy to test. Polymer-bound EDC,433,434
HOBt435,436 and a variety of bases (diethylamine, diisopropylamine, morpholine, DMAP,
piperazine etc.)437 are commercially available.251 This could improve the procedure with
regard to rapidity and easiness, but not solve the problem with by-product formation
and difficulties regarding the O-debenzylation as well as the N-sulfonylation.
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An entirely solid-supported synthesis using mostly standardized Fmoc-strategy could po-
tentially be achieved with the DHUA-linker, which has been used for the synthesis of a
peptide aldehyde (c.f. Scheme 3.1.4).406 It is believed that the benzyl ketone building
block 3.15 could be anchored to the linker mediated by TMSOTf giving the acetal linker
3.51 (see Scheme 3.4.1). This acetal furthermore serves as a protecting group prevent-
ing side-reactions with the electrophilic carbonyl during peptide synthesis. The linker
can be anchored to the solid-support by traditional coupling conditions (BOP, HOBt,
DIPEA) affording 3.52. These two steps are critical and important for utilization of this
method.
Then a selective Nα-deprotection has to be developed. If the conditions are too acidic,
the Pmc group will also be removed as well as cleaving the acetal. Mild and non-
standidized removal conditions may be effective. The free amine 3.53 is then thought
to be subjected to two consequtive peptide coupling reactions using a standardized
Fmoc/tBu approach (e.g. DIC/HOBt, DIPEA)328 leading to a tripeptide, for example
3.54, which is though to be cleaved from the resin and deprotected with 95% TFA in
H2O leading to the desired inhibitor 3.55. One major advantage by using this solid-phase
approach would be the choice of tyrosine and threonine O-protection. When using the
Fmoc-strategy, the hydroxy group is genereally protected as a tert-butyl ether which
is readily removed by treatment with acid. This synthetic approach would simplify the
preparation of Tyr-Thr-Arg-containing peptides, which is of great interest due to their
potential biological activity and improved solubility in aqueous media.
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3.5 Experimental
General procedures - chemistry
Chemicals and reagents were all commercially available and used without further purifica-
tion. Solvents were of HPLC quality and used without further purification. Evaporation
in vacuo was performed on a rotary evaporator at approx. 40 ◦C down to approx. 20
mbar. TLC was performed using silica gel 60 F254 aluminum sheets. The plates were
visualized in UV light (254 nm) and by staining with 5% MoO3/H3PO4 in EtOH and
subsequently heated with a heating gun. Flash chromatography was performed on a
Biotage R© FlashMaster purification system. The eluent ratios given are vol%. 1H NMR
(400 MHz) and 13C NMR (100 MHz) spectra were recorded on a Bruker Avance DRX
400 instrument using deuterated solvents as internal references. Chemical shifts (δ) are
given in ppm and coupling constants (J) in Hertz. HRMS was performed on an Agi-
lent Technologies 1200 Series LC/MSD-TOF instrument using a C18 column (5→95%
MeCN in H2O, 15 minutes). The found mass (m/z) is stated along with the appur-
tenant fragment, which varies less than 5 ppm compared to the calculated exact mass.
MS was determined on a Perkin Elmer 200 Series PE Sciex 3000 LC/MS/MS Turbo
Ionspray system (5→90% MeCN in H2O, 10 minutes). Analytical UPLC was performed
on a Waters Acquity Ultra Performance LC using tree different systems; TFA: 5→95%
MeCN (or variations hereof) in H2O (16 minutes) containing 0.05% TFA, NH4HCO3:
10→40%MeCN (or variations hereof) in H2O (16 minutes) containing 0.25M NH4HCO3,
Na2SO4: 40→70% MeCN (or variations hereof) in H2O (13 minutes) containing 0.2M
Na2SO4 and 0.04M H3PO4 (pH 3.5). Melting points were measured on a Bu¨chi 535
Melting Point Apparatus and given in degrees Celsius (◦C), uncorrected. IR analysis
was carried out on a Bruker Alpha FT-IR spectrometer using attenuated total reflection
(ATR) sampling technique. Only the strongest or structurally most significant peaks
are included in the experimental section, stated in cm−1. Chiral HPLC was run on Wa-
ters Separation Module e2695 with a Photodiode Array Detector 2998 at 214 nm and
254 nm wavelenghts. A Chiralcel R© OD-H (cellulose tris(3,5-dimethylphenylcarbamate)
coated on 5 µm silica-gel) from Chiral Technologies Europe was used with an isochratic
eluent consisting of 80% hexanes and 20% iPrOH (1 mL/min, rt, 650 psi). The enan-
tiomeric excess was calculed based on an average of the integral areas. Purification by
preparative, reverse-phase HPLC was performed on a Waters DeltaPrep system using a
Phenomenex C18 column (250×12.2Ø mm, 5 micron) with UV/Visible detection on a
Waters 2480 Detector. Fractions were analyzed by LC-MS and analytical HPLC and all
pure fractions were combined and evaporated in vacuo to remove most of the MeCN.
The residue was transferred to one or more freeze-drying glasses, capped with a lid filter
and freezed quickly by immersion in an acetone/dry ice bath (–78 ◦C). When complete
frozen, the compound was lyophilized in a Christ Alpha 2-4 LSC Lyo Chamber (room
temperature, 0.001 mbar) for one or two days depending on the batch size. Products
were obtained as TFA-salts which were quantified by HPLC-CLND on an Agilent Tech-
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nologies 1200 Series connected to an Agilent Interface 35900E / Antek HPLC-CLND.
(2S)-5-(3-(2,2,5,7,8-Pentamethyl-3,4-dihydro-2H-chromen-6-ylsulfonyl)
guanidino)-2-(tert-butoxycarbonyl)amino-N-methoxy-N-methylpentan-
amide (Boc-Arg(Pmc)-weinreb amide) (3.14)
Boc-Arg(Pmc)-OH (3.13) (4.80 g, 8.88 mmol, 1.00 equiv) was suspended in DCM (60
mL), and subsequently dissolved by addition of Et3N (1.36 mL, 1.35 g, 13.32 mmol,
1.50 equiv). PyBOP (6.93 g, 13.32 mmol, 1.50 equiv) was added and after a few mi-
nutes followed by N,O-dimethylhydroxylamine hydrochloride (1.30 g, 13.32 mmol, 1.50
equiv) and Et3N (1.36 mL, 1.35 g, 13.32 mmol, 1.50 equiv). The clear, pale yellow
solution was stirred at room temperature for 1 hour and then pH was adjusted to 5–6
by addition of Et3N. Stirring was continued for another 1 hour. The colorless reaction
mixture was diluted with DCM (250 mL), washed successively with 1M HCl (2 × 100
mL), sat. aqueous NaHCO3 (2 × 100 mL) and finally with brine (2 × 100 mL). The
organic layer was dried over anhydrous Na2SO4 and evaporated to dryness in vacuo.
Purified by flash chromatography (50→90% EtOAc in heptane) afforded the Weinreb
amide 3.14 as a white foam (4.81 g, 93%). Rf = 0.31 (EtOAc).
1H NMR (CDCl3) δ
6.29 (broad s, 1H), 6.12 (s, 2H), 5.49 (d, J = 8.3 Hz, 1H), 4.68–4.64 (m, 1H), 3.74
(s, 3H), 3.44–3.32 (m, 1H), 3.20 (s, 3H), 3.17–3.11 (m, 1H), 2.63 (t, J = 6.7 Hz, 2H),
2.58 (d, J = 5.8 Hz, 6H), 2.11 (s, 3H), 1.82–1.79 (m, 2H), 1.72 (s, 3H), 1.68–1.48
(m, 3H), 1.42 (s, 9H), 1.31 (s, 6H). 13C NMR (CDCl3) δ 172.5, 156.3, 156.0, 153.5,
135.6, 134.9, 133.5, 124.0, 117.9, 80.3, 73.6, 61.6, 46.3, 41.0, 32.8, 32.1, 31.1, 28.3,
26.7, 24.7, 21.4, 18.4, 17.4, 12.1. HRMS (m/z) calcd. for C27H46N5O7S [M + H]
+:
584.3113, found: 584.3141. HPLC purity (TFA): >97.2%. Mp 93–97 ◦C. IR (neat)
υ 3436, 3340, 2974, 2934, 1707, 1650, 1620, 1545 (strong), 1449, 1367, 1246, 1163,
1105, 607 cm−1.
(3S)-6-(3-(2,2,5,7,8-Pentamethyl-3,4-dihydro-2H-chromen-6-ylsulfonyl)
guanidino)-3-(tert-butoxycarbonyl)amino-1-phenylhexan-2-one (Boc-
Arg(Pmc)-bk) (3.15)
Weinreb amide 3.14 (8.03 mmol, 1.00 equiv) was dissolved in dry THF (30 mL) under
an atmosphere of N2. The colorless solution was cooled to 0
◦C and 2.0M BnMgCl
in THF (22.0 mL, 7.27 g, 48.19 mmol, 6.00 equiv) was added dropwise while stirring.
Stirring at 0 ◦C was continued for 10 minutes and then the reaction mixture was slowly
heated to room temperature over the course of 2 hours. The brownish reaction mixture
was cooled to 0 ◦C again and 1M HCl (35 mL) was carefully added while stirring at
such a rate that the temperature did not rise above 20 ◦C. The mixture was transferred
to a separatory funnel with EtOAc (70 mL) and the aqueous layer was discarded. The
organic layer was washed with 1M HCl (2 × 35 mL), sat. aqueous NaHCO3 (2 × 35
mL) and brine (2 × 35 mL), dried over anhydrous Na2SO4 and evaporated to dryness
in vacuo. Purification by flash chromatography (10→70% EtOAc in heptane) afforded
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the desired benzyl ketone as a white solid (3.54 g, 72%). Rf = 0.25 (75% EtOAc in
heptane). 1H NMR (CDCl3) δ 7.30–7.21 (m, 3H), 7.15–7.13 (m, 2H), 6.17 (s, 3H),
5.46 (d, J = 7.6 Hz, 1H), 4.32 (m, 1H), 3.78–3.69 (m, 2H), 3.26–3.02 (m, 2H), 2.61
(d, J = 5.6 Hz, 2H) 2.55 (d, J = 7.3 Hz, 6H), 2.09 (s, 3H), 1.79–1.17 (m, 4H), 1.50
(broad s, 3H), 1.40 (s, 9H), 1.29 (s, 6H). 13C NMR (CDCl3) δ 206.8, 156.1, 153.6,
135.5, 134.8, 133.2, 129.6, 128.7, 127.2, 124.1, 117.9, 80.2, 73.6, 46.4, 40.7, 32.7,
29.1, 28.3, 26.7, 25.0, 21.4, 18.5, 17.5, 12.1. HRMS (m/z) calcd. for C32H47N4O6S
[M + H]+: 615.3211, found: 615.3234. HPLC purity (TFA): >99.0%. Mp 100–104 ◦C.
IR (neat) 3420, 3349, 3010, 2974, 1708, 1618, 1546 (strong), 1452, 1366, 1242, 1163,
1104 (strong), 845, 609 cm−1. Chiral HPLC: 18.11 minutes (minor) and 23.78 minutes
(major) gave an enantiomeric excess of 99%.
General synthesis of protected dipeptide benzyl ketones (A)
The arginyl benzyl ketone building block 3.15 (3.86 mmol, 1.00 equiv) was dissolved in
20% TFA in DCM (30 mL). The reaction mixture was stirred at room temperature for
30 minutes upon which it became slightly colored. LC-MS confirmed full conversion.
The mixture was diluted with DCM (10 mL), evaporated to dryness in vacuo and the
residue was coevaporated with DCM (3 × 10 mL) affording the free amine (TFA-salt)
as a viscous colored oil.
Meanwhile, a N-Boc protected amino acid (4.24 mmol, 1.10 equiv) was dissolved in
DCM (30 mL) and HOAt (577 mg, 4.24 mmol, 1.10 equiv) and EDC·HCl (813 mg, 4.24
mmol, 1.10 equiv) were added. The reaction mixture was stirred at room temperature
for 30 minutes which afforded the activated amino acid.
The free amine (TFA-salt) was redissolved in DCM (30 mL) and the mixture was
added to the stirred solution of the activated amino acid. pH was adjusted to 5–6 by
slowly addition of DIPEA (approx. 1–2 mL). The reaction mixture became instantly
yellow. The mixture was stirred at room temperature for 1 hour at which time LC-MS
showed full conversion (>95%). The reaction mixture was diluted with DCM (300 mL)
and washed with 0.5M HCl (2 × 200 mL), sat. aqueous NaHCO3 (2 × 200 mL) and
finally with brine (2 × 200 mL). The organic layer was dried over anhydrous Na2SO4
and evaporated to dryness in vacuo. Purification by flash chromatography afforded the
protected dipeptide benzyl ketone.
Boc-Thr(Bn)-Arg(Pmc)-bk (3.16)
Following the general synthesis of protected dipeptide benzyl ketones (A) with Boc-
Thr(Bn)-OH and Boc-Arg(Pmc)-bk (3.15) as starting materials and purification by
flash chromatography (60→100% EtOAc in heptane) afforded the product as a white
foam (2.09 g, 67%). Rf = 0.24 (80% EtOAc in heptane). HRMS (m/z) calcd. for
C43H60N5O8S [M + H]
+: 806.4157, found: 806.4192. HPLC purity (TFA): >96.4%.
Boc-Leu-Arg(Pmc)-bk (3.17)
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Following the general synthesis of protected dipeptide benzyl ketones (A) with Boc-
Leu-OH and Boc-Arg(Pmc)-bk (3.15) as starting materials and purification by flash
chromatography (60→100% EtOAc in heptane) afforded the product as a pale, white
foam (1.29 g, 62%). HRMS (m/z) calcd. for C38H58N5O7S [M + H]
+: 728.4052,
found: 728.4060. HPLC purity (TFA): >94.8%.
Boc-Phe-Arg(Pmc)-bk (3.18)
Following the general synthesis of protected dipeptide benzyl ketones (A) with Boc-
Phe-OH and Boc-Arg(Pmc)-bk (3.15) as starting materials and purification by flash
chromatography (40→80% EtOAc in heptane) afforded the product as a white foam
(1.54 g, 60%). Rf = 0.51 (80% EtOAc in heptane).
1H NMR (CDCl3) δ 7.30–7.11
(m, 10H), 6.26 (s, 2H), 6.16 (broad s, 1H), 5.34 (d, J = 5.6 Hz, 1H), 4.56 (m, 1H),
4.45 (m, 1H), 3.72–3.63 (m, 2H), 3.13–3.06 (m, 3H), 2.93–2.88 (m, 1H), 2.63–2.61
(m, 2H), 2.58 (d, J = 8.8 Hz, 6H), 2.11 (s, 3H), 1.94 (s, 1H), 1.80–1.77 (m, 2H),
1.65–1.51 (m, 1H), 1.51–1.39 (m, 2H), 1.32 (s, 9H), 1.30 (s, 6H). 13C NMR (CDCl3)
δ 206.1, 172.3, 156.1, 153.6, 136.4, 135.5, 134.8, 133.3, 133.2, 129.6, 129.2, 128.6,
128.5, 127.1, 126.9, 124.1, 117.9, 80.2, 73.6, 60.4, 57.3, 55.9, 46.3, 40.6, 38.2, 32.8,
28.2, 26.7, 25.0, 21.4, 18.6, 17.5, 12.1. HRMS (m/z) calcd. for C41H56N5O7S [M +
H]+: 762.3895, found: 762.3922. HPLC purity (TFA): >91.7%.
General synthesis of protected tripeptide benzyl ketones (B)
The protected dipeptide benzyl ketone (1.79 mmol, 1.00 equiv) was dissolved in 20% TFA
in DCM (30 mL) at 0 ◦C and stirred for up to 4 hours upon which the mixture became
slightly colored. LC-MS confirmed full conversion. The reaction mixture was diluted
with DCM (10 mL), evaporated to dryness in vacuo and the residue was coevaporated
with DCM (3 × 10 mL) affording the free amine (TFA-salt) as a viscous colored oil.
Meanwhile, a N-Boc protected amino acid (1.97 mmol, 1.10 equiv) was dissolved in
DCM (30 mL) and HOAt (268 mg, 1.97 mmol, 1.10 equiv) and EDC·HCl (378 mg, 1.97
mmol, 1.10 equiv) were added. The reaction mixture was stirred at room temperature
for 30 minutes and then cooled to 0 ◦C.
The free amine (TFA-salt) was redissolved in DCM (30 mL) and the mixture was
added to the stirred solution of the activated amino acid at 0 ◦C. pH was adjusted to 5–6
by slowly addition of DIPEA ( 1–2 mL). The reaction mixture became instantly yellow.
The mixture was stirred at 0 ◦C for 1 hour at which time LC-MS showed full conversion
(>95%). The reaction mixture was diluted with DCM (300 mL) and washed with 0.5M
HCl (2 × 200 mL), sat. aqueous NaHCO3 (2 × 200 mL) and finally with brine (2 ×
200 mL). The organic layer was dried over anhydrous Na2SO4 and evaporated to dryness
in vacuo. Purification by flash chromatography afforded the protected tripeptide benzyl
ketone.
Boc-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.19)
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Following the general synthesis of protected tripeptide benzyl ketones (B) with Boc-
Tyr(Bn)-OH and Boc-Thr(Bn)-Arg(Pmc)-bk (3.16) as starting materials and purifica-
tion by flash chromatography (25 → 90% EtOAc in heptane), afforded the product as
pale, yellow foam (1.56 g, 62%). Rf = 0.43 (95% EtOAc in heptane). HRMS (m/z)
calcd. for C59H75N6O10S [M + H]
+: 1059.5260, found: 1059.5304. HPLC purity (TFA):
>69.3%.
Boc-Tyr(Bn)-Leu-Arg(Pmc)-bk (3.20)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Boc-
Tyr(Bn)-OH and Boc-Leu-Arg(Pmc)-bk (3.17) as starting materials and purification by
flash chromatography (25→90% EtOAc in heptane), afforded the product as pale, yellow
solid (339 mg, 39%). Rf = 0.65 (EtOAc). HRMS (m/z) calcd. for C54H73N6O9S [M
+ H]+: 981.5154, found: 981.5202. HPLC purity (TFA): >79.2%.
Boc-Phe-Leu-Arg(Pmc)-bk (3.21)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Boc-
Phe-OH and Boc-Leu-Arg(Pmc)-bk (3.17) as starting materials and purification by
flash chromatography (75→100% EtOAc in heptane), afforded the product as white
solid (224 mg, 29%). Rf = 0.42 (90% EtOAc in heptane). HRMS (m/z) calcd. for
C47H67N6O8S [M + H]
+: 875.4736, found: 875.4762. HPLC purity (TFA): >85.2%.
Boc-Phe-Phe-Arg(Pmc)-bk (3.22)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Boc-
Phe-OH and Boc-Phe-Arg(Pmc)-bk (3.18) as starting materials and purification by
flash chromatography (75→100% EtOAc in heptane) afforded the product as a white
foam (882 mg, 54%). Rf = 0.51 (80% EtOAc in heptane). MS (m/z) calcd. for
C50H65N6O8S [M + H]
+: 909.5, found: 909.9. HPLC purity (TFA): >88.5%.
Boc-D-Phe-Phe-Arg(Pmc)-bk (3.23)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Boc-
D-Phe-OH and Boc-Phe-Arg(Pmc)-bk (3.18) as starting materials and purification by
flash chromatography (75→100% EtOAc in heptane) afforded the product as a white
foam (237 mg, 27%). MS (m/z) calcd. for C50H65N6O8S [M + H]
+: 909.5, found:
909.8. HPLC purity (TFA): >79.6%.
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Cbz-Phe-Phe-Arg(Pmc)-bk (3.24)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Cbz-
Phe-OH and Boc-Phe-Arg(Pmc)-bk (3.18) as starting materials and purification by
flash chromatography (25→90% EtOAc in heptane), afforded the product as a pale, yel-
low glass (157 mg, 32%). Rf = 0.73 (EtOAc). HRMS (m/z) calcd. for C53H63N6O8S
[M + H]+ 943.4423, found 943.4465. HPLC purity (TFA): >69.3%.
Cbz-D-Phe-Phe-Arg(Pmc)-bk (3.25)
Following the general synthesis of protected tripeptide benzyl ketones (B) with Cbz-D-
Phe-OH and Boc-Phe-Arg(Pmc)-bk (3.18) as starting materials and purification by flash
chromatography (25→90% EtOAc in heptane), afforded the product as a pale, yellow
glass (133 mg, 27%). HRMS (m/z) calcd. for C53H63N6O8S [M + H]
+ 943.4423, found
943.4458. HPLC purity (TFA): >80.6%.
Ac-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.26)
Boc-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.19) (86 mg, 0.08 mmol, 1.00 equiv) was dis-
solved in 20% TFA in DCM (5 mL) at room temperature and stirred for 30 minutes.
Then diluted with DCM (10 mL) and evaporated in vacuo and coevaporated to dryness
in vacuo with DCM (3 × 10 mL). The unprotected tripeptide (TFA-salt) was dissolved
in DCM (7 mL) and DIPEA (44 µmL, 31 mg, 0.24 mmol, 3.00 equiv) and Ac2O (22
µL, 21 mg, 0.20 mmol, 2.50 equiv) were slowly added while stirring. pH adjusted to
7–8 by addition of DIPEA. Stirring was continued at room temperature for 30 minu-
tes, then diluted with DCM (25 mL) and washed with 1.0M HCl (2 × 25 mL), sat.
aqueous NaHCO3 (2 × 25 mL) and brine (2 × 25 mL). The organic phase was dried
over anhydrous Na2SO4 and evaporated to dryness in vacuo. Purification by flash chro-
matography (0→15% MeOH in DCM) afforded the N-acylated tripeptide 3.26 as a pale
yellow glass (54 mg, 67% (2 steps)). Rf = 0.37 (5% MeOH in DCM). MS (m/z) calcd.
for C56H69N6O9S [M + H]
+: 1001.5, found: 1001.8. HPLC purity (TFA): >92.1%.
Ac-Phe-Phe-Arg(Pmc)-bk (3.27)
Boc-Phe-Phe-Arg(Pmc)-bk (3.22) (250 mg, 0.28 mmol, 1.00 equiv) was dissolved in
20% TFA in DCM (10 mL) at room temperature and stirred for 30 minutes. Then
diluted with DCM (10 mL) and evaporated to dryness in vacuo and the residue was
coevaporated with DCM (3 × 10 mL). The unprotected tripeptide (TFA-salt) was dis-
solved in DCM (25 mL) and Ac2O (75 µL, 70 mg, 0.69 mmol, 2.50 equiv) was added
slowly while stirring. pH was adjusted to 7–8 by addition of DIPEA. Stirring was contin-
ued at room temperature for 30 minutes, then diluted with DCM (50 mL) and washed
with 1.0M HCl (2 × 50 mL), sat. aqueous NaHCO3 (2 × 50 mL) and brine (2 × 50
mL). The organic phase was dried over anhydrous Na2SO4 and evaporated to dryness
in vacuo. Purification by flash chromatography (5→20% MeOH in DCM) afforded the
N-acylated tripeptide 3.27 as a pale, yellow solid (165 mg, 70% (2 steps)). Rf = 0.61
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(10% MeOH in DCM). MS (m/z) calcd. for C47H59N6O7S [M + H]
+: 851.4, found:
851.7. HPLC purity (TFA): >89.6%.
General N-sulfonylation of tripeptides (C)
The protected tripeptide (0.28 mmol, 1.00 equiv) was dissolved in 20% TFA in DCM
(10 mL) and stirred for 30 minutes at room temperature. The reaction mixture was
diluted with DCM (10 mL) and evaporated to dryness in vacuo. The residue was then
coevaporated with DCM (3 × 15 mL). The free amine (TFA-salt) was dissolved in DCM
(25 mL) and BnSO2Cl (58 mg, 0.30 mmol, 1.10 equiv) was added at once and pH was
adjusted to 7–8 by addition of DIPEA. The reaction mixture was stirred at room tem-
perature until full conversion was observed on LC-MS (if ever observed). The reaction
mixture was diluted with DCM (50 mL) and washed with 1M HCl (2 × 50 mL), sat.
aqueous NaHCO3 (2 × 50 mL) and brine (2 × 50 mL). The organic layer was dried over
anhydrous Na2SO3 and evaporated to dryness in vacuo. The crude product was purified
by flash chromatography, either by 0→20% MeOH in DCM or by heptane→EtOAc, but
none of the systems were able to remove all impurities. Therefore some of the products
were used without further purification.
BnSO2-Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.28)
Following the general N-sulfonylation of tripeptides (C) with Boc-Tyr(Bn)-Thr(Bn)-
Arg(Pmc)-bk (3.19) as starting material afforded the product as a pale, yellow solid
(223 mg, 23%). Rf = 0.73 (EtOAc). HRMS (m/z) calcd. for C61H73N6O10S2 [M +
H]+: 1113.4824, found: 1113.4873. HPLC purity (TFA): >77.6%.
BnSO2-Tyr(Bn)-Leu-Arg(Pmc)-bk (3.29)
Following the general N-sulfonylation of tripeptides (C) with Boc-Tyr(Bn)-Leu-Arg(Pmc)-
bk (3.20) as starting material afforded the product which was used without further
purification. MS (m/z) calcd. for C56H71N6O9S2 [M + H]
+: 1035.5, found: 1035.6.
HPLC purity (TFA): >59.9%.
BnSO2-Phe-Leu-Arg(Pmc)-bk (3.30)
Following the general N-sulfonylation of tripeptides (C) with Boc-Phe-Leu-Arg(Pmc)-bk
(3.21) as starting material and purification by flash chromatography (0→20% MeOH in
DCM) affording the desired product at a pale, yellow solid (164 mg, 74%). Rf = 0.46
(5% MeOH in DCM). MS (m/z) calcd. for C49H65N6O8S2 [M + H]
+: 929.4, found:
929.4. HPLC purity (TFA): >50.8%.
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BnSO2-Phe-Phe-Arg(Pmc)-bk (3.31)
Following the general N-sulfonylation of tripeptides (C) with Boc-Phe-Phe-Arg(Pmc)-bk
(3.22) as starting material (reaction time: 16 hours and additional 0.5 equiv BnSO2Cl
was added) and purification by flash chromatography (25→100% EtOAc in heptane)
afforded the product as a white solid (84 mg, 32%). Rf = 0.43 (5% MeOH in DCM).
MS (m/z) calcd. for C52H63N6O8S2 [M + H]
+: 963.4, found: 963.9. HPLC purity
(TFA): >63.5%.
BnSO2-D-Phe-Phe-Arg(Pmc)-bk (3.32)
Following the general N-sulfonylation of tripeptides (C) with Boc-D-Phe-Phe-Arg(Pmc)-
bk (3.23) as starting material afforded the desired product, which was used without fur-
ther purification. MS (m/z) calcd. for C52H63N6O8S2 [M + H]
+: 963.4, found: 963.7.
HPLC purity (TFA): >39.1%.
(2S)-3-Phenyl-2-(phenylmethylsulfonamido)propanoic acid (3.34)432
A solution of H-Phe-OH (3.33) (3.77 g, 22.81 mmol, 1.00 equiv) was dissolved in 1M
NaOH (30 mL) and dioxane (30 mL). Then 1M NaOH (50 mL) and BnSO2Cl (5.00 g,
26.23 mmol, 1.50 equiv) in dioxane (50 mL) was added simultanously in approx. 10
equal portions. Between each addition the mixture was stirred vigorously for 15 minutes
at 0 ◦C. After the final addition, the reaction mixture was stirred for 2 hours. The
crude product was washed with Et2O (3 × 50 mL) and the aqueous layer was acid-
ified with conc. HCl to pH 1 and sat. with NaCl. Extraction with EtOAc (3 × 50
mL) gave an organic phase which was added heptane (50 mL) and extracted with sat.
aqueous NaHCO3 (3 × 50 mL). The combined aqueous layers were evaporated in vacuo
to remove the remaining EtOAc, and finally it was acidified by slowly addition of conc.
HCl. The product precipitated as an oil, which was extracted with Et2O (3 × 50 mL)
and the product was obtained by evaporation to dryness in vacuo giving a white solid
(2.48 g, 35%). 1H NMR (DMSO-d6) δ 12.85 (broad s, 1H), 7.67 (d, J = 8.6 Hz, 1H),
7.34–7.22 (m, 8H), 7.15 (d, J = 5.3 Hz, 2H), 4.07–4.04 (m, 1H), 4.02–3.99 (m, 1H),
3.97–3.94 (m, 1H), 3.00 (dd, J = 13.5, 5.7 Hz, 1H), 2.81 (dd, J = 13.6, 9.1 Hz, 1H).
MS (m/z) calcd. for C16H18NO4S [M + H]
+: 320.1, found: 320.1. Mp 152–158 ◦C
(lit.:432 156–157 ◦C).
General catalytic hydrogenolysis for O-debenzylation (D)
O-Benzylated tripeptide (0.38 mmol, 1.00 equiv) was dissolved in MeOH (36 mL) in
a pressure-resistant chamber and AcOH (4 mL) was added together with Pd/C (150
mg). The chamber was sealed with a lid connected to a manometer and thorougly
purged with N2 while stirring. Then, H2 gas (80 bar) was applied a couple of times for
complete replacement of the internal atmosphere. Finally, the chamber was filled with
H2 gas (80 bar) and the mixture was stirred vigorously by placing the reaction chamber
on a magnetic stirrer. Stirring was continued for 24 hours at room temperature. The
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chamber was then ventilated several times with N2 before the lid was removed. The
black mixture was filtered through a plug of Celite R© and washed with MeOH (3 × 25
mL). The combined filtrates were evaporated to dryness in vacuo and the residue was
coevaporated with DCM (3× 25 mL). The product was used without further purification.
N
H
NH
H
NHN
O
OH
N
OBnO
N
H
BnO
Boc
3.19
H2, Pd/C
Pmc
Solvent N
H
NH
H
NHN
O
OH
N
OHO
N
H
HO
Boc
3.38
Pmc
+  3.35 − 3.37
entry solventa P (bar) temp. (◦C) time (h) 3.19b 3.35b 3.37b 3.38b
1 A 3 rt 16 43 43 0 14
2 A 80 rt 16 0 84 0 16
3 B 3 rt 16 3 97 0 0
4 B 40 40 16 0 39 22 39
5 B 80 50 3 0 73 0c 18
6 B 80 50 16 0 0 45c 10
7 C 40 rt 3 52 48 0 0
8 C 40 rt 5 43 57 0 0
9 C 40 rt 16 0 40 0 60
10 C 80 rt 16 0 21 5 74
11 C 80 rt 24 0 6 7 87
12 C 80 rt 72 0 0 22 78
13 C 80 30 16 0 13 7 80
14 C 80 35 16 0 0 26 74
a: A: EtOH, B: MeOH, C: MeOH and 10% AcOH. b: Distribution of compoounds in the crude product (%),
determined by LC-MS, UV 214 nm. c: The di O-debenzylated and reduced by-product 3.36 was also formed.
Boc-Tyr-Thr-Arg(Pmc)-bk (3.38)
Following the general hydrogenolysis for O-debenzylation (D) with Boc-Tyr(Bn)-Thr(Bn)-
Arg(Pmc)-bk (3.19) (400 mg, 0.38 mmol, 1.00 equiv) as starting material gave full
conversion (>95%) after 24 hours at room temperature. Only minor amounts of the
reduced tyrosine (4%) was present based on LC-MS analysis. MS (m/z) calcd. for
C45H63N6O10S [M + H]
+: 879.4, found: 879.7. HPLC purity (TFA): >80.1%.
Ac-Tyr-Thr-Arg(Pmc)-bk (3.39)
Following the general hydrogenolysis for O-debenzylation (D) with Ac-Tyr(Bn)-Thr(Bn)-
Arg(Pmc)-bk (3.19) (271 mg, 0.27 mmol, 1.00 equiv) as starting material gave only
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50% conversion after 24 hours at room temperature. Therefore, the reaction mixture
was once again subjected to H2 (80 bar) for totally 2.5 days, which then gave full con-
version (>95%). Approx. 10% of the reduced tyrosine was also formed. MS (m/z)
calcd. for C42H57N6O9S [M + H]
+: 821.4, found: 821.7.
BnSO2-Tyr-Thr-Arg(Pmc)-bk (3.40)
Following the general hydrogenolysis for O-debenzylation (D) with BnSO2-Tyr(Bn)-
Thr(Bn)-Arg(Pmc)-bk (3.28) (224 mg, 0.20 mmol, 1.00 equiv) as starting material did
not give any traces of the desired product. After several days only the starting material
and the corresponding mono O-debenzylated compound was observed by LC-MS.
BnSO2-Tyr-Leu-Arg(Pmc)-bk (3.41)
Following the general hydrogenolysis procedure for O-debenzylation (D) with BnSO2-
Tyr(Bn)-Thr(Bn)-Arg(Pmc)-bk (3.29) (529 mg, 0.51 mmol, 1.00 equiv) as starting
material did not give any traces of the desired product. After several days only the
starting material and the corresponding mono O-debenzylated compound was observed
by LC-MS.
General procedure for deprotection, purification and lyophilization (E)
The protected tripeptide was dissolved in 95% TFA in DCM (10 mL) at room temper-
ature and stirred for 30 minutes, at which time LC-MS showed full conversion (>95%).
The crude product was evaporated to dryness in vacuo the residue was coevaporated
with DCM (3 × 15 mL). Then dissolved in 10% MeCN in H2O (≈ 50 mL) and the insol-
uble compounds (primarily the cleaved Pmc-group) were removed by filtration through
a Corning R© vacuum filter (0.22 µm polyethersulfone membrane, sterile). The filtrate
was purified by reverse-phase preparative HPLC.
H-Tyr-Thr-Arg-bk (3.42)
Following the general procedure for deprotection, purification and lyophilization (E) with
Boc-Tyr-Thr-Arg(Pmc)-bk (3.33) (332 mg, 0.38 mmol, 1.00 equiv) as starting material
and a preparative HPLC purification using a gradient of 13→33% MeCN in H2O. Upon
lyophilization the product was afforded as a white TFA-salt (67 mg peptide determined
by HPLC-CLND, 35% (3 steps). 1H NMR (DMSO-d6) δ 9.39 (broad s, 1H), 8.69 (d,
J = 8.1 Hz, 1H), 8.41 (d, J = 7.1 Hz, 1H), 8.02 (broad s, 3H), 7.78–7.72 (m, 1H),
7.31–7.21 (m, 4H), 7.15–7.13 (m, 2H), 7.10–7.08 (m, 2H), 6.70 (d, J = 8.3 Hz, 2H),
5.10 (broad s, 1H), 4.36–4.29 (m, 2H), 4.17–4.06 (m, 2H), 3.85 (s, 2H), 3.15–3.05 (m,
3H), 2.79–2.73 (m, 1H), 1.87–1.77 (m, 1H), 1.64–1.54 (m, 1H), 1.54–1.43 (m, 2H),
1.13 (d, J = 6.1 Hz, 3H). 13C NMR (DMSO-d6) δ 206.5, 170.0, 168.6, 158.5, 158.1,
157.8, 156.8, 156.5, 134.6, 130.5, 129.8, 128.1, 126.4, 124.8, 118.6, 115.7, 115.3, 66.8,
57.8, 53.5, 44.6, 36.3, 26.5, 24.9, 19.9. HRMS (m/z) calcd. for C26H37N6O5 [M +
H]+: 513.2820, found: 513.2840. HPLC purity (TFA): 93.0%, (NH4HCO3): 98.7%.
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Ac-Tyr-Thr-Arg-bk (3.43)
Following the general procedure for deprotection, purification and lyophilization (E) with
Ac-Tyr-Thr-Arg(Pmc)-bk (3.34) (222 mg, 0.27 mmol, 1.00 equiv) as starting material
and a preparative HPLC purification using a gradient of 15→35% MeCN in H2O. Upon
lyophilization the product was afforded as a white TFA-salt (22 mg peptide determined
by HPLC-CLND, 14% (3 steps). An equivalent portion was also collected but that
contained 22% of the reduced tyrosine (determined by HPLC). HRMS (m/z) calcd.
for C28H39N6O6 [M + H]
+: 555.2926, found: 555.2951. HPLC purity (TFA): 89.3%,
(NH4HCO3): 90.9%, (Na2SO3): 87.9%.
BnSO2-Phe-Leu-Arg-bk (3.44)
Following the general procedure for deprotection, purification and lyophilization (E) with
BnSO2-Tyr-Thr-Arg(Pmc)-bk (3.35) (350 mg, 0.38 mmol, 1.00 equiv) as starting ma-
terial and a preparative HPLC purification using a gradient of 28→48% MeCN in H2O.
Upon lyophilization the product was afforded as a white TFA-salt (75 mg peptide deter-
mined by HPLC-CLND, 30% (2 steps)). HRMS (m/z) calcd. for C35H47N6O5S [M +
H]+: 663.3323, found: 663.3338. HPLC purity (TFA): 97%, (Na2SO3): 95.3%.
H-Phe-Phe-Arg-bk (3.45)
Following the general procedure for deprotection, purification and lyophilization (E)
with Boc-Phe-Phe-Arg(Pmc)-bk (3.22) as starting material and a preparative HPLC
purification using a gradient of 20→40% MeCN in H2O. Upon lyophilization the product
was afforded as a white TFA-salt (58 mg peptide determined by HPLC-CLND, 49% (2
steps)). 1H NMR (DMSO-d6) δ 8.94 (d, J = 7.8 Hz, 1H), 8.76 (d, J = 7.1 Hz),
8.10 (broad s, 3H), 7.84–7.80 (m, 1H), 7.29–7.16 (m, 15H), 7.09 (d, J = 7.6 Hz, 2H),
4.71–4.66 (m, 1H), 4.29–4.24 (m, 1H), 4.04 (broad s, 1H), 3.70–3.57 (m, 4H), 3.15–3.03
(m, 4H), 2.93–2.86 (m, 2H), 1.83–1.75 (m, 1H), 1.58–1.48 (m, 1H), 1.44–1.38 (m, 2H).
13C NMR (DMSO-d6) δ 206.3, 170.8, 168.1, 158.9, 158.6, 158.3, 158.0, 156.9, 137.1,
134.7, 134.5, 129.7, 129.5, 129.2, 128.5, 128.2, 128.1, 127.2, 126.6, 126.5, 118.6, 115.6,
57.9, 54.1, 53.1, 44.6, 37.7, 37.0, 26.4, 25.0. HRMS (m/z) calcd. for C31H39N6O3 [M
+ H]+ 543.3078, found 543.3099. HPLC purity (TFA): 95.4%, (NH4HCO3): 100%,
(Na2SO3): 97.8%.
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Ac-Phe-Phe-Arg-bk (3.46)
Following the general procedure for deprotection, purification and lyophilization (E) with
Ac-Phe-Phe-Arg(Pmc)-bk (3.27) (133 mg) as starting material and a preparative HPLC
purification using a gradient of 20→40% MeCN in H2O. Upon lyophilization the product
was afforded as a white TFA-salt (52 mg peptide determined by HPLC-CLND, 57% (2
steps)). HRMS (m/z) calcd. for C33H41N6O4 [M + H]
+ 585.3184, found 585.3205.
HPLC purity (TFA): 95.9%, (NH4HCO3): 98.8%, (Na2SO3): 95.9%.
BnSO2-Phe-Phe-Arg-bk (3.47)
Following the general procedure for deprotection, purification and lyophilization (E) with
BnSO2-Phe-Phe-Arg(Pmc)-bk (3.31) (84 mg) as starting material and a preparative
HPLC purification using a gradient of 25→45% MeCN in H2O. Upon lyophilization the
product was afforded as a white TFA-salt (15 mg peptide determined by HPLC-CLND,
24% (3 steps)). HRMS (m/z) calcd. for C38H45N6O5S [M + H]
+ 697.3167, found
697.3183. HPLC purity (TFA): 94.5%, (NH4HCO3): 96.9%, (Na2SO3): 97.2%.
BnSO2-D-Phe-Phe-Arg-bk (3.48)
Following the general procedure for deprotection, purification and lyophilization (E) with
BnSO2-D-Phe-Phe-Arg(Pmc)-bk (3.32) (240 mg) as starting material and a preparative
HPLC purification using a gradient of 25→45% MeCN in H2O. Upon lyophilization the
product was afforded as a white TFA-salt (51 mg determined by HPLC-CLND, 29%).
HRMS (m/z) calcd. for C38H45N6O5S [M + H]
+ 697.3167, found 697.3175. HPLC
purity (TFA): 95.4%, (Na2SO3): 85.0%.
Cbz-Phe-Phe-Arg-bk (3.49)
Following the general procedure for deprotection, purification and lyophilization (E)
with Cbz-Phe-Phe-Arg(Pmc)-bk (3.24) (150 mg) as starting material and a preparative
HPLC purification using a gradient of 28→48% MeCN in H2O. Upon lyophilization the
product was afforded as a white TFA-salt (23 mg determined by HPLC-CLND, 21% (2
steps)). HRMS (m/z) calcd. for C39H45N6O5 [M + H]
+ 677.3446, found 677.3435.
HPLC purity (TFA): 97.4%, (Na2SO3): 74.3%.
Cbz-D-Phe-Phe-Arg-bk (3.50)
Following the general procedure for deprotection, purification and lyophilization (E) with
Cbz-D-Phe-Phe-Arg(Pmc)-bk (3.25) (91 mg) as starting material and a preparative
HPLC purification using a gradient of 28–48% MeCN in H2O. Upon lyophilization the
product was afforded as a white TFA-salt (20 mg determined by HPLC-CLND, 22% (2
steps)). HRMS (m/z) calcd. for C39H45N6O5 [M + H]
+ 677.3446, found 677.3443.
HPLC purity (TFA): 99.4%, (Na2SO3): 83.4%.
General procedures - Biology
Chemicals and reagents were all commercially available and used without further purifi-
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cation. FVIIa (1.39 mg/mL solution in GlyGly buffer at pH 6.0 stored at –80 ◦C), TF
(sTF1−219) (0.91 mg/mL solution, approx. 36.7 µM, stored at –20
◦C) and thrombin (20
U/mL, 20 µL stored at –80 ◦C) were obtained in-house at Novo Nordisk A/S. hFXa (100
U) was purchased from Enzyme Research, USA. A HEPES stock buffer was prepared by
dissolving HEPES (29.79 g, 125 mmol), NaCl (14.61 g, 250 mmol), CaCl2 (1.84 g, 16.6
mmol) and Tween80 (0.25 g) in H2O to a total volume of 250 mL. pH was adjusted
to 7.4 and the buffer was filtered through a 0.22 µm cellulose acetate sterilizing, low
protein binding membrane purchased from Corning Incorporated. The stock buffer was
stored at 5 ◦C (up to 3 months). The actual assay buffer (50 mM HEPES, 100 mM
NaCl, 6.6 mM CaCl2, 0.01% Tween80) was prepared immediately prior to use by diluting
the stock buffer 10 times with H2O. Inhibitor solutions were made by dissolving approx.
8 mg lyophilized inhibitor in a few drops of DMSO and then diluting with assay buffer
(5.0 mL). For those compounds showing poor solubility in the buffer, further dissolution
was made to get appropriate solubilities. Inhibitor solutions of no more than approx.
1500 µM were prepared. The concentration of each inhibitor solution was determined
by HPLC-CLND. Chromogenic substrates (S-2288, S-2238 and S-2765) were purchased
from Chromogenix, Italy, and dissolved in H2O prior to use. The assays were run in a 96-
well assay plate. The chromogenic substrate was added at last just immediately before
absorbance reading at a SpectraMax M2e Molecular Devices plate reader. The OD405
(absorbance at 405 nm) was monitored over the course of 15 minutes with 40 second
interval readings (assay plate was automatically shaken). The OD405 was plotted against
time and the enzyme velocity (vn) was calculated as the slope of the curve, which was
linear with the tested enzyme concentration and within the time frame of 15 minutes.
Initial screenings were performed using the highest available inhibitor concentration for
estimation of IC50 values. Only those compounds showing more than 80% inhibition of
the enzyme at the highest tested inhibitor concentration, was taken to a Ki determina-
tion. Ki values were determined by varying the inhibitor concentration, ideally at least
10 times higher and 10 times lower than Ki with a constrant concentration of enzyme
and chromogenic substrate. Linear fitting of (v0/vn)-1 versus [I] gave Ki = 1/slope,
where v0 is the enzyme velocity in the absence of inhibitor and vn is enzyme velocity
(OD405 per time unit) at a given inhibitor concentration [I]. All results were measured
as triplicates and the final Ki value was calculated as an average.
FVIIa competitive binding assay
FVIIa and TF were thawed to 0 ◦C on ice prior to use. FVIIa was diluted to a 200
nM concentration (10 µL FVIIa stock solution was diluted with 490 µL + 900 µL assay
buffer affording a 9.93 µg/mL concentration, Mw ≈ 50,000 g/mol). TF was also diluted
to a 200 nM concentration (20 µL TF stock solution was diluted with 980 µL + 2662
µL assay buffer affording a 4.97 µg/mL concentration). S-2288 (H-D-Ile-Pro-Arg-pNA,
25 mg) was dissolved in H2O (1.0 mL) giving a stock concentration of 43.3 mM. In a
96-well assay plate was mixed FVIIa (10 µL ), TF (50 µL), assay buffer and/or inhibitor
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solution (135 µL) and finally the assay was started by addition of S-2288 (5 µL) giving
a total volume of 200 µL in each well with final concentrations as following: FVIIa: 10
nM, TF: 50 nM and S-2288: 1 mM and varying inhibitor concentrations. The plate was
immediately monitored at OD405 as described above.
Thrombin (thr) competitive binding assay
Thrombin was thawed to 0 ◦C on ice prior to use, and then diluted to a 0.4 U/mL activ-
ity (480 uL buffer + 20 uL thr). S-2238 (H-D-Phe-Pip-Arg-pNA, 25 mg) was dissolved
in H2O (2.5 mL) giving a stock concentration of 16 mM. In a 96-well assay plate was
mixed thrombin (5 µL), assay buffer and/or inhibitor solution (185 µL) and finally the
assay was started by addition of S-2238 (10 µL) giving a total volume of 200 µL in
each well with final concentrations of following: thr: 20 mU/mL and S-2238: 400 µM
and varying inhibitor concentrations). The plate was immediately monitored at OD405
as described above.
FXa competitive binding assay
hFXa was dissolved and diluted in the assay buffer to a 0.1 U/mL activity (hFXa was
dissolved in 1000 µL assay buffer. 5 µL of this solution was diluted with 4995 µL assay
buffer). S-2765 (Cbz-D-Arg-Gly-Arg-pNA, 25 mg) was dissolved in H2O (2.0 mL) giving
a stock concentration of 17 mM. In a 96-well assay plate was mixed hFXa (15 µL), assay
buffer and/or inhibitor solution (180 µL) and finally the assay was started by additon of
S-2765 (5 µL) affording a total volume of 200 µL in each well with final concentrations
as following: hFXa: 5.0 mU/mL and S-2765: 436 µM and varying inhibitor concentra-
tions). The plate was immediately monitored at OD405 as described above.
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Chapter 4
Rh-Catalyzed Enantioselective
Synthesis of Diaryl Amines
4.1 Biologically active aryl amines
The majority of small-molecule drugs and drug candidate contains an amine function-
ality. Therefore asymmetric synthesis of amines is of great importance in medicinal
chemistry. With the exception of α-amino acids, general asymmetric syntheses af α-
branched amines were previously only little explored. Therefore, Professor Jonathan
Ellman and his group at the University of California at Berkeley has investigated this
area for more than a decade.
N
H
N
OH
Et2N
O
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Figure 4.1.1: Examples of biologically active aryl amines.438–442
Since the late 1940s diarylmethyl piperazines have been of considerably interest due to
their antihistaminic properties.443,444 During the 1980s, racemic cetirizine (formulated
as the dihydrochloride salt) was developed by UCB Pharma as a second generation an-
tihistamine.445 In Europe it was launched in the late 1980s as Zyrtec R© and became a
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blockbuster. The active (R)-enantiomer of cetirizinea, levocetirizine, was launched in
Europe in 2001 and in the US in 2007,447 as a third generation antihistaminic agent
under the trademark of Xyzal R© (see Figure 4.1.1). Levocetirizine is a non-sedating his-
tamine H1-receptor antagonist and is used for the treatment of allergies, such as allergic
rhinitis, conjunctivitis, pruritus and urticaria. Levocetirizine is administrated in only half
the dose (5 mg) compared to the racemic cetirizine, and it has a twofold higher affinity
for the human H1-receptor.
439,449 Thus, it is believed that Xyzal R© has fewer side effects
than Zyrtec R©.
Other aryl amines with interesting pharmacological properties have been reported. Ben-
zhydrylpiperazine 4.1 has been found to act as a potent δ-opioid receptor agonist (anal-
gesic)440,441 and the arylalkyl amine, cinacalcet (see Figure 4.1.1), as an allosteric mod-
ulator of the CaR (calcium-sensing receptor). Cinacalcet has recently been approved
for the treatment of secondary hyperparathyroidism.442 The importance of this class
of amines is also demonstrated by the many compounds claimed in the patent litera-
ture, e.g. patent protection of pyridine N-oxide derivatives of diarylmethyl piperazines
reported by Schering Corporation as PAF (platelet activating factor) antagonists and
antihistamines (see Figure 4.1.2 for examples of two heterocycle derivatives).450
N
S
Cl
N
N
O
O
N
N
S
N
N
O
O
Cl
Figure 4.1.2: Pyridine N-oxide derivatives of diarylmethyl piperazines are poten-
tial PAF antagonists and antihistamines.450 Claimed and synthesized in a patent
from 1995 by Schering Corporation.
aSepracor110,446 has incorrectly reported that levocetirizine is the (S)-enantiomer. The correct
configuration is (R)-(–), which is confirmed by several publications, e.g. from UCB Pharma,439 FDA447
and in a review on stereoconfiguration of antiallergic drugs from 2008.448
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4.2 Synthesis of aryl amines
4.2.1 Auxiliary-based syntheses
In 1997 the Ellman group reported the first use of (R)-tert-butanesulfinamide (4.2) as
a chiral auxiliary for the asymmetric synthesis of α- and α,α-dibranched amines.451,452
This method utilizes a 1,2-addition of an organolithium or a Grignard reagent to a N-
tert-butanesulfinimine with high diastereoselectivity, followed by an acidic methanolysis
of the sulfinamide product affording the corresponding amine in high yield. 4.2 repre-
sents the ideal chiral auxiliary serving as an activating group for nucleophilic addition to
the imine,451 preventing imine hydrolysis or competitive α-deprotonation, it gives clean
reactions and it is easy to remove.452 In fact, 4.2 is a superior chiral auxiliary compared
to the p-toluenesulfinamide group reported by Davis;453 the former has a lower mole-
cular weight, reacts much easier with aldehydes and ketones and provides an enhanced
diastereofacial selectivity.451,452
Asymmetric synthesis of levocetirizine was previously performed either by resolution,454,455
with stoichiometric heavy metal chiral oxazaborolidine reduction456 or by preparative chi-
ral HPLC separation.457 Sepracor446 and AstraZeneca110,458 have recently reported the
use of the Ellman-Davis sulfinamide chemistry for the formal synthesis of levocetirizine
through diastereoselective synthesis of the amine intermediate (R)-4.3 (see Scheme
4.2.1).
Cl
O
H + S
O
NH2
Cl
N
H
S
O
Li
THF, −78 oC, 4h
99%
78%
73:27 dr
HN
S
O
Cl
HCl / MeOH
25 oC, 30 min
94%
NH2
Cl
(R)-4.3
(R)-Levocetirizine
4.2
MgSO4 
(10 equiv)
cat. PPTS
DCM, rt, 24h
Scheme 4.2.1: Formal asymmetric synthesis of (R)-levocetirizine via diastereo-
selective organolithium addition to a N-tert-butanesulfinimine affording the (R)-
enantiomer of the amine intermediate 4.3.458
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Interestingly, it was demonstrated that (S)-4.3 was achieved with Grignard reagents
through a six-membered chelating transition state, whereas organolithium reagents af-
forded the (R)-4.3 through a non-chelating addition (see Figure 4.2.1).458 Sepracor later
reported an improved diastereoselective synthesis (93:7 dr) of (R)-4.3 in 80% yield using
triisopropylbenzene sulfinamide instead of tert-butanesulfinamide.110
Cl
H
N
S
O
MgBr
S
O Mg R2
N
H
R1
#
NH2
Cl
Chelating six-membered
transition state model
(S)-4.3
Li
O
N
R1 H R
2Li
Non-chelating addition model
NH2
Cl
(R)-4.3
S
O
N
H R
1
H R2
86% yield
88:12 dr
4M HCl
MeOH
rt, 30 min
97% yield
Toulene, 
−45 oC, 4h
THF, −78 oC, 4h
O
NH
R1
H R2
78% yield
27:73 dr
4M HCl
MeOH
rt, 30 min
94% yield
Figure 4.2.1: Choice of organometallic reagent determines the diastereo-
facial attack; Grignard reagents afford the (S)-configuration through a six-
membered chelating transition state, whereas organolithium reagents afford the
(R)-configuration through a non-chelating addition.458 R1 = 4-ClC6H4, R
2 =
C6H5
4.2.2 Catalytic enantioselective syntheses
Even though the Ellman-Davis method has many advantages, the use of organolithium
or Grignard reagents is subject to some concerns. These highly reactive species re-
quire inconvenient reaction conditions (low temperature and dry solvents) and they are
incompatible with many functional groups such as nitro, ketone and amine functionali-
ties. The use of arylboronic acids has therefore been investigated, because this group
of reagents represents a unique class of organometallic compounds. Arylboronic acids
are stable compounds and many of them are commercially available with a variety of
different functionalities (more than 1000 different arylboronic acids are commercially
available).459 Although arylboronic acids are poor nucleophiles, rhodium(I) complexes
has been found to catalyze their addition to N-phenylsulfonimines as reported in 2000
by Miyaura and co-workers.460 High functional group tolerance was demonstrated by re-
lated rhodium-catalyzed additions of arylbornic acids to aldehydes and α,β-unsaturated
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ketones.461,462
In 2004 asymmetric methods were independently published by the Tomioka463 and
Hayashi464 groups, inspired by early work on enantioselective addition of arylstannanes.465
Tomioka and co-workers463 obtained only modest enantioselectivity with 3 mol% Rh(acac)(C2H4)2
and a variety of amidophosphane ligands (see Figure 4.2.2) applied to N-tosylarylimines.
On the other hand, Hayashi and co-workers464 obtained both high yield and high enan-
tioselectivity with 1.5 mol% [RhCl(C2H4)2]2 and the chiral diene (R,R)-Ph-bod* using
similar substrates (see Scheme 4.2.2 for an example).
N
Ts
Cl
+
B(OH)2
N
H
Ts
Cl
1.5 mol%
[RhCl(C2H4)2]2
KOH/H2O,
dioxane, 60 oC, 6h
Ph
Ph
3 mol%
N-Tosylarylimine
96% yield
98% ee
Scheme 4.2.2: Enantioselective addition of an arylboronic acid to a N-
tosylarylimine. Many similar examples were reported by Hayashi and co-workers
giving high yield and enantioselectivity.464
A number of other chiral ligands has been reported in the literature for this type of
chemistry, such as binaphtholic phosphites,466 tetrahydropentalenes,467 (S)-ShiP468 and
(R,R)-deguPHOS469 (see Figure 4.2.2).
One major limitation of these methods is the removal of the N-tosyl group, which is
difficult and requires harsh conditions, typically using large excess of SmI2.
463 These
conditions severely limit the presence of some functional groups, and in fact protode-
halogenation has been observed by the use of SmI2/HMPA,
464 which would be rather
inconvenient, e.g. for the industrial synthesis of levocetirizine. The Hayashi group im-
proved this limitation by replacing the N-tosyl group with N-nosyl which was successfully
cleaved by treatment with PhSH and K2CO3.
470
Another major limitation, especially noted by Hayashi, is that these additions are lim-
ited to arylimines.464 This was however solved by the Ellman group. The enantiose-
lective addition to N-tosylalkylimines or N-diphenylphosphinoimines could be catalyzed
by Rh(acac)(coe)2 in the presence of a chiral ligand, (R,R)-deguPHOS, (see Scheme
4.2.3).471 In this study from 2008 a variety of chiral ligands was tested, among others
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N
PPh2
O
Amidophosphane
Ph
Ph
(R,R)-Ph-bod*
O
O P N
Ph
Ph
Binaphtholic phosphite
H
H
Ph
Ph
Tetrahydropentalene
O
O
P
OPh
(S)-ShiP
N
Bn
PPh2Ph2P
(R,R)-deguPHOS
Figure 4.2.2: Chiral ligands widely used in rhodium-catalyzed enantioselective
additions of arylboronic acids to N-sulfonimines.463,464,466–469
the tetrahydropentalene and (S)-ShiP illustrated in Figure 4.2.2, but (R,R)-deguPHOS
was found to be the best.471 Fortunately, this ligand is commercially available and does
not require a lengthy synthesis as some of the other chiral ligands, such as (R,R)-Ph-
bod*. A diastereoselective version has also been reported using dppbenz as ligand with
N-tert-butanesulfinalkylimines469 and N-tert-butanesulfinimino esters.472
N
Ts
H +
B(OH)2
Cl
3 mol% Rh(acac)(coe)2
3.3 mol% (R,R)-deguPHOS
K3PO4, 4Å MS
dioxane, 70 oC, 20h
HN
Ts
Cl
N-Tosylalkylimine 80% yield
96% ee
Scheme 4.2.3: Enantioselective synthesis of an α-aryl alkylamine using
Rh(acac)(coe)2 and (R,R)-deguPHOS. Many examples are reported by the Ell-
man group.471
4.2.3 Diaryl amines from α-carbamoyl sulfones
Concurrently, the Ellman group also worked on improving the enantioselective synthe-
sis of diaryl amines using the same catalytic conditions; Rh(acac)(coe)2 and (R,R)-
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deguPHOS (see Table 4.2.1).473 Besides of these changes, the imine substrate was also
changed. Activated imines are very reactive and difficult to manipulate and purify,474
but Ellman and co-workers found, that α-carbamoyl sulfones could be used as N-Boc
protected imine precursors,473 inspired by previous reports using this approach for imine
preparation.475–477
Table 4.2.1: Synthesis of various N-Boc diaryl amines.473
N
H
SO2Ph
R1Boc
α-Carbamoyl sulfone
+
5 mol% Rh(acac)(coe)2
5.5 mol% (R,R)-deguPHOS
K2CO3, Et3N, 4Å MS
dioxane, 70 oC, 20h
N
H
R1Boc
B(OH)2
R2
R2
entry R1 R2 yield (%)a ee (%)b
1 Ph 4-Cl 76 98c
2 Ph 4-Me 70 96
3 Ph 4-MeO 76 93c
4 Ph 4-CF3 51 95
c
5 Ph 3-Cl 55 99
6 Ph 3-Me 66 95
7 Ph 3-Ac 52 94
8 Ph 2-Me 62 93
9 4-MeC6H4 H 71 90
10 3-MeC6H4 H 70 95
11 2-MeC6H4 H 63 97
12 4-BrC6H4 H 59 90
13 2-thienyld H 71 96
14 4-MeOC6H4 H 76 96
c
15 4-CF3C6H4 H 69 79
c
a: Isolated yields after chromatography. b: Enantiomeric purity determined by
chiral HPLC analysis. c: Absolute configuration established by comparison of the
optical rotation of amine obtained upon Boc cleavage to literature values. 458,465
N-Boc imines are considerably hydrolytic labile, but the corresponding α-carbamoyl sul-
fones are stable and solid compounds generating the imine in situ upon treatment with
base. The use of N-Boc protection is furtermore superior compared to e.g. the N-tosyl
group, because of the low molecular weight, easy cleavage conditions (typically TFA or
HCl) and simple removal of deprotection by-products due to their volatility.478 These
improvements make the synthesis of the free amine much more straightforward.
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B(OH)2
Rh
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H
N
Boc
K2CO3
PhO2S
HN
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B(OH)2L + L
B(OH)2
N Boc
B(OH)2
H2O
Rh OH
*P
*P
B(OH)2
Product
A
B
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D
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Product
Figure 4.2.3: Proposed mechanism for the rhodium-catalyzed enantioselective
addition of boronic acid to in situ generated arylimine.479
As illustrated in Table 4.2.1 these optimized reaction conditions gave good yields and
high enantioselectivites for almost all substrates. The chemistry demonstrates both com-
patibility with heterocyclic imines and with ortho-substituted derivatives. Dioxane was
found to be the best solvent with regard to yield and enatioselectivity.473 Unfortunately,
full conversion was never achieved, which might be a result of competitive substrate
hydrolysis473 or more likely by decomposition of the Rh(I)-aryl complex resulting in for-
mation of an arene.480
In analogy to mechanisms proposed in the literature,479,481–483 a resonable mechanism
can be established for this chemistry (see Figure 4.2.3). Initially, a transmetallation
between the arylboronic acid and the rhodium catalyst takes place forming a Rh(I)-
aryl complex (A). Rhodium hereby gets a free coordination site which is believed to
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coordinate the imine (B). Through an insertion, the aryl-group is then added to the
imine affording a catalyst product species (C). The final step in the catalytical cycle
is the regeneration of the Rh(I)-aryl complex through a transmetallation with a new
arylboronic acid (D). The desired product is formed by protonation of the boron species.
Alternatively, the product is formed directly by protonation from water, originating from
the arylboronic acid (E), regenerating the Rh(I)-aryl complex.479
4.2.3.1 Utilization of α-carbamoyl sulfones as imine precurcors
α-Carbamoyl sulfones are easily synthesized from the corresponding aldehyde, tert-butyl
carbamate and benzenesulfinic acid sodium salt in the presence of formic acid.476 Upon
treatment with base the N-Boc imine is formed (see Scheme 4.2.4).
H R
O
SO2Na
H2N O
O
MeOH, HCOOH
N
H
SO2Ph
RBoc
α-Carbamoyl sulfone                                      N-Boc imine
N R
Boc
K2CO3
Scheme 4.2.4: Synthesis of α-carbamoyl sulfones from the corresponding alde-
hyde and subsequent in situ formation of the N-Boc imine upon treatment with
an inorganic base.473
Ellman and co-workers473 found that addition of both K2CO3 (6 equiv) and Et3N (1.5
equiv) was necessary to improve the yield of the α-aryl arylmethylamine (see Table
4.2.1). K2CO3 is believed to act as base for generation of the imine, but the action of
Et3N is rather unclear. In the absence of Et3N, the yield dropped 20%. Since K2CO3
is not fully soluble in dioxane, Et3N might neutralize the acidic boronic acid to prevent
decomposition of the Rh(I)-aryl complex.480
4.2.3.2 Arylboronic acid versus boroxine as coupling partner
With respect to the arylboron reagent, Batey and co-workers484 demonstrated that aryl-
boronic acid gave the highest yield and stereoselectivity in similar chemistry compared
to other boronic acid equivalents such as phenylpinacol boronate ester, phenylisopropyl
boronate ester and phenyl potassium trifluoroborate salt (see Figure 4.2.4).
In most reports it is not stated explicitly whether the boronic acid or the correspond-
ing boroxine was used, despite the fact, that commercially available arylboronic acids
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O
B O B
OB
Boroxine
B O
O
Pinacol boronate
B OiPr
OiPr
Isopropyl boronate
BF3K
Trifluoroborate salt
Figure 4.2.4: Examples of different arylboron reagents tested in the rhodium-
catalyzed addition to imines.463,484
contain varying amounts of boroxine (see Figure 4.2.5).251 However, Tomioka and co-
workers463 found that one of their major improvements was using the arylboroxine instead
of the arylboronic acid. This was not true for the rhodium-catalyzed addition to in situ
generated N-Boc imines reported by the Ellman group;473 the arylboronic acids were
recrystallized from water to decompose any present boroxine.485,486
B(OH)2
3 O
B O B
OB + 3 H2O
Recrystallization
Heating
Figure 4.2.5: Arylboronic acids can exist both as a single boronic acid and as a
boroxine, which is a cyclic anhydride of the corresponding boronic acid.487
Arylboroxines have been known for a long time, and it is well known that the ease of
formation is dependent on the substituents, e.g. boroxine formation is favored by or-
tho-hydroxy substituents488 and electron-donating groups.487 Heating converts boronic
acids into the corresponding boroxine by elimination of water.489 On the other hand,
hydrolysis of boroxines readily proceeds in the presence of water485,486 and is accelerated
by electron-withdrawing groups.487 The equilibrium between the arylboronic acids and
the corresponding boroxine was found to be reversible at room temperature and driven
by entropic forces in solution.487
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4.3 Aim of project
Despite the many optimizations, this chemistry still suffers from a number of drawbacks.
The optimal catalyst, Rh(acac)(coe)2, is currently not commercially available and has
to be synthesized from [RhCl(coe)2]2 and Na(acac) under a strictly inert atmosphere,
preferably in a nitrogen-filled glovebox (see Scheme 4.3.1).490 Rh(acac)(coe)2 is highly
air-sensitive required that the reaction is set up in a glovebox and run in small sealed
vials. This is inconvenient for most research laboratories; it is tedious and scaling-up is
difficult. Moreover, the preparation of dry and degassed solvents and reagents is time-
consuming.
Cl
Rh
Cl
Rh
ONa O
toluene 
40 oC, N2, overnight
O
Rh
O
2
81%
Scheme 4.3.1: Synthesis of Rh(acac)(coe)2 from [RhCl(coe)2]2.
490
It was therefore desirable to further optimize the reaction with regard to the catalyst
and to develop a practically more convenient procedure compared to the previous results
from the Ellman group (c.f. Table 4.2.1).473 The aim of the project is outlined below:
• Implementation of a commercially available Rh-catalyst
• Catalyst is preferably air-stable
• Good yield and excellent enantioselectivity
• Dependency of boroxine should be investigated
• Usage of glovebox should be omitted
• A functionalized diaryl amine should be scaled up to gram-scale
In addition to the implementation of a commercially available Rh-catalyst, dependency
of boroxine should also be investigated. So far, no general procedure for determination
of boroxine in the arylboronic acid batch does exist. And the actual dependency of
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boroxine on this particular reaction still remains unexplored eventhough it might be
important. Finally, the optimized reaction should be utilized for a gram-scale synthesis
of a functionalized diaryl amine to demonstrate the usefulness of the chemistry.
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4.4 Results and discussion
4.4.1 Optimization of model reaction
4.4.1.1 Initial screening of rhodium catalysts
Based on the many reports on enantioselective addition of arylboronic acids to imines, it
seems that [RhCl(C2H4)2]2
464,467,470,471 and Rh(acac)(C2H4)2
463,466,468,479 are the most
predominant catalysts. Presumably, the explanation for this observation is the pro-
found lability of the ethylene ligand ensuring fast ligand exchange with the chiral lig-
and. Other rhodium catalysts with less labile ligands have also been reported, such
as [RhCl(cod)]2
463 and the cationic catalyst [Rh(cod)(MeCN)]BF4.
460,484 However, the
latter has been found to be an ineffective catalyst in several reactions, either because of
low yield469,472 or low enantioselectivity.468
Table 4.4.1: Screening of commercially available Rh-catalysts.
N
H
SO2Ph
Boc
+
B(OH)2
5 mol% rhodium
5.5 mol% (R,R)-deguPHOS
K2CO3, Et3N, 4Å MS
dioxane, 70 oC, 20h
N
H
Boc
4.4                                  4.5                                                                                    4.6(glovebox)
entry catalyst price ($)a yield (%)b ee (%)c
1 [RhCl(coe)2]2 1.50 47 95
2 Rh(acac)(C2H4)2 1.28 72 92
3 [RhCl(C2H4)2]2 0.84 38 90
4 Rh(acac)(cod) 1.30 53 85
5 [RhCl(cod)]2 0.50 63 40
6 [Rh(OH)(cod)]2 0.62 87 24
7 Rh(acac)(coe)2 –
d 70 96
a: Estimated price per reaction based on the cheapest available supplier. b: Purified by
flash chromatography. c: Determined by chiral HPLC. d: Catalyst is not commercially
available.
Inspired by these reports, a broad range of commercially available neutral rhodium cat-
alysts were screened with (R,R)-deguPHOS as chiral ligand in a model reaction forming
the diaryl amine 4.6 from the α-carbamoyl sulfone 4.4 and 4-methylphenylboronic acid
(4.5) (see Table 4.4.1). The reaction conditions reported by Ellman and co-workers473
in 2007 were chosen. These conditions gave 70% yield and 96% ee with the original
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catalyst, Rh(acac)(coe)2, and the presented substrates 4.4 and 4.5 (entry 7). Synthesis
of starting materials for the screening experiments are described in section 4.4.1.3.
[RhCl(coe)2]2, Rh(acac)(C2H4)2 and [RhCl(C2H4)2]2 were the only catalysts giving com-
parable or higher enantioselectivities than the original catalyst (entry 1–3).473 This
corresponds to the enhanced lability of the coe- and ethylene-ligands. However, only
Rh(acac)(C2H4)2 gave similar yield to Rh(acac)(coe)2 (entry 2), whereas the two other
catalysts gave much lower yields (entries 1 and 3). Rh(acac)(cod) gave modest yield
with acceptable enantiomeric excess; 53% yield, 85% ee (entry 4). Unfortuantely, none
of these rhodium catalysts are significantly more stable than Rh(acac)(coe)2 and opti-
mization would be difficult due to their air-sensitivity. Contrarily, good to excellent yield
was achieved with [RhCl(cod)]2 and [Rh(OH)(cod)]2 (entries 5–6), but not surprisingly,
the enantioselectivities were very low. On the other hand, these two catalysts were the
cheapest commercially rhodium catalysts available (see Table 4.4.1). The cyclooctadi-
ene (cod) ligand is tightly bound to rhodium and ligand exchange with (R,R)-deguPHOS
only occurs slowly. Apparently, the rhodium catalyst itself catalyzes the racemic addition
to the imine, resulting in a low stereoselectivity.
N
Rh
N
H
N
H
SO2Ph
K2CO3
4.4                                                          4.7                                                                  4.6
Boc Boc
Boc
Decomposition
O
H
4.8
P*
P*
H
Overall
protodeborylation
Arene
Scheme 4.4.1: Destiny of the starting material 4.4, which is converted to the
imine 4.7 in situ. If the rhodium catalyst does not work, decomposition leading
to the aldehyde 4.8 takes place, otherwise the desired cross-coupling yields the
diaryl methyl amine 4.6.
Analyzing these initial screenings revealed that full conversion was never achieved, not
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even with [Rh(OH)(cod)]2 which gave the highest yield. The crude product typically
contained only product 4.6 and the starting material represented by the corresponding
imine 4.7 and small amounts of the corresponding aldehyde 4.8 (see Scheme 4.4.1).
Decomposition of the boronic acid is also likely to happen via an overall protodeboryla-
tion by decomposition of the reactive Rh(I)-aryl complex. This will generate an arene,
which for 4.5 produces toluene. Volatile by-products can be difficult to detect in crude
products.
4.4.1.2 Preincubation of catalyst and (R,R)-deguPHOS
[Rh(OH)(cod)]2 and [RhCl(cod)]2 are the two most desirable catalysts based on their
enhanced air-stability and low price. Both catalysts gave good to excellent yield in the
initial screening experiments, but very low enantioselectivities. To increase the apparent
ligand exchange with (R,R)-deguPHOS, preincubation of catalyst and ligand prior to ad-
dition of starting materials was tested (see Table 4.4.2). Preincubation was introduced
previously in the Ellman group for improvement of enantioselectivity.471 Two different
methods were used; catalyst/ligand-only and all-at-once preincubation. The former is
a preincubation of catalyst and ligand only, followed by addition of starting materials,
bases, molecular sieves and the latter is a preincubation with bases and molecular sieves
present.
Table 4.4.2: Preincubation of Rh-catalyst and (R,R)-deguPHOS.
N
H
SO2Ph
Boc
+
B(OH)2
5 mol% rhodium
5.5 mol% (R,R)-deguPHOS
preincubated 1h, 70 oC
K2CO3, Et3N, 4Å MS
dioxane, 70 oC, 20h
N
H
Boc
4.4                                  4.5                                                                                    4.6(glovebox)
entry precatalyst method yield (%)a ee (%)b
1 [Rh(OH)(cod)]2 Cat/ligand-only
c 90 6
2 [Rh(OH)(cod)]2 All-at-once
d 81 16
3 [RhCl(cod)]2 Cat/ligand-only
c 75 96
4 [RhCl(cod)]2 All-at-once
d 85 91
a: Purified by flash chromatography. b: Determined by chiral HPLC. c: Preincubation of
catalyst and ligand only for 1 hour at 70 ◦C, followed by addition of starting materials,
bases and MS. d: Preincubation of catalyst and ligand with bases and molecular sieves
for 1 hour at 70 ◦C, followed by addition of starting materials.
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It was gratifying to discover that preincubation indeed had a huge impact on the enan-
tioselectivity when [RhCl(cod)]2 was used. Catalyst/ligand-only preincubation gave up
to 96% ee (entry 3), whereas the all-at-once method gave a slightly lower selectivity,
namely 91% ee (entry 4). This is a major improvement compared to the method with
no preincubation, which gave a selectivity of only 40% ee (see Table 4.4.1, entry 6).
On the other hand, preincubation experiments with [Rh(OH)(cod)]2 did not increase the
enantioselectivty at all (see Table 4.4.2, entries 1–2). In fact, the selectivity was found
to be somewhat reduced when preincubation was employed with this catalyst.
To further explore the impact of preincubation, a set of experiments with [RhCl(cod)]2
was set up (see Table 4.4.3). The two preincubation methods were tested against dif-
ferent times, to investigate the impact of time on enantioselectivity.
Table 4.4.3: Time of preincubation of [RhCl(cod)]2 and (R,R)-deguPHOS.
N
H
SO2Ph
Boc
+
B(OH)2
2.5 mol% [RhCl(cod)]2
5.5% (R,R)-deguPHOS
preincubated at 70 oC
K2CO3, Et3N, 4Å MS
dioxane, 70 oC, 20h
N
H
Boc
4.4                                  4.5                                                                                    4.6(glovebox)
entry method time (min) yield (%)a ee (%)b
1 Cat/ligand-onlyc 15 63 82
2 Cat/ligand-onlyc 60 75 96
3 Cat/ligand-onlyc 120 71 89
4 All-at-onced 15 78 85
5 All-at-onced 60 85 91
6 All-at-onced 120 64 92
a: Purified by flash chromatography. b: Determined by chiral HPLC. c: Prein-
cubation of catalyst and ligand only for 1 hour at 70 ◦C, followed by addition of
starting materials, bases and MS. d: Preincubation of catalyst and ligand with
bases and molecular sieves for 1 hour at 70 ◦C, followed by addition of starting
materials.
As shown in Table 4.4.3, the best enantioselectivity was obtained with the catalyst/ligand-
only method at 70 ◦C for 1 hour (entry 2). Preincubation in just 15 minutes did also
increase the selectivity (82% ee, entry 1), whereas preincubation in 2 hours lowered the
enantioselectivity slightly to 89% ee (entry 3). These results indicate, that a too short
preincubation does not ensure a sufficient ligand exchange with (R,R)-deguPHOS and
a too long preincubation apparently slightly decomposes the reactive rhodium complex.
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The results furthermore indicate, that the all-at-once method (entries 4–6) was not ben-
eficial to the catalyst/ligand-only method.
Substitution of Rh(acac)(coe)2 with the commercially available and inexpensive [RhCl(cod)]2
is of great importance. The latter catalyst is air-stable, commercially available and the
cheapest one of those tested here. [RhCl(cod)]2 is 2.5 times cheaper than Rh(acac)(C2H4)2.
491
Especially the enhanced catalyst stability makes the further optimization easier and de-
velopment of a procedure outside the glovebox is more reasonable to succeed (see Section
4.4.2).
4.4.1.3 Synthesis of α-carbamoyl sulfone
As mentioned in section 4.2.3.1 α-carbamoyl sulfones are easily synthesized from the
correspoding aldehyde, tert-butyl carbamate (4.9) and benzenesulfinic acid sodium salt
(4.10) in the presence of formic acid. Thus, the α-carbamoyl sulfone 4.4 was syn-
thesized from benzaldehyde (4.8) in 64–70% yield according to a literature procedure,
which reported a 80% yield (see Scheme 4.4.2).476 The synthesis employs cheap starting
materials and no purification step is required because the product 4.4 precipitates from
the solvent mixture. This makes the synthesis convenient and nevertheless efficient and
easy to scale up in gram-scale.
N
H
SO2Ph
MeOH:H2O (1:2)
rt, 2 days
H
O
+ + HCOOH
64−70% yield
O NH2
O SO2Na Boc
 4.8                               4.9                               4.10                                                               4.4
Scheme 4.4.2: Synthesis of the α-carbamoyl sulfone 4.4 in 64–70% yield ac-
cording to a literature procedure.476
4.4.1.4 Investigation of the dependency of boroxine and water
According to the results obtained by Ellman and co-workers,473 boronic acids were re-
crystallized from water prior to use.485,486 The content of boroxine is primarily dependent
on the drying procedure, because drying of boronic acids are known to form the cor-
responding boroxine.489 The batch of boronic acid used so far contained only traces
of boroxine determined by 1H NMR in dry DMSO-d6. However, the exact influence
of boroxine on this chemistry has not yet been investigated. Four different batches of
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4-methylphenylboronic acid (4.5) were therefore prepared, using different drying condi-
tions, and tested in the model reaction (see Scheme 4.4.4).
Table 4.4.4: Investigation of the dependency of boroxine and water.
N
H
SO2Ph
Boc
+
B(OH)2
5 mol% [RhCl(cod)]2
5.5 mol% (R,R)-deguPHOS
K2CO3, Et3N, 4Å MS
dioxane, 70 oC, 20h
N
H
Boc
4.4                                  4.5                                                                                    4.6(glovebox)
(different batches)
entry drying boroxine (%)a water (%)a conv. (%)b
1 Not recryst.c 17 19 40
2 –d <5 80 56
3 2h (rt)e <5 22 74
4 1h (100 ◦C)f 84 <5 25
a: Composition determined by 1H NMR in dry DMSO-d6 based on integrals. b: Conver-
sion determined by 1H NMR integrals compared to 1,3,5-trimethoxybenzene as internal
reference. c: Used directly from the bottle without recrystallization. d: Recrystallized
from H2O but not dried to remove excess water. e: Recrystallized from H2O and dried in
high vacuum at room temperature. f : Recrystallized from H2O and dried in high vacuum
at 100 ◦C.
In the first experiment 4.5 was used directly from the bottle and thus not recrystallized
from water (entry 1). This resulted in a reduced conversion (40%), which might be a
result of either the content of boroxine (17%) or water (19%). Then a non-dried batch
of recrystallized 4.5 was tested giving modest results (entry 2); 56% conversion was
achieved which indicate that a high content of water (80%) did not reduce the yield
significantly. Apparently, the molecular sieves are efficient enough to avoid hydrolysis of
the in situ generated imine. Drying of the recrystallized batch of 4.5 for 2 hours at room
temperature removed most of the water (22% remains) and only traces of boroxine was
formed (<5%). This batch gave superior results, 74% conversion. Finally a batch of
4.5 containing 84% boroxine and only traces of water was prepared by drying at 100 ◦C
for an hour. This batch gave only 25% conversion which clearly indicated, that boroxine
is indeed undesired. Unfortunately, preparation of boronic acids in this way is highly
dependent on initial water content and drying capacity of the vacuum pump. Therefore
sequential drying is recommended using 1H NMR in dry DMSO-d6 to analyze the batch
regularly during the drying process. Boronic acids should not contain more than 5%
boroxine and approximately 20–30% water (cf. entry 3).
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4.4.2 Synthesis of functionalized diaryl amine
4.4.2.1 Small-scale glovebox procedure
With the optimized reaction conditions in hand, a more functionalized diaryl amine was
chosen for further optimization and up-scaling. This was done to demonstrate the useful-
ness of the chemistry. The Boc-protected (4-chlorophenyl)-(thiophen-2-yl)methylamine
4.13 was chosen as target molecule (see Table 4.4.5). 4.13 was synthesized identi-
cally with the optimized procedure described previosuly from 2-thiophenyl α-carbamoyl
sulfone 4.11 (see section 4.4.2.2) and from recrystallized 4-chlorophenylboronic acid
(4.12).
Table 4.4.5: Initial synthesis of target molecule performed in the glovebox.
N
H
SO2Ph
+
B(OH)2
2.5 mol% [RhCl(cod)]2
5.5 mol% (R,R)-deguPHOS
preincubation 1h, 70 oC
N
H
K2CO3, Et3N, 4Å MS
dioxane, 70 oC
(glovebox)
Cl
Cl
S S
Boc Boc
4.11                             4.12                                                                                             4.13
entry time (h) conv. (%)a
1 1 25
2 5 42
3 10 67
4 20 65
5 40 66
aConversion determined by 1H NMR using 1,3,5-
trimethoxybenzene as internal standard.
An investigation of the reaction time was conducted, since this parameter has not yet
been considered. As shown in Table 4.4.5 a maximized conversion was achieved after
10 hours at 70 ◦C (entry 3). Interestingly, the conversion was neither increased nor
decreased after approximately 10 hours (entries 3–5).
4.4.2.2 Optimization of 2-thiophenyl α-carbamoyl sulfone synthesis
Synthesis of the 2-thiophenyl α-carbamoyl sulfone 4.11 was initially performed using
the same procedure as for the synthesis of 4.4 (c.f. Scheme 4.4.2). Thiophene-2-
carbaldehyde (4.14) was used as the starting material but only 30% yield was achieved
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at room temperature (see Table 4.4.6, entry 1). This is significantly lower than for the
synthesis of 4.4 which gave up to 70% isolated yield.
Table 4.4.6: Optimization of the 2-thiophenyl α-carbamoyl sulfone synthesis.
SH
O
+ +
HCOOH
H2O:MeOH,
rt
SN
H
SO2Ph
O NH2
O SO2Na Boc
4.14                              4.9                          4.10                                                      4.11
entry H2O:MeOH
a time (days) yield (%)b
1 2:1 3 30
2 2:1 5 29
3 5:1 3 55
4 7:1 3 57
5 10:1 3 60
6 1:0 1 44
7 1:0 3 66
8 1:0 5 74
aSolvent mixture is given in volume ratio. bIsolated yield after trituration with
H2O and Et2O.
An attempt to increase the yield of 4.11, the reaction time was prolonged to 5 days, but
that did not have any impact on the isolated yield (entry 2). Increasing the temperature
from room temperature to 50 ◦C was unfavored; no product was isolated at all. This
was probably due to the thermo instability of the product.
Another approach for improving the yield of 4.11 would be to decrease its solubilily in
the solvent mixture. A series of experiments using an increasing amount of water (entry
3–5) improved the yield significantly and 60% yield of the α-carbamoyl sulfone 4.11 was
isolated after three days using H2O:MeOH (10:1) (entry 5). Ultimately, the reaction was
run in pure water (entry 6–8), and the isolated yield was slightly increased to 66% after
three days (entry 7). Extending the reaction time further increased the yield to 74%
after a total of 5 days (entry 8). Besides of these optimizations, reducing the solvent
volume was also tested, but with no improvement of the isolated yield. Increasing the
equivs of the aldehyde 4.14 from 1.5 to 2.5 equivalents gave only a slightly improvement
of the yield. On large scale (40 mmol), 4.11 was obtained in 60–75% isolated yield as a
white solid after a reaction time of three days utilizing the optimized reaction conditions.
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4.4.2.3 Large-scale procedure using cannulation technique
At first, the optimized reaction conditions were applied to the synthesis of the function-
alized diaryl amine 4.13 on small scale (0.25 mmol) (see Table 4.4.7). Utilization of
Schlenk flasks, reaction bombs and sealed vials outside the glovebox were tested, but
all of them resulted in severe yield reduction giving only 14–39% conversion. The main
problem was the preincubation, because the reaction flask had to be opened for addition
of starting materials, bases and molecular sieves. Even though a nitrogen atmosphere
was maintained carefully during preincubation, during addition of starting materials and
during the actual reaction, oxygen apparently still got into the flasks and deactivated
the reactive rhodium catalyst.
Figure 4.4.1: Cannulation technique for transfering the preincubation cata-
lyst/ligand to the starting materials, bases and molecular sieves. A: catalyst/ligand
solution, B: starting materials, bases and molecular sieves, C: the cannula, D: gas
bubbler for receiving flask, E: nitrogen-inlet for receiving flask which must be
closed in order to start the cannulation, F: valve to close the overall outlet to
force the nitrogen flow through the cannula.
To solve this problem, it was apparent that a complete inert atmosphere had to be
applied and maintained throughout the entire procedure. Furthermore, the chosen tech-
nique should be easy to scale up. It was therefore evident to use a cannulation technique
for transferring the preincubated rhodium catalyst and ligand mixture to a solution of
the starting materials without exposure to air (see Figure 4.4.1). Application of regular
round-bottomed flasks has several advantages; first of all they are readily available, sec-
ondly up-scaling is easy and finally they make it possible to evacuate and back-fill with
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nitrogen several times to establish the sufficient inert atmosphere.
Table 4.4.7: Synthesis and up-scaling of functionalized amine.
N
H
SO2Ph
+
B(OH)2
2.5 mol% [RhCl(cod)]2
5.5 mol% (R,R)-deguPHOS
preincubation 1h, 70 oC
N
H
K2CO3 (6 equiv), Et3N (1.5 equiv)
4Å MS, dioxane, 70 oC, overnight
(cannulation)
Cl
Cl
S S
Boc Boc
4.11                             4.12                                                                                             4.13
entry scale (mmol) yield (%)a ee (%)b
1 0.25 65 99
2 10 57 95
3 20 59 95
4 20 65 95
a: Purified by chromatography. b: Determined by chiral HPLC.
With the implementation of the cannulation technique, synthesis of the target molecule
4.13 was performed on several scales up to 20 mmol (7.07 g) (see Table 4.4.7, entries
3–4). The large scale synthesis gave a 59–65% purified yield and an enantioselectivity
of 95% ee.
4.4.2.4 Determination of absolute configuration
So far, the absolute configuration of the diaryl amines 4.6 and 4.13, and all the products
reported by Ellman and co-workers473 were established based on comparision of litera-
ture values of optical rotations of a few amines obtained after Boc cleavage (cf. Table
4.2.1). Crystals were grown of 4.13 from a saturated solution in EtOH using slow evap-
oration to determine the absolute configuration. The absolute configuration was shown
by anomalous dispersion to be (S) using X-ray crystallography (see Figure 4.4.2), which
confirms the previous tentative assignment unequivocally. (R,R)-deguPHOS apparently
provides the same stereofacial addition which is reasonable when the same stereoisomer
of the ligand is used. Determination of the absolute configuration of 4.13 was performed
in cooperation with graduate student MaryAnn Robak and the X-ray Diffraction Facility
at UC Berkeley, College of Chemistry.
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Figure 4.4.2: Absolute configuration of 4.13 was shown to be (S) using X-ray
crystallography. The crystals were grown from a saturated solution in EtOH by
slow evaporation.
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4.5 Conclusion
A series of neutral rhodium catalysts were screened in a model reaction forming the diaryl
amine 4.6. The synthesis employed an enantioselective addition of 4-methylphenylboronic
acid (4.5) to an in situ generated imine originated from the α-carbamoyl sulfone 4.4. It
was found that [RhCl(cod)]2 gave similar yields to the original catalyst, Rh(acac)(coe)2,
but with poor enantioselectivity. This is presumably a result of insufficient ligand ex-
change with the chiral ligand (R,R)-deguPHOS. Preincubation was therefore introduced
by stirring the catalyst and ligand for 1 hour at 70 ◦C prior to addition of starting mate-
rials, bases (K2CO3 and Et3N) and molecular sieves. An enantioselectivity of 95–99% ee
was hereby obtained with a purified yield of 4.6 typically in the range of 63–75%. The
utilization of [Rh(OH)(cod)]2 was also tested, but it was not possible to obtain enan-
tioselectivites above 24% ee with this catalyst, even with preincubation. The influence
of boroxine present in the boronic acid batch was carefully investigated. It was evident
that a substantial amount of boroxine (84%) had an unfavorable effect on the yield of
4.6 giving conversions as low as 25%. Actually, only small amounts of boroxine (17%)
gave a reduced conversion (down to 40%). On the other hand, water did not have the
same impact on the outcome. A wet batch of the boronic acid 4.5 (80% water) did
only reduce the conversion to 56% (compared to 74% which was the best result). In
conclusion, it was found that boronic acids should not contain more than 5% borox-
ine and approximately 20–30% water. Finally, the optimized reaction conditions were
tested for the synthesis of the highly functionalized diaryl amine 4.13 from 2-thiophenyl
α-carbamoyl sulfone 5.11 and 4-chlorophenylboronic acid (4.12). Yields in the range of
57–67% and enantioselectivities up to 99% ee were obtained by carring out the synthesis
in a glovebox. Synthesis of 4.11 was optimized by changing the solvent mixture from
H2O:MeOH (2:1) to pure H2O which resulted in a siginificant increase of yield going from
30% to 66% after 3 days. The synthesis of 4.13 was scaled up 80 times to a 20 mmol
scale (7.07 g) and performed outside the glovebox by using a cannulation technique to
transfer the preincubated catalyst and ligand giving up to 65% purified yield and 95% ee.
Absolute configuration was determined to be (S) using X-ray crystallography. Through
substitution of the rhodium catalyst, introduction of a preincubation step, analysis of
the boroxine influence and utilization of a cannulation technique, the enantioselective
addition of boronic acids to in situ generated imines has been optimized. Now, it repre-
sents a very useful method for the synthesis of diaryl amines using commercially available
starting materials only and with no use of a glovebox. Moreover, it is easy to scale up in
practically any quantity, and it was demonstrated that yield and enantioselectivity were
retained at large scale.
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4.6 Experimental
General procedures
The chemicals were all commercially available and used without further purification un-
less otherwise stated. Solvents were of HPLC quality. 1,4-Dioxane was passed through a
column of dry, activated, basic alumina under a N2 atmosphere. The solvent was trans-
fered to the reaction flask via a syringe without exposure to air. 4-Methylphenylboronic
acid (4.5) and 4-chlorophenylboronic acid (4.12) were recrystallized from H2O prior to
use (see below for details). DMSO-d6 was dried over 4A˚ 3.2 mm pellets molecular sieves
prior to use. Powdered molecular sieves (4A˚, <5 microns) were activated under high
vacuum at 230–260 ◦C overnight. Et3N was freshly distilled over CaH2 under a N2 atmo-
sphere. If Et3N had to be used in the glovebox, it was degassed using three consecutive
freeze-pump-thaw cycles. Evaporation in vacuo was performed on a rotary evaporator at
approx. 40 ◦C down to approx. 20 mbar. TLC was performed using Dynamic Adsorbents,
Inc. glass plates coated with 250 µm F254 silica gel. 15 vol% EtOAc in hexanes was used
as the eluent and the plates were visualized by UV (Spectroline R©, Model EF-140C, short
wave UV 254 nm) and subsequently stained with PMA (10 g phosphomolybdic acid +
100 mL absolute EtOH). Unless otherwise stated, air-sensitive reactions were run in a
VAC Omni-lab glovebox filled with dry nitrogen. Flash chromatography was performed
using Merck KGaA silica gel 60 (0.040–0.063 mm, 230–400 mesh ASTM) according to
a general procedure reported by Still.492 1H NMR (300 MHz) and 13C NMR (75 MHz)
spectra were recorded on a Bruker Avance AV-300 and 1H NMR (400 MHz) and 13C
NMR (100 MHz) spectra on a Bruker AVB-400 using deuterated solvents as internal
references. Chemical shifts (δ) are given in ppm and coupling constants (J) in Hertz.
Optical rotation was measured on a Perkin-Elmer 241 polarimeter. Melting points were
measured on a Mel-Temp R© 3.0 from Laboratory Devices, Inc. USA, and they are given
in degree Celsius (◦C) uncorrected. MS was determined on a HPLC/MS system from
Agilent and IR was measured on a FT-IR spectrometer using attenuated total reflection
(ATR) sampling technique. Enantiomeric excess was determined by chiral HPLC using
an Agilent 1100 series instrument and a Chiralpak R© AS-H column (amylose tris[(S)-α-
methylbenzyl-carbamate] coated on a 5 µm silica gel), L = 250 mm, I.D. = 4.6 mm,
from Danicel Technologies, LTD. 4 vol% EtOH in hexanes was used for analyzing 4.6,
whereas 1% EtOH in hexanes was used for analyzing 4.13. Both protocols were run
isochratic with a flow rate of 1.00 mL/min at max. 70 bar for 25 minutes. For both
compounds, a racemate synthesized with dppbenz was used to determine the retention
times of each enantiomer and secure sufficient baseline separation. Elemental analysis
and X-ray crystallography were obtained from in-house facilities at College of Chemisty,
University of California at Berkeley.
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tert-Butyl phenyl(phenylsulfonyl)methylcarbamate (4.4)476
tert-Butyl carbamate (4.9) (5.00 g, 42.68 mmol, 1.0 equiv) and benzenesulfinic acid
sodium salt (4.10) (14.00 g, 85.28 mmol, 2.0 equiv) were suspended in MeOH (40 mL)
and H2O (80 mL). Benzaldehyde (4.8) (6.5 mL, 6.80 g, 64.08 mmol, 1.5 equiv) and
95% HCOOH (3.2 mL, 3.80 g, 82.55 mmol, 2.0 equiv) were added. A clear, colorless
solution appeared. The flask was loosely closed with a glass stopper and the reaction
mixture was stirred vigorously at room temperature for 2 days. During that time a white
precipiate formed. The suspension was filtered and the crude product was triturated
with H2O (2 × 20 mL) and Et2O (2 × 20 mL). Dried overnight in high vacuum afforded
pure 4.4 as a white solid (9.40–10.30 g, 64–70%). 1H NMR (300 MHz, CDCl3) δ 7.92
(d, J = 7.6 Hz, 2H), 7.66–7.63 (m, 1H), 7.56–7.52 (m, 2H), 7.43 (m, 5H), 5.93 (d, J
= 10.6 Hz, 1H), 5.76 (d, J = 10.1 Hz, 1H), 1.26 (s, 9H). The spectral values were in
accordance with the literature.476 Mp 180–181 ◦C (lit.:476 N/A ◦C).
Recrystallization of 4-methylphenylboronic acid (4.5)
In a conical flask was added 4.5 (10 g) and H2O (400 mL) and the flask was loosely
closed with a watch glass. The suspension was heated to boiling over the course of 25
minutes on a heating plate (115 ◦C) under vigorous stirring. Boiling was maintained
for 5 minutes to fully dissolve the boronic acid. The hot solution was filtered through a
filter paper using gravity filtration to remove insoluble particles. The colorless solution
was cooled to ambient temperature overnight and then cooled in an ice bath for 1 hour.
The crystallized boronic acid 4.5 and was isolated by vacuum filtration and dried by con-
tinuing the vacuum filtration for additional 15 minutes. To remove further amounts of
water the boronic acid was dried in high vacuum at room temperature until 1H NMR in
dry DMSO-d6 showed a composition of no more than 5% boroxine and approx. 20–30%
water, which was equivalent to 8.0–8.6 g of white microplates. 4.5 exhibits the following
chemical shifts: 1H NMR (300 MHz, DMSO-d6) δ 7.92 (s, broad, 2H), 7.68 (d, J = 7.2
Hz, 2H), 7.13 (d, J = 7.5, 2H), while the corresponding boroxine exhibits these shifts:
δ 7.77 (d, J = 7.5 Hz, 2H), 7.18 (d, J = 7.4 Hz, 2H).
(R)-tert-Butyl phenyl(4-methylphenyl)methylcarbamate (4.6)
In a nitrogen-filled glovebox, [RhCl(cod)]2 (3.1 mg, 6.25 µmol, 0.025 equiv) was sus-
pended in dry dixoane (1 mL) in a small oven-dried vial. (R,R)-deguPHOS (7.4 mg,
13.75 µmol, 0.055 equiv) was added and the vial was capped and stirred for 1 hour at 70
◦C outside the glovebox. Then, the vial was brought back to the glovebox and opened.
Upon preincubation the catalyst completely dissolved and the resultant mixture was a
clear, dark orange solution. Dioxane (3 mL) was added followed by the α-carbamoyl
sulfone 4.4 (86.0 mg, 0.25 mmol, 1.0 equiv) and recrystallized 4-methylphenylboronic
acid (4.5) (67.9 mg, 0.50 mmol, 2.0 equiv). Finally, dry K2CO3 (207 mg, 1.50 mmol,
6.0 equiv), dry and degassed Et3N (52 µL, 38.0 mg, 0.38 mmol, 1.5 equiv) and acti-
vated, powdered 4A˚ molecular sieves (400 mg) were added and the vial was sealed and
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stirred vigorously overnight (or as indicated) at 70 ◦C outside the glovebox. The crude
product was cooled to ambient temperature and filtered through Celite R©, which was
washed with EtOAc (40 mL). The combined organic filtrates were evaporated to dryness
in vacuo and subsequently purified by flash chromatography (5→15 vol% EtOAc in hex-
anes) affording 5.6 as a white solid (55.7 mg, 75%) with 96% ee determined by chiral
HPLC; (R)-enantiomer (major): 10.5 minutes, (S)-enantiomer (minor): 12.6 minutes.
1H NMR (300 MHz, CDCl3) δ 7.33–7.23 (m, 5H), 7.12 (m, 4H), 5.88 (m, 1H), 5.15
(m, 1H), 2.31 (s, 3H), 1.43 (s, 9H). The spectral values were in accordance with the
literature.473 MS (ESI+) m/z 310 (M+ + Na). Mp 123–126 ◦C (lit.:473 N/A ◦C).
tert-Butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate (4.11)
In a round-bottomed flask benzenesulfinic acid sodium salt (4.10) (13.13 g, 80.00 mmol,
2.0 equiv) was dissolved in H2O (105 mL). tert-Butyl carbamate (4.9) (4.69 g, 40.00
mmol, 1.0 equiv) was added, but did not dissolve. 2-Thiophene-carboxaldehyde (4.14)
(5.50 mL, 6.73 g, 60.00 mmol, 1.5 equiv) was added forming a yellow emulsion. 95%
HCOOH (3.10 mL, 3.68 g, 80.00 mmol, 2.0 equiv) was added. The flask was loosely fit-
ted with a glass stopper and the white, opaque, biphasic mixture was stirred vigorously at
room temperature. After a couple of hours the water phase became clear. The product
4.11 was formed as yellow chunks, which became more dispersed in the water phase as
the reaction proceeded. After 3 days of stirring the suspension was filtered. The yellow
chunks were crushed with a spatula, and the product was triturated with H2O (2 × 10
mL) and Et2O (2 × 10 mL). After each trituration the solvent was removed by vacuum
filtration. Finally, it was dried for an hour under high vacuum to give the α-carbamoyl
sulfone 3.13 as a white solid (9.34 g, 66%). 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J
= 7.6 Hz, 2H), 7.65 (t, J = 7.2 Hz, 1H), 7.54 (t, J = 7.6 Hz, 2H), 7.42 (dd, J = 5.1,
1.2 Hz, 1H), 7.27 (d, J = 3.4 Hz, 1H), 7.07 (dd, J = 4.9, 3.7 Hz, 1H), 6.19 (d, J =
10.8 Hz, 1H), 5.68 (d, J = 10.5 Hz, 1H), 1.26 (s, 9H). 13C NMR (100 MHz, CDCl3) δ
153.3, 136.5, 134.2, 131.5, 129.6, 129.4, 129.2, 127.8, 127.4, 81.5, 70.3, 28.1. Elem.
anal. calcd. for C16H19NO4S2: C, 54.37; H, 5.42; N, 3.96; found: C, 54.00; H, 5.68; N,
4.00. Mp 162–164 ◦C (decomp.). IR (neat) υ 3347, 2955, 1699, 1511, 1306, 1144 cm−1.
Recrystallization of 4-chlorophenylboronic acid (4.12)
4-Chlorophenylboronic acid (4.12) was recrystallized analogously to 4.5. It exhibits the
following chemical shifts: 1H NMR (300 MHz, DMSO-d6) δ 8.16 (s, broad, 2H), 7.79
(d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3, 2H), while the corresponding boroxine exhibits
these shifts: δ 7.86 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H).
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(S)-tert Butyl (4-chlorophenyl)(thiophen-2-yl)methylcarbamate (4.13)
An oven-dried three-necked round-bottomed flask with a magnetic stir bar was equipped
with a vacuum adaptor in the middle neck and glass stoppers in the two other necks. The
adaptor was connected to a Schlenk line and the flask was cooled to ambient temperature
under high vacuum. The flask was carefully back-filled with nitrogen and then charged
with [RhCl(cod)]2 (247 mg, 0.50 mmol, 0.025 equiv) and (R,R)-deguPHOS (583 mg,
1.10 mmol, 0.055 equiv) by removing one of the glass stoppers. A septum was used to
seal the flask and the other glass stopper was exchanged with an adaptor equipped with
a thermometer. The flask was then evacuated under high vacuum and carefully back-
filled with nitrogen three times. A positive flow of nitrogen was thereafter maintained
to ensure an oxygen-free atmosphere inside the flask. Dry dioxane (80 mL) was added
through the septum via a syringe and the flask was submerged into an oil bath (70 ◦C),
and the mixture was stirred for 1 h (internal temperature reached 65 ◦C after 20 min).
Initially, the catalyst was not fully soluble in dioxane, but as the preincubation proceeded
it completely dissolved. The solution of the active catalyst was clear and dark orange.
Meanwhile, an oven-dried, three-necked round-bottomed flask with a magnetic stir
bar was equipped with a vacuum adaptor in the middle neck and glass stoppers in
the two other necks. The adaptor was connected to a Schlenk line and the flask was
cooled to ambient temperature under high vacuum. The flask was carefully back-filled
with nitrogen and then charged with α-carbamoyl sulfone 4.11 (7.07 g, 20.00 mmol, 1.0
equiv), recrystallized 4-chlorophenylboronic acid (4.12) (6.26 g, 40.00 mmol, 2.0 equiv),
dry K2CO3 (16.58 g, 120.00 mmol, 6.0 equiv) and activated, powdered 4A˚ molecular
sieves (32 g) by removing one of the glass stoppers. A septum was used to seal the
flask, and the other glass stopper was exchanged with an adaptor equipped with a
thermometer. The flask was then evacuated under high vacuum and carefully back-filled
with nitrogen three times. A positive nitrogen inflow was thereafter maintained to ensure
an oxygen-free atmosphere inside the flask. Dry dioxane (240 mL) was added through
the septum via a syringe immediately before the preincubation was complete (described
above). Additionally, dry Et3N (4.20 mL, 3.04 g, 30.00 mmol, 1.5 equiv) was added via
a syringe. The white suspension was stirred vigorously at room temperature while adding
the preincubated solution of catalyst and ligand via cannula transfer resulting in a yellow
suspension. The reaction flask was submerged into an oil bath (70 ◦C), and the yellow
suspension was stirred vigorously for 16 h (internal temperature: 70 ◦C). The yellow
suspension was allowed to cool to ambient temperature over the course of one hour and
vacuum filtered through Celite R©, which was rinsed with EtOAc (300 mL). The combined
yellow filtrates were evaporated to dryness in vacuo to give a yellow solid. The crude
product was purified by flash chromatography using a gradient of 5→15 vol% EtOAc in
hexanes which affording the title compound 5.13 as a white solid (3.82–4.21 g, 59–65%)
with 95% ee determined by chiral HPLC; (R)-enantiomer (minor): 11.1 minutes, (S)-
enantiomer (major): 13.5 minutes. The absolute configuration was determined by X-ray
crystallography to be the (S)-enantiomer. Crystals were grown by preparing a saturated
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solution of 4.13 in EtOH, which was filtered to remove insoluble particles. The filtrate
was transfered to a scintillation glass and fitted loosely with a lid and allowed to slowly
evaporate undisturbed at room temperature. The slow evaporation afforded needle-
like crystals of 4.13 which were isolated by filtration. 1H NMR (400 MHz, CDCl3) δ
7.33–7.25 (m, 5H), 7.23 (dd, J = 5.0, 1.1 Hz, 1H), 6.92 (dd, J = 5.0, 3.6 Hz, 1H), 6.78
(d, J = 3.7 Hz, 1H), 6.08 (broad s, 1H), 5.26 (broad s, 1H), 1.43 (s, 9H). 13C NMR
(100 MHz, CDCl3) δ 154.6, 145.6, 140.3, 133.5, 128.7, 128.2, 126.8, 125.6, 125.3, 80.2,
70.1, 28.3. MS (ESI+) m/z 346 (M+ + Na, 100%), 347 (17%), 348 (40%). Elem.
anal. calcd. for C16H18ClNO2S: C, 59.34; H, 5.60; N, 4.33; found: C, 59.14; H, 5.58;
N, 4.33. mp 138–140 ◦C. IR (neat) υ 3347, 2979, 2921, 2361, 1686, 1515, 1233, 1169
cm−1. [α]20D +11.0 (c = 0.5, EtOH).
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Palladium-Catalyzed r-Arylation of Tetramic Acids
Morten Storgaard,†,‡ Florencio Zaragoza Do¨rwald,‡,§ Bernd Peschke,‡ and David Tanner*,†
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A mild, racemization-free, palladium-catalyzed R-arylation of tetramic acids (2,4-pyrrolidinediones) has
been developed. Various amino acid-derived tetramic acids were cleanly arylated by treatment with 2
mol % of Pd(OAc)2, 4 mol % of a sterically demanding biaryl phosphine, 2.3 equiv of K2CO3 or K3PO4,
and aryl chlorides, bromides, or triflates in THF. With conventional heating, conversions >95% could
be attained after 1 h at 80 °C, whereas microwave-induced heating led to much shorter reaction times (5
min at 110 °C). The electron density of the aryl electrophile had no effect on their reactivity: both electron-
rich and electron-poor aryl chlorides and bromides or triflates led to good yields. Ortho-substituted aryl
halides and heteroaryl halides, however, did not undergo the title reaction.
Introduction
Tetramic acids are -keto-γ-lactams which are slightly acidic
(pKa ≈ 6.4).1,2 Depending on solvent, concentration, and
temperature, tetramic acids can exist as both an enol (4-hydroxy-
3-pyrrolin-2-one) and a keto tautomer (2,4-pyrrolidindione) (see
Figure 1).1,3,4
The structural unit of tetramic acids has been known for more
than 100 years,5 and it is found in many biologically active
natural products,3 typically either as 3-acyl or 4-O-alkyl
derivatives, examples being althiomycin,6a,b dolastatin 15,6c,d
and epicoccamide.6e Tetramic acids are important intermediates
in the synthesis of statins,7a,b -hydroxy γ-amino acids,7c and
lactams7d which are inhibitors of renin. Renin is involved in
the renin-angiotensin system (blood pressure and fluid regulat-
ing system in the body), hypertension, congestive heart failure,
and development of HIV. Furthermore, tetramic acid derivatives
have been reported as key intermediates for the synthesis of
analogues of penicillins and cephalosporins7e and 4-substituted
3-hydroxy-1H-pyrrole-2,5-dione derivatives7f which are inhibi-
tors of glycolic acid oxidase and thus potentially useful drugs
for the treatment of calcium oxalate renal lithiasis (kidney
stones) and primary hyperoxalurias, which is an inborn error
of metabolism resulting in increased urinary excretion of oxalate.
2-Ethyl-4,6-dimethylphenyl-substituted tetramic acid derivatives
have been described in the patent literature as novel pesticides
† Technical University of Denmark.
‡ Novo Nordisk A/S.
§ Current address: Lonza AG, Rottenstrasse 6, CH-3930 Visp, Switzerland.
(1) Mulholland, T. P. C.; Foster, R.; Haydock, D. B. J. Chem. Soc., Perkin
Trans. 1 1972, 2121–2128.
(2) Mulholland, T. P. C.; Foster, R.; Haydock, D. B. J. Chem. Soc., Perkin
Trans. 1 1972, 1225–1231.
(3) (a) Royles, B. J. L. Chem. ReV. 1995, 95, 1981–2001. (b) Schobert, R.;
Schlenk, A. Bioorg. Med. Chem. 2008, 16, 4203–4221.
(4) Steyn, P. S.; Wessels, P. L. Tetrahedron Lett. 1978, 47, 4707–4710.
(5) (a) Benary, E. Chem. Ber. 1907, 40, 1079–1083. (b) Benary, E. Chem.
Ber. 1911, 44, 1759–1765.
FIGURE 1. Tetramic acids can exist as both an enol and a keto
tautomer.1,3,4
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and herbicides.7g Recently, methods for incorporation of amino
acid-derived tetramic acids into peptides have been developed,8
giving rise to more stable tripeptides. Tetramic acids derived
from amino acids are easily synthesized in good yield from
commercially available N-Boc amino acids and Meldrum’s acid
(2,2-dimethyl-1,3-dioxane-4,6-dione) via DCC (N,N′-dicyclo-
hexylcarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide) activation (see Scheme 1).8,9
Only a few examples in the literature have described the
3-aryl tetramic acids,10a,b the most important being the use of
3-phenyl 5-olefinic tetramic acids as novel glycine site N-
methyl-D-aspartate receptor antagonists, for the treatment of
neurological diseases.10c The development of a solid-phase
synthesis of substituted 3-aryl tetramic acids has also been
described.10d However, none of these methods utilize the easy
synthesis of N-Boc protected tetramic acids described above,
and the methods are not general, requiring the use of strong
base (e.g., KHMDS or NaOEt) and many synthetic steps. None
of these methods make it easy to efficiently synthesize a broad
range of 3-aryl-substituted amino acid-derived tetramic acids
as potentially interesting biologically active compounds. We
therefore wished to develop a useful method for the synthesis
of 3-aryl tetramic acids from the readily available N-Boc amino
acid-derived tetramic acids.
Specifically, we want to use these compounds as building
blocks for C-terminal modified peptides toward the preparation
of peptidyl enzyme inhibitors. For example, ring-opening of the
3-aryl tetramic acids followed by decarboxylation would lead
to a new type of amino benzyl ketones (see Figure 2), which
subsequently can be coupled to the C-terminal of a peptide.
Traditionally, R-arylated ketones or carboxylic acid deriva-
tives have been synthesized by nucleophilic aromatic substitution
reactions (SNAr) of aryls substituted with electron-withdrawing
groups by reaction with stabilized enolates11 or via copper-
catalyzed enolate reaction with 2-bromobenzoic acid.12 These
methods all have drawbacks and are not very general. Usually,
they require harsh reaction conditions, which are not suitable
for protected, enantiomerically pure amino acid derivatives.
Using a palladium-catalyzed R-arylation would be much more
efficient since these reactions are typically more general, mild,
and broad in substrate scope.
The literature reports a number of palladium-catalyzed
R-arylation conditions for different substrates containing elec-
tron-withdrawing groups such as ketones,13a aldehydes,13b
malonates,13c cyanoesters,13c sulfones,13d esters,13e amides,13f
protected amino acids,13g piperidinones,13h and nitriles.13i Only
a few examples of R-arylation of 1,3-dicarbonyls have been
described, and most of them are nonchiral and synthetically
undemanding compounds. Most of the examples have been
reported by Buchwald and co-workers,13a using substrates such
as diethyl malonate, 1,3-cyclohexanedione, and 1,3-cyclopen-
tanedione. Very recently more functionalized substrates have
been subjected to palladium-catalyzed arylation, e.g. the sp2
arylation of azine N-oxides,14 R-arylation of highly function-
(6) (a) Yamaguchi, H.; Nakayama, Y.; Takeda, K.; Tawara, K. J. Antibiot.,
Ser. A 1957, 10, 195–200. (b) Fujimoto, H.; Kinoshita, T.; Suzuki, H.; Umezawa,
H. J. Antibiot. 1970, 23, 271–275. (c) Pettit, G. R.; Kamano, Y.; Dufresne, C.;
Cerny, R. L.; Herald, C. L.; Schmidt, J. M. J. Org. Chem. 1989, 54, 6005–
6006. (d) Pettit, G. R.; Thornton, T. J.; Mullaney, J. T.; Boyd, M. R.; Herald,
D. L.; Singh, S.-B.; Flahive, E. J. Tetrahedron 1994, 50, 12097–12108. (e)
Wright, A. D.; Osterhage, C.; Ko¨nig, G. M. Org. Biomol. Chem. 2003, 1, 507–
510.
(7) (a) Jouin, P.; Catro, B.; Nisato, D. J. Chem. Soc., Perkin Trans. 1 1987,
1177–1182. (b) Schmidt, U.; Riedl, B.; Haas, G.; Griesser, H.; Vetter, A.;
Weinbrenner, S. Synthesis 1993, 216–220. (c) Fehrentz, J.-A.; Bourdel, E.;
Califano, J.-C.; Chaloin, O.; Devin, C.; Garrouste, P.; Lima-Leite, A.-C.; Llinares,
M.; Rieunier, F.; Vizavonna, J.; Winternitz, F.; Loffet, A.; Martinez, J.
Tetrahedron Lett. 1994, 35, 1557–1560. (d) Wittenberger, S. J.; Baker, W. R.;
Donner, B. G.; Hutchins, C. W. Tetrahedron Lett. 1991, 32, 7655–7658. (e)
Hlubucek, J. R.; Lowe, G. J. Chem. Soc., Chem. Commun. 1974, 419–420. (f)
Rooney, C. S.; Randall, W. C.; Streeter, K. B.; Ziegler, C.; Cragoe, E. J., Jr.;
Schwam, H.; Michelson, S. R.; Williams, H. W. R.; Eichler, E.; Duggan, D. E.;
Ulm, E. H.; Noll, R. M. J. Med. Chem. 1983, 26, 700–714. (g) Fischer, R.;
Lehr, S.; Feucht, D.; Losel, P.; Malsam, O.; Bojack, G.; Auler, T.; Hills, M. J.;
Kehne, H.; Rosinger, C. H. United States Patent Application Publication, US2007/
0225167, September 27, 2007.
(8) (a) Hosseini, M.; Kringelum, H.; Murray, A.; Tønder, J. E. Org. Lett.
2006, 8, 2103–2106. (b) Hosseini, M.; Grau, J. S.; Sørensen, K. K.; Søtofte, I.;
Tanner, D.; Murray, A.; Tønder, J. E. Org. Biomol. Chem. 2007, 5, 2207–2210.
(c) Hosseini, M.; Tanner, D.; Murray, A.; Tønder, J. E. Org. Biomol. Chem.
2007, 5, 3486–3494.
(9) (a) Ma, D.; Ma, J.; Ding, W.; Dai, L. Tetrahedron: Asymmetry 1996, 7,
2365–2370. (b) Courcambeck, J.; Bihel, F.; Michelis, C. D.; Que´le´ver, G.; Kraus,
J. L. J. Chem. Soc., Perkin Trans. 1 2001, 1421–1430.
(10) (a) Larsen, S.; Bernstein, J. J. Am. Chem. Soc. 1950, 72, 4447–4452.
(b) Andrews, M. D.; Brewster, A.; Moloney, M. G. Tetrahedron: Asymmetry
1994, 5, 1477–1478. (c) Mawer, I. M.; Kulagowski, J. J.; Leeson, P. D.;
Grimwood, S.; Marshall, G. R. Bioorg. Med. Chem. Lett. 1995, 5, 2643–2648.
(d) Matthews, J.; Rivero, R. A. J. Org. Chem. 1998, 63, 4808–4810.
(11) Heckmann, J. Ann. Chem. 1883, 220, 128–146.
(12) Bruggink, A.; McKillop, A. Tetrahedron 1975, 31, 2607–2619.
(13) (a) Fox, J. M.; Huang, X.; Chieffi, A.; Buchwald, S. L. J. Am. Chem.
Soc. 2000, 122, 1360–1370. (b) Terao, Y.; Fukuoka, Y.; Satoh, T.; Miura, M.;
Nomura, M. Tetrahedron Lett. 2002, 43, 101–104. (c) Beare, N. A.; Hartwig,
J. F. J. Org. Chem. 2002, 67, 541–555. (d) Mitin, A. V.; Kashin, A. N.;
Beletskaya, Russ. J. Org. Chem. 2004, 40, 802–812. (e) Lloyd-Jones, G. C.
Angew. Chem., Int. Ed. 2002, 41, 953–956. (f) Hama, T.; Liu, X.; Culkin, D. A.;
Hartwig, J. F. J. Am. Chem. Soc. 2003, 125, 11176–11177. (g) Lee, S.; Beare,
N. A.; Hartwig, J. F. J. Am. Chem. Soc. 2001, 123, 8410–8411. (h) Filippis, A.;
de Pardo, D. G.; Cossy, J. Tetrahedron 2004, 60, 9757–9767. (i) Culkin, D. A.;
Hartwig, J. F. Acc. Chem. Res. 2003, 36, 234–245.
(14) Schipper, D. J.; Campeau, L.-C.; Fagnou, K. Tetrahedron 2009, 65,
3155–3164.
FIGURE 2. Retrosynthetic analysis of amino benzyl ketones.
SCHEME 1. General Synthesis of N-Boc-Protected Amino
Acid-Derived Tetramic Acids8,9
SCHEME 2. Proposed r-Arylation of Tetramic Acids with
an Aryl Halide (X ) Cl, Br, I)
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alized cyclohexanones,15 and asymmetric intramolecular R-ary-
lation of aldehydes.16 However, to the best of our knowledge,
tetramic acids have never before been subjected to this kind of
transformation (see Scheme 2), and we set out to determine
suitable reaction conditions.
Even though no general reaction conditions exist in the
literature, it was possible to discern a general trend for the
reaction of substrates similar to tetramic acids, e.g., 1,3-
dicarbonyl compounds, cyclic substrates, and amino acids, from
the literature. It was found that an R-arylation is usually
conducted with either Pd(OAc)2 or Pd2(dba)3 with use of an
aryl bromide or iodide.13 Aryl chlorides are often too unreactive
for this type of chemistry. Many different solvents can be used,
but THF, toluene, dioxane, MeCN, or DMF are the most
common. The bases used can be divided into two groups: weak
inorganic bases such as Cs2CO3, K2CO3, K3PO4, Na3PO4, or
Na2CO3 and strong organic bases such as NaOtBu, KHMDS,
NaHMDS, LDA, or LiN(SiMe2Ph)2. The choice of base is
strongly dependent on the pKa value of the substrate but, in
general, strong bases can be used for most simple substrates.
However, if base-sensitive functionalities are present in the
molecule or deprotonation can cause racemization, strong bases
may give problems. Sometimes strong bases even require a two-
step procedure with addition of base at reduced temperature
and then the actual arylation at elevated temperature.13h Buch-
wald and co-workers13a reported the first use of a weak inorganic
base, K3PO4, in palladium-catalyzed R-arylations of ketones.
Finally, a very important parameter is the choice of ligand. This
can be difficult, since many different ligands have been reported
to work in R-arylation of carbonyl substrates, with a broad
variety of stereo- and electronic properties. In general the ligands
are either mono- or bis-phosphines. With a rational selection
of parameters it should be easier to find the optimal reaction
conditions for the R-arylation of tetramic acids (see Scheme
2).
Results and Discussion
Initially, we tried to arylate Boc-pyPhe-OH (1) (the prefix
“py” is used to indicate that the amino acid is converted to a
tetramic acid8) with 4-bromoanisole (2) in the presence of 2
mol % of Pd(OAc)2 in THF at 80 °C overnight for the synthesis
of the 3-aryl tetramic acid 3 (see Table 1). Four different weak
inorganic bases were chosen: Cs2CO3, K3PO4, Na2CO3, and
K2CO3, respectively, in 2.3 equiv inspired by results published
by Buchwald and co-workers.13a We prioritized the screening
of a variety of weak bases because they are much more
compatible with functional groups, and because tetramic acids
(15) Zhao, Y.; Zhou, Y.; Liang, L.; Yang, X.; Du, F.; Li, L.; Zhang, H. Org.
Lett. 2009, 11, 555–558.
(16) Garcı´a-Fortanet, J.; Buchwald, S. L. Angew. Chem., Int. Ed. 2008, 47,
8108–8111.
FIGURE 3. Ligands used in the initial screening experiments.
TABLE 1. Results from Initial Screening of Bases and Ligands
entry ligand base conv (%)a
1 4-8b all fourb <5
2 9 Cs2CO3 15
3 9 K3PO4 36
4 9 Na2CO3 -c
5 9 K2CO3 36
a Determined by 1H NMR. b Ligands 4-8 tested with Cs2CO3, K3PO4,
Na2CO3, and K2CO3, respectively, in 20 experiments. c No significant
product formation determined by 1H NMR or LC-MS.
TABLE 2. Increased Temperature and Prolonged Reaction Time
entry base temp (°C) time (h) conv (%)a
1 Cs2CO3 80 72 21
2 K3PO4 80 72 33
3 Na2CO3 80 72 <5
4 K2CO3 80 72 32
5 Cs2CO3 100 16 25
6 K3PO4 100 16 71
7 Na2CO3 100 16 <5
8 K2CO3 100 16 52
a Determined by 1H NMR.
Storgaard et al.
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are slightly acidic. The phosphine ligands P(tBu)3 (4), P(o-tolyl)3
(5), rac-BINAP (6), Xantphos (7), and DPPF (8) (see Figure
3) were screened with the four bases in 20 initial experiments.
Unfortunately, none of these conditions gave rise to any
significant product formation (conv <5%) and only starting
materials were isolated upon acidic workup (see Table 1, entry
1). However, to our gratification screening experiments with 4
mol % of biaryl phosphine ligand 9 gave promising results. Not
surprisingly, a major difference among the bases was observed,
K3PO4 and K2CO3 giving comparable results, 36% conversion
(entries 3 and 5), whereas Na2CO3 did not give any product
formation at all (entry 4). Cs2CO3 gave an intermediate result
with a conversion of 15% (entry 2).
To further increase the conversion with 4 mol % of biaryl
phosphine ligand 9 and 2.3 equiv of K3PO4, a series of
experiments at elevated temperature (100 °C) and a series with
prolonged reaction time (3 days) was conducted (see Table 2).
No significant change in conversions was observed after 3 days
(entries 1-4). On the other hand, the conversion was increased
at 100 °C overnight, especially with K3PO4, which almost gave
a 2-fold increase in conversion to 71% (entry 6). In both
experimental series, the use of Na2CO3 still did not give any
significant product formation (entries 3 and 7).
We reasoned that inefficient activation of the catalyst may
cause the low to moderate conversions obtained so far. Therefore
we tested the screening reaction at 80 °C with all four bases,
respectively, with 2 mol % of Pd2(dba)3 as a direct source of
Pd(0). However, we found that there was no improvement in
conversion, and we therefore assumed that the problem with
low conversion was not due to the nature of the palladium
catalyst.
Having a set of reaction conditions giving a moderate
conversion and a catalyst that presumably is sufficiently
activated, we screened a set of different equivalents with regard
to 4-bromoanisole (2), Pd(OAc)2, biaryl phosphine ligand 9, and
K3PO4 (see Table 3). Increasing the equivalents of 2 from 1.0
to 2.0 only increased the conversion slightly (entry 1), whereas
increasing the equivalents of K3PO4 to 5.0 gave a significant
reduction in conversion (entry 2). Furthermore, we examined
the effect of catalyst and ligand loading. Increasing the loading
of both catalyst and ligand to 4 and 8 mol %, respectively, gave
full conversion of the starting material to the desired product 3
(entry 3). The same was true with increased ligand loading only
(entry 4). It was found that an excess of ligand was essential,
since 4 mol % of Pd(OAc)2 and 4 mol % of biaryl phosphine
ligand 9 gave a conversion of 79% (entry 5).
On the basis of these results, it seemed likely that screening
other biaryl phosphine ligands might give full conversion
without increased ligand loading. We therefore screened three
classes of commercially available biaryl phosphine ligands: a
series of di-tert-butyl biaryl phosphines 10-12 (see Figure 4),
a series of dicyclohexyl biaryl phosphines 13-19, and a single
diphenyl biaryl phosphine 20 (see Figure 5). Only 2-di-tert-
butylphosphino-2′,4′,6′-triisopropylbiphenyl (12) gave full con-
version with 4 mol % of ligand loading (see Table 4, entry 3),
the two other di-tert-butyl biaryl phosphines (10 and 11) gave
only poor conversion (entries 1 and 2). All dicyclohexyl biaryl
phosphine ligands 13-19 and the diphenyl biaryl phosphine
ligand 20 gave only traces of product. Apparently, this reaction
requires a sterically hindered and electron-rich ligand and the
di-tert-butyl substituents are essential for reactivity, which is
demonstrated by the absence of reactivity with the analogous
dicyclohexyl biaryl phosphine ligand 16.
Before moving on with substrate scope and limitations, we
analyzed the enantiomeric purity of the product 3, by means of
chiral HPLC. Fortunately, little racemization had occurred (ee
97%), which was expected due to the use of mild base.
Having arrived at these optimized reaction conditions we
wished to examine the scope and limitations of the reaction by
testing other different aryl coupling partners, namely aryl
chlorides, iodides, tosylates, and triflates. For comparison
reasons we chose to screen 4-methoxy derivates only (see Table
5). To our delight, 4-chloroanisole (21) reacted identically (entry
1) compared to 4-bromoanisole (2), as did aryl triflate 24 (entry
4). Use of aryl triflates expands the scope of the reaction further
because it allows conversion of phenols into functional coupling
partners very easily. Aryl iodide 22 and aryl tosylate 23 gave
TABLE 3. Variation of Equivalents of Aryl Bromide 2, Pd(OAc)2,
Ligand 9, and K3PO4
entry
Ar-Br 2
(equiv)
Pd(OAc)2
(mol %)
ligand 9
(mol %)
K3PO4
(equiv)
conv
(%)a
1 2.0 2 4 2.3 43
2 1.0 2 4 5.0 15
3 1.0 4 8 2.3 >95
4 1.0 2 8 2.3 >95
5 1.0 4 4 2.3 79
a Determined by 1H NMR.
FIGURE 4. Di-tert-butyl biaryl phosphine ligands.
FIGURE 5. Dicyclohexyl (13-19) and diphenyl (20) biaryl phosphine
ligands.
Palladium Catalyzed R-Arylation of Tetramic Acids
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only traces of the product 3 (entries 2 and 3). This observation
is important because aryl chlorides are generally much cheaper
than the corresponding iodides and a wider range of com-
mercially available compounds exists.
To fine-tune the chemistry, reaction time and temperature
were taken into consideration again. It was found that the
reaction is in fact complete in less than an hour at 80 °C with
4-chloroanisole (21) as the coupling partner. The product is
stable under the reaction conditions and the reaction time can
be extended to 16-20 h with no product decomposition. In
addition, lower temperatures were also tested. At room tem-
perature no reaction occurred and at 60 °C only 11% conversion
was observed after 1 h. Therefore a temperature at 80 °C was
chosen for further experiments.
With these suitable reaction conditions in hand, we once again
examined the catalyst loading. Reducing the loading of
Pd(OAc)2 to 1 mol % and ligand 12 to 2 mol %, only 35%
conversion was achieved after 1 h. However, full conversion
was achieved with overnight reaction times. As previously
shown, K3PO4 and K2CO3 gave similar conversions. We chose
to use K2CO3 exclusively because it is the most inexpensive.
Control experiments with no palladium catalyst or ligand were
performed, but no product was formed, as expected.
Using the optimized reaction conditions we tested a broad
range of aryl chlorides with different substituents, electron-
donating (EDG) as well as electron-withdrawing groups (EWG),
and with different disubstitution patterns (see Table 6). Both
meta- and para-disubstituted aryl chlorides reacted efficiently
giving full conversion after 1 h for most of the substrates.
Electron-donating groups such as ethers, alcohols, and amines
(entries 3, 6, and 7) worked well and the same was true for a
variety of electron-withdrawing groups like nitriles, nitro groups,
ketones, and esters (entries 10, 12, 13, and 15). Chlorobenzene
(25) itself also reacted smoothly giving full conversion after
1 h (entry 1). Coupling of 4-chlorophenol (29), 4-chloroaniline
(30), and 4-chlorobenzoic acid (37) did not proceed to comple-
tion after 1 h (entries 6, 7, and 14), but full conversion was
achieved overnight (16 h). Apparently, the unprotected func-
tional groups slowed down the reaction. Protection of the aniline
nitrogen as in (N-Boc)-4-chloroaniline (31) gave full conversion
after 1 h (entry 8). In the case of a free aliphatic amine (entry
9), the unprotected nitrogen completely quenched the reaction.
To synthesize a halogen-substituted product, we tested the
chemistry with 1-bromo-4-chlorobenzene (39) (entry 16) and
the 4-chloro product 54 was formed exclusively. This is
reasonable because bromides react faster than chlorides. Finally,
we examined a couple of similar ortho-substituted aryl chlorides,
but none of them gave any significant product formation after
16 h (entries 4 and 11). For the case of 2-chloroanisole (27) we
also tested 2-bromoanisole (28) to examine if the more reactive
bromide would react, but that was not the case (entry 5). It is
not surprising that ortho-substituted aryl halides did not react
at all, since there is much more steric hindrance around the
halogen. Use of less sterically demanding ligands did not solve
this problem.
In all cases, the crude product was isolated as the enol
tautomer upon acidic workup. However, during flash chroma-
tography we discovered some degree of shifting in equilibrium
toward the keto tautomer, which gives more complex NMR
spectra. To shift back the equilibrium we found that suspension
in EtOAc and treatment with 10% KHSO4 was suitable, which
eventually dissolved the compound completely as the solubilities
of the keto and enol tautomers are quite different. An example
of this equilibrium shifting is shown in Figure 6 with the 3-aryl
tetramic acid 3. To the left is shown the enol tautomer and the
appurtenant 1H NMR spectrum in DMSO-d6 and to the right
the two possible keto tautomers. The 1H NMR spectrum of
3-keto is more complex because of broad peaks which might
be a result of the coexistence of both a cis and trans tautomer.
For both the enol and the keto tautomers, LC-MS (5f95%
MeCN in H2O added 0.05% TFA) showed one peak with the
same retention time. The acidic conditions apparently shift the
equilibrium to one of the tautomers independent of the initial
TABLE 4. Screening of Different Biaryl Phosphine Ligands
entry ligand conv (%)a
1 10 5
2 11 21
3 12 >95
4 13-20 <5
a Determined by 1H NMR.
TABLE 5. Testing of Different Coupling Partners: Aryl Halides,
Tosylate, and Triflate
a Determined by 1H NMR.
Storgaard et al.
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equilibrium position. In the 1H NMR spectra (see Figure 6) the
chemical shift of H5 is 4.71 ppm (dd) for the enol tautomer but
4.28 ppm (m) for the keto tautomers (H5′). The coupling pattern
of the H6 diastereotopic protons also changes; for the enol-
tautomer 3 the two protons are two well-resolved double
doublets (H6a + H6b), whereas the keto tautomers (3-keto) show
a multiplet in the region slightly upfield (H6′a + H6′b). On the
basis of 1H NMR it was not possible to determine the ratio
between the cis/trans tautomers.
Besides the aryl chlorides we also examined the scope of
the reaction with a series of chloro-substituted heterocycles (see
Figure 7). Three different pyridines 55-57, 2-chloropyrimidine
(58), 5-chloro-1-methyl-1H-imidazole (59), two chloro thiophenes
(60 and 61), and finally a bromo-substituted heterocycle,
3-bromothiophene (62), were tested. Unfortunately, none of
them gave any significant formation of product after 16 h. It is
plausible that the heteroatoms simply coordinate to palladium
resulting in an unreactive complex.
The reaction between Boc-pyPhe-OH (1) and 4-chloroanisole
(27) was tested with microwave heating and it was found that
full conversion (>95%) was achieved within only 5 min at 110
°C.
Finally, we wanted to expand the scope with other tetramic
acids than Boc-pyPhe-OH (1). A series of functionalized tetramic
acids were chosen: Boc-pyTyr(tBu)-OH (63), Boc-pyLys(Cbz)-
OH (64), Boc-pyArg(Pbf)-OH (65), Boc-pyThr(OtBu)-OH (66),
Boc-pyAsp(OtBu)-OH (67), and the glycine-derived tetramic
acid Boc-pyGly-OH (68). These were all subjected to the
optimized reaction conditions with 4-chloroanisole (21) as the
coupling partner (see Table 7). The chosen tetramic acids
represent a broad variety of functional side chains and different
protecting groups. Most of them gave similar yields compared
to the previous results, but Boc-pyAsp(tBu)-OH (67) and
especially Boc-pyGly-OH (68) gave much lower yield of the
corresponding 3-aryl tetramic acids 73 and 74, respectively
(entries 5 and 6).
So far, all reactions were conducted in THF. We then revisited
the initial reaction and tested some other solvents (see Table
8). Dioxane, MeCN, and DMF gave very low conversions (<5%)
no matter which base was used (Cs2CO3, K3PO4, Na2CO3, and
K3CO3, respectively) (entries 1-3). However, running the
reaction in toluene gave a significantly different result (entries
4-7). First of all, conversions were all much higher than the
equivalent experiments in THF (cf. Table 1, entries 2-5), even
with Na2CO3 a conversion of 29% was achieved (see Table 8,
entry 6). Full conversion was achieved with K3PO4, which gave
only 36% conversion in THF with the very same ligand (9).
Steric properties of the ligand are therefore not the only factor
dependent on the efficiency of the catalytic system.
Surprisingly, the crude product isolated from the toluene/
K3PO4 reaction was exclusively the keto tautomer (3-keto cis/
trans, see Figure 6), whereas THF gave the enol tautomer 3
when the same acidic workup procedure was used. To inves-
tigate this point further, we tried to shift the equilibrium of the
enol tautomer 3 by dissolving it in toluene, but nothing happened
based on TLC analysis. When adding aqueous 10% KHSO4 the
enol tautomer was slowly shifted toward the keto tautomers (3-
keto cis/trans), which have a significantly different Rf value.
Isolation as the keto tautomers is unfortunately not always
straightforward, and we discovered that it is easily shifted back
to the enol tautomer. Formation of the less stable keto tautomers
is not easy and it is rather unpredictable, probably because the
TABLE 6. Substrate Scope with Different Substituted Aryl
Chlorides
a Purified by flash chromatography. b No significant product formation
determined by 1H NMR or LC-MS. c Not purified by flash
chromatography, but crude 1H NMR is provided in the Supporting
Information. d Only the 4-chlorobenzene product was observed
determined by the isotope pattern of the molecular ion (LC-MS) of the
product (see the Supporting Information).
Palladium Catalyzed R-Arylation of Tetramic Acids
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equilibrium shifting is dependent on concentration, temperature,
pH, and solvent. This is comparable with the literature regarding
the keto-enol equilibrium of tetramic acids,1,3,4 as previously
described.
On the basis of the literature,13a we propose the following
mechanism for the coupling reaction (see Figure 8). The catalytic
cycle is assumed to be initiated by reduction of Pd(II) to the
active Pd(0), which might happen by a homocoupling of the
tetramic acids. Oxidation of phosphine ligands is another well-
known pathway for generation of Pd(0). However, Barder and
Buchwald reported recently that dialkylbiaryl phosphines are
highly resistant toward oxidation by molecular oxygen.17
Following reduction of Pd(II) to Pd(0), oxidative addition of
the aryl halide 25 takes place, then transmetalation by the
potassium enolate of the tetramic acid 1. Upon reductive
elimination the product is released and Pd(0) re-enters the
catalytic cycle. The desired product 40 can be isolated by acidic
workup.
In conclusion, we have developed a new, mild, and racem-
ization-free palladium-catalyzed R-arylation of tetramic acids
giving rise to 3-aryl amino acid-derived tetramic acids. Through
optimization it was found that 2 mol % of Pd(OAc)2 and 4 mol
% of 2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl
(12) gave full conversion in THF at 80 °C after 1 h for most
substrates. The two weak inorganic potassium bases, K2CO3
and K3PO4, worked equally well. The product could be isolated
as either the enol or the keto tautomer depending on reaction
solvent and the workup conditions, but shifted back to the enol
tautomer upon EtOAc/10% KHSO4 treatment. A variety of
different substrates was tested and a range of functionalities are
tolerated, e.g., Boc- or Cbz-protected amines, Pbf-protected
guadinine groups, ethers, esters, ketones, alcohols, nitriles, and
nitro groups. Heterocycles and unprotected amines are not
compatible with this chemistry. Aryl chlorides, bromides, and
triflates all coupled nicely, whereas aryl iodides and tosylates
did not work. With respect to the substitution pattern of the
aryl chloride, electron-withdrawing as well as electron-donating
groups showed similar reactivity and meta- and para-substituted
aryl chlorides reacted identically. Due to steric hindrance ortho-
substituted aryl chlorides did not react. The title reaction can
be facilitated by microwave heating with reaction time down
to 5 min at 110 °C.
Synthesis of the previously mentioned amino benzyl ketones
is currently under development in our laboratory. These building
blocks will ultimately be used for the preparation of C-terminal
modified peptidyl enzyme inhibitors.
Experimental Section
General Arylation Procedure. A vial was charged with dry
THF (3.0 mL), tetramic acid (1.00 mmol, 1.00 equiv), 2-di-tert-
butylphosphino-2′,4′,6′-triisopropylbiphenyl (12) (17 mg, 0.04
mmol, 0.04 equiv), K2CO3 (318 mg, 2.30 mmol, 2.30 equiv), and
an aryl chloride (1.00 mmol, 1.00 equiv). N2 was bubbled through
the reaction mixture and Pd(OAc)2 (4 mg, 0.02 mmol, 0.02 equiv)
was added, then the vial was filled with N2, sealed with a screw
cap, and placed in an aluminum heating block. The mixture was
stirred vigorously at 80 °C for 1 h (or 16 h, cf. Tables 6 and 7).
After being cooled to ambient temperature, the crude mixture was
transferred to a separatory funnel with 10% aqueous KHSO4 (10
mL) and extracted with EtOAc (30 mL + 20 mL). The combined
organic phases were dried over anhydrous Na2SO4, filtered, and
evaporated in vacuo. The yellow crude product was purified by
flash chromatography (5f10% MeOH in EtOAc, in some cases
up to 20% MeOH) affording the pure product typically as a keto/
enol tautomer mixture. The product was subsequently suspended
(17) Barder, T. E.; Buchwald, S. L. J. Am. Chem. Soc. 2007, 129, 5096–
5101.
FIGURE 6. Observed tautomeric equilibrium and appurtenant 1H NMR spectra (upfield region); the spectrum to the left belongs to the enol
tautomer of 3 and the spectrum to the right to the keto tautomer (3-keto cis/trans).
FIGURE 7. Heteroaryl halides which did not undergo the title
R-arylation.
Storgaard et al.
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in EtOAc (50 mL). Ten percent aqueous KHSO4 (50 mL) was added
and the biphasic system was stirred vigorously at room temperature
until complete dissolution of the compound. The mixture was
transferred to a separatory funnel and the organic layer was
separated. The aqueous layer was extracted with EtOAc (20 mL)
and the combined organic layers were dried over anhydrous Na2SO4,
filtered, evaporated in vacuo, and dried overnight in high vacuum,
which afforded the pure product mostly as the enol tautomer.
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-(4-meth-
oxyphenyl)-1,5-dihydropyrrol-2-one (3). Following the general
method for the arylation afforded 79% (313 mg) of the desired
product as a pale brown solid. 1H NMR (DMSO-d6) δ 12.11 (br s,
1H), 7.48 (d, J ) 8.6 Hz, 2H), 7.21-7.13 (m, 3H), 6.98 (d, J )
6.8 Hz, 2H), 6.86 (d, J ) 8.8 Hz, 2H), 4.71 (dd, J ) 4.3, 2.3 Hz,
1H), 3.72 (s, 3H), 3.44 (dd, J ) 14.0, 4.9 Hz, 1H), 3.26 (dd, J )
13.8, 1.9 Hz, 1H), 1.53 (s, 9H). 13C NMR (DMSO-d6) δ 168.9,
167.6, 157.7, 149.0, 134.2, 129.5, 128.7, 127.9, 126.8, 122.9, 113.2,
TABLE 7. Substrate Scope with Different Tetramic Acids
a Purified by flash chromatography. b Flash chromatography did not
successfully purify the product.
TABLE 8. Initial Reaction Conducted in Toluene and Screened
with Four Different Bases
entry solvent base conv (%)a
1 dioxane all fourb <5
2 MeCN all fourb <5
3 DMF all fourb <5
4 toluene Cs2CO3 86
5 toluene K3PO4 >95
6 toluene Na2CO3 29
7 toluene K2CO3 88
a Determined by 1H NMR. b Tested with the four bases Cs2CO3,
K3PO3, Na2CO3, and K2CO3, respectively.
FIGURE 8. Proposed reaction mechanism for the R-arylation of
tetramic acids.
Palladium Catalyzed R-Arylation of Tetramic Acids
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105.1, 81.2, 57.9, 55.0, 34.6, 27.9. HRMS (m/z) calcd for
C46H50N2O10Na [2M + Na]+ 813.3358, found 813.3367. Anal.
Calcd for C23H25NO5: C, 69.86; H, 6.37; N, 3.54. Found: C, 69.84;
H, 6.52; N, 3.49. Mp 142-145 °C. IR (neat) ν 2975, 2930, 1750
(strong), 1363, 1284, 1251, 1147, 1095, 833, 699 cm-1. Chiral
HPLC: 4.57 min (minor) and 5.78 min (major) gave an enantiomeric
excess of 97%.
Microwave-Assisted Synthesis of (5S)-5-Benzyl-1-(tert-buty-
loxycarbonyl)-4-hydroxy-3-(4-methoxyphenyl)-1,5-dihydropy-
rrol-2-one (3). A microwave vial was charged with Boc-pyPhe-
OH (1) (289 mg, 1.00 mmol, 1.00 equiv), 2-di-tert-butylphosphino-
2′,4′,6′-triisopropylbiphenyl (12) (17 mg, 0.04 mmol, 0.04 equiv),
Pd(OAc)2 (4 mg, 0.02 mmol, 0.02 equiv), and K2CO3 (318 mg,
2.30 mmol, 2.30 equiv). Dry THF (3.0 mL) was added and used to
carefully rinse the inside of the vial (for safety reasons no solid
may be stuck on the glass!). 4-Chloroanisole (21) (143 mg, 0.08
mL, 1.00 equiv) was added and N2 was bubbled into the vial to
secure an inert reaction atmosphere. The vial was capped, sealed,
and heated to 110 °C in a microwave synthesizer for 5 min. After
being cooled to ambient temperature, the crude product was
neutralized with 10% KHSO4 (10 mL) and EtOAc (30 + 20 mL)
was added. The combined organic layers were dried over anhydrous
Na2SO4 and evaporated in vacuo. The crude product was analyzed
by 1H NMR in DMSO-d6, which showed full conversion (>95%),
and the spectrum was identical with that of the product obtained
by conventional heating (80 °C, 1 h).
(5S)-5-Benzyl-1-(tert-butyloxycarbonyl)-4-hydroxy-3-phenyl-
1,5-dihydropyrrol-2-one (40). Following the general method for
the arylation afforded 75% (273 mg) of the desired product as a
pale brown solid. 1H NMR (DMSO-d6) δ 12.30 (br s, 1H), 7.52
(dd, J ) 8.3, 1.3 Hz, 2H), 7.28 (t, J ) 7.6 Hz, 2H), 7.22-7.15 (m,
4H), 7.01-6.98 (m, 2H), 4.73 (dd, J ) 4.8, 2.5 Hz, 1H), 3.45 (dd,
J ) 13.9, 4.8 Hz, 1H), 3.27 (dd, J ) 14.0, 2.4 Hz, 1H), 1.54 (s,
9H). 13C NMR (DMSO-d6) δ 170.2, 167.4, 149.0, 134.2, 130.5,
129.5, 127.9, 127.7, 127.5, 126.8, 126.3, 105.4, 81.2, 57.9, 34.6,
27.9. HRMS (m/z) calcd for C44H46N2O8Na [2M + Na]+ 753.3146,
found 753.3153. Anal. Calcd for C22H23NO4: C, 72.31; H, 6.34;
N, 3.83. Found: C, 71.97; H, 6.60; N, 3.96. Mp 86-88 °C. IR
(neat) ν 3082, 3061, 2977, 2928, 1753, 1702, 1661, 1645 (strong),
1397, 1359, 1298, 1149, 694 cm-1.
(5S)-5-(4-tert-Butoxybenzyl)-1-(tert-butyloxycarbonyl)-4-hy-
droxy-3-(4-methoxyphenyl)-1,5-dihydropyrrol-2-one (69). Fol-
lowing the general method for the arylation afforded 69% (324
mg) of the desired product as a pale brown solid. 1H NMR (DMSO-
d6) δ 12.02 (s, 1H), 7.42 (d, J ) 9.1 Hz, 2H), 6.88 (d, J ) 8.6 Hz,
2H), 6.83 (d, J ) 9.1 Hz, 2H), 6.77 (d, J ) 8.6 Hz), 4.66 (dd, J )
4.6, 2.8 Hz, 1H), 3.71 (s, 3H), 3.39 (dd, J ) 13.9, 4.6 Hz, 1H),
3.19 (dd, J ) 13.9, 2.5 Hz, 1H), 1.53 (s, 9H), 1.16 (s, 9H). 13C
NMR (DMSO-d6) δ 168.8, 167.6, 157.7, 153.7, 149.0, 130.0, 128.9,
128.7, 123.2, 122.8, 113.1, 105.4, 81.1, 77.7, 57.9, 55.0, 34.1, 28.4,
27.9. HRMS (m/z) calcd for C54H66N2O12Na [2M + Na]+ 957.4508,
found 957.4516. Mp 147-153 °C. IR (neat) ν 2975, 2932, 1748,
1643, 1607, 1514, 1392, 1363, 1290, 1247, 1150 (strong), 1095,
894, 830 cm-1.
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RHODIUM-CATALYZED ENANTIOSELECTIVE ADDITION OF 
ARYLBORONIC ACIDS TO IN SITU GENERATED N-BOC 
ARYLIMINES. PREPARATION OF (S)-TERT-BUTYL (4-
CHLOROPHENYL)(THIOPHEN-2-YL)METHYLCARBAMATE 
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2.5% [RhCl(cod)]2 
5.5% (R,R)-deguPHOS
K2CO3 (6 equiv), Et3N (1.5 equiv),
4Å sieves, dioxane, 70 oC, 16 h
N
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(Ph)2P P(Ph)2
(R,R)-deguPHOS
A.
B.
 
 
Submitted by Morten Storgaard and Jonathan A. Ellman.1 
Checked by Jason A. Bexrud and Mark Lautens. 
 
1. Procedure 
 
A. tert-Butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate (1). In a 
250-mL, round-bottomed flask benzenesulfinic acid sodium salt (13.13 g, 
80.0 mmol, 2.0 equiv) (Note 1) is dissolved in H2O (105 mL) (Note 2). tert-
Butyl carbamate (4.69 g, 40.0 mmol, 1.0 equiv) (Note 3) is added, but does 
not dissolve. 2-Thiophene-carboxaldehyde (5.50 mL, 6.73 g, 60.0 mmol, 1.5 
equiv) (Note 4) is added forming a yellow emulsion. Formic acid (3.10 mL, 
3.68 g, 80.0 mmol, 2.0 equiv) (Note 5) is added. The flask is loosely fitted 
with a rubber septum and the white, opaque, biphasic mixture is stirred 
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vigorously at room temperature (23 °C). After a couple of hours the water 
phase becomes clear. The product 1 is formed as yellow chunks, which 
become more dispersed in the water phase as the reaction proceeds. After 3 
days (Note 6) of stirring the suspension is vacuum filtered (Note 7). The 
yellow chunks are crushed with a spatula, and the product is triturated with 
H2O (2 × 10 mL) and Et2O (2 × 10 mL) (Note 8). After each trituration the 
solvent is removed by vacuum filtration. Finally, it is dried for an hour under 
high vacuum (Note 9) to give the imine precursor 1 as a white solid (8.21 g, 
58%) (Notes 10 and 11).  
B. (S)-tert-Butyl (4-chlorophenyl)(thiophen-2-yl)methylcarbamate (2). 
An oven-dried (Note 12), 250-mL, three-necked round-bottomed flask with 
a magnetic stir bar is equipped with a vacuum adaptor in the middle neck 
and glass stoppers in the two other necks (one of which is loosely fitted to 
allow an outflow of nitrogen gas). The adaptor is connected to a nitrogen gas 
line (Note 13) and the flask is purged with nitrogen as it is allowed to cool to 
ambient temperature (23 °C). The flask is then charged with [RhCl(cod)]2 
(247 mg, 0.50 mmol, 0.025 equiv) (Note 14) and (R,R)-deguPHOS (583 mg, 
1.1 mmol, 0.055 equiv) (Note 15) by removing one of the glass stoppers. A 
septum is used to seal the flask and the other glass stopper is exchanged with 
an adaptor equipped with a thermometer. The flask is then purged with 
nitrogen for 5 min and a positive nitrogen flow is thereafter maintained to 
ensure an oxygen-free atmosphere inside the flask (Note 16). Dry dioxane 
(80 mL) (Note 17) is added through the septum via a syringe and the flask is 
submerged into an oil bath (70 °C), and the mixture is stirred for 1 h 
(internal temperature: 65 °C, reached after 20 min). Initially, the precatalyst 
is not fully soluble in dioxane, but as the preincubation proceeds it 
completely dissolves. The solution of the active catalyst is clear and dark 
orange. 
Meanwhile (Note 18), a 500-mL, oven-dried, three-necked round-
bottomed flask (Note 19) with a magnetic stir bar is equipped with a vacuum 
adaptor in the middle neck and glass stoppers in the two other necks (one of 
which is loosely fitted to allow outflow of nitrogen gas). The adaptor is 
connected to a nitrogen gas line and the flask is purged with nitrogen as it is 
allowed to cool to ambient temperature (23 °C). The flask is then charged 
with tert-butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate (1) (7.07 g, 
20.0 mmol, 1.0 equiv), 4-chlorophenylboronic acid (6.26 g, 40.00 mmol, 2.0 
equiv) (Notes 20 and 21), K2CO3 (16.58 g, 120.0 mmol, 6.0 equiv) (Note 22) 
and 4Å powdered molecular sieves (32 g) (Note 23) by removing one of the 
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glass stoppers. A septum is used to seal the flask, and the other glass stopper 
is exchanged with an adaptor equipped with a thermometer. The flask is then 
purged with nitrogen for 5 min, and a positive nitrogen inflow is maintained 
to ensure an oxygen-free atmosphere inside the flask. Dry dioxane (240 mL) 
is added through the septum via a syringe immediately before the 
preincubation is complete (described above). Additionally, dry triethylamine 
(4.20 mL, 3.04 g, 30.00 mmol, 1.5 equiv) (Note 24) is added via a syringe. 
The white suspension is stirred vigorously at room temperature (23 °C) 
while adding the preincubated solution of catalyst and ligand via cannula 
transfer (Note 25) resulting in a yellow suspension. The reaction flask is 
submerged into an oil bath (70 °C), and the yellow suspension is stirred 
vigorously for 16 h (internal temperature: 70 °C) (Note 26). The yellow 
suspension is allowed to cool to ambient temperature (23 °C) over the course 
of one hour and vacuum filtered through a plug of CeliteTM (Note 27), which 
is rinsed with EtOAc (300 mL) (Note 28). The combined yellow filtrates are 
evaporated in vacuo (Note 29) to give a yellow solid (Note 30). The crude 
product is purified by flash chromatography (6.5 × 20 cm, 270 g silica gel) 
(Note 31) using a gradient of 5 to 15% EtOAc in hexanes and fractions of 50 
mL. The column is eluted with 500 mL of 1:19 EtOAc:hexanes (Note 32), 
500 mL of 1:12 EtOAc:hexanes, 1500 mL of 1:9 EtOAc:hexanes, 500 mL of 
1:7 EtOAc:hexanes and finally with 500 mL of 1:5 EtOAc:hexanes. 
Fractions 32–65 (Note 33) are combined, evaporated in vacuo and dried 
overnight under high vacuum affording the title compound 2 as a white solid 
(4.92 g, 76%) (Notes 34 and 35) with 93% ee (Notes 36 and 37). 
 
2. Notes 
 
1. Benzenesulfinic acid sodium salt (98%) was purchased from 
Sigma-Aldrich and used without further purification. 
2. Deionized water (H2O) was used in all cases where the procedures 
call for water. 
3. tert-Butyl carbamate (98%) was purchased from Sigma-Aldrich 
and was used without further purification.  
4. 2-Thiophene-carboxaldehyde (98%) was purchased from Sigma-
Aldrich and was used without further purification.  
5. Formic acid (HCOOH) (reagent grade, >95%) was purchased from 
Sigma-Aldrich and was used without further purification. 
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6.  This reaction was originally published by Wenzel and Jacobsen2 
giving only a 44% yield of product 1 when MeOH:H2O (1:2) was used as 
the solvent and with a 3 day reaction time. We attempted to increase the 
yield by heating the reaction mixture to 50 °C, but this resulted in product 
decomposition. Increasing the reaction concentration resulted in only a slight 
increase in the yield of 1. Reducing the amount of MeOH resulted in the 
most significant increase in yield. Ultimately, running the reaction in pure 
H2O gave the reported yield. Lower yields were achieved with a reaction 
time of only 1 day (44%), while a further increase in the yield can be 
achieved after 5 days (74%).  
7. Wilmad Labglass sintered glass funnel, 60 mL, size M, was used. 
8. Diethyl ether (Et2O), anhydrous HPLC grade, stabilized, was 
purchased from Fisher Scientific Chemicals and was used without further 
purification. 
9.  High vacuum refers to 0.025 mmHg at 23 °C. 
10.  tert-Butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate (1) 
exhibits the following properties: mp 160–162 °C (decomp.). 1H NMR (400 
MHz, CDCl3) δ: 1.26 (s, 9 H), 5.62 (d, J = 10.0 Hz, 1 H), 6.18 (d, J = 10.8 
Hz, 1 H), 7.05–7.09 (m, 1 H), 7.26–7.28 (m, 1 H), 7.41–7.43 (m, 1 H), 7.52–
7.57 (m, 2 H), 7.63–7.65 (m, 1 H), 7.90–7.94 (m, 2 H). 13C NMR (100 MHz, 
CDCl3) δ: 28.2, 70.4, 81.7, 127.6, 128.0, 129.3, 129.6, 129.8, 131.7, 134.3, 
136.7, 153.4. IR (neat) 3347, 2955, 1699, 1510, 1306, 1150 cm-1. Anal. 
calcd for C16H19NO4S2: C, 54.37; H, 5.42; N, 3.96; found: C, 54.39; H, 5.40; 
N, 3.87.  
11. A second run by the checkers provided 10.57 g (75%) of 1 with a 
melting point range of 159–161 °C.  The submitters reported a yield of 8.46 
g (60%) with a melting point range of 162–164 °C.  
12.  Oven-dried refers to drying of flasks, glass stoppers, adaptors and 
magnetic stir bars in an oven (150 °C) overnight before use. The glassware 
was assembled while still hot and cooled to ambient temperature (23 °C) 
under high vacuum. The submitters cooled the glassware under high 
vacuum. 
13.  The nitrogen gas line was a standard dual manifold with multiple 
ports with stopcocks that allow vacuum or nitrogen to be selected without 
the need for placing the flask on a separate line. One manifold was 
connected to a source of nitrogen dried through a tube of Drierite® (>98% 
CaSO4, >2% CoCl2), while the other was connected to a high-vacuum Fisher 
Scientific Maxima® C Plus Model M8C pump (0.025 mm Hg). The nitrogen 
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gas line was vented through an oil bubbler that was connected to the 
manifold through a valve (making it possible to disconnect the bubbler 
during cannula transfer), while solvent vapors were prevented from 
contaminating the pump through a dry ice/isopropanol cold trap.  
14.  [RhCl(cod)]2 (chloro(1,5-cyclooctadiene)rhodium(I) dimer), 98%, 
which is air stable, was purchased from Strem and was used without further 
purification.  
15.  (R,R)-deguPHOS ((3R,4R)-1-benzyl-3,4-bis-diphenylphosphanyl-
pyrrolidine), 98%, was purchased from Strem and was used without further 
purification. 
16.  The active catalyst is very sensitive to air. It is important to 
introduce a nitrogen atmosphere to the flask and maintain a positive pressure 
of nitrogen throughout the preincubation and the reaction to prevent catalyst 
decomposition. 
17.  1,4-Dioxane, HPLC grade, was purchased from Fisher Scientific 
Chemicals and passed through a column of dry, activated, basic alumina 
under a nitrogen atmosphere. The solvent is transferred to the flask via a 
syringe without exposure to air.  
18.  This part of the procedure can be performed while stirring the 
precatalyst and ligand, but the dioxane and Et3N should not be added until 
just immediately before the active catalyst is ready (1 h at 70 °C). This is to 
avoid premature hydrolysis of the in situ generated imine, which results in a 
decreased yield of the title compound 2. 
19.  A 500-mL flask was used instead of a 1000-mL to reduce the risk 
of catalyst decomposition – minimizing unoccupied volume reduces the risk 
of oxygen contamination.  
20.  4-Chlorophenylboronic acid (95%) was purchased from Sigma-
Aldrich and recrystallized from H2O before use as described in Note 21.  
21.  Commercially available arylboronic acids contain boroximes 
(anhydride trimers) that do not add efficiently to the in situ generated imine. 
Therefore, to maximize formation of the title compound 2, we found it very 
important to recrystallize and dry the arylboronic acid before use. This was 
carried out as follows: in a 1000-mL conical flask was added 4-
chlorophenylboronic acid (10 g) (Note 20) and H2O (400 mL) and the flask 
was covered with a watch glass. The suspension was heated to boiling over 
the course of 25 minutes on a heating plate (115 °C) under vigorous stirring 
with a magnetic stir bar. The boiling point was maintained for 5 minutes to 
fully dissolve the boronic acid. The hot solution was filtered through filter 
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paper using gravity filtration to remove insoluble particles. The colorless 
solution was cooled to ambient temperature (23 °C) overnight and then was 
cooled in an ice bath for 1 hour (internal temperature: 5 °C). During the 
cooling process the aryboronic acid precipitated and was isolated by vacuum 
filtration and dried by continuing the vacuum filtration for an additional 15 
minutes. To remove further amounts of water the boronic acid was dried in 
high vacuum at room temperature (23 °C) until 1H NMR analysis in DMSO-
d6 showed a composition of no more than approx. 5% boroxime and 30% 
H2O, at which point the mass of product was 8.0–8.6 g of white microplates. 
The drying procedure is important because reaction of pure boroxime will 
cause a reduction in the yield of the title compound 2 down to 52%. 
Depending on the initial amount of water in the recrystallized batch and the 
vacuum pump capacity, the time of drying may vary. Usually we were able 
to obtain the above-mentioned composition requirements within 5–15 
minutes of drying in high vacuum. It is highly recommended to dry the 
arylboronic stepwise, e.g. 5 minutes at a time and then analyze the 
arylboronic by NMR. In DMSO-d6 (dried prior to use over 4Å molecular 
sieves, 3.2 mm pellets) 4-chlorophenylboronic acid exhibits the following 
chemical shifts (300 MHz): δ 8.16 (s, broad), 7.79 (d, J = 8.3, 2H), 7.39 (d, J 
= 8.3, 2H), while the corresponding boroxime exhibits these shifts: δ 7.86 
(d, J = 8.1, 2H), 7.42 (d, J = 8.1, 2H). The composition can be determined 
using the integrals directly if the DMSO is water-free. Occasionally, we 
found it difficult to remove the excess of water without increasing the 
amount of boroxime to strictly more than 5%. In such cases the batch should 
be recrystallized again.  
22.  Potassium carbonate (K2CO3), anhydrous, was purchased from EM 
Science (an affiliate of Merck KGaA) and was dried overnight before use 
under high vacuum at 100 °C in a thermostatically controlled oil bath.  
23.  Molecular sieves, 4Å, <5 microns, powdered, were purchased from 
Sigma-Aldrich and activated under high vacuum at 230–260 °C overnight. 
Heating was achieved by a Glas-Col® heating mantle, 2/3 filled with sand 
and connected to a Powerstat® variable autotransformer (in: 120 V, 50/60, 
~1 PH, out: 0–140 V, 10 A, 1.4 KVA). The transformer was adjusted to 
approx. 250 °C as measured with a thermometer placed directly into the 
sand. 
24.  Triethylamine was purchased from Fisher Scientific Chemicals and 
was freshly distilled from CaH2 under a nitrogen atmosphere before use. 
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25.  Cannulation technique (Figure 1) was used to conveniently transfer 
the active catalyst solution (A) to the mixture of starting materials, bases and 
molecular sieves (B) through a cannula (C) without exposure to air. Before 
inserting the cannula into the flasks, an extra oil bubbler (D) was attached to 
flask B via a needle through the septum. The cannula (C) was then inserted 
into flask A and after a minute the other end of C was inserted into flask B. 
To cannulate the catalyst solution (A), the nitrogen inlet to flask B (E) and 
the Schlenk line oil bubbler (F) were both closed making the extra oil 
bubbler (D) the only outlet from the system. After complete cannulation E 
and F were both opened again, and the extra bubbler (D) and cannula (C) 
were removed.  
26.  It is not convenient to monitor the progress of the reaction by TLC 
because the diagnostic compound (the imine formed in situ from 1) is 
unstable and does not elute without decomposition on TLC. Therefore, we 
ran a number of reactions on small scale (0.250 mmol) at different reaction 
times. We found that the amount of the title product 2 reaches a 65–67% 
NMR yield after 10 hours. Neither product decomposition nor an increase in 
yield are observed with prolonged reaction times, e.g., 40 hours at 70 °C. 
For convenience we chose a 16 h reaction time.    
27.  CeliteTM powder, 545 filter aid, not acid washed, was purchased 
from Fisher Scientific and was used without further purification. The filter 
plug was prepared by mixing CeliteTM (20 g) with EtOAc (80 mL) and 
filtered through a Kimax® sintered glass funnel, 150 mL – 60F. 
28.  Ethyl acetate (EtOAc), HPLC grade, was purchased from Fisher 
Chemicals and was used without further purification.  
29.  Evaporation in vacuo was carried out on a Büchi Rotavapor R-114 
at 45 mmHg with a Büchi Waterbath B-480 at 35 °C, unless otherwise 
stated.  
30.  The 1H NMR (CDCl3) spectrum of the crude product was recorded 
to determine if the reaction proceeded as expected. Besides EtOAc, dioxane 
and the peaks corresponding to the title compound 2 (Note 34), the crude 
product also contains 2-thiophene-carboxyaldehyde (9.68 ppm), and other 
decomposition compounds: δ 7.86, 7.75, 4.57 and 1.28 ppm. If the reaction 
has been performed correctly there should be only trace amounts of the the 
in situ generated imine (9.05 and 1.57 ppm) in the crude product, and the 
crude product should be a yellow solid rather than an oil. 
31.  Silica gel 60 (0.040–0.063 mm), 230–400 mesh ASTM, was 
purchased from Merck KGaA and used without further purification.  
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32.  Hexanes, HPLC grade, was purchased from Fisher Scientific and 
used without further purification.  
33.  TLC of fractions is performed using Dynamic Adsorbents, Inc. 
glass plates coated with 250 mm F-254 silica gel. 15% EtOAc in hexanes is 
used as the eluent. Visualization is achieved with UV (Spectroline®, Model 
EF-140C, short wave ultraviolet 254 nm) and subsequently with PMA 
staining (10 g phosphomolybdic acid + 100 mL absolute EtOH) by 
immersion and heating with a heat gun. The title compound 2 is visible by 
UV and stains dark brown with PMA at an Rf = 0.41. Trace amounts of 2-
thiophene-carboxaldehyde, which is generated by decomposition of tert-
butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate (1), elutes at Rf = 0.35. 
This aldehyde is only visible by UV and does not stain with PMA. Fractions 
containing both thiophene-carboxaldehyde and 2 are collected because this 
aldehyde is easy to remove under vacuum (boils at 75 – 77 °C at 11 mmHg). 
Fractions containing an impurity with Rf = 0.22 (visible by UV and stains 
brown with PMA) were not collected.  
34.  The title compound (2) exhibits the following properties: mp 138–
140 °C. 1H NMR (400 MHz, CDCl3) δ: 1.43 (s, 9 H), 5.20 (broad s, 1 H), 
6.10 (broad s, 1 H), 6.77–6.80 (m, 1 H), 6.90–6.94 (m, 1 H), 7.22–7.34 (m, 5 
H). 13C NMR (100 MHz, CDCl3) δ: 28.6, 54.2, 80.5, 125.5, 125.9, 127.1, 
128.5, 129.0, 133.7, 140.6, 145.9, 154.9. IR (neat) 3347, 2979, 2921, 2361, 
1686, 1515, 1233, 1169 cm-1. [α]D20 +11.0 (c = 0.5, EtOH). MS (ESI+) m/z 
346 (M+ + Na, 100%), 347 (17%), 348 (40%). Anal. calcd. for 
C16H18ClNO2S: C, 59.34; H, 5.60; N, 4.33; found: C, 59.50; H, 5.63; N, 
4.23.  
35.  The checkers also performed the reaction at half-scale and isolated 
pure product in a 65% yield at 96% ee. The submitters report a full-scale 
reaction to provide product in 65% yield at 95-99% ee. 
36.  The absolute configuration was shown by anomalous dispersion to 
be (S) using X-ray crystallography. This configuration is consistent with 
prior additions of this type [see Reference 13].  
37.  Enantiomeric excess is determined by chiral HPLC using an 
Agilent 1100 series instrument and a Chiralpak® AS-H column (amylose 
tris[(S)-α-methylbenzyl-carbamate] coated on 5 mm silica gel), L = 250 mm, 
I.D. = 4.6 mm, from Danicel Technologies, LTD. 1% EtOH in hexanes is 
used as the eluent (isochratic) with a flow rate of 1.00 mL/min (max. 70 bar) 
for 25 minutes. For optimal performance the column is equilibrated with the 
solvent system for at least 45 minutes before running the sample. A sample 
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is prepared by dissolving approx. 1 mg compound in 1 mL of 1% EtOH in 
hexanes and filtering through a 4 mm nylon syringe filter (0.45 mm) 
purchased from National Scientific. 5.0 mL of this solution is used for 
injection. To determine the retention times for both enantiomers, a racemate 
of 2 (synthesized with dppBenz as ligand) can be analyzed: (R)-enantiomer 
(minor): 11.1 minutes and (S)-enantiomer (major): 13.5 minutes. Samples 
are analyzed at the following wavelengths: 222, 230, 250 and 254 nm each 
of which gave similar %ee. 
 
Waste Disposal Information 
 
All hazardous materials should be handled and disposed of in 
accordance with “Prudent Practices in the Laboratory”; National Academy 
Press; Washington, DC, 1995. 
 
3. Discussion 
 
Synthesis of enantiomerically pure functionalized amines is of great 
importance because such compounds are widely used in drugs. The 
rhodium-catalyzed enantioselective addition of arylboronic acids to in situ 
generated N-Boc aromatic imines is a general and easy method for the 
preparation of N-Boc protected diaryl methanamines. The first reported 
example of addition of arylboronic acids to an imine was the addition to N-
sulfonyl aldimines published in 2000 by Miyaura and co-workers.3 A 
number of enantioselective variants were later developed using chiral 
ligands, such as N-Boc-L-valine amidomonophosphanes,4 (1R,4R)-
bicyclo[2.2.2]-octadienes,5 (S)-ShiP,6 monodentate phosphoramidites,7,8 
binaphtholic phosphites,8 tetrahydropentalenes,9 and (R,R)-deguPHOS.10 
Most of the methods are limited to aromatic imines, but more recently 
enantioselective catalytic additions to aliphatic imines have also been 
reported.11,12 
However, these methods suffer from a number of drawbacks. For 
example, all of the methods utilize unstable imine substrates, and many of 
the methods necessitate the use of very harsh conditions to remove the N-
substituent present in the addition products. Some of these problems were 
previously solved by the Ellman group using N-Boc aromatic imines 
generated in situ from easily prepared and stable α-carbamoyl sulfones in an 
enantioselective addition with arylboronic acids (Table 1).13 Commercially 
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available (R,R)-deguPHOS was used as the chiral ligand to obtain 
enantiomeric excesses up to 99%. However, Rh(acac)(coe)2 was used as the 
precatalyst, and it is currently not commercially available. Moreover, 
Rh(acac)(coe)2 is highly air-sensitive necessitating that the reactions be set 
up in a nitrogen-filled glovebox,13 which is inconvenient for most research 
laboratories.  
Table 1. Synthesis of various N-Boc amines.13 
 
BocHN Ar1
SO2Ph
BocHN Ar1
Ar2
5% Rh(acac)(coe)2
5.5% (R,R)-deguPHOS
Ar2B(OH)2 (2 equiv)
K2CO3 (6 equiv), Et3N (1.5 equiv)
4Å sieves, dioxane, 70 oC, 20 h  
 
Entry Ar1 Ar2 Yield (%)a ee (%)b 
1 Ph 4-ClC6H4 76 98c 
2 Ph 4-MeC6H4 70 96 
3 Ph 4-MeOC6H4 76 93c 
4 Ph 4-CF3C6H4 51 95c 
5 Ph 3-ClC6H4 55 99 
6 Ph 3-MeC6H4 66 95 
7 Ph 3-AcC6H4 52 94 
8 Ph 2-MeC6H4 62 93 
9 4-MeC6H4 Ph 71 90 
10 3-MeC6H4 Ph 70 95 
11 2-MeC6H4 Ph 63 97 
12 4-BrC6H4 Ph 59 90 
13 2-thienyl Ph 71 96 
14 4-MeOC6H4 Ph 76 96c 
15 4-CF3C6H4 Ph 69 79c 
a Isolated yields after chromatography. b Determined by chiral HPLC analysis. c 
Absolute configuration established by comparison of the optical rotation of 
amine obtained upon Boc cleavage to literature values.14 
 
Optimization of this chemistry was therefore revisited. We found that 
the inexpensive and air-stable precatalyst, [RhCl(cod)]2, performed equally 
well to Rh(acac)(coe)2. Unfortunately, an enantiomeric excess of only 40% 
was achieved with this precatalyst. To improve the enantiomeric excess, we 
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therefore performed a series of preincubation experiments whereby 
[RhCl(cod)]2 and (R,R)-deguPHOS were stirred at 70 oC in dioxane prior to 
adding the starting materials, bases and molecular sieves. We found that one 
hour of preincubation resulted in a dramatic improvement in the 
enantiomeric excess to at least 95% ee. Shorter preincubations gave lower 
enantiomeric excess, whereas longer incubations were not beneficial. 
Furthermore, we discovered that the presence of significant quantities 
of the boroxime (cyclic anhydride) in the boronic acid resulted in a 
decreased yield of the title compound 2. Decreased yields may occur 
because the boroxime adds only slowly to the in situ generated imine, which 
competitively hydrolyzes under the reaction conditions. Commercially 
available boronic acids contain varying amounts of boroxime and therefore 
should be recrystallized from water before use. To avoid too much water in 
the reaction mixture, the boronic acid should also be dried prior to use. 
Boronic acids should not contain more than 5% boroxime and preferentially 
no more than 30% water as determined by 1H NMR in dry DMSO-d6.  
 
Figure 1: Cannulation technique 
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To expand the usability of the chemistry and to make it easier to 
perform on larger scale the reaction was set up using Schlenk techniques. 
This reaction set up provides for efficient reactions on both small and large 
scale, but it is important to transfer the active catalyst solution by 
cannulation technique to completely avoid exposure to air.  
In conclusion, the title product 2 has been prepared in good yield and 
with high enantioselectivity. We believe that these optimized conditions 
should be compatible with the same range of different α-carbamoyl sulfones 
and arylboronic acids reported previously (Table 1).13 This method, which 
utilizes the commercially available (R,R)-deguPHOS chiral ligand and the 
commercially available and air stable [RhCl(cod)]2 precatalyst, does not 
require the use of a glovebox and represents a straightforward and general 
method for the enantioselective synthesis of N-protected diaryl 
methanamines.  
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Appendix 
Chemical Abstracts Nomenclature; (Registry Number) 
 
tert-Butyl phenylsulfonyl(thiophen-2-yl)methylcarbamate: Carbamic acid, 
N-[(phenylsulfonyl)-2-thienylmethyl]-, 1,1-dimethylethyl ester; 
(479423-34-2) 
tert-Butyl carbamate: Carbamic acid, 1,1-dimethylethyl ester; (4248-19-5)  
2-Thiophene-carboxaldehyde; (98-03-3) 
Benzenesulfinic acid sodium salt; (873-55-2) 
[RhCl(cod)]2; (12092-47-6) 
(R,R)-deguPHOS: Pyrrolidine, 3,4-bis(diphenylphosphino)-1-
(phenylmethyl)-, (3R,4R)-; (99135-95-2)  
4-Chlorophenylboronic acid: Boronic acid, B-(4-chlorophenyl)-; (1679-18-
1) 
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